dacarbazine has been researched along with Astrocytoma, Grade IV in 1704 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.23) | 18.7374 |
| 1990's | 6 (0.35) | 18.2507 |
| 2000's | 325 (19.07) | 29.6817 |
| 2010's | 1293 (75.88) | 24.3611 |
| 2020's | 76 (4.46) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, B; Liang, R; Yu, Z | 1 |
| Bender, S; Brada, M; Cseh, A; Gattamaneni, R; Harris, F; James, A; Jefferies, S; McBain, C; Pemberton, K; Saran, F; Schaible, J; Welsh, L | 1 |
| Ameratunga, M; McLean, C; Zaman, FY | 1 |
| Sun, X; Xu, X; Xu, Y; Zhan, W; Zhao, L; Zhu, Y | 1 |
| Bitar, M; Makalowski, J; Schirrmacher, V; Stuecker, W; Van de Vliet, P; Van Gool, SW | 1 |
| Germano, IM; Olson, JJ; Ormond, DR; Wen, P; Ziu, M | 1 |
| Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W | 1 |
| Arunsingh, MA; Basu Achari, R; Bhattacharyya, T; Biswas, B; Chakraborty, S; Chandra, A; Chatterjee, S; Das, A; Goyal, L; Mallick, I; Mishra, D; Parihar, M; Roy, P; Saha, S; Zameer, L | 1 |
| Chamallamudi, MR; Kumar, G; Kumar, N; Nandakumar, K; Rao, V; Thorat, ND; Vibhavari, RJA | 1 |
| In Yoon, H; Lee, SW; Lim, DH; Wee, CW | 1 |
| Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY | 1 |
| Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F | 1 |
| Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B | 1 |
| Internò, V; Porta, C; Rudà, R; Sergi, MC; Soffietti, R | 1 |
| Celis-López, MÁ; Cid-Sánchez, DR; Contreras-Palafox, GA; Flores-Vázquez, JG; Gutiérrez-Aceves, GA; Heredia-Gutiérrez, JC; Hernández-Sánchez, LC; Macías-González, MDS; Moreno-Jiménez, S; Moscardini-Martelli, J; Olmos-Guzmán, A; Ortiz-Arce, CS; Pérez, SR; Rodríguez-Camacho, A; Suárez-Campos, JJE; Torres-Ríos, JA | 1 |
| Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S | 1 |
| Bindra, RS; Gueble, SE; Herzon, SB; Huseman, ED; Lin, K; Sundaram, RK | 1 |
| Ligon, KL; Lim-Fat, MJ; Nassar, AH; Rahman, R; Shi, DD; Wen, PY; Youssef, GC | 1 |
| Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S | 1 |
| Gao, J; Kang, ZF; Mai, A; Ting, WJ; Tu, JY; Yao, QM; Ye, SW | 1 |
| Gong, X; Liu, C; She, L; Su, L | 1 |
| Carpentier, A; Chinot, O; Cornu, P; Delattre, JY; Dufour, H; Emery, E; Faillot, T; Guillamo, JS; Guyotat, J; Hajage, D; Honnorat, J; Laigle-Donadey, F; Lebbah, S; Menei, P; Metellus, P; Paquis, P; Peruzzi, P; Proust, F; Wager, M | 1 |
| Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F | 1 |
| Baek, JY; Beom, SH; Cha, Y; Choi, J; Choi, MK; Hong, YS; Kim, J; Kim, JE; Kim, JH; Kim, SY; Kim, TW; Lee, JS; Lim, SB; Oh, CR; Park, IJ; Park, JH | 1 |
| Chen, ZS; Claret, FX; Elkabets, M; Kong, D; Liang, H; Lin, HW; Peng, X; Sun, F; Wang, F; Wang, R; Wang, Y; Yu, Z; Zhang, L; Zhang, S; Zhong, Z; Zhou, Z | 1 |
| Amoroso, B; Aronchik, I; Chang, H; Filvaroff, E; González León, P; Hanna, B; Manuel Sepúlveda, J; Mendez, C; Moreno, V; Nikolova, Z; Pérez-Núñez, Á; Reardon, DA; Sanchez-Perez, T; Stephens, D; Vogelbaum, MA; Zuraek, M | 1 |
| Bady, P; Buri, MC; Chiesi, D; Gusyatiner, O; Hegi, ME; Lomazzi, R; Messerer, M; Tancredi, A | 1 |
| Brehmer, S; Bullinger, L; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Hau, P; Herrlinger, U; Kowalski, T; Krex, D; Potthoff, AL; Ringel, F; Sabel, M; Schäfer, N; Schaub, C; Schmidt-Graf, F; Schneider, M; Schnell, O; Seidel, C; Steinbach, JP; Tabatabai, G; Tonn, JC; Tzaridis, T; Vajkoczy, P; Vatter, H; Weller, J; Zeiner, PS; Zeyen, T | 1 |
| Elsaid, AA; Elsaka, R; Kitagwa, JM; Mahmoud, AA; Meheissen, MAM; Refaat, T; Shaikh, H | 1 |
| Aldegheri, V; Bosio, A; Caccese, M; Cerretti, G; Chioffi, F; Della Puppa, A; Denaro, L; Guarneri, V; Lombardi, G; Padovan, M; Zagonel, V | 1 |
| Huang, Q; Yang, L; Ye, Z | 1 |
| Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C | 1 |
| Alalami, H; Bannykh, S; Fan, X; Hu, J | 1 |
| Baghbanzadeh, A; Baradaran, B; Barpour, N; Doustvandi, MA; Javadrashid, D; Mohammadpour, ZJ; Mohammadzadeh, R | 1 |
| Bryant, C; Haynes, C; Kim, YN; Nakhai, SA; Pai, SB; Patil, K; Srivastava, S; Thompson, EW | 1 |
| Chen, CC; Li, M; Ma, J; Wang, Z | 1 |
| Bonsanto, MM; Leppert, J; Rades, D; Trillenberg, P; Yu, NY; Zemskova, O | 1 |
| Bradshaw, TD; Lewis, W; Moody, CJ; Stevens, MFG; Summers, HS; Williams, HEL | 1 |
| Harter, PN; Herms, J; Katzendobler, S; Niedermeyer, S; Niyazi, M; Stoecklein, VM; Thon, N; Tonn, JC; Trumm, C; Weller, J | 1 |
| Afzal, M; Castresana, JS; Hasan, H; Shahi, MH | 1 |
| Barberis, A; Bocci, G; Buffa, FM; Caffo, M; De Salvo, GL; Harris, AL; Ius, T; Lombardi, G; Mazzanti, CM; Montemurro, N; Paiar, F; Pasqualetti, F; Soffietti, R; Zanotti, S | 1 |
| Castresana, JS; Denizler-Ebiri, FN; Güven, M; Taşpınar, F; Taşpınar, M | 1 |
| Ali, A; Alnahhas, I; Cappelli, L; Kayne, A; Khan, MM; Miller, R; Niazi, M; Poiset, S; Shi, W | 1 |
| Ji, N; Wang, J; Wang, N; Wang, P; Yue, S | 1 |
| Grzywna, E; Krajcer, A; Lewandowska-Łańcucka, J | 1 |
| Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X | 1 |
| Fionda, C; Fontanella, RA; Gaetano, C; Illi, B; Malatesta, S; Salvatori, L; Somma, MP; Stabile, H | 1 |
| Arijs, I; Balvers, RK; Beerepoot, LV; Biswas, A; Byrne, AT; Chi Yen, RT; Connor, K; Dilcan, G; Dirven, CMF; Fabro, F; Idbaih, A; Jimenez-Cowell, K; Ju, J; Kers, TV; Kleijn, A; Klein, M; Kremer, A; Kros, JM; Lambrechts, D; Lamfers, MLM; Lawler, SE; Leenstra, S; Li, Y; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Stubbs, AP; van den Bent, MJ; Verreault, M | 1 |
| Duffy, C; Galldiks, N; Glas, M; Goldbrunner, R; Grauer, O; Hattingen, E; Hau, P; Herrlinger, U; Krex, D; Nitsch, L; Paech, D; Potthoff, AL; Radbruch, A; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Weller, J; Zeiner, PS; Zeyen, T | 1 |
| Chen, Y; Qi, H; Qu, W; Tu, J | 1 |
| Berglund, AE; Etame, AB; Macaulay, RJ; Wu, Q | 1 |
| Alcaniz, J; Benesch, M; Birkl-Toeglhofer, AM; Golob-Schwarzl, N; Haybaeck, J; Hoffmann, J; Huber, HJ; Krassnig, S; Leber, SL; Leoni, M; Mahdy-Ali, K; Naumann, M; Orthmann, A; Pennauer, M; Raicht, A; Skofler, C; von Campe, G; Wälchli, T; Weis, S; Wohlrab, C | 1 |
| Arijs, I; Beerens, C; Biswas, A; Byrne, AT; Chien, MP; Connor, K; Dilcan, G; Fabro, F; Feller, KJ; Idbaih, A; Kers, TV; Kremer, A; Lambrechts, D; Lamfers, MLM; Leenstra, S; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Tching Chi Yen, R; Verreault, M | 1 |
| Frandsen, S; Geissler, UW; Gredal, O; Møller, S; Nørøxe, DS; Pedersen, AJ | 1 |
| Bian, L; Li, D; Li, K; Lin, B; Liu, X; Xi, Z; Yan, J; Yang, Q | 1 |
| Arantes, PR; Cao, Z; Masterson, K; Morás, AM; Moura, DJ; Nugent, M; Steffens, L | 1 |
| Handelman, SK; Jain, HV; Sorribes, IC | 1 |
| Khasraw, M; Lwin, Z; Nowak, AK; Sim, HW | 1 |
| Haggiagi, A; Lassman, AB | 1 |
| Alam, A; Mohile, N; Wasilewski, A | 1 |
| Chatterjee, A; Gupta, T; Patil, V | 1 |
| Balana, C; Carrato, C; Vaz, MA | 1 |
| Liu, Y; Milano, MT; Mohile, NA; Richardson, M; Serventi, JN; Strawderman, MS; Walter, KA; Warren, KT | 1 |
| Grossman, SA | 1 |
| Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C | 1 |
| Akimoto, J; Narita, Y; Tanaka, S | 1 |
| Bardhi, R; Daveluy, S; Farshchian, M | 1 |
| de Groot, JF; Gao, F; Koul, D; Li, X; Wu, S; Yung, WKA | 1 |
| Anghileri, E; Fabi, A; Gaviani, P; Lanzetta, G; Lombardi, G; Pace, A; Pronello, E; Prosperini, L; Rizzato, S; Rudà, R; Scaringi, C; Simonetti, G; Targato, G; Villani, V | 1 |
| Alghamdi, B; Alkhayyat, S; Baeesa, S; Bardeesi, A; Bari, MO; Butt, NS; Dallol, A; Kurdi, M; Lary, AI; Maghrabi, Y; Mohamed, F; Saeedi, R; Samkari, A | 1 |
| Greenspoon, JN; Mir, T; Pond, G | 1 |
| Ma, W; Zhao, B | 1 |
| Bastiancich, C; Bozzato, E; Henley, I; Newland, B | 1 |
| Adegboyega, G; Bandyopadhyay, S; Kanmounye, US; Ozair, A; Vaqas, B | 1 |
| Winkler, F | 1 |
| Annavarapu, S; Davies, K; Gogate, A; Pham, T; Robert, N; Singh, P | 1 |
| Friesen, C; Misch, M; Onken, J; Vajkoczy, P | 1 |
| Efferth, T; Giordano, FA; Krishna, S; Schmiedek, P; Schöttler, U; Wenz, F | 2 |
| Baumert, BG; Brands, E; Dik, R; Fedrigo, CA; Narayan, RS; Peters, GJ; Slotman, BJ; Sminia, P; Stalpers, LJ; Westerman, BA | 1 |
| Han, Y; Huang, BS; Huang, D; Luo, QZ; Tang, QP; Wu, LX | 1 |
| Chang, CW; Chen, HH; Chiang, CS; Chiang, WH; Chiu, HC; Huang, WC; Lin, YW; Lu, IL; Tsai, YC | 1 |
| Khazaei, M; Pazhouhi, M | 1 |
| Cheng, W; Han, S; Jiang, Y; Meng, L; Tie, X; Wu, A; Xia, J | 1 |
| Behling, F; Bisdas, S; Borchers, C; Dangel, E; Gohde, J; Koch, M; Lepski, G; Naumann, A; Noell, S; Paulsen, F; Ritz, R; Schittenhelm, J; Skardelly, M; Tabatabai, G; Tatagiba, MS; von Hehn, U; Zips, D | 1 |
| Alattar, AA; Ali, MA; Brandel, MG; Carroll, KT; Carter, B; Chen, CC; Hirshman, B; Lanman, T; Lochte, B | 1 |
| Costa, B; Da Settimo, F; Daniele, S; Giacomelli, C; Giustiniano, M; La Pietra, V; La Regina, G; Marinelli, L; Martini, C; Novellino, E; Pietrobono, D; Silvestri, R; Taliani, S; Trincavelli, ML | 1 |
| Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P | 1 |
| Barnaby, SN; Cayton, TC; Chalastanis, A; Cole, LE; Ghelfi, ST; Hurley, LA; James, CD; Kouri, FM; Lee, A; May, JL; Merkel, TJ; Mirkin, CA; Savalia, N; Sita, TL; Sprangers, AJ; Stegh, AH | 1 |
| Chen, H; Cheng, X; Huang, S; Liu, J; Lou, S | 1 |
| Jiang, T; Schiff, D; Wen, PY | 1 |
| Alexander, B; Ballman, K; Grossman, SA; Schreck, KC | 1 |
| Algara, M; Foro Arnalot, P; Granados, R; Membrive, I; Ortiz, A; Pera, O; Reig, A; Rodriguez, N; Sanz, X | 1 |
| Kesari, S; Ram, Z | 1 |
| Balça-Silva, J; do Carmo, A; Dubois, LG; Echevarria-Lima, J; Ferrer, VP; Lopes, MC; Matias, D; Moura-Neto, V; Pontes, B; Rosário, L; Sarmento-Ribeiro, AB | 1 |
| Fujioka, K; Ikeda, K; Manome, Y; Murayama, Y; Suzuki, Y | 1 |
| Combs, SE; Straube, C | 1 |
| Asuthkar, S; Bach, SE; Guda, MR; Lathia, JD; Sahu, K; Tsung, AJ; Tuszynski, J; Velpula, KK | 1 |
| Kang, CS; Lv, SG; Wang, QX; Wu, MJ; Xiao, B; Xu, B; Ye, MH; Zhu, XG | 1 |
| Haririan, I; Irani, M; Sadeghi, GMM | 1 |
| Dong, Y; Furuta, T; Hayashi, Y; Kinoshita, M; Minamoto, T; Miyashita, K; Nakada, M; Sabit, H; Uchiyama, N | 1 |
| Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhou, X | 1 |
| Allemanni, G; Banelli, B; Daga, A; Forlani, A; Marubbi, D; Pistillo, MP; Profumo, A; Romani, M | 1 |
| Battelli, C; Blaszyk, H; Chow, KH; Emery, IF; Florman, J; George, J; Gopalan, A; Wood, S; Yun, K | 1 |
| Baernreuther, J; Kamp, MA; Rapp, M; Sabel, M; Steiger, HJ; Turowski, B | 1 |
| Liu, L; Liu, Y; Wang, P; Xue, Y; Yao, Y; Yu, Q | 1 |
| Fan, X; Lan, T; Qu, Y; Song, Y; Wang, H; Yu, C; Zhan, Q; Zhang, M; Zhang, Z; Zhao, Z | 1 |
| Du, XL; Lu, G; Zhu, JJ; Zhu, P | 1 |
| Binz, A; Herzog, ED; Kfoury, N; Kim, A; Marpegan, L; Rubin, JB; Simon, T; Slat, EA; Sponagel, J | 1 |
| Alter, RA; Boockvar, JA; Chakraborty, S; Fanous, AA; Filippi, CG; Pisapia, DJ; Tsiouris, AJ; White, TG | 1 |
| Aghi, MK; Berger, MS; Choi, S; Chou, A; Flanigan, PM; Jahangiri, A; Kuang, R; McDermott, MW; Molinaro, AM; Truong, A | 1 |
| Liang, DS; Liu, YJ; Ma, YC; Qi, XR; Wu, ZF; Yang, ZZ; Zhang, WJ | 1 |
| Abdollahi, A; Dokic, I; Klein, C; Oancea-Castillo, LR; Régnier-Vigouroux, A; Weber, KJ | 1 |
| Bielecka-Wajdman, AM; Lesiak, M; Ludyga, T; Obuchowicz, E; Sieroń, A | 1 |
| Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J | 1 |
| Hu, Q; Jiang, T; Li, R; Liu, YW; Nie, E; Wang, XF; Wang, Z; Yan, W; You, YP; Zeng, AL; Zhou, X | 1 |
| Chen, T; Fu, A; Li, J; Li, M; Song, X; Zhu, J | 1 |
| Dai, J; Ma, K; Niu, L; Pan, Y; Wang, X; Yin, H; Yuan, G; Zhang, Y; Zhou, W | 1 |
| Bomal, E; Choi, J; Kakkar, A; Maysinger, D; Moquin, A; Na, L | 1 |
| Cappabianca, P; Cavallo, LM; Frio, F; Grujicic, D; Illic, R; Lavrnic, S; Milicevic, M; Milosevic, S; Nikitovic, M; Raicevic, S; Savic, D; Solari, D; Somma, T | 1 |
| An, M; Beattie, CE; Jaros, BD; Welker, AM | 1 |
| Choi, SH; Kim, E; Kim, IH; Kim, JW; Kim, TM; Lee, ST; Park, CK; Wee, CW; Yoo, RE | 1 |
| Nabors, LB | 1 |
| Abadi, MFS; Ahmadi, M; Akbarnejad, Z; Dini, L; Eskandary, H; Farsinejad, A; Nematollahi-Mahani, SN; Vergallo, C | 1 |
| Rushworth, SA; Steverding, D | 1 |
| Li, J; Long, C; Peng, P; Wei, W | 1 |
| Koshy, M; Rusthoven, CG; Sher, DJ | 1 |
| Laperriere, N; Mason, WP; Perry, JR | 1 |
| Jahan, N; Lee, JM; Shah, K; Wakimoto, H | 1 |
| Herrera-Rios, D; Hoerbelt, T; Jiang, T; Kahlert, UD; Koch, K; Li, G; Maciaczyk, D; Maciaczyk, J; Marquardt, V; Ouwens, DM; Pauck, D; Picard, D; Remke, M; Steiger, HJ; Zhang, W; Zhao, L | 1 |
| Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J | 1 |
| Back, M; Brazier, D; Cook, R; Gzell, C; Harris, G; Jayamanne, D; Kastelan, M; Khasraw, M; Louw, S; Parkinson, J; Schembri, G; Wheeler, H | 1 |
| Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Onishi, S; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F | 1 |
| Fu, Z; Guo, H; Lian, C; Liu, B; Xu, N; Yang, Z; Zeng, H | 1 |
| Snyder, J; Walbert, T | 1 |
| Chitkara, D; Italiya, K; Mittal, A; Sharma, S | 1 |
| Chang, E; Chen, Z; Cheshier, S; Chin, FT; Daldrup-Link, HE; Falconer, RA; Gambhir, SS; Klockow, J; Li, K; Loadman, PM; Mitra, S; Mohanty, S; Morais, GR; Pisani, L; Rao, J; Yerneni, K | 1 |
| Golomb, G; Grad, E; Guez, D; Last, D; Levi-Kalisman, Y; Mardor, Y; Meirow, H; Nordling-David, MM; Salomon, S; Sharabi, S; Yaffe, R | 1 |
| Dong, Y; Guan, F; Li, D; Li, H; Liu, X; Wang, H; Yan, D; Yang, B; Yuan, X | 1 |
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Ahn, SS; Chang, JH; Cho, J; Choi, HJ; Hong, CK; Kang, SG; Kim, DS; Kim, EH; Kim, SH; Lee, KS; Lee, SK; Moon, JH; Park, HH; Roh, TH; Suh, CO | 1 |
| Basso, G; Boso, D; Calvanese, L; D'Auria, G; Della Puppa, A; Dettin, M; Falcigno, L; Maule, F; Persano, L; Porcù, E; Rampazzo, E; Scabello, A; Zamuner, A | 1 |
| Ishikawa, E; Matsuda, M; Matsumura, A; Nakao, J; Takano, S; Yamamoto, T | 1 |
| Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P | 1 |
| Cuppini, L; DiMeco, F; Fariselli, L; Gaviani, P; Marchetti, M; Milanesi, I; Pinzi, V; Salmaggi, A; Silvani, A; Simonetti, G; Tramacere, I | 1 |
| Balça-Silva, J; Canedo, NHS; Correia, AH; De Souza, JM; Do Carmo, A; Dubois, LG; Girão, H; Gonçalves, AC; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB | 1 |
| Fu, Z; Guo, H; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Ito, M; Kiyohara, Y; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Yamaguchi, K | 1 |
| Deitz, AC; Desai, VCA; He, J; Holick, CN; Lanes, S; Quinlan, SC | 1 |
| Chaudhari, P; Goda, JS; Mohanty, BS; Mutalik, S; Prabhu, S; Rai, S; Rao, BSS; Udupa, N | 1 |
| Choi, CG; Jung, SC; Kim, HS; Kim, HW; Kim, JH; Kim, SJ; Park, JE; Ryu, KH; Shim, WH | 1 |
| Ananiadou, D; Giatromanolaki, A; Ilemosoglou, M; Kostoglou, G; Koukourakis, M; Lamprou, I; Papadopoulou, M; Pouliliou, S; Sivridis, E; Tsolou, A | 1 |
| Kim, Y; Magrath, JW | 1 |
| Cui, C; Li, Y; Liu, B; Lu, C; Song, H; Tian, H; Zhao, J; Zou, S | 1 |
| Bergin, P; Blackley, E; Gill, S; Haydon, A; McLean, C; Moore, M; Tay, RY | 1 |
| Chan, DT; Hsieh, SY; Kam, MK; Loong, HH; Ng, SC; Poon, DM; Poon, WS; Tsang, WK | 1 |
| Bilguvar, K; Chen, S; Chow, RD; Dong, MB; Errami, Y; Gunel, M; Guzman, CD; Martinez, MA; Platt, RJ; Renauer, P; Schmidt, F; Sharp, PA; Wang, G; Ye, L; Youngblood, MW; Zhang, F; Zhang, S | 1 |
| Jbeli, AH; Yu, J | 1 |
| Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T | 1 |
| Chang, KY; Chang, WC; Chen, KY; Chou, SW; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Hung, JJ; Kao, TJ; Ko, CY; Liou, JP; Liu, JJ; Liu, MS; Tsai, SY | 1 |
| Buslei, R; Distel, L; Fietkau, R; Putz, F; Stritzelberger, J | 1 |
| de Moraes, FY; Laperriere, N | 1 |
| Zhu, JJ; Zhu, P | 1 |
| Guo, Z; Li, L; Li, P; Song, L; Sun, G; Tan, Q; Yan, X; Yi, H; Yu, D; Zeng, Z | 1 |
| Ashby, L; Butowski, N; Davis, TA; Drappatz, J; Finocchiaro, G; Goldlust, SA; Green, J; Hamilton, MG; He, Y; Hirte, H; Iwamoto, F; Keler, T; Lim, M; Mechtler, L; O'Rourke, DM; Perry, J; Recht, LD; Sampson, JH; Stupp, R; Tran, DD; Turner, CD; Weller, M; Wick, W; Wong, M; Yellin, MJ | 1 |
| Avgeropoulos, N; Benouaich-Amiel, A; David, C; Demireva, P; Goldlust, S; Kanner, AA; Mehdorn, M; Pannullo, S; Salmaggi, A; Silvani, A; Zhu, JJ | 1 |
| He, Z; Jie, M; Li, HF; Lin, JM; Liu, H; Mao, S | 1 |
| Grossman, SA; Kleinberg, L | 1 |
| Kortmann, RD; Seidel, C | 3 |
| Bilodeau, D; Moroney, C; Mueller, C; Myrehaug, S; Perry, JR; Sahgal, A; Soliman, H; Tsang, DS; Tsao, MN; Tseng, CL | 1 |
| Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J | 1 |
| Amankulor, NM; Kim, WJ; Newman, WC | 1 |
| Chai, JN; Chheda, MG; Diamond, MS; Fernandez, E; Gorman, MJ; Hubert, CG; McKenzie, LD; Prager, BC; Rich, JN; Richner, JM; Shan, C; Shi, PY; Tycksen, E; Wang, X; Zhang, R; Zhu, Z | 1 |
| Buglione, M; Detti, B; Doino, D; Fiorentino, A; Fusco, V; Greto, D; Krengli, M; Livi, L; Lonardi, F; Magrini, SM; Marrazzo, L; Marzano, S; Masini, L; Migliaccio, F; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S | 1 |
| Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F | 1 |
| Cheng, ZX; Wang, ZY; Yin, WB | 1 |
| Jing, D; Shen, L; Yu, H; Zhang, Q; Zhao, Y | 1 |
| Chang, KY; Chang, WC; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Huang, CT; Hung, JJ; Liu, JJ; Tsai, KK | 1 |
| Anjo, SI; Baltazar, F; Costa, BM; Gomes, ED; Granja, S; Manadas, B; Salgado, AJ; Vieira de Castro, J | 1 |
| Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM | 1 |
| de Groot, JF; Nam, JY | 1 |
| Chen, H; Chen, Q; Han, C; Lan, J; Liu, Q; Lou, M; Que, S; Wang, L; Xue, Y; Zhang, X | 1 |
| Lan, J; Lin, Y; Qian, Z; Qiu, Y; Que, S; Yang, X; Zhou, S; Zhou, Z | 1 |
| Battaglia, G; Carbone, SF; Cerase, A; Miracco, C; Nardone, V; Pastina, P; Pirtoli, L; Rubino, G; Sebaste, L; Tini, P | 1 |
| Kumar, V; Leonardi, D; Radin, D | 1 |
| Choi, SH; Kang, KM; Kim, JH; Lim, WH; Nam, JG; Sohn, CH; Yoo, RE; Yun, TJ | 1 |
| Ahluwalia, MS; Braun, K | 1 |
| Andrews, DW; Blumenthal, DT; Brown, PD; Dignam, JJ; Gilbert, MR; Hopkins, K; Howard, SP; Lessard, N; Mehta, MP; Scannell Bryan, M; Shi, W; Souhami, L; Tzuk-Shina, T; Valeinis, E; Werner-Wasik, M; Youssef, EF | 1 |
| Roussakow, SV | 1 |
| Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA | 1 |
| Chen, L; Hu, Z; Li, Z; Liu, C; Liu, L; Lu, D; Teng, L; Wang, L; Zhao, L | 1 |
| Du, S; Du, Y; Ren, J; Yan, Z; Ying, G; Zhu, Z | 1 |
| Huang, H; Ma, L; Peng, J; Peng, Y; Shao, M; Wang, L; Xia, Z; Zhong, G; Zhu, Z | 1 |
| Ahluwalia, MS; Ashby, LS; Chinnaiyan, P; Fiveash, JB; Kee, AY; Malone, SC; Mehta, MP; Michael Yu, HH; Mohile, NA; Rojiani, AM; Shih, HA; Stella, PJ; Stieber, VW; Wen, PY; Wendland, MM; Werner-Wasik, M; Won, M | 1 |
| Wang, H; Zhang, L | 1 |
| Battaglia, G; Cerase, A; Miracco, C; Nardone, V; Pastina, P; Pirtoli, L; Rubino, G; Sebaste, L; Tini, P | 1 |
| Azab, AK; Fettig, N; Goddu, SM; Jin, A; Kapoor, V; Luderer, MJ; Muz, B; Puente, P; Rogers, B; Salama, NN; Shah, S; Shoghi, K; Thotala, D; Tsien, C | 1 |
| Ichimura, K; Kumagai, K; Mori, K; Nakashima, K; Namba, H; Narita, Y; Otani, N; Sakai, R; Sasaki, N; Shirakihara, T; Takeuchi, S; Tomiyama, A; Toyooka, T; Wada, K; Yamaguchi, H; Yamamoto, Y | 1 |
| Gangoso, E; Marques-Torrejon, MA; Pollard, SM | 1 |
| Biau, J; Chautard, E; Dalloz, P; De Schlichting, E; Dillies, AF; Dupic, G; Durando, X; Fogli, A; Godfraind, C; Khalil, T; Müller-Barthélémy, M; Pereira, B; Verrelle, P | 1 |
| Han, L; Kamdar, MR | 1 |
| Berger, G; Chiocca, EA; Grauwet, K; Hussey, AM; Lawler, SE; Lippard, SJ; Nowicki, MO; Wang, DI; Zhang, H | 1 |
| Baghi Yazdi, M; Mortaz, M; Sefidrokh Sharahjin, N; Shabani, M; Taghipour Zahir, S | 1 |
| Day, PJ; Ghanate, AD; Immanuel, SRC; Marriage, F; Panchagnula, V; Parmar, DS; Raghunathan, A | 1 |
| Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S | 1 |
| Ahluwalia, MS; Brem, S; Bruna, J; Di Meco, F; Fink, K; Hegi, ME; Hirte, H; Hottinger, A; Idbaih, A; Kanner, A; Kim, CY; Kirson, ED; Lavy-Shahaf, G; Lhermitte, B; Lieberman, F; Nicholas, G; Paek, SH; Palti, Y; Ram, Z; Read, W; Steinberg, D; Stragliotto, G; Stupp, R; Taillibert, S; Toms, S; Tran, D; Weinberg, U; Weller, M; Zhu, JJ | 1 |
| Jani, P; Pandya, N; Tandel, H; Vanza, J | 1 |
| Schecker, J; Schlegel, J; Schneider, F; Schönfelder, M; Wu, W; Würstle, S | 1 |
| Anders, NM; Figg, WD; George, RT; Gilbert, M; Grossman, SA; Harfi, TT; Jackson, S; McAreavey, D; Nduom, EK; Peer, C; Rudek, MA; Weingart, J; Ye, X | 1 |
| Classen, CF; Linnebacher, M; Schneider, B; Walther, M; William, D | 1 |
| Dong, T; Dong, Y; Gao, Y; Gong, Y; Li, Q; Pei, C; Ren, H; Su, J; Sun, Q; Xiao, Y; Xing, W; Zhen, Z; Zhou, P | 1 |
| Asllani, I; Baumann, M; Beuthien-Baumann, B; Gommlich, A; Hofheinz, F; Jentsch, C; Krause, M; Krukowski, P; Maus, J; Mutsaerts, HJMM; Petr, J; Platzek, I; Seidlitz, A; Troost, EGC; van den Hoff, J; van Osch, MJP | 1 |
| Ghia, AJ | 1 |
| Cohen, RJ; Mehta, MP | 1 |
| Hoang, N; Puduvalli, VK | 1 |
| Chang, HH; Chen, Y; Cheng, YC; Sung, YC; Tsai, WC | 1 |
| Coburger, J; Hlavac, M; Knoll, A; König, R; Pala, A; Schmitz, AL; Schneider, M; Wirtz, CR | 1 |
| Cui, Y; Feng, H; He, H; Ji, A; Li, J; Li, S; Lin, J; Lu, Y; Qiu, G; Song, C; Zou, Y | 1 |
| Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M | 1 |
| Ahmed, EM; Bandopadhyay, G; Coyle, B; Grabowska, A | 1 |
| Bu, XY; Kong, LF; Luo, JC; Ma, CX; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW; Zhou, ZL | 1 |
| Aprile, G; De Carlo, E; De Maglio, G; Fasola, G; Follador, A; Gerratana, L; Gurrieri, L; Macerelli, M; Masiero, E; Pisa, FE; Pizzolitto, S; Puglisi, F; Rizzato, S | 1 |
| Blasiak, J; Pawlowska, E; Szatkowska, M; Szczepanska, J | 1 |
| Cui, Y; Feng, H; He, H; Li, J; Li, S; Lin, J; Qiu, G; Song, C; Wei, W; Wu, X; Xu, Q; Zuo, J | 1 |
| Chumakova, A; Lathia, JD | 1 |
| Chan, D; Chan, KY; Ho, J; Lam, S; Lee, M; Ma, E; Mak, C; Poon, WS; Wong, ST; Wong, WK; Woo, P | 1 |
| Chen, ZY; Deng, SZ; Feng, WY; Guo, ML; He, MY; Li, YM; Liu, YW; Qi, ST; Sun, XG; Xiang, W; Yi, GZ; Zhao, L | 1 |
| Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M | 1 |
| Bonacorso, HG; Costa Nunes, F; Creczynski-Pasa, TB; de Melo, LJ; Feitosa, SC; Martins, MAP; Rode, M; Silva, AH; Silva, LB; Winter, E; Zanatta, N | 1 |
| Coelho, MAN; Gosselet, F; Lima, J; Loureiro, JA; Pereira, MC; Ramalho, MJ; Sevin, E | 1 |
| Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M | 1 |
| Abeysekera, IR; Hai, L; Huang, Y; Li, J; Li, T; Liu, P; Ma, H; Tao, Z; Tong, L; Xie, Y; Yang, X; Yi, L; Yu, S; Yuan, F | 1 |
| Geurts, M; van den Bent, MJ | 1 |
| Alcaín, FJ; Ariza, J; Arjona-Gutiérrez, J; De la Mata, M; Durán-Prado, M; Ferrín, G; Frontiñán-Rubio, J; Gil-Agudo, A; Gómez, MV; Lozano, E; Martínez-González, A; Moreno, M; Nieva-Velasco, CM; Peinado, JR; Pérez-García, VM; Pérez-Romasanta, L; Pesic, M; Santiago-Mora, RM; Villalba, JM | 1 |
| Alter, RA; Boockvar, JA; Chakraborty, S; Demopoulos, A; Filippi, CG; Fralin, S; Kulason, KO; Langer, DJ; Ortiz, R; Pramanik, B; Ray, A; Schneider, JR; Tan, K; Wong, T | 1 |
| Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y | 1 |
| Carvajal, S; Galvis, A; Giraldo, D; Loaiza, S; Ortiz, L | 1 |
| Jin, S; Li, W; Liang, J; Liang, T; Qian, Z; Qiu, X; Sun, L; Yang, F; Zhang, M | 1 |
| Bähr, O; Belka, C; Braun, C; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Kortmann, RD; Krex, D; Mack, F; Niessen, M; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Steinbach, JP; Stuplich, M; Tzaridis, T; Vatter, H; Weyerbrock, A | 1 |
| Adamski, V; Adelung, R; Ceynowa, F; Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M | 1 |
| Bruhn, H; Hallbeck, M; Lind, J; Milos, P; Strandéus, M; Vrethem, M | 1 |
| Hegazy, AM; Hirao, A; Ino, Y; Ito, C; Kasahara, A; Kobayashi, M; Nakada, M; Nomura, N; Peng, H; Tadokoro, Y; Takase, Y; Todo, T; Ueno, M; Vu, HT | 1 |
| Fu, C; Liu, X; Yang, X; Zhang, C | 1 |
| Buonerba, C; Cerbone, L; Cordua, N; De Placido, S; Di Lorenzo, G; Lamberti, G; Marinelli, A; Peluso, G | 1 |
| Hanif, F; Jawed, H; Malhi, SM; Perveen, K; Simjee, SU | 1 |
| de Groot, JF; Harrison, RA | 1 |
| Cheng, YS; Kiang, KMY; Leung, GKK; Li, N; Zhang, P | 1 |
| Fortunato, JT; Pan, E; Reys, B; Singh, P | 1 |
| Chang, HH; Chen, Y; Cheng, YC; Tsai, WC; Tsao, MJ | 1 |
| Hou, S; Sha, LG; Xu, P; Zhang, G | 1 |
| Beberok, A; Buszman, E; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Almeida, T; Azqueta, A; Ferreira, J; Ramos, AA; Rocha, E | 1 |
| Chang, KF; Tsai, NM; Wang, JC | 1 |
| Bhattacharya, D; Chakarvarty, S; Kondapi, AK; Kumari, S; Rangaraj, N; Rao, NM | 1 |
| Chen, TC; Fayngor, RA; Hofman, FM; Jhaveri, N; Marín-Ramos, NI; Thein, TZ | 1 |
| Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H | 1 |
| Brambilla, D; Cavusoglu, M; Grandjean, J; Leroux, JC; Luciani, P; Martin, E; Papachristodoulou, A; Roth, P; Rudin, M; Signorell, RD; Silginer, M; Weller, M; Werner, B | 1 |
| Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ | 1 |
| Guonan, C; Naijie, L; Xin, Z; Xingyi, J | 1 |
| Bähr, O; Belka, C; Borchers, C; Galldiks, N; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Krex, D; Mack, F; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Seidel, C; Steinbach, JP; Tabatabai, G; Tzaridis, T; Vatter, H; Weller, J; Weyerbrock, A | 1 |
| Cerase, A; Marampon, F; Mazzei, MA; Nardone, V; Pastina, P; Pirtoli, L; Sebaste, L; Tini, P; Tombolini, V | 1 |
| Banasavadi-Siddegowda, Y; Beullens, M; Chow, LM; Joshi, K; Kig, C; Kim, SH; Kornblum, HI; Mao, P; Mo, X; Nakano, I; Nardini, D; Sobol, RW; Waclaw, R | 1 |
| Bigner, DD; Choudhury, GR; Ghorpade, A; Keir, ST; Li, W; Liu, R; Poteet, E; Ryou, MG; Simpkins, JW; Tang, L; Wen, Y; Winters, A; Yan, H; Yang, SH; Yuan, F | 1 |
| Agarwal, A; Jain, R; Kumar, S; Mikkelsen, T; Narang, J; Poptani, H; Schultz, L; Siddiqui, S; Wang, S | 1 |
| Felsberg, J; Goeppert, M; Rapp, M; Sabel, M; Steiger, HJ | 1 |
| Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W | 1 |
| Fiveash, JB; Friedman, GK; Harrison, DK; Reddy, AT; Spiller, SE | 1 |
| Borawska, MH; Car, H; Fiedorowicz, A; Markiewicz-Żukowska, R; Naliwajko, SK; Sawicka, D | 1 |
| Botti, A; Cagni, E; Ciammella, P; D'Abbiero, N; Galeandro, M; Iori, M; Iotti, C; Pisanello, A; Podgornii, A | 1 |
| Aguas, J; Barceló, I; Belenguer, A; Brell, M; Bruna, J; Crespo, JA; de Andrés, P; Erro, E; Escudero, D; Estela, J; Fuentes, R; García-Castaño, A; García-Romero, JC; Gelabert, M; Gil, M; Graus, F; Henríquez, I; Lema, M; Manzano, A; Martino, J; Mas, G; Mata, E; Muñoz-Carmona, D; Murcia, M; Navas, I; Pardo, J; Pascual, C; Pérez, P; Rojas-Marcos, I; Simón, A; Verger, E; Vilas, D; Vivanco, R | 1 |
| Deangelis, LM; Deutsch, MB; Lassman, AB; Panageas, KS | 1 |
| Biris, AS; Bratu, I; Casciano, D; Florea, A; Florian, S; Olenic, L; Orza, A; Pall, E; Pana, O; Soriţău, O; Tomuleasa, C | 1 |
| Anderson, SK; Ballman, KV; Carlson, BL; Cen, L; Decker, PA; Giannini, C; Grogan, PT; Kitange, GJ; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Grah, JJ; Juretic, A; Katalinic, D; Paladino, J; Plestina, S; Santek, F; Stern-Padovan, R; Supe, M; Zarkovic, K | 1 |
| Furuta, T; Hamada, J; Hayashi, Y; Misaki, K; Nakada, M; Nakanuma, Y; Sato, Y | 1 |
| Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Meira, LB | 1 |
| Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB | 1 |
| Canpinar, H; Castresana, JS; Ilgaz, S; Ozdemir, M; Ozkan, T; Oztuna, D; Rey, JA; Sunguroğlu, A; Taspinar, M; Ugur, HC | 1 |
| Bueno e Silva, MM; Filippi-Chiela, EC; Garicochea, B; Ledur, PF; Lenz, G; Pelegrini, AL; Thomé, MP; Zamin, LL | 1 |
| Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M | 1 |
| Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC | 1 |
| Amano, T; Fujioka, Y; Hata, N; Iwaki, T; Mizoguchi, M; Murata, H; Nakamizo, A; Sasaki, T; Suzuki, SO; Yoshimoto, K | 1 |
| Chaichana, K; Chen, L; Ford, E; Guerrero-Cazares, H; Kleinberg, L; Lim, M; McNutt, T; Quinones-Hinojosa, A; Redmond, K; Ye, X | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Morelli, MB; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Li, X; Liu, J; Wang, T; Yang, S; You, C | 1 |
| Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ | 1 |
| Sun, J; Yang, SY; Yang, XJ | 1 |
| Bauer, M; Bechmann, I; Dehghani, F; Durante, M; Gaunitz, F; Giese, A; Gutenberg, A; Hellwig, C; Meixensberger, J; Merz, F; Renner, C; Schäfer, M; Schopow, K; Stöcker, H; Taucher-Scholz, G | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Harrabi, S; Weber, KJ | 1 |
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I | 2 |
| Archer, GE; Bigner, DD; Choi, BD; Heimberger, AB; Herndon, JE; Mitchell, DA; Norberg, P; Reap, EA; Sampson, JH; Sanchez-Perez, L; Sayour, EJ; Schmittling, RJ | 1 |
| Boockvar, JA; Brüning, A; Cappello, F; Chang, WW; Cvek, B; Dou, QP; Duenas-Gonzalez, A; Efferth, T; Focosi, D; Ghaffari, SH; Halatsch, ME; Karpel-Massler, G; Kast, RE; Keizman, D; Ketola, K; Khoshnevisan, A; Magné, N; Marosi, C; McDonald, K; Muñoz, M; Paranjpe, A; Pourgholami, MH; Sardi, I; Sella, A; Srivenugopal, KS; Tuccori, M; Wang, W; Wirtz, CR | 1 |
| Gonzales, DM; Jasmin, JF; Lisanti, MP; Mercier, I; Pestell, RG; Quann, K; Sotgia, F; Wang, C | 1 |
| Alexander, BM; Ligon, KL; Wen, PY | 1 |
| Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW | 1 |
| Bar, EE; Chu, Q; Eberhart, CG; Orr, BA; Semenkow, S | 1 |
| Garside, R; Grant, R; Hart, MG; Rogers, G; Stein, K | 1 |
| Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S | 1 |
| Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; Peters, KB; Reardon, DA; Sumrall, AL; Turner, S; Vredenburgh, JJ | 1 |
| Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C | 1 |
| Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Bischoff, P; Burckel, H; Josset, E; Noël, G | 1 |
| Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M | 1 |
| Alksne, JF; Carter, BS; Chen, CC; Gonda, DD; Lawson, J; Murphy, K; Rose, B; Russell, M; Scanderbeg, DJ; Waters, JD | 1 |
| Chen, SE; Choi, SS; De Groot, JF; Lei, X; Rogers, JE | 1 |
| Bechter, OE; Clement, PM; De Vleeschouwer, S; Demaerel, P; Geussens, Y; Menten, J; Sciot, R; Van Calenbergh, F; Van Gool, S; Van Mieghem, E; Wilms, G; Wozniak, A | 1 |
| Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H | 1 |
| Dunst, M; Huber, HJ; Kilbride, SM; Kögel, D; Mittelbronn, M; Murphy, ÁC; Murphy, BM; Prehn, JH; Rehm, M; Schmid, J; Seifert, V; Senft, C; Weissenberger, J; Weyhenmeyer, B | 1 |
| Abramson, JS; Batchelor, TT; Clark, SW; Taylor, J; Wang, DL | 1 |
| Cao, B; Dhruv, H; Eschbacher, JM; Kloss, J; Loftus, JC; Ross, JT; Schumacher, CA; Tran, NL; Tuncali, S; Williams, BO; Yang, Z | 1 |
| Fedulau, AS; Furuyama, N; Hamada, J; Hayashi, Y; Kawakami, K; Minamoto, T; Nakada, M; Pyko, IV; Sabit, H; Teng, L | 1 |
| Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M | 1 |
| Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, KO; Ney, D; Reddy, K; Waziri, A | 1 |
| Cuperlovic-Culf, M; Morin, P; St-Coeur, PD; Touaibia, M | 1 |
| Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L | 1 |
| Classen, CF; Linnebacher, M; Mullins, CS; Schneider, B; Schubert, J | 1 |
| Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ | 1 |
| Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Allavena, G; Angeletti, F; Comincini, S; Durando, F; Miracco, C; Morini, M; Palumbo, S; Pirtoli, L | 1 |
| Arranz, JL; Balañá, C; Benavides, M; Bugés, C; Cano, JM; de la Peñas, R; García-Bueno, JM; Gil, M; Lopez, D; Martin, JM; Molina-Garrido, MJ; Perez-Segura, P; Rodriguez, A; Sanz, SM; Sepúlveda, JM; Vaz, MA | 1 |
| Ayad, NG; Bregy, A; Clarke, J; Komotar, RJ; Pastori, C; Penas, C; Shah, AH; Wahlestedt, C | 1 |
| Brabletz, S; Brabletz, T; Deleyrolle, LP; Devers, KG; Kladde, MP; Kupper, MD; Nabilsi, NH; Neal, D; Reynolds, BA; Sarkisian, MR; Siebzehnrubl, D; Siebzehnrubl, FA; Silver, DJ; Steindler, DA; Suslov, O; Tugertimur, B; Yachnis, AT | 1 |
| Caroli, M; Condomitti, G; Di Vito, C; Galli, R; Giussani, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P | 1 |
| Shi, L; Sun, G; Wan, Y; Wang, Z; Zhang, S | 1 |
| Chunta, JL; Grills, IS; Huang, J; Krueger, SA; Lee, DY; Marples, B; Martinez, AA; Park, SS; Wilson, GD | 1 |
| Qi, XC; Qian, C; Wang, YR; Xie, DJ; Yan, QF; Yang, SX; Zhu, YX | 1 |
| Shi, L; Sun, G; Wan, Y; Wang, Z; Zeng, Y; Zhang, S | 1 |
| Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S | 1 |
| Li, C; Li, X; Liu, X; Yan, B; Zhang, Q; Zhou, H | 1 |
| Blume, C; Boström, J; Greschus, S; van Landeghem, F; von Lehe, M | 1 |
| Brassesco, MS; Carlotti, CG; de Oliveira, JC; de Paula Queiroz, RG; Machado, HR; Morales, AG; Neder, L; Pezuk, JA; Scrideli, CA; Tone, LG | 1 |
| Dilnawaz, F; Sahoo, SK | 1 |
| Annovazzi, L; Bosia, A; Caldera, V; Campia, I; Ghigo, D; Kopecka, J; Mellai, M; Riganti, C; Salaroglio, IC; Schiffer, D | 1 |
| Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P | 1 |
| Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S | 1 |
| Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F | 1 |
| Boothman, DA; Burma, S; Chakraborty, S; Cochran, B; Habib, AA; Li, L; Puliyappadamba, VT; Raisanen, J; Tang, H; Wu, J; Xie, Y | 1 |
| Chen, B; Chen, L; Chen, X; Jiang, T; Li, S; Wang, J; Wang, L; Wang, Y; Wu, C; Zhang, X; Zhang, Z | 1 |
| Aboody, KS; Ahmed, AU; Auffinger, B; Balyasnikova, IV; Han, Y; Kim, CK; Lesniak, MS; Rincón, E; Thaci, B; Tobias, AL; Zhang, L | 1 |
| Hay, JW; Messali, A; Villacorta, R | 2 |
| Camphausen, K; Fine, HA; Ho, J; Iwamoto, F; Kim, L; Krauze, A; Kreisl, T; McNeil, K; Ning, H; Ondos, J; Shankavaram, U; Smith, S; Sul, J | 1 |
| Carter, AF; DeTroye, AT; Harmon, MS; Lesser, GJ; Morrell, RM; Tooze, JA | 1 |
| Classen, CF; Krohn, M; Linnebacher, M; Mullins, CS; Schneider, B; Stockhammer, F | 1 |
| Fenton, E; Khalil, A; Molnar, P; Sattar, MT; Zakaria, Z | 1 |
| Eich, M; Kaina, B; Nikolova, T; Roos, WP | 1 |
| Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M | 1 |
| Alitto, AR; Anile, C; Balducci, M; Chiesa, S; Colosimo, C; D'Agostino, GR; De Bonis, P; Fiorentino, A; Frascino, V; Mangiola, A; Mantini, G; Mattiucci, GC; Valentini, V | 1 |
| Kuo, LT; Lin, LW; Tsai, SY; Yang, CY | 1 |
| Al-Zahrani, A; Atenafu, E; Laperriere, N; Lwin, Z; MacFadden, D; Mason, WP; Menard, C; Miller, BA; Sahgal, A | 1 |
| Behm, T; Bock, HC; Horowski, A; Mielke, D; Rohde, V; Schneider, S; Stockhammer, F | 1 |
| Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Michaelsen, SR; Poulsen, HS; Stockhausen, MT | 1 |
| Aboukais, R; Assaker, R; Maurage, CA; Zairi, F | 1 |
| Decrey, G; Eisele, G; Weller, M; Wolpert, F | 1 |
| Bellyei, S; Boronkai, A; Cseh, A; Hocsak, E; Pozsgai, E; Racz, B; Sumegi, B; Szabo, A | 1 |
| Darefsky, AS; Dubrow, R; Jacobs, DI; King, JT; Laurans, MS; Park, LS; Rose, MG | 1 |
| Cheng, WY; Chiang, IP; Chiang, SF; Chiou, SH; Chow, KC; Huang, CY; Lin, JC; Lin, TY; Shen, CC; Shieh, SH; Sudhakar, JN; Yang, CL; You, WC | 1 |
| Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F | 1 |
| Cong, ZX; Pan, H; Wang, HD; Wang, JW; Zhang, DD; Zhang, L; Zhou, Y; Zhu, L | 1 |
| Cheng, JX; Dong, Y; Han, N; Liu, BL; Yin, AA; Zhang, LH; Zhang, X | 1 |
| Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J | 1 |
| Aldape, KD; Armstrong, TS; Baumert, B; Blumenthal, DT; Brown, PD; Chakravarti, A; Curran, WJ; Erridge, S; Gilbert, MR; Hegi, ME; Hopkins, KI; Jaeckle, KA; Mahajan, A; Mehta, MP; Schultz, CJ; Stupp, R; Tzuk-Shina, T; Wang, M; Wefel, JS; Won, M | 1 |
| Armstrong, TS; Bottomley, A; Brachman, DG; Choucair, AK; Coens, C; Gilbert, MR; Mehta, M; Mendoza, TR; Wang, M; Wefel, JS; Werner-Wasik, M; Won, M | 1 |
| Clark, B; Mackinnon, M; Martin, S; Nowicki, S; Owusu-Agyemang, K; Paul, J; St George, J; Stewart, W; Teo, M | 1 |
| Kim, SS; Kim, SY; Lim, SH; Seong, S | 1 |
| Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Fusco, V | 1 |
| Han, G; Hu, X; Li, Y; Liu, J; Wang, L; Yue, Z; Zhao, R; Zhao, W; Zhou, X | 1 |
| Aldave, G; de Gallego, J; Díez-Valle, R; Domínguez, PD; Gállego Pérez-Larraya, J; Marigil, M; Tejada, S | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC | 1 |
| Chonan, M; Jokura, H; Kanamori, M; Katakura, R; Kato, H; Kawagishi, J; Kawaguchi, T; Kayama, T; Kumabe, T; Mano, Y; Saito, R; Shibahara, I; Sonoda, Y; Tominaga, T; Watanabe, M; Yamashita, Y | 1 |
| Al-Nuaimi, SK; Alnaami, IM; Gourishankar, S; Mehta, V; Murtha, AD; Senthilselvan, A; Walling, S | 1 |
| Cai, S; Cheng, JX; Dong, Y; Liu, BL; Yin, AA; Zhang, LH; Zhang, X | 1 |
| Beal, K; Chan, TA; Folkert, M; Gutin, PH; Pentsova, E; Spratt, DE; Yamada, Y; Zumsteg, ZS | 1 |
| Ancukiewicz, M; Batchelor, TT; Chi, AS; Dietrich, J; Duda, DG; Eichler, AF; Emblem, KE; Gerstner, ER; Hochberg, FH; Iafrate, AJ; Ivy, SP; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Loeffler, JS; Lu-Emerson, C; Pinho, MC; Plotkin, SR; Polaskova, P; Rosen, BR; Snuderl, M; Sorensen, AG; Wen, PY | 1 |
| Alonso-Basanta, M; Dorsey, JF; Fang, P; Hahn, SM; Lustig, RA; Maity, A | 1 |
| Back, M; Guo, L; Gzell, C; Kastelan, M; Wheeler, H | 2 |
| Chamberlain, MC | 11 |
| Chen, JX; Liu, JP; Liu, YH; Mao, Q; Wang, X; You, C | 1 |
| Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y | 1 |
| Arita, K; Furukawa, T; Hirano, H; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Shinsato, Y; Tokimura, H; Yamamoto, M; Yonezawa, H; Yunoue, S | 1 |
| Cloughesy, TF; Liau, LM; Liu, Y; McBride, W; Menjivar, JC; Mischel, PS; Nelson, SF; Schaue, D; Tian, JY; Tso, CL; Tso, JL; Yamada, K; Ye, F; Yong, WH; Zhang, Y | 1 |
| Nagaishi, M; Nakano, T; Nakazato, Y; Noda, SE; Oike, T; Shirai, K; Sugawara, K; Suzuki, Y; Tamaki, T; Yokoo, H | 1 |
| Chen, P; Hu, Y; Hyytiäinen, M; Keski-Oja, J; Li, H; Li, L; Ylivinkka, I | 1 |
| Cerhova, J; Chakravarti, A; Engellandt, K; Geiger, KD; Juratli, TA; Krex, D; Lautenschlaeger, T; Schackert, G; von Kummer, R | 1 |
| Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M | 1 |
| Chang, PY; Chou, KN; Lin, YC; Liu, MY | 1 |
| Cloughesy, TF; Ellingson, BM; Harris, RJ; Lai, A; Li, S; Nghiemphu, PL; Pope, WB; Teixeira, S; Tran, AN; Woodworth, DC | 1 |
| Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY | 1 |
| Chang, S; Costello, JF; Fouse, SD; James, CD; Nakamura, JL | 1 |
| Kayama, T; Kitanaka, C; Narita, Y; Okada, M; Sato, A; Seino, M; Seino, S; Shibui, S; Shibuya, K; Suzuki, S; Watanabe, E | 1 |
| Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G | 1 |
| Chung, H; Jo, S; Kim, IC; Kim, S; Kim, TU; Lee, H; Yim, JH | 1 |
| Balañà, C; Comas, S; Villà, S | 1 |
| Lin, ZX; Yang, LJ; Zhou, CF | 1 |
| Abrey, L; Das, A; Han, K; Jin, J; Reardon, DA; Ren, M; Wick, W | 1 |
| Bagó, A; Bajcsay, A; Fedorcsák, I; Kásler, M; Lövey, J; Mangel, L; Sipos, L | 1 |
| Bazsó, P; Fekete, Z; Kiss, E; Lahm, E; Nagy, P; Pápai, Z; Takácsi-Nagy, Z; Vachaja, J | 1 |
| Boothman, DA; Burma, S; Chakraborty, S; Habib, AA; Hatanpaa, KJ; Koduru, P; Li, L; Puliyappadamba, VT; Rehman, A; Saha, D; Souza, RF; Vemireddy, V | 1 |
| Bachoo, R; Burma, S; Gao, X; Gil del Alcazar, CR; Habib, AA; Hardebeck, MC; Li, L; Mukherjee, B; Tomimatsu, N; Xie, XJ; Yan, J | 1 |
| Gabel, D; Sander, A; Wosniok, W | 1 |
| Ammirati, M; Chotai, S; Grecula, J; Lamki, T; Newton, H; Wei, L | 1 |
| Dhermain, F | 1 |
| Casaubon, LK; Mason, WP; Petrescu, N; Tsai, JP | 1 |
| Balañà, C; Capdevila, L; Carrato, C; Cros, S; Cuadra, JL; Etxaniz, O; Hostalot, C; Massuet, A; Ramirez, JL; Romeo, M; Sanz, C; Villà, S | 1 |
| Balzarini, L; Mancini, C; Marvisi, M | 1 |
| Ali, AN; Crocker, IR; Curran, WJ; Hardy, CW; Ogunleye, T; Shu, HK | 1 |
| Dubus, P; Figarella-Branger, D; Ichimura, K; Karayan-Tapon, L; Lavenu, A; Legrain, M; Mosser, J; Quillien, V; Sanson, M | 1 |
| Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W | 1 |
| Boros, S; Cato, K; Donovan, P; Hall, B; Harding, A; Jayalath, R; Legaie, R; Olson, S; Olsson, G; Reynolds, BA | 1 |
| Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C | 1 |
| Bardin, AL; Carson-Walter, E; Cui, W; Folts, CJ; Noble, M; Stevens, BM; Vescovi, A; Walter, K | 1 |
| Howard, S; Ian Robins, H; Magnuson, W; Mohindra, P | 1 |
| Bernstein, M; Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Templeton, AJ; Zadeh, G | 1 |
| Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Sahgal, A | 1 |
| Adamson, DC; Di, C; Fee, BE; Kang, C; Lin, J; Rivas, M; Zeng, L | 1 |
| Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S | 1 |
| Boots-Sprenger, SH; Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Tannous, BA; Teng, J; Tops, B; Vandertop, WP; Wesseling, P; Wurdinger, T | 1 |
| Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K | 1 |
| Ahlzadeh, GE; Candolfi, M; Castro, MG; Ghiasi, H; Kamran, N; Lowenstein, PR; Paran, C; Puntel, M; Wibowo, M; Yagiz, K | 1 |
| Cloughesy, TF; Kornblum, HI; Laks, DR; Lasky, JL; Lee, WN; Lin, HJ; Moore, TB; Pak, Y; Panosyan, EH; Wang, Y; Xia, P | 1 |
| Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR | 1 |
| Bynevelt, M; Lau, PK; Lee, G; Nowak, AK | 1 |
| Deenen, R; Florea, AM; Frei, K; Happold, C; Lamszus, K; Reifenberger, G; Roth, P; Silginer, M; Weller, M | 1 |
| Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T | 1 |
| Abrey, L; Brandes, AA; Carpentier, AF; Cernea, D; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Hoang-Xuan, K; Kavan, P; Mason, W; Nishikawa, R; Saran, F; Wick, W | 1 |
| Aldape, KD; Armstrong, TS; Blumenthal, DT; Brachman, DG; Brown, PD; Chakravarti, A; Colman, H; Curran, WJ; Dignam, JJ; Gilbert, MR; Jaeckle, KA; Jeraj, R; Mehta, MP; Pugh, S; Schiff, D; Stieber, VW; Sulman, EP; Tremont-Lukats, IW; Vogelbaum, MA; Wefel, JS; Werner-Wasik, M; Won, M | 1 |
| Fine, HA | 1 |
| Jee, TK; Kong, DS; Lee, JI; Nam, DH; Oh, SW; Seol, HJ | 1 |
| Bakó, G; Barzó, P; Bognár, L; Daróczi, B; Hideghéty, K; Mózes, P; Szántó, E; Szántó, J; Tóth, J | 1 |
| Allen, JE; Berg, A; Cheng, Y; Connor, J; El-Deiry, WS; Huang, SY; Liu, CG; Liu, X; Lu, Z; Ren, X; Webb, BS; Yang, JM; Yang, W; Yuan, Y; Zhang, L; Zhang, Y | 1 |
| Dolan, ME; Godley, LA; Moen, EL; Stark, AL; Zhang, W | 1 |
| Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y | 1 |
| Cui, Y; Lei, Q; Li, G; Luo, Z; She, X; Wang, Z; Wu, M; Xu, G; Yu, Z | 1 |
| Archinet, A; Badaoui, N; Bauchet, L; Cartalat-Carel, S; d'Hombres, A; Ducray, F; Frappaz, D; Guyotat, J; Honnorat, J; Jouanneau, E; Jouvet, A; Louis-Tisserand, G; Meyronet, D; Sunyach, MP | 1 |
| Arvold, ND; Reardon, DA | 1 |
| Caiafa, P; Calabrese, R; Ciccarone, F; Graziani, G; Muzi, A; Pallini, R; Pelacchi, F; Ricci-Vitiani, L; Runci, D; Tentori, L | 1 |
| Borawska, MH; Markiewicz-Zukowska, R; Moskwa, J; Naliwajko, SK; Puscion-Jakubik, A; Socha, K; Soroczynska, J | 1 |
| Ahmed, AU; Auffinger, B; Dey, M; Guo, D; Han, Y; Lee, G; Lesniak, MS; Tobias, AL | 1 |
| Wachtel, MS; Yang, S | 1 |
| Davis, T; Felsberg, J; Gramatzki, D; Hentschel, B; Kaulich, K; Loeffler, M; Pietsch, T; Reifenberger, G; Schackert, G; Simon, M; Tonn, JC; von Deimling, A; Weiss, WA; Weller, M; Westphal, M | 1 |
| Bachoo, RM; Hatanpaa, KJ; Maher, EA; Mashimo, T; Mickey, BE; Pan, E; Sagiyama, K; Sherry, AD; Takahashi, M; Togao, O; Vemireddy, V | 1 |
| Barnett, KD; Brown, SL; deCarvalho, AC; Ecsedy, JA; Hong, X; Lehman, NL; Mikkelsen, T; O'Donnell, JP; Pearl, DK; Salazar, CR; Van Brocklyn, JR | 1 |
| Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE | 1 |
| Malkki, H | 1 |
| Chen, J; Fu, X; Jiang, D; Shi, L; Wan, Y; Wang, Z | 1 |
| Beijnen, JH; Beumer, JH; Buil, LC; Christner, SM; de Gooijer, MC; Lin, F; Roig, EM; van Tellingen, O; Würdinger, T | 1 |
| Elicin, O; Inac, E; Karacam, S; Uzel, EK; Uzel, OE | 1 |
| Greco, SJ; Ligon, KL; Munoz, JL; Rameshwar, P; Ramkissoon, SH; Rodriguez-Cruz, V | 2 |
| Buslei, R; Derer, A; Fietkau, R; Frey, B; Gaipl, US; Muth, C; Rubner, Y; Sieber, R; Strnad, A | 1 |
| Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L | 1 |
| Drappatz, J; Hamilton, RL; Laymon, CM; Lieberman, FS; Mountz, JM; Oborski, MJ | 1 |
| Bekar, A; Berghoff, AS; Budak, F; Cecener, G; Egeli, U; Kocaeli, H; Preusser, M; Ricken, G; Taskapılıoglu, MO; Tezcan, G; Tolunay, S; Tunca, B | 1 |
| Allavena, G; Angeletti, F; Comincini, S; Manai, F; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M | 1 |
| Ghosh, S; Ifediba, MA; Medarova, Z; Moore, A; Yoo, B | 1 |
| Choi, SH; Han, TJ; Kim, IH; Kim, TM; Lee, SH; Lim, YJ; Paek, SH; Park, CK; Park, SH | 1 |
| Reardon, DA; Wen, PY | 1 |
| Benoit, JP; Boesen, K; Lagarce, F; Messaoudi, K; Saulnier, P | 1 |
| Clark, PA; Cong, D; Hu, S; Kuo, JS; Pointer, KB; Shen, H; Shi, Y; Sun, D; Zhu, W | 1 |
| Perry, JR | 1 |
| Al-Zahrani, A; Coate, L; Laperriere, N; Lwin, Z; Macfadden, D; Mason, WP; Massey, C; McNamara, MG; Menard, C; Millar, BA; Sahgal, A | 1 |
| Cohen, MS; Grogan, PT; Sarkaria, JN; Timmermann, BN | 1 |
| Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I | 1 |
| Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY | 1 |
| Aldape, K; Armstrong, TS; Curran, WJ; Dignam, J; Gilbert, MR; Hegi, M; Mehta, MP; Pugh, S; Stupp, R; Wefel, JS; Won, M | 1 |
| Al Aswy, H; Berthois, Y; Boudouresque, F; Delfino, C; Fina, F; Metellus, P; Nanni-Metellus, I; Ouafik, L; Pirisi, V | 1 |
| Borisova, LM; Ermakova, KV; Kiselyova, MP; Kubasova, IY; Luk'yanets, EA; Meerovich, GA; Oborotova, NA; Smirnova, ZS | 1 |
| Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC | 1 |
| Bandey, I; Chiou, SH; Huang, AP; Tsai, JC; Tu, PH | 1 |
| Biffoni, M; De Majo, M; De Maria, R; di Martino, S; Giannetti, S; Larocca, LM; Morgante, L; Pallini, R; Pelacchi, F; Petricoin, EF; Ricci-Vitiani, L; Runci, D; Signore, M; Stancato, L | 1 |
| Chang, EH; Dagata, JA; Farkas, N; Kim, E; Kim, SS; Nishida, M; Pirollo, KF; Rait, A | 1 |
| Anderson, JC; Bonner, JA; Bredel, M; Choradia, NV; Duarte, CW; Rohrbach, TD; Thottassery, JV; Welaya, K; Willey, CD; Yancey Gillespie, G; Yang, ES | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Sugino, T; Yamaguchi, K | 1 |
| Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA | 1 |
| Gao, X; Li, XM; Li, ZQ; Liang, GB; Luo, LH; Song, ZQ; Su, JY; Zhu, TZ | 1 |
| Akiyama, Y; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Oshita, C; Sugino, T; Yamaguchi, K | 1 |
| Gabor Miklos, GL; Haines, IE | 1 |
| Chinot, OL; Cloughesy, T; Wick, W | 1 |
| Cao, P; Li, XM; Liang, GB; Liu, Y; Luo, LH; Xu, YH; Zhu, TZ | 1 |
| Gergel, T; Lacroix, M; Toms, SA; Turner, SG; Wu, H | 1 |
| Baumgartner, U; Glück, A; Haemmig, S; Kappeler, A; Mariani, L; Tschan, MP; Vajtai, I; Vassella, E; Zbinden, S | 1 |
| Lan, Q; Li, RJ; Sang, DP | 1 |
| Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM | 1 |
| Bai, Y; Flavahan, W; Lathia, JD; Mattson, MP; Rich, JN; Zhang, P | 1 |
| Clementi, E; Corti, M; Guari, Y; Larionova, J; Lascialfari, A; Nano, R; Orlando, T; Paolini, A; Pasi, F; Pineider, F; Sacchi, L | 1 |
| Rovere, RK | 1 |
| Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Raktoe, RS; Vandertop, WP; Wesseling, P; Wurdinger, T | 1 |
| Ho, AS; Kiang, KM; Lee, D; Leung, GK; Sun, S; Xu, FF; Zhang, XQ | 1 |
| Linn, J | 1 |
| Ladizinski, B; Sankey, C | 1 |
| Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K | 1 |
| Anderson, CM; Bayouth, JE; Buatti, JM; Capizzano, AA; Clerkin, PP; Magnotta, V; McGuire, SM; Morris, A; Muruganandham, M; Smith, BJ; Smith, MC | 1 |
| Amaravadi, RK; Brem, S; Chang, YC; Davis, LE; Desideri, S; Fisher, J; Grossman, SA; Heitjan, DF; Hu, J; McAfee, Q; Mikkelson, T; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rosenfeld, MR; Supko, JG; Tan, KS; Troxel, AB; Wang, D; Ye, X | 1 |
| Abe, T; Hashimoto, K; Ikuta, S; Ishihara, T; Ishikawa, E; Karasawa, K; Maruyama, T; Matsuda, M; Matsumura, A; Matsutani, M; Muragaki, Y; Nakazato, Y; Ohno, T; Tsuboi, K; Uemae, Y; Yamamoto, T | 1 |
| Fields, B; Macomson, S; Mansour, J; Rixe, O | 1 |
| Cui, Y; Lei, Q; Li, G; She, X; Wang, Z; Wu, M; Xiang, J; Xu, G; Yu, Z | 1 |
| Bressler, LR; Gabay, MP; Letarte, N; Long, KE; Stachnik, JM; Villano, JL | 1 |
| Ang, AL; See, SJ; Tan, CW; Tham, CK | 1 |
| Bloch, O; Oh, T; Parsa, AT; Rutkowski, MJ; Safaee, M; Sayegh, ET; Sun, MZ; Tihan, T | 1 |
| Figg, WD; Goey, AK | 1 |
| Hu, X; Shao, J; Wang, L; Wen, C; Yin, H; You, C; Zhang, W; Zhou, C; Zhou, Y | 1 |
| Greco, SJ; Munoz, JL; Nagula, V; Rameshwar, P; Rodriguez-Cruz, V; Scotto, KW | 1 |
| Azadi, J; Bow, H; Brem, H; Hutt-Cabezas, M; Hwang, L; Joshi, A; Mangraviti, A; Martin, KL; Rudek, MA; Tyler, BM; Wicks, RT; Zhang, I; Zhao, M | 1 |
| Cocuzza, P; Fabbrini, MG; Fatigante, L; Ferrazza, P; Monzani, F; Pasqualetti, F; Pasqualetti, G | 1 |
| Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S | 1 |
| Chinot, O; Delattre, JY; Hoang-Xuan, K; Idbaih, A; Loundou, A; Sanson, M; Tabouret, E | 1 |
| Capelli, E; Di Liberto, R; Nano, R; Paolini, A; Pasi, F | 1 |
| Agnihotri, S; Barszczyk, MS; Buczkowicz, P; Burrell, K; Chornenkyy, Y; Clarke, ID; Dirks, PB; Fernandez, NA; Gajadhar, A; Golbourn, B; Hawkins, C; Head, R; Jones, C; Pajovic, S; Remke, M; Rutka, JT; Sabha, N; Sobol, RW; Taylor, MD; Ternamian, C; Zadeh, G | 1 |
| Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR | 1 |
| Akimoto, J; Narita, Y; Oka, H; Tanaka, S; Tashiro, T | 1 |
| Abrey, LE; Barradas-Panchal, R; Baser, RE; Beal, K; Brennan, CW; Chan, TA; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, C; Gutin, P; Hormigo, A; Huse, JT; Kaley, TJ; Karimi, S; Lassman, AB; Mellinghoff, I; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Reiner, AS; Sanchez, J; Tabar, V; Zhang, J | 1 |
| Baklaushev, VP; Chekhonin, VP; Golanov, AV; Gorlachev, GE; Goryainov, SA; Gubskii, IL; Gurina, OI; Kobyakov, GL; Konovalov, AN; Potapov, AA; Yusubalieva, GM; Zorkina, YA | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Akers, J; Bao, ZS; Carter, B; Chen, CC; Chen, HM; Fan, XL; Hu, BQ; Hu, HM; Jiang, T; Kang, CS; Li, J; Li, MY; Li, RQ; Liu, YW; Qiu, XG; Ramakrishnan, V; Song, WS; Su, XD; Wang, Z; Yan, W; Yang, MY; Yao, K; Ye, WL; You, YP; Yu, K; Zhang, CB; Zhang, W | 1 |
| Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S | 1 |
| Galldiks, N; Goldbrunner, R; Hamisch, C; Kickingereder, P; Kocher, M; Ruge, MI; Suchorska, B; Treuer, H; Visser-Vandewalle, V; Voges, J | 1 |
| Chinot, OL | 1 |
| Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T | 1 |
| Armoiry, X; Aulagner, G; Breant, V; Cartalat-Carel, S; Diebold, G; Ducray, F; Fouquet, A; Frappaz, D; Guyotat, J; Henaine, AM; Honnorat, J | 1 |
| Aiken, R | 1 |
| Ashary, A; Cabrera-Aldana, EE; Chaichana, KL; Gokaslan, A; Jusue-Torres, I; Lemos, AM; Olivi, A; Quinones-Hinojosa, A | 1 |
| Arús, C; Candiota, AP; Delgado-Goñi, T; Julià-Sapé, M; Pumarola, M | 1 |
| Chakravarti, A; Chu, Z; Denton, N; Dmitrieva, N; Hardcastle, J; Jacob, NK; Kaur, B; Kwon, CH; Marsh, R; Meisen, WH; Qi, X; Thorne, AH; Van Meir, EG; Wojton, J | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE | 2 |
| Bekar, A; Bilir, A; Budak, F; Cecener, G; Demir, C; Egeli, U; Erkan, LG; Evrensel, T; Guvenc, G; Malyer, H; Sahin, S; Taskapilioglu, MO; Tezcan, G; Tunca, B; Yalcin, M; Yilmaz, G | 1 |
| Adeberg, S; Bostel, T; Combs, SE; Debus, J; Harrabi, S; König, L; Welzel, T | 1 |
| Aubry, M; Boniface, R; de Tayrac, M; Delattre, JY; Etcheverry, A; Figarella-Branger, D; Idbaih, A; Karayan-Tapon, L; Marie, Y; Menei, P; Mosser, J; Quillien, V; Sanson, M; Vauleon, E | 1 |
| Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK | 1 |
| Chang, EH; Kim, E; Kim, SS; Pirollo, KF; Rait, A | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Brennan, CW; DeAngelis, LM; Omuro, AM; Thomas, AA | 1 |
| Cheng, Z; Gao, Z; Guo, H; Shen, X; Wu, L; Xiong, Y; Yang, L; Zhang, Y; Zhu, X | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Huber, KM; Jain, AK; Kavitha, CV; Keating, A; Pierce, A; Serkova, NJ; Wempe, MF | 1 |
| Choi, J; Kopp-Schneider, A; Noack, J; Régnier-Vigouroux, A; Richter, K | 1 |
| Chen, D; Mohamad, O; Song, M; Yu, SP | 1 |
| Bartosiuk, E; Borawska, MH; Kochanowicz, J; Mariak, Z; Markiewicz-Żukowska, R; Moskwa, J; Naliwajko, SK; Socha, K; Surażyński, A | 1 |
| Badiyan, SN; Chicoine, MR; Dacey, R; DeWees, T; Dowling, JL; Huang, J; Jalalizadeh, R; Kim, AH; Leuthardt, EC; Linette, G; Markovina, S; Rich, KM; Robinson, CG; Simpson, JR; Tran, DD; Zipfel, GJ | 1 |
| Chun, W; Kim, SS; Lee, HJ; Lee, JW; Lim, SY; Vo, VA | 1 |
| Bradshaw, TD; Hummersone, M; Matthews, CS; Stevens, MF; Zhang, J | 1 |
| Costea, DE; Enger, PØ; Huang, B; Leiss, L; Li, X; Liang, X; Sakariassen, PØ; Skaftnesmo, KO; Wang, J; Yan, T; Yang, N; Zhu, H | 1 |
| Barnes, PD; Bubalo, J; Fu, R; Gahramanov, S; Lacy, C; Nasseri, M; Neuwelt, AJ; Neuwelt, EA; Nguyen, TM; Tyson, RM | 1 |
| Chang, YZ; Chen, CM; Hsieh, TY; Hung, HC; Liao, CL; Lin, CL; Liu, GY | 1 |
| Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H | 1 |
| Arita, K; Bakhtiar, Y; Fujio, S; Habu, M; Hanaya, R; Hiraki, Y; Hirano, H; Kawano, H; Ogita, M; Oyoshi, T; Sugata, S; Tokimura, H; Uchida, H; Yamahata, H; Yatsushiro, K; Yonezawa, H; Yunoue, S | 1 |
| Nam, DH; Park, C; Yeom, SY | 1 |
| Fei, Z; He, X; Liu, W; Wang, Y | 1 |
| Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Stechishin, OD; Weiss, S | 1 |
| Chaumeil, MM; Gaensler, K; Ito, M; Jalbert, LE; Mukherjee, J; Nelson, SJ; Park, I; Pieper, RO; Ronen, SM | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ | 1 |
| Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q | 1 |
| Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT | 1 |
| Barnholtz-Sloan, JS; Bauchet, L; Woehrer, A | 1 |
| Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE | 1 |
| Hsieh, CH; Lee, HT; Lin, YJ; Shyu, WC; Wang, CC; Wu, CP | 1 |
| Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J | 1 |
| Berger, MS; Bollen, AW; Breshears, JD; Cotter, JA; Ivan, ME; Theodosopoulos, PV | 1 |
| Guo, H; Guo, M; Wang, Y; Yang, L | 1 |
| Archer, G; DeLeon, G; Desjardins, A; Friedman, AH; Friedman, HS; Mitchell, DA; Norberg, P; Reap, E; Sampson, JH; Sayour, EJ; Schmittling, R | 1 |
| Schiff, D; Taylor, JW | 1 |
| Cobbs, C; Schroeder, B; Shah, N | 1 |
| Fan, TY; Lei, BX; Li, HZ; Liu, YW; Qi, ST; Wang, H; Xiang, P; Yu, M | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Ryoo, I; Sohn, CH; Yun, TJ | 1 |
| Daniele, S; Martini, C; Natali, L; Trincavelli, ML; Zappelli, E | 1 |
| Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S | 1 |
| Adeyi, O; Fung, S; Mason, M; Millar, BA | 1 |
| Bu, G; Li, M; Li, W; Zhao, Y; Zhou, B; Zhou, Y | 1 |
| Chen, TC; Cho, HY; Golden, EB; Hofman, FM; Jahanian, A; Louie, SG; Schönthal, AH | 1 |
| Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G | 1 |
| Arcella, A; Bozzao, A; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Scaringi, C; Terrenato, I | 1 |
| Cai, Q; Chen, Q; Ding, J; Dong, H; He, Y; Ji, B; Liu, B; Tian, D; Wang, J; Wang, L; Wu, L; Yuan, X; Zhang, S; Zhu, X | 1 |
| Iwamoto, FM; Lassman, AB | 1 |
| Silvestris, F; Stucci, S; Tucci, M | 1 |
| Picard, M; Stupp, R; Weller, M | 1 |
| Asslaber, M; Bruckmann, L; Hoffermann, M; Kariem Mahdy, A; Payer, F; von Campe, G | 1 |
| Alder, JE; Boissinot, M; Droop, A; Hayes, J; Hughes, TA; Lawler, SE; Shaw, L; Short, SC; Thygesen, H; Tumilson, C; Westhead, D | 1 |
| Debatin, KM; Dwucet, A; Halatsch, ME; Hlavac, M; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Siegelin, MD; Welscher, N; Westhoff, MA; Wirtz, CR | 1 |
| Carlson, JA; Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, KO; Ney, DE; Reddy, K; Waziri, AE | 1 |
| Anderson, SK; Brown, PD; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Ligon, KL; Ma, DJ; McGraw, S; Peller, PJ; Sarkaria, JN; Schiff, D; Uhm, JH | 1 |
| Begini, P; Delle Fave, G; Gallina, S; Marignani, M; Minniti, G; Purchiaroni, F | 1 |
| Cai, T; Fang, J; Gong, C; Liu, Q; Tan, C; Wang, Z; Zhou, R; Zou, R | 1 |
| Battastini, AM; Bishop, AJR; Braganhol, E; Bristot, IJ; Figueiró, F; Forcelini, CM; Gelain, DP; Klafke, K; Moreira, JCF; Morrone, M; Paludo, FJ; Terra, SR; Zanotto-Filho, A | 1 |
| Escalon, E; Lollett, IV; Melnick, SJ; Quirin, KW; Ramachandran, C | 1 |
| Bochenek-Cibor, J; Krupa, M; Moskała, M; Trojanowski, T | 1 |
| Cartron, PF; Cheray, M; Nadaradjane, A; Pacaud, R; Vallette, FM | 1 |
| Balça-Silva, J; do Carmo, A; Girão, H; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB | 1 |
| Bader, GD; Bayani, J; Bernstein, M; Clarke, ID; Cusimano, M; Dirks, PB; Head, R; Kushida, M; Lan, X; Lionel, AC; Meyer, M; Pressey, JC; Reimand, J; Scherer, SW; Squire, JA; Woodin, MA; Zhu, X | 1 |
| Reijneveld, JC; Richel, DJ; Stalpers, LJ; van Furth, WR; van Linde, ME; Verheul, HM; Verhoeff, JJ | 1 |
| Chen, L; Li, X; Liu, L; Liu, Y; Xue, Y; Yu, B | 1 |
| Chen, S; Cheng, Y; Deng, J; Liang, P; Wang, F; Xie, Z; Xu, Z; Zhai, X; Zhang, Q; Zhao, H | 1 |
| Archer, GE; Baehring, JM; Bigner, DD; Cruickshank, S; Davis, TA; Green, JA; Groves, MD; Heimberger, AB; Jensen, R; Keler, T; Lai, RK; Mrugala, MM; Paleologos, NA; Reardon, DA; Recht, LD; Sampson, JH; Schuster, J; Sloan, A | 1 |
| Kim, HR; Kim, KH; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Seol, HJ | 1 |
| Basu, A; Basu, P; Basu, SK; Bhattacharya, RN; Biswas, NK; Chandra, V; Chatterjee, A; Chattopadhyay, A; Das, S; Das, T; Dhara, S; Kumar, S; Maitra, A; Mukherjee, A; Sarkar-Roy, N; Tripathy, LN | 1 |
| Lei, Q; Li, G; Liu, C; Ma, J; Wang, W; Wang, Z; Wu, M; Xiang, J; Xiao, L; Xiong, J; Xu, G; Yang, H; Yang, J; Yu, Z; Zeng, L | 1 |
| Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD | 1 |
| Eigenbrod, S; Jansen, NL; Janssen, H; Kreth, FW; Kretzschmar, H; la Fougere, C; Linn, J; Pöpperl, G; Simon, M; Suchorska, B; Tonn, JC; Weller, M | 1 |
| Lok, E; Swanson, KD; Wong, ET | 1 |
| Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X | 1 |
| Alexandru-Abrams, D; Bota, DA; Hsu, FP; Paff, M | 1 |
| Gondi, V; Mehta, MP | 1 |
| Badiyan, SN; Huang, J; Robinson, CG | 1 |
| Benoit, JP; Danhier, F; Lagarce, F; Lemaire, L; Messaoudi, K | 1 |
| Barboriak, DP; Boxerman, JL; Gilbert, MR; Prah, M; Schmainda, KM; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B | 1 |
| Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG | 1 |
| Chang-Halpenny, CN; Lien, WW; Yeh, J | 1 |
| Hong, SH; Hong, YK; Joe, YA; Kim, HK; Kim, HS; Lee, NH; Lee, SW; Yi, HY | 1 |
| Curran, W; Dignam, JJ; Gilbert, MR; Mehta, M; Wang, M; Won, M | 1 |
| Chen, Y; Gao, H; Hu, X; Huang, H; Jiang, Z; Lei, T; Li, P; Liu, P; Mu, Q; Sayari, AJ; Shen, J; Wang, L; Yu, F; Zheng, X | 1 |
| Cerasti, D; Crafa, P; D'Abbiero, N; Froio, E; Ghadirpour, R; Iaccarino, C; Maggi, M; Michiara, M; Nicoli, D; Orlandi, E; Pedrazzi, G; Pisanello, A; Ruggeri, F; Servadei, F; Torricelli, F | 1 |
| Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z | 1 |
| Biau, J; Chautard, E; Dalloz, P; Durando, X; Hager, MO; Khalil, T; Lemaire, JJ; Ouédraogo, ZG; Verrelle, P | 1 |
| Bonetti, MF; Branca, C; Buglione, M; Buttolo, L; Cominelli, M; Dalerba, P; Facchetti, F; Finocchiaro, G; Furlan, D; Galli, R; Grisanti, S; Liserre, B; Liserre, R; Mazzoleni, S; Medicina, D; Pellegatta, S; Pellegrini, V; Pizzi, M; Poliani, PL | 1 |
| Clavreul, A; Lagarce, F; Messaoudi, K | 1 |
| Nagane, M | 1 |
| Brown, DV; D'Abaco, GM; Daniel, PM; Gogos, A; Mantamadiotis, T; Morokoff, AP; Ng, W | 1 |
| Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH | 1 |
| Chiu, DT; Fang, C; Kievit, FM; Mu, Q; Press, OW; Stephen, ZR; Wang, K; Zhang, M | 1 |
| Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V | 1 |
| Correia, S; Costa, BM; Costa, S; Gonçalves, CS; Gonçalves, T; Lopes, JM; Oliveira, AI; Pinto, AA; Pinto, L; Pojo, M; Reis, RM; Rocha, M; Rodrigues, AJ; Sousa, N; Xavier-Magalhães, A | 1 |
| Chuang, SE; Hu, TS; Lai, GM; Lai, IC; Lai, TY; Lui, TN; Shih, PH; Wang-Peng, J; Yao, CJ; Yeh, CT | 1 |
| Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T | 1 |
| Borghetti, P; Buglione, M; Fontanella, MM; Gipponi, S; Grisanti, S; Liserre, R; Magrini, SM; Pedretti, S; Poliani, LP; Spena, G; Spiazzi, L; Triggiani, L | 1 |
| McDonald, H; Olmez, I; Ozpolat, B; Shen, W | 1 |
| Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L; Idbaih, A; Labussiere, M; Levasseur, C; Milane, A; Schmitt, C | 1 |
| Cai, Q; Chen, Q; Daofeng, T; Dong, H; Guo, Z; Ji, B; Liu, B; Liu, Y; Wang, J; Wang, L; Wu, L; Zhang, S; Zhu, X | 1 |
| Balducci, N; Biolato, M; Di Napoli, N; Diletto, B; Grieco, A; Miele, L; Tafuri, MA; Vecchio, FM | 1 |
| Berger, MS; Chang, S; Das, S; Gosio, J; Perry, J; Sahgal, A; Zarnett, OJ | 1 |
| Bartsch, JW; Biniossek, ML; Carl, B; Conrad, C; Culmsee, C; Dolga, AM; Dong, F; Eibach, M; Koller, G; Nimsky, C; Schieber, S; Schilling, O; Schlomann, U; Strik, H | 1 |
| Sonoda, Y | 1 |
| Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M | 1 |
| Aizer, AA; Alexander, BM; Arvold, ND; Chiocca, EA; Christianson, LW; Claus, EB; Dunn, IF; Golby, AJ; Horvath, MC; Johnson, MD; Lee, EQ; Ligon, KL; Nayak, L; Reardon, DA; Tanguturi, SK; Wen, PY | 1 |
| Hattermann, K; Held-Feindt, J; Kubelt, C; Mehdorn, HM; Sebens, S | 1 |
| Berger, MS; Butowski, NA; Chang, SM; Clarke, JL; Han, SJ; Molinaro, AM; Prados, MD; Rutledge, WC; Taylor, JW | 1 |
| Boucard, C; Chinot, O; Delfino, C; Denicolai, E; Figarella-Branger, D; Graillon, T; Metellus, P; Nanni, I; Ouafik, L; Padovani, L; Tabouret, E; Tchoghandjian, A | 1 |
| Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM | 1 |
| Jiang, T; Liu, Y; Wang, Z; Yan, W; Yang, P; You, Y | 1 |
| Fei, X; Shi, L; Wang, Z | 1 |
| Chong, DQ; Dinesh, N; Ho, IA; Ho, MM; Lai, SH; Lam, PY; Newman, JP; Ng, WH; Sia, KC; Tham, CK; Toh, XY; Yulyana, Y | 1 |
| Gao, Z; Hao, S; Liu, Y; Yu, L | 1 |
| Chen, H; Li, W; Li, X; Zheng, H | 1 |
| Annovazzi, L; Battaglia, L; Caldera, V; Chirio, D; Melcarne, A; Mellai, M; Riganti, C; Schiffer, D | 1 |
| Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H | 1 |
| Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F | 1 |
| Alexander, BM; Ancukiewicz, M; Batchelor, TT; Beroukhim, R; Drappatz, J; Duda, DG; Gerard, M; Huse, JT; Jain, RK; Kaley, TJ; Lassman, AB; Lee, EQ; Ligon, KL; McCluskey, CS; Mikkelsen, T; Muzikansky, A; Norden, AD; Purow, BW; Ramkissoon, S; Schiff, D; Smith, KH; Weiss, SE; Wen, PY; Wong, ET | 1 |
| Budach, W; Rapp, M; Sabel, M; Sadat, H; Slotty, PJ; Steiger, HJ | 1 |
| Carlson, JA; Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K | 1 |
| Abdulkarim, B; Azoulay, M; Guiot, MC; Owen, S; Panet-Raymond, V; Patyka, M; Petrecca, K; Sabri, S; Santos, F; Shenouda, G; Souhami, L | 1 |
| Brenke, C; Capper, D; Ening, G; Osterheld, F; Schmieder, K | 1 |
| Annovazzi, L; Biunno, I; Cassoni, P; Cattaneo, M; De Blasio, P; Melcarne, A; Mellai, M; Schiffer, D; Storaci, AM | 1 |
| Bryukhovetskiy, I; Bryukhovetsky, A; Khotimchenko, R; Khotimchenko, Y; Mischenko, P; Tolok, E | 1 |
| Balaj, L; Breakefield, XO; Carter, BS; Chung, J; Hochberg, FH; Lee, H; Lee, K; Min, C; Shao, H; Weissleder, R | 1 |
| Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhan, Q; Zhou, D | 1 |
| Kast, RE | 1 |
| Adjabi, A; Almokhles, H; Chargari, C; Falk, AT; Forest, F; Fournel, P; Garin, C; Guy, JB; Hoarau, D; Kawaye, S; Magné, N; Mery, B; Nuti, C; Peoc'h, M; Rivoirard, R | 1 |
| Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH | 1 |
| Caciagli, F; Ciccarelli, R; D'Alimonte, I; Di Iorio, P; Giuliani, P; Lanuti, P; Nargi, E; Pallini, R; Ricci-Vitiani, L; Zuccarini, M | 1 |
| Danhier, F; des Rieux, A; Fourniols, T; Leprince, JG; Préat, V; Randolph, LD; Staub, A; Vanvarenberg, K | 1 |
| Bromberg, JE; van den Bent, MJ | 1 |
| Lan, F; Pan, Q; Yu, H; Yue, X | 1 |
| Kovic, B; Xie, F | 1 |
| Bottomley, A; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Mason, WP; Nishikawa, R; Ravelo, A; Saran, F; Taphoorn, MJ; Theodore-Oklota, C; Wick, W | 1 |
| Chung, C; Kiehl, TR; Laperriere, N; Lovblom, LE; Mason, W; McNamara, MG; Ménard, C; Millar, BA; Perkins, BA; Tieu, MT | 1 |
| Fietkau, R; Knippen, S; Lahmer, G; Putz, F; Semrau, S | 1 |
| Benecke, R; Grossmann, A; Hildebrandt, G; Kirschstein, T; Piek, J; Rösche, J | 1 |
| Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM | 1 |
| Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; McSherry, F; Miller, E; Peters, KB; Reardon, DA; Vredenburgh, JJ | 1 |
| Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM | 1 |
| Cabrini, G; Dechecchi, MC; Fabbri, E; Gambari, R; Lo Nigro, C | 1 |
| Fritsch, J; Hattermann, K; Held-Feindt, J; Krossa, S; Mehdorn, HM; Scheidig, AJ; Schmitt, AD | 1 |
| Agarwal, A; Churi, S; Epari, S; Goda, JS; Gupta, T; Jalali, R; Lewis, S; Moiyadi, A; Padmavati, A; Shetty, P | 1 |
| Butz, L; Dittmann, K; Huber, SM; Klumpp, L; Ruth, P; Stegen, B; Zips, D | 1 |
| Cao, Y; Guo, A; Jiao, Y; Li, H; Li, Y; Liu, Y; Qu, X; Wang, S; Xu, X; Zhao, J | 2 |
| Li, A; Li, Z; Lu, H; Luo, R; Tian, T; Zhang, M | 1 |
| Appelt, JU; Brehmer, S; Gehweiler, J; Giordano, FA; Schmiedek, P; Seiz-Rosenhagen, M; von Deimling, A; Welzel, G; Wenz, F | 1 |
| Alkhafaji, A; Belin, C; Carpentier, AF; Doridam, J; Januel, E; Levy-Piedbois, C; Marantidou, A; Ursu, R | 1 |
| Becher, OJ; Carter, BS; Cavenee, WK; Chen, CC; Chen, HZ; Desai, A; Esashi, F; Furnari, FB; Futalan, D; Kennedy, R; Li, J; Nitta, M; Sarkaria, JN; Shen, Y; Steed, T; Stevens, D; Taich, Z; Treiber, JM; Wykosky, J | 1 |
| Liu, S; Yuan, Y; Zhao, Y; Zhou, L | 1 |
| Bentayeb, H; Dayen, C; Delentaigne Delogivieres, X; Douadi, Y; Drouard, M; Le Meunier, F; Lecuyer, E; Rault, I; Solomalalarivelo, F; Suguenot, R; Trouve, C | 1 |
| Chen, K; Gao, J; Guan, J; He, H; Kong, X; Li, Y; Liu, S; Ma, W; Wang, R; Wang, Y; Xing, B; Yan, C; Yang, Y; Zhou, Q | 1 |
| Cao, Y; Junck, LR; Kim, MM; Lawrence, TS; Mammoser, AG; Parmar, HA; Pramanik, PP; Tsien, CI | 1 |
| Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK | 1 |
| Atif, F; Patel, NR; Stein, DG; Yousuf, S | 1 |
| Amatu, A; Barault, L; Bardelli, A; Bleeker, FE; Cassingena, A; Cassoni, P; De Braud, F; de Witt Hamer, P; Di Nicolantonio, F; Esteller, M; Falcomatà, C; Fiano, V; Milione, M; Moutinho, C; Pietrantonio, F; Rudà, R; Sartore-Bianchi, A; Siena, S; Siravegna, G; Soffietti, R; Venesio, T; Wesseling, P | 1 |
| Cher, L; Dally, M; Drummond, K; Gan, HK; Murphy, M; Rosenthal, MA; Thursfield, V | 1 |
| Debatin, KM; Halatsch, ME; Karpel-Massle, G; Karpel-Massler, G; Nonnenmacher, L; Schneele, L; Schneider, M; Siegelin, MD; Ströbele, S; Westhoff, MA; Zhou, S | 1 |
| Abrey, LE; Bais, C; Bourgon, R; Chinot, OL; Cloughesy, T; Garcia, J; Hegde, P; Henriksson, R; Kharbanda, S; Lai, A; Li, C; Mason, W; Moore, N; Nishikawa, R; Peale, F; Phillips, HS; Sandmann, T; Saran, F; Wick, W | 1 |
| Anhua, W; Jia, L; Long, L; Yunchao, B; Zhitao, J | 1 |
| Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN | 1 |
| Barbeau, LM; Granton, PV; Paesmans, K; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S | 1 |
| Fei, X; Shi, L; Wang, Z; You, Y | 1 |
| Mellinghoff, IK; Nichol, D | 1 |
| Moukhlissi, M; Naciri, F | 1 |
| Aalberti, S; Arcella, A; Bartolo, M; Cantore, G; Frati, A; Giangaspero, F; Grillea, G; Madonna, M; Oliva, MA; Pavone, L; Staffieri, S | 1 |
| Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ | 1 |
| Desjardins, A | 1 |
| Mayer, TM | 1 |
| Du, J; Mao, G; Song, S; Zhu, X | 1 |
| Munoz, JL; Rameshwar, P; Scotto, KW; Walker, ND | 1 |
| Taylor, LP | 1 |
| Batchelor, TT; Dietrich, J; Gerstner, ER; Jafari-Khouzani, K; Kalpathy-Cramer, J; Polaskova, P; Prust, MJ | 1 |
| Adeberg, S; Bernhardt, D; Bostel, T; Combs, SE; Debus, J; Harrabi, S; Welzel, T; Wick, W | 1 |
| Alvarez, P; Bandiera, P; Farace, C; Madeddu, R; Malaguarnera, G; Melguizo, C; Oliver, JA; Ortiz, R; Prados, J; Rama, AR | 1 |
| Cai, T; Chen, YD; Liu, Q; Wang, ZF; Wu, H | 1 |
| Brem, H; Burger, P; Chaichana, KL; Gallia, GL; Grossman, R; Olivi, A; Quiñones-Hinojosa, A; Sidransky, D; Soudry, E; Tyler, B; Weingart, J; Ye, X | 1 |
| Hu, M; Lan, F; Xia, T; Yu, H; Yue, X | 1 |
| Arevalo-Perez, J; Kaley, T; Lyo, J; Peck, KK; Shi, W; Thomas, AA; Young, RJ; Zhang, Z | 1 |
| Alongi, F; Fersino, S; Fiorentino, A; Giaj Levra, N; Mazzola, R; Ricchetti, F | 1 |
| Alexander, BM; Arvold, ND; Tanguturi, SK | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ | 1 |
| Dubey, A; Koul, R; Salim, M; Tai, P; Vu, K | 1 |
| Bai, CF; Cai, MQ; Dai, WZ; Jia, SZ; Lin, L; Liu, BX; Wang, LM; Wang, WH; Xu, XY; Zhang, XF; Zhou, RJ | 1 |
| Cuperlovic-Culf, M; Morin, P; Poitras, JJ; St-Coeur, PD; Touaibia, M | 1 |
| Chang, EH; DeMarco, J; Kim, E; Kim, SS; Pirollo, KF; Rait, A | 1 |
| Chen, CM; Huang, LJ; Kuo, SC; Lin, CL; Lin, CT; Syu, JP; Way, TD | 1 |
| Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S | 1 |
| Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H | 1 |
| Cho, HJ; Johnson, MD; Joo, KM; Jung, YS; Kim, BS; Kim, J; Kim, Y; Kong, DS; Lee, IH; Lee, J; Lee, JI; Nam, DH; Nam, SH; Park, CK; Park, PJ; Park, WY; Seol, HJ; Yoon, Y | 1 |
| Hegi, ME; Stupp, R | 2 |
| Fulda, S; Marschall, V | 1 |
| Fan, L; He, J; Qiao, Y; Tan, J; Wang, Q; Wu, H; Yang, Q; Zhang, Y | 1 |
| Aasland, D; Berte, N; Christmann, M; Kaina, B; Kitzinger, R; Krämer, OH; Meise, R; Tomicic, MT | 1 |
| Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F | 1 |
| Anghileri, E; Bazzoli, E; Bellu, L; Berti, F; D'Avella, D; Dall'Agata, M; Della Puppa, A; Eoli, M; Fabi, A; Faedi, M; Ferrazza, P; Gurrieri, L; Lombardi, G; Nicolotto, E; Pace, A; Pambuku, A; Pasqualetti, F; Rizzato, S; Rudà, R; Villani, V; Zagonel, V | 1 |
| Chen, X; Gao, J; Li, B; Lu, L; Lu, W; Qian, J; Tai, L; Xie, C; Zhang, M | 1 |
| Chen, Y; Li, C; Li, Y; Xie, G; Yu, H; Yu, Z; Zhang, Z; Zhao, G; Zhao, L | 1 |
| Agar, NY; Boddy, AV; Calligaris, D; Carlson, BL; Cen, L; Curtin, NJ; Elmquist, WF; Kizilbash, S; Mittapalli, RK; Murray, J; Parrish, KE; Sarkaria, JN; Schroeder, MA; Sludden, J | 1 |
| Bruce, JN; Cheng, SK; Chow, DS; Estrada, JP; Gartrell, R; Isaacson, SR; Jani, A; Lassman, AB; McKhann, GM; Qureshi, YH; Saad, S; Sisti, MB; Soun, JE; Ung, TH; Wang, TJ | 1 |
| Berdasco, M; Caba, O; Cabeza, L; Gónzalez, B; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J | 1 |
| Bulik, M; Jancalek, R; Kazda, T; Slampa, P | 1 |
| Chen, D; Chen, W; Chen, Y; Chen, Z; Cheng, G; Jiang, T; Liu, N; Lu, D; Luo, H; Peng, C; Qiu, W; Wang, H; Wang, HW; Wang, S; Wu, W; Xu, R; Yang, J; You, Y; Zhang, R; Zhang, S; Zhang, X; Zhao, C; Zhao, L | 1 |
| Ahmed, KA; Caudell, JJ; Chinnaiyan, P; Eschrich, S; Fulp, WJ; Torres-Roca, JF | 1 |
| Adamson, C; Agarwal, VJ; Babu, R; Britt, D; Friedman, AH; Grossi, PM; Iyer, A; Karikari, IO; Komisarow, JM; Rahimpour, S; Thomas, S | 1 |
| Neagu, MR; Reardon, DA | 1 |
| Shi, L; Sun, G | 1 |
| Aldape, K; Chamberlain, M; Conrad, C; De Groot, J; Giglio, P; Gilbert, MR; Grimm, S; Groves, M; Hu, J; Liu, D; Loghin, M; Merrell, R; Paleologos, N; Phuphanich, S; Puduvalli, VK; Rademaker, A; Raizer, JJ; Rudnick, J; Tremont-Lukats, IW; Vaillant, B; Vick, N; Yuan, Y; Yung, WK | 1 |
| Chen, JX; Chen, ZP; Li, ZY; Lu, YC; Ma, WB; Mao, Y; Qi, ST; Shen, H; Wang, JS; Wang, RZ; Wang, X; Yang, QY; Yang, SY; Yang, XJ; Yao, Y; You, C; Zhang, JM; Zhang, LW; Zhang, X; Zhen, HN; Zhou, LF | 1 |
| Ellsworth, S; Grossman, SA; Ye, X | 1 |
| Beauchesne, P; Bernier, V; Carnin, C; Faure, G; Gorlia, T; Noel, G; Pedeux, R; Quetin, P; Quillien, V | 1 |
| Chen, B; Chen, CC; Jiang, T; Li, G; Li, J; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yan, W; Yang, P; Yao, K; You, Y; Zhang, W | 1 |
| Kouri, FM; Ritner, C; Stegh, AH | 1 |
| An, Z; Wang, C; Wang, L; Zhu, N | 1 |
| Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P | 1 |
| Gruden, K; Koren, A; Lah, TT; Motaln, H; Ramšak, Ž; Schichor, C | 1 |
| Godoy, PR; Montaldi, AP; Sakamoto-Hojo, ET | 1 |
| Bourne, TD; Chen, L; LaRocca, R; Parsons, S; Shearer, AJ; Shelton, BJ; Shields, LB; Spalding, AC; Sun, DA | 1 |
| Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT | 1 |
| Colella, M; Fiorica, F | 1 |
| Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH | 1 |
| Antonosante, A; Astarita, C; Benedetti, E; Cifone, MG; Cimini, A; Cinque, B; Courty, J; Cristiano, L; d'Angelo, M; Destouches, D; Dhez, AC; Fidoamore, A; Florio, TM; Galzio, R; Giordano, A; Ippoliti, R; Rosati, F | 1 |
| Gourdie, RG; Guo, S; Jourdan, J; Kanabur, P; Lamouille, S; Murphy, SF; Osimani, AM; Pridham, KJ; Rodgers, CM; Sharma, S; Sheng, Z; Simonds, GR; Varghese, RT | 1 |
| Bui, Y; Cloughesy, TF; Hong, I; Lai, A; Liau, LM; McBride, WH; Menjivar, JC; Nelson, SF; Stream, A; Tso, CL; Tso, JL; Yamada, K; Yang, S; Yong, WH; Zhang, Y | 1 |
| Huang, A; Lei, B; Li, H; Liu, Y; Lu, Y; Pan, J; Qi, S; Wang, H; Xiao, L; Zhou, Q | 1 |
| Ananta, JS; Massoud, TF; Paulmurugan, R | 3 |
| Allemanni, G; Banelli, B; Barbieri, F; Carosio, R; Carra, E; Daga, A; Florio, T; Forlani, A; Marubbi, D; Parodi, F; Pattarozzi, A; Romani, M; Würth, R | 1 |
| Chakrabarti, M; Ray, SK | 1 |
| Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V | 1 |
| Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY | 1 |
| Happold, C; Weller, M | 1 |
| Bregy, A; Hanft, S; Hernández-Durán, S; Komotar, RJ; Manzano, GR; Shah, AH | 1 |
| Coveñas, R; Kast, RE; Lladó, S; Muñoz, M; Ramiro, S; Toro, S | 1 |
| Arita, H; Fukushima, S; Ichimura, K; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Takami, H; Yonezawa, M; Yoshida, A | 1 |
| Bakken, KK; Ballman, KV; Boakye-Agyeman, F; Carlson, BL; Cen, L; Decker, PA; Eckel-Passow, JE; Gupta, SK; Jenkins, RB; Kitange, GJ; Kizilbash, SH; Mladek, AC; Pokorny, JL; Reid, JM; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Verhaak, RG | 1 |
| Taphoorn, MJ | 1 |
| Leung, GK; Poon, MW; Sun, S; Wong, ST; Zhang, XQ; Zhuang, JT | 1 |
| Liang, P; Tang, H; Zhang, L; Zhao, J; Zhuang, Y | 1 |
| Han, J; Lan, F; Wu, Q; Yang, Y; Yu, H; Yue, X | 1 |
| Boyd, AW; Byrne, AT; Day, BW; Flanagan, L; Kögel, D; Murray, DW; O'Brien, DF; Prehn, JH; Rehm, M; Salvucci, M; Stringer, BW; Tivnan, A; Zakaria, Z | 1 |
| Sampson, JH | 1 |
| Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ | 1 |
| Black, KL; Ly, D; Mukherjee, D; Nuño, M; Ortega, A; Patil, CG; Sarmiento, JM | 1 |
| Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F | 1 |
| Duan, Y; Gao, P; Shen, M; Sun, Y; Xu, Y | 1 |
| El-Shorbagy, SH; Khedr, RA; Younis, SG | 1 |
| Cao, Y; Sun, J; Yang, X; Zhang, W | 1 |
| Bi, Y; Chen, X; Cho, K; Dong, X; Han, D; Hou, X; Liu, H; Liu, Y; Peng, F; Shen, C; Teng, L; Wu, J; Zhao, S | 1 |
| Bihari, F; Hebb, MO; Schmid, S; Whitehead, S; Wong, E; Xu, HU | 1 |
| Mohile, NA | 1 |
| Campian, JL; Gao, F; Govindan, A; Huang, J; Leong, J; Mendez, JS | 1 |
| Armoiry, X; Aulagner, G; Cartalat-Carel, S; Diebold, G; Ducray, F; Frappaz, D; Guyotat, J; Hartmann, D; Henaine, AM; Honnorat, J; Paubel, N | 1 |
| Archer, GE; Choi, BD; Congdon, KL; Healy, P; Herndon, JE; Norberg, PK; Reap, EA; Sampson, JH; Sanchez-Perez, L; Saraswathula, A; Sayour, EJ; Schmittling, RJ | 1 |
| Berens, ME; Dhruv, HD; Ensign, SP; Loftus, JC; Mathews, IT; Roos, A; Sarkaria, JN; Symons, MH; Tran, NL; Tuncali, S | 1 |
| Cho, YJ; Hwang, YI; Joo, KM; Kang, W; Kim, M; Kim, N; Kim, SH; Nam, DH; Paddison, PJ; Sa, JK | 1 |
| Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W | 1 |
| Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W | 1 |
| Bash, RE; Ewend, MG; Huey, L; McNeill, RS; Miller, CR; Schmid, RS; Simon, JM; Vitucci, M; Werneke, AM; White, KK; Wu, J | 1 |
| Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP | 1 |
| Dai, S; Gong, Z; Qian, L; Sun, L; Xu, Z; Yan, Y | 1 |
| Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S | 1 |
| Balakrishnan, A; Jaglal, M; Ledford, R | 1 |
| Balana, C; Berrocal, A; Capellades, J; Carrato, C; De la Cruz, JJ; De Las Penas, R; Fernandez, I; Gallego, O; Garcia, A; Gil-Gil, MJ; Giner, P; Henriquez, I; Herrero, A; Luque, R; Martinez-Garcia, M; Peralta, S; Pérez-Segura, P; Ramirez, JL; Reynes, G; Sanz, C; Sepúlveda, JM; Vazquez-Estevez, S; Vieitez, JM; Villà, S | 1 |
| Ai, L; Akgoz, A; Cheng, S; Dai, J; Jiang, T; Leung, K; Li, H; Li, S; Li, X; Qin, L; Qu, J; Rahman, R; Seethamraju, R; Wang, Q; Young, GS | 1 |
| Feng, F; Ling, Z; Sun, C; Wang, L; Wang, S; Wu, B; Xia, L; Yu, Y | 1 |
| Aldaz, P; Arrizabalaga, O; Barrena, C; Carrasco-Garcia, E; Garcia, I; Garros-Regulez, L; Lovell-Badge, R; Manterola, L; Matheu, A; Moncho-Amor, V; Moreno-Cugnon, L; Pollard, S; Ruiz, I; Sampron, N; Villanua, J | 1 |
| Aslan, D; Broholm, H; Christensen, IJ; Dyrbye, H; Grunnet, K; Grønbæk, K; Kristensen, LS; Michaelsen, SR; Poulsen, HS | 1 |
| Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS | 1 |
| Kozak, KR; Kruser, TJ; Mehta, MP | 1 |
| Abrey, LE; Bais, C; Bourgon, R; Chinot, OL; Cloughesy, T; Henriksson, R; Mason, W; Nishikawa, R; Phillips, HS; Saran, F; Taphoorn, MJ; Wick, W | 1 |
| Berglund, A; Etame, AB; Forsyth, PA; Kenchappa, RS; Mulé, JJ; Wang, D | 1 |
| Giatromanolaki, A; Koukourakis, MI; Mitrakas, AG | 1 |
| Borkowska, P; Fila-Daniłow, A; Kowalczyk, M; Kowalski, J; Paul-Samojedny, M; Pudełko, A; Suchanek-Raif, R | 1 |
| Chen, Y; Cheng, Y; Gao, H; Gao, J; Huang, H; Lei, T; Li, G; Li, P; Liu, P; Mu, Q; Sayari, AJ; Sun, Y; Yu, F; Zhai, X | 1 |
| Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H | 1 |
| Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y | 1 |
| Chen, J; Cheng, ZJ; Dwight, T; Howell, VM; Hudson, AL; Ikin, RJ; Khong, P; Parker, NR; Parkinson, JF; Vafaee, F; Wheeler, HR; Zhu, Y | 1 |
| Baruzzi, A; Bertolini, F; Biasini, C; Brandes, AA; Cavallo, MA; Crisi, G; Dazzi, C; Depenni, R; Ermani, M; Faedi, M; Franceschi, E; Michiara, M; Mucciarini, C; Paccapelo, A; Pasini, G; Pavesi, G; Pisanello, A; Servadei, F; Sturiale, C; Urbini, B | 1 |
| Acanda, AM; Alonso, MM; Aragón, T; Fueyo, J; Garzón, AG; Gomez-Manzano, C; Gonzalez-Huarriz, M; Idoate, MA; Jones, C; Lang, FF; Martínez-Irujo, JJ; Martínez-Velez, N; Vera, B; Xipell, E | 1 |
| Choi, C; Choi, K; Kim, E; Lee, J; Ryu, SW | 1 |
| Duan, Y; Li, Y; Shen, M; Sun, Y; Teng, Y; Wang, Y; Xu, Y | 1 |
| Chen, D; Chen, Y; Chen, Z; Liu, N; Luo, H; Peng, C; Qiu, W; Wang, H; Wang, HW; Wang, S; Xu, R; You, Y; Zhao, L | 1 |
| Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI | 1 |
| Carlson, BL; Decker, PA; Kitange, GJ; Lee, JH; Mladek, AC; Nair, AA; Pokorny, JC; Sarkaria, JN; Schroeder, MA; Yan, H; Zhang, Y; Zhang, Z | 1 |
| Ferguson, SD; Ghali, MG; Heimberger, AB; Srinivasan, VM | 1 |
| Belka, C; Brehmer, S; Dunkl, E; Fietkau, R; Friedrich, F; Gerlach, R; Glas, M; Goldbrunner, R; Grau, S; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Kohnen, R; Kortmann, RD; Krex, D; Leutgeb, B; Maciaczyk, J; Mack, F; Mayer-Steinacker, R; Mehdorn, M; Pietsch, T; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Stuplich, M; Tüttenberg, J; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A | 1 |
| Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L | 1 |
| Jiang, P; Li, W; Ma, X; Sun, X; Xu, S; Zhan, R | 1 |
| Pellerino, A; Rudà, R; Soffietti, R | 1 |
| Knisely, JP; Zhang, I | 1 |
| Baronchelli, S; Bentivegna, A; Butta, V; Cilibrasi, C; Dalprà, L; Lavitrano, M; Redaelli, S; Riva, G | 1 |
| Bredlau, AL; Broome, AM; Dixit, S; McKinnon, E; Miller, K; Moore, A | 1 |
| Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL | 1 |
| Gorospe Sarasúa, L; Muñoz Del Toro, JR; Ureña-Vacas, A | 1 |
| Cai, J; Chen, B; Feng, Y; Han, B; Jiang, C; Li, J; Li, Q; Li, R; Li, Y; Sun, Y; Tian, Y; Wang, G; Yi, L | 1 |
| Cai, P; Dahmane, N; Fan, Y; Gong, Y; Huang, M; Kim, HJ; Koumenis, C; Li, C; Liu, T; Ma, P; Mitteer, RA; O'Rourke, DM; Roccograndi, L; Yeo, E; Zhang, D; Zhang, L; Zhang, Z; Zhao, B | 1 |
| Kishor, K; Pandit, PN; Raj, S | 1 |
| Gramatzki, D; Roth, P; Seystahl, K; Weller, M | 1 |
| Arús, C; Candiota, AP; Ciezka, M; Delgado-Goñi, T; Fernández, F; Julià-Sapé, M; Lisboa, PJ; Olier, I; Ortega-Martorell, S; Pumarola, M | 1 |
| Kim, H; Leiby, BE; Shi, W | 1 |
| Finazzi, T | 1 |
| Brem, S; Chawla, S; Mohan, S; Peters, KB; Poptani, H; Skolnik, A; Verma, G; Wang, S | 1 |
| Aoki, H; Echizenya, S; Fujii, Y; Ichikawa, S; Isogawa, M; Kondo, T; Maenaka, K; Matsuda, A; Natsumeda, M; Ogura, R; Ohtsu, N; Otsuguro, S; Sakaitani, M; Tsukamoto, Y | 1 |
| Chan, MD; Debinski, W; Li, KC; Liu, K; Paulsson, A; Qian, X; Tan, H; Wang, G; Wang, M; Yang, T; Yu, H; Zhang, J; Zhou, X | 1 |
| Bernier, V; Blanchard, N; Bonnetain, F; Dalban, C; Lagneau, É; Maingon, P; Mazoyer, F; Mirjolet, C; Noël, G; Truc, G | 1 |
| Chen, S; Cirovic, B; Drachsler, M; Gieffers, C; Kleber, S; Martin-Villalba, A; Mateos, A; Mohr, N; Mueller, W; Sykora, J; Synowitz, M; Tüttenberg, J; Volk, K; Wirtz, CR | 1 |
| Brenner, A; Cavazos, D; Garcia, L; Garcia, M; Gruslova, A; Gustafsson, JA; Li, X; Liu, J; Sareddy, GR; Strom, AM; Tekmal, RR; Vadlamudi, RK; Viswanadhapalli, S | 1 |
| Brandal, P; Johannesen, TB; Tjønnfjord, GE; Vandraas, K | 1 |
| Barnholtz-Sloan, JS; Dazard, JE; Stetson, LC | 1 |
| Bady, P; Brandes, AA; Campone, M; Frenel, JS; Golfinopoulos, V; Gorlia, T; Hamou, MF; Hegi, ME; Homicsko, K; Hopkins, K; Kosch, M; Lhermitte, B; Marosi, C; Pesce, G; Platten, M; Ricard, D; Roth, P; Steuve, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Villa, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W | 1 |
| Khoshnevisan, A; Safari, M | 1 |
| Chen, Z; Gao, Z; Lai, X; Mao, G; Qu, J; Zhang, L; Zhu, J; Zhu, X | 1 |
| Barbeau, LM; Chalmers, AJ; Eekers, DB; Granton, PV; Groot, AJ; Habets, R; Iglesias, VS; King, H; Prickaerts, J; Short, SC; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S | 1 |
| Badakhshi, H; Budach, V; Exner, S; Florange, J; Ghadjar, P; Grün, A; Kaul, D | 1 |
| Amini, A; Gaspar, LE; Jones, BL; Karam, SD; Kavanagh, BD; Koshy, M; Ney, DE; Ormond, DR; Rusthoven, CG; Sher, DJ; Youssef, AS | 1 |
| Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D | 1 |
| Rybalkina, EY; Shushanov, SS; Stavrovskaya, AA | 1 |
| Chen, X; He, X; Hu, P; Lian, H; Liu, W; Tang, F; Wang, Z; Xie, C; Zhang, Y | 1 |
| Abate, F; Blumberg, AJ; Cazzato, E; Elliott, O; Eoli, M; Finocchiaro, G; Frattini, V; Iavarone, A; Ladewig, E; Lasorella, A; Lee, IH; Lee, JK; Liu, Z; Nam, DH; Park, WY; Rabadan, R; Rosenbloom, DI; Shin, YJ; Wang, J; Zairis, S | 1 |
| Guo, H; He, Z; Huang, Y; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H | 1 |
| Kesari, S; Stupp, R; Toms, SA | 1 |
| Kraus, JL; Ross, AH; Weatherbee, JL | 1 |
| Cosgrove, L; Dowson, N; Fay, MF; Head, R; Martin, JH; Rose, SE; Sminia, P | 1 |
| Bredel, M; Chandler, JP; Ferrarese, R; Grimm, SA; Helenowski, I; Levy, RM; Muro, K; Paton, M; Rademaker, A; Raizer, JJ; Rosenow, J | 1 |
| Mitrofanov, AA; Moiseeva, NI; Panteleev, DY; Pavlova, GV; Pustogarov, NA; Rybalkina, EY; Stavrovskaya, AA; Susova, OY | 1 |
| Ikota, H; Kagoshima, K; Matsumura, N; Nagano, T; Nakajima, N; Nobusawa, S; Yamazaki, T; Yokoo, H | 1 |
| Chosdol, K; Das, BC; Jalota, A; Kumar, M; Sinha, S; Yadav, AK | 1 |
| Bracci, S; Chevalier, A; Delattre, JY; Duran-Peña, A; Feuvret, L; Hitchcock, K; Hoang-Xuan, K; Jacob, J; Laigle-Donadey, F; Mazeron, JJ; Navarro, S; Troussier, I | 1 |
| Castilho, RF; De Melo, DR; Facchini, G; Ignarro, RS; Lopes-Cendes, I; Rogerio, F; Vieira, AS | 1 |
| Burma, S; Gil Del Alcazar, CR; Habib, AA; Mukherjee, B; Todorova, PK | 1 |
| Ahluwalia, A; Chau, V; Ge, L; Hoa, NT; Jadus, MR; Kruse, CA; Martini, F | 1 |
| Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A | 1 |
| Chen, Z; Feng, W; He, M; Lei, B; Li, H; Liu, Y; Lu, Y; Qi, S; Sun, X; Wang, H; Xiang, W; Zhao, L | 1 |
| Ahn, KJ; Chang, JH; Cho, SJ; Cho, YH; Chung, DS; Gwak, HS; Hong, CK; Hong, YK; Hwang, SC; Jung, TY; Kang, MK; Kang, SG; Kang, SH; Kim, BS; Kim, CY; Kim, EH; Kim, EY; Kim, IA; Kim, IH; Kim, JH; Kim, SH; Kim, TM; Lee, KH; Lee, SH; Lee, SI; Lee, YS; Lim, DH; Nam, DH; Park, CK; Seol, HJ; Song, JH; Suh, CO; Yoo, H; Yoon, SM | 1 |
| Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME | 1 |
| Dietrich, J; Prust, M | 1 |
| Choi, E; Han, J; Lee, D; Lee, M; Oh, J; Rhim, T; Tan, X | 1 |
| Hertenstein, A; Hielscher, T; Menn, O; Platten, M; Wick, A; Wick, W; Wiestler, B; Winkler, F | 1 |
| Choi, CG; Kim, C; Kim, HS; Kim, JH; Kim, SJ; Shim, WH | 1 |
| Blaes, J; Dong, Z; Green, E; Hertenstein, A; Jugold, M; Lemke, D; Löw, S; Ott, M; Platten, M; Pledl, HW; Sahm, F; Steffen, AC; Weiler, M; Wick, W; Winkler, F; Zorn, M | 1 |
| Belmonte, G; Miracco, C; Pirtoli, L; Tini, P; Toscano, M | 1 |
| Hu, Q; Li, S; Liu, Y; Yan, W; You, Y; Zeng, A | 1 |
| Choi, SH; Heo, DS; Jung, HW; Kim, DG; Kim, IH; Kim, SK; Kim, TM; Lee, SH; Lee, ST; Park, CK | 1 |
| Brock, J; Chalmers, AJ; Lorimer, CF; Saran, F | 1 |
| Bielecka, AM; Obuchowicz, E | 1 |
| Gao, Z; Hao, S; Ji, N; Li, Y; Song, G; Su, Z; Wang, J; Wang, X; Xie, J; Yu, L; Zhang, C; Zhang, P | 1 |
| Battista, S; Colamaio, M; Del Vecchio, L; Federico, A; Fusco, A; Gattordo, R; Gemei, M; Hirata, H; Kuzay, Y; Mari, A; Mimori, K; Pepe, A; Puca, F; Ragozzino, E; Raia, M; Sarnataro, D; Tosti, N | 1 |
| Ambriović-Ristov, A; Berte, N; Christmann, M; Diesler, K; Freund, H; Kaina, B; Majhen, D; Osmak, M; Steigerwald, C; Stojanović, N; Tomicic, MT | 1 |
| Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML | 1 |
| Arita, H; Fujita, K; Fukai, J; Hashimoto, N; Hatae, R; Higuchi, F; Ichimura, K; Ishibashi, K; Kagawa, N; Kanemura, Y; Kawahara, N; Kinoshita, M; Kobayashi, K; Kodama, Y; Komori, T; Maehara, T; Matsushita, Y; Miyakita, Y; Miyaoka, E; Mori, K; Moriuchi, S; Mukasa, A; Nagane, M; Nakamura, H; Nakamura, T; Narita, Y; Nishikawa, R; Nonaka, M; Ohno, M; Okita, Y; Otani, R; Saito, K; Saito, N; Shibuya, M; Shimizu, S; Shimokawa, A; Shinojima, N; Shirahata, M; Shofuda, T; Sumita, K; Suzuki, H; Suzuki, K; Takami, H; Tamura, K; Tanaka, S; Terakawa, Y; Tomogane, Y; Tsuyuguchi, N; Ueki, K; Uzuka, T; Yamasaki, K; Yoshimine, T; Yoshimoto, K | 1 |
| Cho, BJ; Choi, EJ; Han, TJ; Kim, DH; Kim, IA; Paek, SH; Song, SH | 1 |
| Bendszus, M; Chinot, OL; Cloughesy, T; Henriksson, R; Kerloeguen, Y; Mason, W; Nishikawa, R; Revil, C; Saran, F; Wick, W | 1 |
| Ishikawa, E; Ishikawa, H; Matsuda, M; Matsumura, A; Mizumoto, M; Okumura, T; Sakurai, H; Takano, S; Tsuboi, K; Yamamoto, T | 1 |
| Butowski, N; Cha, S; Chang, SM; Clarke, J; Crane, JC; Li, Y; Lupo, JM; Molinaro, A; Nelson, SJ; Olson, M; Prados, M; Roy, R | 1 |
| Carpentier, C; Chiforeanu, D; Chinot, O; Ducray, F; Entz-Werle, N; Escande, F; Figarella-Branger, D; Fina, F; Joly, MO; Karayan-Tapon, L; Lavenu, A; Legrain, M; Levallet, G; Quillien, V; Ramirez, C; Rivet, P; Sanson, M; Vauleon, E; Zalcman, EL | 1 |
| Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M | 1 |
| Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M | 1 |
| Ashby, LS; Smith, KA; Stea, B | 1 |
| Castro, MG; Doherty, R; Lowenstein, PR; Wilson, TJ; Zamler, DB | 1 |
| Boucard, C; Chinot, O; Delfino, C; Denicolai, E; Figarella-Branger, D; Graillon, T; Nanni, I; Padovani, L; Tabouret, E | 1 |
| Butowski, N; Cha, S; Chang, S; Crane, J; Kadambi, AK; Li, Y; Molinaro, A; Nelson, SJ; Olson, M; Park, I; Roy, R | 1 |
| Chang, JH; Cheong, JH; Choi, J; Huh, YM; Jeon, JY; Kang, SG; Kim, EH; Kim, P; Kim, SH; Koh, I; Lee, JH; Lee, SJ; Park, J; Pollak, M; Shim, JK; Yook, JI; Yun, M | 1 |
| Agnihotri, S; Alamsahebpour, A; Aldape, KD; Burrell, KE; Golbourn, B; Jalali, S; Mansouri, S; Taccone, MS; Tonge, PD; Vartanian, A; Wilson, MR; Zadeh, G | 1 |
| Chen, XB; Gao, YT; Liu, HL | 1 |
| Battiste, J; Bota, DA; Connelly, J; Damek, D; Dunbar, E; Iwamoto, F; Mohile, N; Trusheim, J | 1 |
| Bista, A; Shah, BK; Sharma, S | 1 |
| Chen, BD; Chen, L; Li, QZ; Li, WP; Li, ZY; Wang, B; Zhang, XJ | 1 |
| Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M | 1 |
| Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF | 1 |
| Dalsin, E; Filippi-Chiela, EC; Lenz, G; Onzi, GR; Silva, AO | 1 |
| Akasaki, Y; Arai, T; Hayashi, K; Homma, S; Joki, T; Kikuchi, T; Koido, S; Komita, H; Mori, R; Murayama, Y; Ohkusa, T; Suzuki, Y; Tanaka, T; Tasaki, T; Watanabe, N; Yamamoto, Y; Yanagisawa, T | 1 |
| Chang, JH; Chung, YG; Kang, SH; Kim, CH; Kim, JH; Kim, JM; Koh, YC; Kong, DS; Lee, JW; Lim, YJ; Nam, DH | 1 |
| Ikawa, F; Ishifuro, M; Kawamata, T; Kurisu, K; Muragaki, Y; Nishibuchi, I; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F | 1 |
| Cartron, PF; Cheray, M; Nadaradjane, A; Oliver, L; Pacaud, R; Vallette, FM | 1 |
| Amiri, A; Gillard, JW; Le, PU; Machkalyan, G; Maysinger, D; Moquin, A; Petrecca, K; Yoganathan, N | 1 |
| Hartmann, R; Kahlert, UD; Koch, K; Krüger, AC; Maciaczyk, D; Maciaczyk, J; Schröter, F; Suwala, AK; Willbold, D | 1 |
| Boop, FA; Cai, C; Cheng, J; He, P; Pfeffer, LM; Pfeffer, SR; Sims, M; Wang, Y; Yang, CH; Yue, J | 1 |
| Amaral, R; da Fonseca, AC; Garcia, C; Geraldo, LH; Lima, FR; Matias, D | 1 |
| Cisneros Castillo, LR; Oancea, AD; Régnier-Vigouroux, A; Stüllein, C | 1 |
| Li, L; Song, C; Wang, S; Zha, Y; Zhao, H | 1 |
| Hirose, Y; Ohba, S | 1 |
| Cheng, G; Li, H; Li, J; Li, X; Zhang, J | 1 |
| Arvold, ND; Cefalu, M; Dominici, F; Schrag, D; Wang, Y; Zigler, C | 1 |
| Cao, ZX; Feng, XL; He, XY; Song, XP; Wu, QH; Xiao, WW; Zeng, HC; Zhang, B | 1 |
| Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ | 1 |
| Mingyi, M; Qiu, X; Qiu, Y; Tian, T | 1 |
| Chaim, IA; Gupta, SK; Joughin, BA; Kitange, GJ; Lauffenburger, DA; Mazzucato, P; Nagel, ZD; Samson, LD; Sarkaria, JN | 1 |
| Capelli, E; Corbella, F; Fassina, L; Lupo, G; Mognaschi, ME; Nano, R; Pasi, F | 1 |
| Chen, J; Li, C; Tan, Q; Wang, M; Wang, Y; Xie, C; Zhan, W; Zhang, Z | 1 |
| Choi, SH; Kim, BR; Kim, IH; Kim, JH; Kim, TM; Lee, ST; Park, CK; Park, SH; Park, SW; Sohn, CH; Yun, TJ | 1 |
| Clark, PA; Deming, DA; Gaal, JT; Kuo, JS; Pasch, CA; Robins, HI; Strebe, JK | 1 |
| Alla, P; Dagain, A; Faivre, A; Fouet, B; Joubert, C; Nguyen, AT; Sahuc, P; Wybrecht, D | 1 |
| Hatakeyama, S; Ikeda, T; Morisawa, Y; Norizuki, M; Okabe, T; Onishi, T; Sasahara, T; Suzuki, J; Toshima, M; Yokota, H | 1 |
| Armstrong, TS; Batchelor, TT; Chang, SM; Cloughesy, T; Galanis, E; Gilbert, M; Gondi, V; Ismaila, N; Lovely, M; Mehta, M; Mumber, MP; Sloan, A; Sulman, EP; Tsien, C | 1 |
| Belka, C; Eigenbrod, S; Kreth, FW; Kreth, S; Lutz, J; Niyazi, M; Schüller, U; Thon, N; Thorsteinsdottir, J; Tonn, JC | 1 |
| Blair, AA; Ellenbogen, RG; Gebhart, RN; Jeon, M; Silber, JR; Stephen, ZR; Zhang, M | 1 |
| Brem, H; Casaos, J; Choi, J; Eisinger-Mathason, TSK; Felder, R; Frikeche, J; Gorelick, N; Lott, T; Mangraviti, A; Scotland, SJ; Sesen, J; Skuli, N; Tyler, B; Volpin, F | 1 |
| Christensen, BC; Davis, MC; Ernstoff, MS; Fadul, CE; Fisher, JL; Gaur, AB; Hampton, TH; Lewis, LD; Rahme, GJ; Steel, SE; Thomas, AA; Tsongalis, GJ; Whipple, CA | 1 |
| Afghani, N; Mehta, T; Quick, QA; Skalli, O; Tang, N; Wang, J | 1 |
| Baretti, M; Di Tommaso, L; Santoro, A; Simonelli, M | 1 |
| Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhi, T; Zhou, X | 1 |
| Abdulkarim, B; Corredor, AG; Guiot, MC; Owen, S; Panet-Raymond, V; Petrecca, K; Shenouda, G; Souhami, L | 1 |
| Ajit, NE; Burton, GV; El-Osta, H; Peddi, P | 1 |
| Connelly, KE; Dykhuizen, EC; Martin, EC | 1 |
| Borchers, C; Eckert, F; Paulsen, F; Schittenhelm, J; Skardelly, M; Zips, D; Zwirner, K | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K | 1 |
| Lee, TY; Lu, H; Sheng, R; Zhang, C | 1 |
| Cao, H; Chen, R; Chen, Z; Cheng, Q; Huang, J; Jiang, B; Ma, X; Peng, R; Wan, X | 1 |
| Ansell, P; Fichtel, L; Fischer, J; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Mandich, H; Merrell, R; Munasinghe, W; Reardon, DA; Roberts-Rapp, L; Scott, AM; Sulman, EP; van den Bent, M; Xiong, H | 1 |
| Berger, A; Duchesne, M; Godet, J; Karayan-Tapon, L; Milin, S; Pinel, B; Wager, M | 1 |
| Banasavadi-Siddegowda, Y; Bolyard, C; Dmitrieva, N; Jaime-Ramirez, AC; Kaur, B; Relation, T; Wojton, J; Yoo, JY; Zhang, J | 1 |
| Feng, J; Feng, M; Yan, PF; Zhang, FC; Zhao, HY; Zhao, WH | 1 |
| Aldape, K; Barnholtz-Sloan, JS; Becker, AP; Bell, EH; Blumenthal, DT; Brachman, D; Bredel, M; Brown, PD; Chakravarti, A; Curran, W; Flickinger, J; Gilbert, MR; Glass, J; Grosu, AL; Klimowicz, AC; Lee, RJ; Magliocco, A; McElroy, JP; Mehta, M; Pugh, SL; Robe, P; Salavaggione, AL; Souhami, L; Stupp, R; Won, M | 1 |
| Berens, ME; Chow, D; Dhruv, HD; Hartman, LK; Inge, LJ; Kloss, J; Loftus, JC; Mathews, IT; Millard, N; Roos, A; Tran, NL; Tuncali, S; Winkles, JA; Yin, HH | 1 |
| Absalyamova, OV; Inozemtseva, MV; Kobyakov, GL; Lodygina, KS; Poddubskiy, AA; Ryzhova, MV | 1 |
| Guo, H; Liu, H; Liu, J; Liu, T; Shi, F; Wu, L; Wu, Q; Zhang, Q; Zhang, R | 1 |
| Chang, JH; Chang, JS; Cho, JH; Choi, SH; Kim, JW; Kim, SH; Suh, CO | 1 |
| Chen, C; Chen, W; Ge, XS; He, J; Kong, KK; Li, FC; Li, H; Li, JL; Li, P; Wang, F; Xu, XK | 1 |
| Achari, R; Arun, B; Arunsingh, M; Badgami, RK; Chatterjee, S; Mallick, I; Saha, A; Shrimali, RK | 1 |
| Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM | 1 |
| Feng, E; Sui, C; Sun, G; Wang, T | 1 |
| Ballhausen, H; Belka, C; Nachbichler, SB; Niyazi, M; Schupp, G | 1 |
| Biffoni, M; Buccarelli, M; Cenci, T; D'Alessandris, QG; De Maria, R; Larocca, LM; Martini, M; Olivi, A; Pallini, R; Ricci-Vitiani, L; Runci, D; Signore, M; Stancato, L | 1 |
| Chen, BD; Chen, L; Li, QZ; Li, WP; Li, ZY; Zhang, C; Zhang, XJ | 1 |
| Im, CN; Lee, JH; Yun, HH | 1 |
| Chen, Y; Dong, B; Guo, B; Liang, Y; Qiao, W; Xu, W; Zhou, H | 1 |
| Mehta, M; Nishikawa, R; Peters, K; Reardon, D; Wen, P | 1 |
| Li, L; Pei, H; Wang, H; Xia, Q; Xu, K; Zhang, Z | 1 |
| Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y | 1 |
| Bartolini, S; Brandes, AA; Danieli, D; De Biase, D; Ermani, M; Fioravanti, A; Franceschi, E; Ghimenton, C; Lanza, G; Paccapelo, A; Pession, A; Pia Foschini, M; Servadei, F; Silini, EM; Sturiale, C; Talacchi, A; Tallini, G; Volpin, L; Zunarelli, E | 1 |
| Cheng, YS; Ho, ASW; Kiang, KMY; Lee, D; Leung, GKK; Li, N; Poon, MW; Pu, JKS; Sun, S; Zhang, P; Zhang, X | 1 |
| Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C | 1 |
| Bendszus, M; Felsberg, J; Gramatzki, D; Hentschel, B; Herrlinger, U; Kickingereder, P; Loeffler, M; Pietsch, T; Reifenberger, G; Sabel, M; Schackert, G; Schlegel, U; Tonn, JC; Weller, M; Westphal, M; Wick, W | 1 |
| Chang, JH; Choe, G; Choi, SH; Kim, CY; Kim, E; Kim, IA; Kim, IH; Kim, JH; Kim, JW; Kim, N; Kim, SH; Kim, TM; Kim, YJ; Lee, ST; Park, CK; Park, SH; Suh, CO; Wee, CW | 1 |
| Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S | 1 |
| Chamberlain, MC; Mrugala, MM | 1 |
| Del Maestro, R; Guiot, MC; Kavan, P; Lambert, C; Leblanc, R; Muanza, T; Panet-Raymond, V; Roberge, D; Shakibnia, L; Shenouda, G; Souhami, L | 1 |
| Cairncross, JG; de Tribolet, N; Delorenzi, M; Dietrich, PY; Domany, E; Gorlia, T; Hainfellner, JA; Hamou, MF; Hegi, ME; Heppner, FL; Janzer, RC; Kouwenhoven, MC; Lambiv, WL; Migliavacca, E; Murat, A; Regli, L; Shay, T; Stupp, R; Wick, W; Zimmer, Y | 1 |
| Jenkinson, MD | 1 |
| Aoki, H; Fujiwara, T; Georgescu, MM; Hashimoto, Y; Hayashi, Y; Hess, KR; Iwado, E; Kawamura, H; Kondo, S; Kondo, Y; Mills, GB; Sawaya, R; Urata, Y; Yokoyama, T | 1 |
| Ashley, DM; Dobrovic, A; Drummond, KJ; Friedman, HS; Gan, HK; Hawkins, CJ; Johns, TG; Kaye, AH; Lovric, MM; Maxwell, JA; Mikeska, T; Riffkin, CD | 1 |
| Anile, C; Balducci, M; de Bonis, P; Lama, G; Lauriola, L; Maira, G; Mangiola, A; Sica, G | 1 |
| Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Giebel, B; Hau, P; Kunz-Schughart, LA; Leukel, P; Pillai, DR; Proescholdt, M; Reifenberger, G; Röhrl, S; Schwarz, S; Trampe-Kieslich, A; Wischhusen, J | 1 |
| Jiang, T; Li, G; Li, S; Wang, Z | 1 |
| Beule, AC; Bromberg, J; Ernemann, U; Karnath, HO; Marosi, C; Mason, WP; Platten, M; Rorden, C; Stupp, R; van den Bent, M; Weller, M; Wick, A; Wick, W | 1 |
| Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A | 1 |
| Dill, C; Ehninger, G; Illmer, T; Kestel, L; Kramer, M; Krex, D; Pfirrmann, M; Robel, K; Schackert, G; Schaich, M | 1 |
| Deluca, NA; Fellows-Mayle, W; Hadjipanayis, CG | 1 |
| Bozzao, A; Cantore, GP; De Sanctis, V; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Rasio, D; Salvati, M; Valeriani, M | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Black, PM; Bracht, LK; Drappatz, J; Hornick, JL; Kesari, S; Kulke, MH; LaFrankie, DC; Meyerhardt, JA; Norden, A; Redston, M; Wen, P | 1 |
| Brandes, AA; Dietrich, PY; Hottinger, AF; Stupp, R; van den Bent, MJ | 1 |
| Braun, K; Debus, J; Didinger, B; Ehemann, V; Langowski, J; Mueller, G; Pipkorn, R; Spring, H; Waldeck, W; Wiessler, M | 1 |
| Adumala, RR; Altaha, R; Crowell, EB; Hobbs, GR; Vinjamuri, M | 1 |
| Ang, KK; Chakravarti, A; Chinnaiyan, P; Curran, W; Hammond, E; Mehta, MP; Rojiani, AM; Tofilon, PJ; Wang, M; Zhang, HZ | 1 |
| Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C | 1 |
| Boiangiu, I; Gore, A; Machin, D; Sridhar, T; Symonds, RP | 1 |
| Garside, R; Grant, R; Hart, MG; Rogers, G; Somerville, M; Stein, K | 1 |
| Bierau, K; Califice, SF; Chaskis, C; D'Hondt, LA; De Grève, J; Joossens, EJ; Menten, J; Michotte, A; Neyns, B; Sadones, J; Sartenaer, D; Sciot, R; Strauven, T; Svensson, C; Veld, P | 1 |
| Autret-Leca, E; Beau Salinas, F; Carré, P; de Luca, K; Diot, P; Guilleminault, L; Narciso, B | 1 |
| Carlson, BL; Decker, PA; Grogan, PT; James, CD; Kitange, GJ; Lamont, JD; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH | 1 |
| de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA | 1 |
| Ballman, KV; Buckner, JC; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Becker, G; Borberg, SK; Fischedick, AR; Frommolt, P; Grauthoff, H; Herfarth, K; Kocher, M; Müller, RP; Niewald, M; Rühl, U; Staar, S; Steingräber, M; Stuschke, M | 1 |
| Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, T | 1 |
| Jalali, R | 1 |
| Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A | 1 |
| Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD | 1 |
| De Nève, N; Dehoux, M; Dewelle, J; Gaussin, JF; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V | 1 |
| Berger, MS; Dinca, EB; Haas-Kogan, DA; James, CD; Lu, KV; Pieper, RO; Prados, MD; Sarkaria, JN; Vandenberg, SR | 1 |
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M | 1 |
| Heymann, S; Karamanoukian, D; Noël, G; Quetin, P; Schott, R | 1 |
| Bokemeyer, C; Celik, I; Fiedler, W; Hauschild, J; Nippgen, J; Oliveira-Ferrer, L; Schuch, G | 1 |
| Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P | 1 |
| Beumer, JH; Egorin, MJ; Park, DM; Shah, DD | 1 |
| Battastini, AM; Braganhol, E; Brunetto, AL; Cechim, G; de Castro, CG; de Oliveira, MS; Lenz, G; Meurer, L; Roesler, R; Santos, DG; Schwarstmann, G; Schwartsmann, G | 1 |
| Beam, K; Burgan, WE; Camphausen, K; Carter, D; Chakravarti, A; Kwon, HC; Russo, AL; Slusher, BS; Tofilon, PJ; Weizheng, X; Zhang, J | 1 |
| Graziani, G; Tentori, L | 1 |
| Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A | 1 |
| Carlson, BL; Clarke, MJ; Curtin, NJ; Decker, PA; Grogan, PT; Lou, Z; Mladek, AC; Mulligan, EA; Plummer, ER; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A | 1 |
| Bähr, O; Glas, M; Happold, C; Herrlinger, U; Kortmann, RD; Reifenberger, G; Rieger, J; Steinbach, JP; Weller, M; Wick, W; Wiewrodt, D | 1 |
| Lefranc, F | 2 |
| Binello, E; Germano, IM | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Gerstner, ER; Lafrankie, D; McNamara, MB; Norden, AD; Wen, PY | 1 |
| Hoorens, A; Neyns, B; Stupp, R | 1 |
| Eccles, S; Gaspar, N; Jones, C; Pacey, S; Pearson, A; Sharp, SY; Vassal, G; Walton, M; Workman, P | 1 |
| Batchelor, TT; Cahill, DP; Codd, PJ; Curry, WT; Louis, DN | 1 |
| Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P | 1 |
| Bohl, J; Combs, SE; Debus, J; Elsasser, T; Schulz-Ertner, D; Weber, KJ; Weyrather, WK | 1 |
| Bell, D; Khasraw, M; Wheeler, H | 1 |
| Darzynkiewicz, Z; Kurose, A; Ogasawara, K; Ogawa, A; Sato, Y; Sawai, T; Traganos, F | 1 |
| Dehais, C; Laigle-Donadey, F; Mazeron, JJ; Sanson, M | 1 |
| Burton, TR; Eisenstat, DD; Gibson, SB | 1 |
| Beli, I; Chaldeopoulos, D; Fotineas, A; Koukourakis, GV; Kouloulias, V; Kouvaris, J; Maravelis, G; Pantelakos, P; Papadimitriou, C; Zacharias, G | 1 |
| Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IH; Lee, SH; Paek, SH; Park, CK | 1 |
| Fukushima, T; Inoue, T; Komatsu, F; Ohmura, T; Ohta, M; Oshiro, S; Sakamoto, S; Tsugu, H | 1 |
| Bachoo, RM; Boothman, DA; Burma, S; Camacho, CV; Cavenee, WK; Furnari, F; Hatanpaa, KJ; Madden, C; Maher, E; McEllin, B; Mickey, B; Mukherjee, B; Nannepaga, S; Sirasanagandala, S; Tomimatsu, N | 1 |
| Chansakul, P; Ito, M; Kato, T; Kim, SU; Kondo, Y; Natsume, A; Ohno, M; Wakabayashi, T; Yokoyama, H; Yuki, K | 1 |
| Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P | 1 |
| Sarma, N | 1 |
| Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J | 1 |
| Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ | 1 |
| Agati, R; Bacci, A; Benevento, F; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Mazzocchi, V; Scopece, L; Tosoni, A | 1 |
| Stupp, R; Uyl-de Groot, CA; van der Bent, M | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Das, P; Dwary, A; Goyal, S; Gupta, D; Mohanti, BK; Muzumder, S; Sharma, A; Thulkar, S | 1 |
| Alam, F; Baborie, A; Brodbelt, A; Crooks, D; Dunn, J; Haylock, B; Husband, D; Joyce, K; Liloglou, T; Moxham, M; Shenoy, A; Sibson, R; Walker, C; Wong, H | 1 |
| Dubey, A; Erasmus, A; Gauden, AJ; Gauden, SJ; Hunn, A; Waites, P | 1 |
| Chiang, J; Hodes, R; Johnson, F; Kovach, JS; Lonser, R; Lu, J; Zhuang, Z | 1 |
| Chen, FR; Chen, ZP; Fu, J; Liu, XM; Liu, ZG; Ng, HK; Pangjesse, CS; Shi, HL | 1 |
| Baumert, BG; Leffers, P; Tjon-A-Fat, H; Twijnstra, A; van Genugten, JA | 1 |
| Aldape, K; Cahill, DP; Iafrate, AJ; Louis, DN; Miao, J; Nutt, CL; Yip, S | 1 |
| Hall, JR; Short, SC | 1 |
| Cognetti, F; Di Giovanni, S; Fabi, A; Metro, G; Russillo, M; Vidiri, A | 1 |
| Bektas, M; Bigner, DD; Friedman, HS; Johnson, SP; Poe, WE | 1 |
| Konishi, N; Nakamura, M; Nakase, H; Shimada, K | 1 |
| Nishikawa, R | 2 |
| Larocca, LM; Montano, N; Pallini, R | 1 |
| Batchelor, T; Chamberlain, M; Desideri, S; Fine, HA; Fisher, J; Grossman, SA; Mikkelsen, T; Piantadosi, S; Ye, X | 1 |
| Jeon, HJ; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Park, KB | 1 |
| Cionini, L; De Franco, L; Fabrini, MG; Grespi, S; Pasqualetti, F; Perrone, F; Vannozzi, R | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Eichinger, JB; George, BJ; Richard, TJ | 1 |
| Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK | 1 |
| Balducci, M; Calista, F; Cantore, GP; Cellini, N; Cilla, S; Deodato, F; Digesù, C; Esposito, V; Ferro, M; Ianiri, M; Macchia, G; Morganti, AG; Piermattei, A; Romanelli, P; Salvati, M; Valentini, V | 1 |
| Dresemann, G; Engel, E; Fluge, O; Heinrich, B; Hosius, C; Karup-Hansen, A; Krex, D; Mayer-Steinacker, R; Mehdorn, M; Nikolova, Z; Nowak, A; Olver, IN; Parker, R; Rosenthal, MA; Schleyer, E; Sieder, C; Sorenson, G; Steinbach, JP; Wagner, W; Wedding, U; Weller, M | 1 |
| Ballman, KA; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Chen, B; Jiang, T; Li, S; Wang, Z; Zhang, W | 1 |
| Anile, C; Apicella, G; Balducci, M; Cellini, N; Colicchio, G; D'Agostino, GR; De Bari, B; De Renzi, F; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Pompucci, A; Valentini, V | 1 |
| Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Park, KB; Rhee, DJ; Song, SY; Suh, YL | 1 |
| Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ | 1 |
| Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G | 1 |
| Beijnen, JH; de Vries, NA; van Tellingen, O | 1 |
| Inamasu, J; Kuramae, T; Nakatsukasa, M | 1 |
| Aghi, MK; Yang, I | 1 |
| Ahn, BJ; Berger, MS; Chang, SM; Han, SJ; McDermott, MW; Otero, JJ; Parsa, AT; Tihan, T; Yang, I | 1 |
| Collichio, F; Ewend, MG; Grabowski, S; Kimple, RJ; Morris, DE; Papez, M | 1 |
| Chen, B; Jiang, T; Lin, Y; Song, SW; Zhang, W | 1 |
| Cairncross, JG; de Robles, PA; Dharmawardene, M; Easaw, JC; Forsyth, PA; Hamilton, MG; Magliocco, AM; McIntyre, JB; Parney, IF; Roldán, GB; Scott, JN; Yan, ES | 1 |
| Cao, VT; Chae, HJ; Jin, SG; Jung, S; Jung, TY; Kang, SS; Kim, IY; Lee, KH; Moon, KS; Park, CS | 1 |
| Bähr, O; Bamberg, M; Gorlia, T; Hartmann, C; Herrlinger, U; Meyermann, R; Tatagiba, M; von Deimling, A; Weiler, M; Weller, M; Wick, W; Wiewrodt, D | 1 |
| Bhakat, KK; Bocangel, D; Mitra, S; Sengupta, S | 1 |
| Choi, JR; Jang, SJ; Kim, SH; Kim, SJ; Lee, CH; Lee, ST; Park, TS; Song, J; Suh, B | 1 |
| Jeremic, B; Kortmann, R; Miriamanoff, R; Okunieff, P; Roa, W; Shibamoto, Y; Small, C; Xing, JZ | 1 |
| Baltas, D; Chatzisotiriou, A; Fountzilas, G; Fragkoulidi, A; Iliadis, G; Kalogera-Fountzila, A; Misailidou, D; Selviaridis, P; Tselis, N; Zamboglou, N | 1 |
| Bernsen, HJ; Jeuken, JW; Poelen, J; Prick, MJ; Wesseling, P | 1 |
| Chalmers, AJ; Lovegrove, N; Martindale, C; Ruff, EM; Short, SC | 1 |
| Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ | 1 |
| Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ | 1 |
| Cote, G; Dunn, SE; Faury, D; Fotovati, A; Gao, Y; Guns, E; Jabado, N; Lee, C; Toyota, B; Wang, M | 1 |
| Cifarelli, CP; Dassoulas, K; Han, S; Olson, C; Rainey, J; Sheehan, J | 1 |
| Fukushima, T; Kataoka, H; Takeshima, H | 1 |
| Cartalat-Carel, S; Chinot, O; Delattre, JY; Figarella-Branger, D; Honnorat, J; Kaloshi, G; Laigle-Donadey, F; Sanson, M; Taillandier, L | 1 |
| Park, DM; Rich, JN; Sathornsumetee, S | 1 |
| Backes, H; Brunn, A; Burghaus, L; Galldiks, N; Heiss, WD; Jacobs, AH; Kracht, LW; Ullrich, RT | 1 |
| Batchelor, TT; Ciampa, A; Doherty, LM; Drappatz, J; Gerard, M; Kesari, S; Lafrankie, DC; Ligon, KL; Muzikansky, A; Norden, AD; Phan, P; Sceppa, C; Schiff, D; Weiss, SE; Wen, PY; Wong, ET; Young, G | 1 |
| Berger, W; Buchroithner, J; Filipits, M; Fischer, J; Lötsch, D; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S; Weis, S | 1 |
| Linz, U | 1 |
| Butowski, N; Chang, SM; Hristova-Kazmierski, M; Lamborn, KR; Musib, L; Nicol, SJ; Parvataneni, R; Polley, MY; Prados, MD; Thornton, DE | 1 |
| Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A | 1 |
| Butowski, N; Chang, SM; Clarke, JL; Lamborn, KR; Polley, MY; Prados, M | 2 |
| Dong, SM; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Nam, DH; Suh, YL | 1 |
| Aviv, R; Davey, P; Lam, K; Morrison, M; Perry, J; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN | 1 |
| Freyschlag, CF; Krafft, U; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F | 1 |
| Abdulkarim, B; Aghi, M; Chahal, M; Christensen, JG; Famulski, K; Graham, K; Jacques, A; Lesniak, D; Murray, D; Sabri, S; Xu, Y | 1 |
| Cadosch, D; Collen, TD; Fournier, JY; Gautschi, OP; Hildebrandt, G; Hoederath, P; Hundsberger, T; Land, M | 1 |
| Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA | 1 |
| Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB | 1 |
| Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M | 1 |
| Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P | 1 |
| Ayers-Ringler, J; Banerjee, A; Berger, MS; Gupta, N; Hashizume, R; James, CD; Prados, MD; VandenBerg, SR | 1 |
| Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B | 1 |
| Black, P; Brady, LW; Cohen, SC; Emrich, JG; Gracely, EJ; Jenrette, JM; Kim, JH; Li, L; Quang, TS; Yaeger, TE | 1 |
| Dolezalova, H; Fadrus, P; Hrstka, R; Kren, L; Lakomy, R; Lzicarova, E; Michalek, J; Novakova, J; Slaby, O; Smrcka, M; Svoboda, M; Valik, D; Vyzula, R | 1 |
| Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
| Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X | 1 |
| Jung, S; Jung, TY; Kang, SS; Kim, IY; Kim, YH; Lee, KH; Moon, KS; Park, CS | 1 |
| Bendinelli, S; Casalini, F; Costa, B; Da Pozzo, E; Da Settimo, F; Gabelloni, P; Martini, C; Nuti, E; Orlandini, E; Rossello, A | 1 |
| Beauchamp, D; Blough, MD; Cairncross, JG; Kelly, JJ; Ramirez, AL; Stechishin, O; Weiss, S; Westgate, MR | 1 |
| Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK | 1 |
| Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M | 1 |
| Alegria, C; Almeida, R; Amorim, J; Augusto, I; Braga, F; Caeiro, C; Carvalho, E; Castro, L; Costa, BM; Costa, P; Damasceno, M; Guimarães, I; Honavar, M; Jaraquemada, T; Linhares, P; Lopes, JM; Martinho, O; Nabiço, R; Osório, L; Pardal, F; Pinheiro, C; Pires, M; Reis, RM; Resende, M; Silva, A | 1 |
| Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH | 1 |
| Birol Sarica, F; Cekinmez, M; Cem Onal, H; Erdogan, B; Mertsoylu, H; Nur Altinors, M; Pehlivan, B; Sen, O; Topkan, E; Tufan, K | 1 |
| Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M | 1 |
| Grisdale, K; Groves, MD; Hunter, K; Ritterhouse, M; Williams, MD | 1 |
| Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Hayashi, K; Kamada, K; Matsuo, T; Matsuse, M; Mitsutake, N; Nagata, I; Saenko, V; Suzuki, K; Takakura, S; Ujifuku, K; Yamashita, S | 1 |
| Blechschmidt, C; Czabanka, M; Koch, A; Misch, M; Plotkin, M; Stockhammer, F; Tuettenberg, J; Vajkoczy, P | 1 |
| Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V | 1 |
| Blank, A; Bobola, MS; Kolstoe, DD; Silber, JR | 1 |
| Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A | 1 |
| Cortes, U; Dkhissi, F; Dusanter-Fourt, I; Karayan-Tapon, L; Le Corf, A; Martin-Lannerée, S; Tourani, JM; Turhan, AG; Villalva, C; Wager, M | 1 |
| Butowski, NA; Cha, S; Chang, SM; Elkhaled, A; Jalbert, L; Khayal, IS; Nelson, SJ; Polley, MY | 1 |
| Ameziane, N; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; Steenbergen, RD; van den Berg, J; van der Meide, WF; van Nifterik, KA; Wedekind, LE | 1 |
| Bankiewicz, K; Hachisu, R; Iwamizu, H; Kato, T; Motomura, K; Natsume, A; Sugita, T; Toda, H; Wakabayashi, T; Watanabe, R; Yuki, K | 1 |
| Emmerich, J; Giménez-Pando, J; Gómez-González, E; Márquez-Rivas, J; Ollero-Ortiz, A; Quiroga-Cantero, E; Ramirez, G; Rivas, E | 1 |
| Brem, H; Chaichana, KL; Halthore, AN; Olivi, A; Parker, SL; Quinones-Hinojosa, A; Weingart, JD | 1 |
| Avgeropoulos, NG; Baker, CH; Bobustuc, GC; Jenkins, WD; Konduri, SD; Limaye, A; Pearl, G | 1 |
| Ekholm, SE; Korones, DN; Mangla, R; Milano, MT; Singh, G; Zhong, J; Ziegelitz, D | 1 |
| Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N | 1 |
| Biggs, MT; Cook, RJ; Hegi, ME; Henson, JD; Little, NS; McDonald, KL; McDonnell, J; Muntoni, A; Reddel, RR; Robinson, BG; Royds, JA; von Deimling, A; Wheeler, HR | 1 |
| Mukherji, SK; Rajdev, P; Wesolowski, JR | 1 |
| Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V | 1 |
| Gupta, A; Gupta, DK; Jain, A; Jha, P; Mallick, S; Puri, T; Sarkar, C; Sharma, MC; Srivastava, A; Suri, V | 1 |
| Giusti, V; Gorlia, T; H-Stenstam, B; Hopewell, JW; Pellettieri, L; Sköld, K | 1 |
| Batchelor, TT; Chamberlain, MC; Desideri, S; Grossman, SA; Lesser, GJ; Peereboom, DM; Rosenfeld, MR; Salazar, AM; Ye, X | 1 |
| Kumabe, T; Nishihara, M; Saito, R; Satoh, T; Sonoda, Y; Sugiyama, S; Tominaga, T; Yamashita, Y; Yokosawa, M; Yokoyama, M | 1 |
| Blasel, S; Franz, K; Gasser, T; Oszvald, A; Rathert, J; Seifert, V; Senft, C | 1 |
| Donze, J; Liu, L; McGraw, M; Palomo, JM; Rahmathulla, G; Robinson, CG; Vogelbaum, MA | 1 |
| Chen, J; Pan, T; Shi, L; Wang, Z; Yang, J; Zhang, S | 1 |
| Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T | 1 |
| Berti, F; Bertoni, F; Biti, G; Buglione, M; Cipressi, S; De Renzis, C; Detti, B; Fariselli, L; Fatigante, L; Fusco, V; Krengli, M; Lioce, M; Lupattelli, M; Magrini, SM; Maluta, S; Mantovani, C; Muto, P; Parisi, S; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S; Sotti, G; Tombolini, V | 1 |
| Coenen, HH; Eble, MJ; Holy, R; Kaiser, HJ; Klotz, J; Langen, KJ; Nussen, S; Pinkawa, M; Piroth, MD; Stoffels, G | 1 |
| Bekele, BN; Bobustuc, GC; Colman, H; Conrad, CA; Gilbert, MR; Groves, MD; Hsu, SH; Levin, VA; Puduvalli, VK; Qiao, W; Walbert, T; Yung, WK | 1 |
| Ahn, HS; Cho, BK; Kim, DG; Kim, IH; Kim, SK; Lee, JY; Park, SH; Phi, JH; Song, KS; Wang, KC | 1 |
| Grommes, C; Papanicolaou, G; Redelman-Sidi, G | 1 |
| Molczyk, A; Łata, S | 1 |
| Arcella, A; Buttarelli, F; D'Elia, A; Esposito, V; Giangaspero, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Salvati, M; Scarpino, S | 1 |
| Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B | 1 |
| Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M | 1 |
| Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK | 1 |
| Goldbecker, A; Herrmann, J; Raab, P; Tryc, AB; Weissenborn, K; Worthmann, H | 1 |
| Chen, C; Damek, DM; Franklin, W; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Olsen, C; Rusthoven, KE; Waziri, A | 1 |
| Daou, MC; Gilbert, CA; Moser, RP; Ross, AH | 1 |
| Bello, L; Bertani, G; Mårlind, J; Neri, D; Pedretti, M; Sala, C; Verpelli, C | 1 |
| Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L | 1 |
| Beery, E; Fenig, E; Gil-Ad, I; Israeli, M; Lahav, M; Nordenberg, J; Tzadok, S; Uziel, O; Weizman, A | 1 |
| Combs, SE; Debus, J; Haberer, T; Habermehl, D; Haselmann, R; Jäkel, O; Kieser, M; Nikoghosyan, A; Rieken, S; Unterberg, A; Wick, W | 1 |
| Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L | 1 |
| Bontempi, G; Bruyère, C; Decaestecker, C; Gras, T; Haibe-Kains, B; Kiss, R; Le Calvé, B; Le Mercier, M; Lefranc, F; Lonez, C; Ruysschaert, JM; Rynkowski, M | 1 |
| Huang, CY; Kuo, LT; Lien, HC; Liu, KL; Liu, MT; Tseng, HM | 1 |
| Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM | 1 |
| Franz, K; Fraunholz, I; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, R; Peters, K; Reardon, DA; Rich, JN; Sampson, J; Threatt, S; Vredenburgh, JJ | 1 |
| Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S | 1 |
| Belka, C; Eigenbrod, S; Grasbon-Frodl, EM; Kreth, FW; Kreth, S; Kretzschmar, HA; Lutz, J; Popperl, G; Thon, N; Tonn, JC | 1 |
| Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W | 1 |
| Jin, YH; Liu, HY; Shu, F; Wang, QJ; Wang, Z; Yang, Y; Zhang, WB | 1 |
| Hegi, ME; Stupp, R; Tabatabai, G; Weller, M; Wick, W | 1 |
| Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S | 1 |
| Aldape, KD; Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Gilbert, MR; Heimberger, AB; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sawaya, R; Schmittling, RJ; Shi, W; Vredenburgh, JJ | 1 |
| Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A | 1 |
| Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY | 1 |
| Bax, DA; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Reis, RM; Sharp, SY; Vassal, G; Viana-Pereira, M; Workman, P | 1 |
| Chen, Z; Mao, Y; Wang, Y; Wu, J; Yao, Y; Zhang, C; Zhou, L | 1 |
| Dawirs, S; Dörner, L; Hedderich, J; Mehdorn, HM; Nabavi, A; Schwartz, F | 1 |
| Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ | 1 |
| Butowski, NA; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Nelson, SJ; Polley, MY | 1 |
| Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M | 1 |
| Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IA; Kim, IH; Kim, JE; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Nam, DH; Paek, SH; Park, BJ; Park, CK; Rhee, CH | 1 |
| Ang, C; Guiot, MC; Kavan, P; Ramanakumar, AV; Roberge, D | 1 |
| Choi, SH; Han, JH; Jung, HW; Kim, CY; Kim, DG; Kim, J; Kim, SK; Kim, TM; Lee, AR; Lee, SH; Park, CK; Park, SH; Yim, SY | 1 |
| Cappella, P; Pesenti, E; Rizzitano, S; Scabini, M; Stellari, F; Texido, G | 1 |
| Ahn, JM; Jin, J; Jin, Y; Jo, MY; Joo, KM; Kim, JK; Kim, Y; Lee, SJ; Lim, J; Nam, DH; Yoon, MJ | 1 |
| Mehta, MP; Nieder, C | 1 |
| Cloughesy, T | 1 |
| Brem, S; Wong, ET | 1 |
| Black, K; Cloughesy, T; Elashoff, R; Fehrenbacher, L; Filka, E; Green, RM; Kolevska, T; Lai, A; Liau, LM; Mischel, PS; Nghiemphu, PL; Peak, S; Phuphanich, S; Polikoff, J; Pope, WB; Selch, M; Solis, OE; Spier, CE; Tran, A; Yong, WH | 1 |
| Aldape, KD; Archer, GE; Bigner, DD; Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gilbert, MR; Heimberger, AB; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sawaya, R; Schmittling, R; Shi, W; Vredenburgh, JJ | 1 |
| Aoki, T; Fujimaki, T; Itoh, K; Kajiwara, K; Kurisu, K; Mineta, T; Narita, Y; Sawamura, Y; Shibui, S; Terasaki, M; Yamada, A | 1 |
| Chen, YF; Flickinger, JC; Heron, DE; Huq, MS; Landsittel, D; Mintz, A; Paravati, AJ | 1 |
| Marosi, C; Pichler, J | 1 |
| Barcia, J; García-Taboada, E; Guzmán, M; Hernández-Tiedra, S; Lorente, M; Rodríguez-Fornés, F; Salazar, M; Torres, S; Velasco, G | 1 |
| Agnihotri, S; Cairns, R; Guha, A; Hawkins, C; Micallef, J; Mukherjee, J; Sabha, N; Wolf, A | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W | 1 |
| Boyer, P; Dufour, P; Fischer-Lokou, D; Froelich, S; Gaub, MP; Kehrli, P; Maitrot, D; Noël, G; Schott, R | 1 |
| Cornes, P; Greenslade, M; Herbert, C; Hopkins, K; Sawyer, H; Williams, M | 1 |
| Payer, F | 1 |
| Aftab, DT; Berger, MS; Haas-Kogan, DA; James, CD; Mueller, S; Ozawa, T; Polley, MY; Prados, MD; Prasad, G; Sottero, T; Weiss, WA; Yang, X | 1 |
| Ito, I; Mitsuya, K; Nakajima, T; Nakasu, S; Nakasu, Y; Tashiro, H; Watanabe, R | 1 |
| Côté, AL; Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH | 1 |
| Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Hamilton, RL; Heideman, RL; Holmes, EJ; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T | 1 |
| Achawal, S; Dixit, S; Hingorani, M; Scott, I | 1 |
| Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S | 1 |
| Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA | 1 |
| Oymak, E; Parlak, C; Pehlivan, B; Topkan, E; Topuk, S | 1 |
| Brunetti, E; Bucci, B; D'agnano, I; De Paula, U; De Salvo, M; Gagliassi, R; Marchese, R; Maresca, G; Raza, GH; Stigliano, A | 1 |
| Brown, AR; Goellner, EM; Grimme, B; Lin, YC; Mitchell, L; Sobol, RW; Sugrue, KF; Tang, JB; Trivedi, RN; Wang, XH | 1 |
| Eigenbrod, S; Felsberg, J; Hentschel, B; Kreth, FW; Löffler, M; Pietsch, T; Reifenberger, G; Sabel, MC; Schackert, G; Thon, N; Tonn, JC; Weller, M; Westphal, M | 1 |
| Chinot, OL; Cloughesy, T; Das, A; de La Motte Rouge, T; Modrusan, Z; Moore, N; Phillips, H; Zeaiter, A | 1 |
| Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J | 2 |
| Hiramatsu, R; Hirota, Y; Kawabata, S; Kirihata, M; Kuroiwa, T; Maruhashi, A; Miyata, S; Miyatake, S; Ono, K; Sakurai, Y; Takekita, Y | 1 |
| Gevertz, JL | 1 |
| Agnihotri, S; Aldape, K; Clarke, ID; Dirks, PB; Fuller, GN; Gajadhar, A; Guha, A; Hawkins, C; Kesari, S; McGlade, CJ; Mischel, PS; Munoz, DM; Restrepo, A; Smith, CJ; Stanford, WL; Wolf, A | 1 |
| Abe, T; Higashi, H; Kishida, Y; Kondo, Y; Motomura, K; Nakasu, Y; Namba, H; Natsume, A; Wakabayashi, T; Wakai, K | 1 |
| Abe, K; Amano, T; Hiwatashi, A; Honda, H; Kamano, H; Nakamizo, A; Shioyama, Y; Shirakawa, Y; Suzuki, S; Torisu, R; Yamashita, K; Yoshimoto, K; Yoshiura, T | 1 |
| Stummer, W; van den Bent, MJ; Westphal, M | 1 |
| Barrie, M; Chinot, O; Colin, C; Coulibaly, B; Delfino, C; Figarella-Branger, D; Fina, F; Loundou, A; Metellus, P; Nanni-Metellus, I; Ouafik, L; Tchogandjian, A | 1 |
| Bailey, B; Baluyut, AR; Cai, S; Chan, RJ; Ernstberger, A; Goebel, WS; Jones, DR; Juliar, BE; Mayo, LD; Pollok, KE; Sinn, AL; Wang, H | 1 |
| Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G | 1 |
| Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH; Lallana, EC; Lewis, LD; Li, Z; Rhodes, CH; Szczepiorkowski, ZM; Tosteson, TD; Wishart, HA | 1 |
| Enomoto, T; Ishikawa, E; Matsumura, A; Morishita, Y; Nakai, K; Ohno, T; Sakamoto, N; Sato, M; Satomi, K; Takano, S; Tsuboi, K; Yamamoto, T | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Bangert, A; Cristofanon, S; Debatin, KM; Fulda, S; Häcker, S | 1 |
| Hasegawa, M; Helleday, T; Kinashi, Y; Kondo, N; Masunaga, S; Mori, E; Noda, T; Ohnishi, T; Ono, K; Suzuki, M; Takahashi, A; Thompson, LH; Zdzienicka, MZ | 1 |
| Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH | 1 |
| Camci, C; Dirier, A; Kalender, ME; Pehlivan, Y; Sevinc, A; Turkbeyler, IH | 1 |
| Cejna, M; DeVries, A; Eiter, H; Maier, R; Muxel, B; Muxel, M; Roessler, K; Zachenhofer, I | 1 |
| Bok, R; James, CD; Nelson, SJ; Ozawa, T; Park, I; Phillips, JJ; Ronen, SM; Vigneron, DB | 1 |
| Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK | 1 |
| Davis, ME; Stoiber, AM | 1 |
| Bommer, M; Haenle, MM; Klaus, B; Mayer-Steinacker, R; Scheuerle, A; Schmid, M; Schönsteiner, SS | 1 |
| Aviv, R; Davey, P; Lam, K; Oh, J; Perry, JR; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN | 1 |
| Han, N; Hauser, K; Herion, TW; Huber, PE; Lahn, M; Peschke, P; Timke, C; Weber, KJ; Wirkner, U; Zhang, M | 1 |
| Lesniak, MS | 1 |
| Barrie, M; Beauchesne, P; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, O; Delattre, JY; Ducray, F; Gállego Pérez-Larraya, J; Guillamo, JS; Honnorat, J; Huchet, A; Matta, M; Mokhtari, K; Monjour, A; Taillandier, L; Tanguy, ML | 1 |
| Archer, GE; Bigner, DD; Congdon, KL; Cui, X; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sanchez-Perez, L; Schmittling, RJ; Snyder, DJ; Vredenburgh, JJ | 1 |
| Cho, BK; Kim, SK; Lee, JY; Park, CK; Park, SH; Wang, KC | 1 |
| Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ | 1 |
| Abysheva, SN; Bakholdin, DV; Ievleva, AG; Imianitov, EN; Luchin, EI; Matsko, DE; Matsko, MV; Potapova, ON; Ulitin, AIu; Zavgorodniaia, EV | 1 |
| Ananda, S; Brown, C; Cher, L; Dowling, A; Nowak, AK; Rosenthal, MA; Simes, J | 1 |
| Berberat, J; Bodis, S; Merlo, A; Rogers, S | 1 |
| Demir, H; Joshi, K; Miyazaki, T; Nakano, I; Ray-Chaudhury, A; Yamada, R | 1 |
| Buttmann, M; Flentje, M; Guckenberger, M; Mayer, M; Sweeney, RA; Vince, GH | 1 |
| Feng, K; Fu, Z; Shi, L; Wan, Y; Wang, Y; Wang, Z; Wu, F; Yan, W; You, Y; Zhang, J; Zhang, S | 1 |
| Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M | 1 |
| Brower, V | 1 |
| Darefsky, AS; Dubrow, R; King, JT | 1 |
| Bao, Z; Chen, L; Han, L; Jiang, T; Kang, C; Li, S; Liu, Y; Shi, Z; Wang, Y; Yan, W; Yang, P; You, G; Zhang, W | 1 |
| Delattre, JY | 1 |
| Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S | 1 |
| Desjardins, A; Friedman, HS; Lou, E; Peters, KB; Reardon, DA; Sampson, JH; Sumrall, A; Turner, S; Vredenburgh, JJ | 1 |
| Bianchi, F; D'Alessandris, QG; Doglietto, F; Fernandez, E; Lauretti, L; Maira, G; Montano, N; Pallini, R | 1 |
| Abdollahi, A; Combs, SE; Debus, J; Hartmann, C; Rieken, S; von Deimling, A; Wick, W | 1 |
| Chen, TC; Cho, H; Hofman, FM; Jhaveri, N; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Wang, W | 1 |
| Kayama, T; Kitanaka, C; Matsuda, K; Sato, A; Seino, S; Sunayama, J; Suzuki, K; Tachibana, K; Tomiyama, A; Watanabe, E | 1 |
| Das, UN; Faragó, N; Fehér, LZ; Kitajka, K; Puskás, LG | 1 |
| Day, PJ; Lee, NP; Leung, GK; Lui, WM; Ng, GK; Pu, JK; Sun, S; Wong, TS; Zhang, XQ | 1 |
| Addas, A; Al-Hussaini, M; Al-Rashdan, A; Almousa, A; Alsharbaji, A; Elyan, M; Ezam, N; Hashem, SA; Mohamad, I; Nour, A; Salem, A; Sughayer, M | 1 |
| Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A | 1 |
| Arpa, D; Cardali, S; Conti, A; De Renzis, C; Granata, F; Pontoriero, A; Romanelli, P; Siragusa, C; Tomasello, C; Tomasello, F | 1 |
| Beier, CP; Beier, D; Schulz, JB | 1 |
| Albanese, A; Anile, C; Balducci, M; Chiesa, S; D'Agostino, GR; De Bari, B; De Rose, F; Diletto, B; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Micciche', F; Morganti, AG; Valentini, V | 1 |
| Ahluwalia, MS | 1 |
| Berdel, C; Fleckenstein, J; Ketter, R; Licht, N; Niewald, M; Rübe, C | 1 |
| Kayama, T; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Ueno, H | 1 |
| Fei, Y; HuiXia, H; LanXiao, W; Lei, Y; Si, G; SongTao, Q; XueLin, Z; YanQing, D | 1 |
| Desjardins, A; Sampson, JH | 1 |
| Eagan, P; Golfinos, JG; Gruber, D; Gruber, ML; Kunnakkat, S; Narayana, A; Parker, E; Raza, S; Zagzag, D | 1 |
| Franz, K; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C | 1 |
| Johnson, DR; O'Neill, BP | 1 |
| Brown, D; Cao, Y; Chenevert, T; Gomez-Hassan, D; Heth, J; Junck, L; Lawrence, T; Normolle, D; Piert, M; Schipper, M; Ten Haken, RK; Tsien, CI | 1 |
| Chambers, CR; Lam, N | 1 |
| Bakker, A; Benedetti, G; De Rosa, A; Ferruzzi, P; Giordano, C; Magnoni, L; Magrini, R; Mennillo, F; Miragliotta, V; Mori, E; Pericot Mohr, Gl; Rossi, M; Thomas, R; Tunici, P | 1 |
| Annamalai, AK; Antoun, NM; Burnet, NG; Burton, H; Cheow, HK; Dean, AF; Gurnell, M; Halsall, DJ; Jefferies, SJ; Kandasamy, N; Kirollos, RW; Kovacs, K; Pickard, JD; Shaw, AS; Simpson, HL | 1 |
| Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C | 1 |
| Chang, YL; Chen, MT; Chen, YW; Cherng, JY; Chien, Y; Chiou, GY; Chiou, SH; Huang, PI; Lo, WL; Shih, YH; Wang, ML; Yang, YP | 1 |
| Arivazhagan, A; Chandramouli, BA; Hegde, AS; Kondaiah, P; Kumar, DM; Mondal, N; Patric, IR; Prasanna, K; Rao, MR; Sagar, V; Santosh, V; Somasundaram, K; Sridevi, S; Srividya, MR; Thennarasu, K; Thota, B | 1 |
| Bauman, GS; Cao, JQ; Fisher, BJ; Macdonald, DR; Megyesi, JF; Watling, CJ | 1 |
| Alksne, J; Cornell, M; Kesari, S; Lawson, JD; Mundt, AJ; Murphy, KT; Pan, H | 1 |
| Corbella, F; Di Liberto, R; Facoetti, A; Mazzini, G; Nano, R; Paolini, A; Pasi, F | 1 |
| Bradshaw, TD; Stevens, MF; Zhang, J | 1 |
| Augurio, A; Buonaguidi, R; Céfaro, GA; Di Nicola, M; Galzio, RJ; Genovesi, D; Taraborrelli, M; Trignani, M; Vinciguerra, A | 1 |
| Casalegno-Garduno, R; Classen, CF; Enders, A; Freund, M; Linnebacher, M; Mani, J; Schmitt, A; Schmitt, M; Stockhammer, F; Xu, X | 1 |
| Afzal, P; Campbell, AP; Dixit, S; Hingorani, M | 1 |
| Gunjur, A; Lau, E; Ryan, G; Taouk, Y | 1 |
| Bressler, LR; Letarte, N; Villano, JL | 1 |
| Agnihotri, S; Aldape, K; Carlson, BL; Diefes, KL; Gajadhar, AS; Gorlia, T; Guha, A; Hawkins, C; Hegi, M; Kelly, J; Margison, GP; McGown, G; Mischel, PS; Sarkaria, JN; Ternamian, C; Thorncroft, M | 1 |
| Borges, KS; Brassesco, MS; Carlotti, CG; Castro-Gamero, AM; da Silva Silveira, V; de Oliveira, HF; de Paula Queiroz, RG; Moreno, DA; Scrideli, CA; Tone, LG | 1 |
| Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S | 1 |
| Hirose, Y; Kanai, R; Louis, DN; Martuza, RL; Rabkin, SD; Sgubin, D; Wakimoto, H; Yip, S; Zaupa, CM | 1 |
| Enger, PØ; Leiss, L; Li, X; Skaftnesmo, KO; Sleire, L; Wang, J; Yan, T | 1 |
| Black, J; Shen, H; Webb, S; Wheeler, H | 1 |
| Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S | 1 |
| Kilickap, S; Oztoprak, I; Yucel, B | 1 |
| Chatzisotiriou, A; Eleftheraki, AG; Fountzilas, G; Iliadis, G; Kotoula, V; Lambaki, S; Misailidou, D; Selviaridis, P; Televantou, D | 1 |
| Dunne, M; Faul, C; Fitzpatrick, D; Forde, P; McArdle, O; O'Neill, B; Rock, K | 1 |
| Belka, C; Niyazi, M; Schwarz, SB; Suchorska, B | 1 |
| Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P | 1 |
| Abrams, J; Harlan, L; Mann, B; Yabroff, KR; Zeruto, C | 1 |
| Cenci, T; D'Alessandris, QG; De Maria, R; Larocca, LM; Maira, G; Martini, M; Montano, N; Pallini, R; Pelacchi, F; Ricci-Vitiani, L | 1 |
| Bady, P; Besuchet Schmutz, N; Diserens, AC; Gorlia, T; Hamou, MF; Hartmann, C; Hegi, ME; Janzer, RC; Kouwenhoven, MC; Lambiv, WL; Martinet, D; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; van den Bent, MJ; von Deimling, A; Weller, M; Wesseling, P | 1 |
| Audrain, O; Carsin, B; Gedouin, D; Hamlat, A; Lecouillard, I; Lesimple, T; Louvel, G; Mesbah, H; Quillien, V; Riffaud, L; Vauleon, E | 1 |
| Alexiou, GA; Argyropoulou, MI; Fotakopoulos, G; Fotopoulos, AD; Goussia, A; Kyritsis, AP; Ntoulia, A; Tsekeris, P; Voulgaris, S; Zikou, A | 1 |
| Decker, R; Gharib, M; Gorlia, T; Lacombe, D; Lai, C; Rampling, R; Sanson, M; Stoffregen, C; Taal, W; van den Bent, MJ | 1 |
| Ewelt, C; Felsberg, J; Jakobs, O; Martus, P; Meinel, T; Reifenberger, G; Stummer, W | 1 |
| Hofstra, DE; Koo, S; Marty, FM; Shearer, JF; Sigler, L; Sutton, DA; Thompson, EH; Wickes, BL; Yeh, WW | 1 |
| Calderaro, F; Cevenini, G; Comincini, S; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M | 1 |
| Estrada-Bernal, A; Palanichamy, K; Ray Chaudhury, A; Van Brocklyn, JR | 1 |
| Bernaudin, M; Chapon, F; Colin, P; Diebold, MD; Dugué, AE; Emery, E; Guillamo, JS; Lechapt-Zalcman, E; Levallet, G; Menei, P; Peruzzy, P; Vital, A | 1 |
| Comet, B; Le Rhun, E; Ramirez, C; Reich, M | 1 |
| Adams, BR; Beckta, JM; Golding, SE; O'Connor, MJ; Rosenberg, E; Valerie, K; Wignarajah, S | 1 |
| Hedderich, J; Mehdorn, HM; Nabavi, A; Stark, AM; van de Bergh, J | 1 |
| Easaw, JC; Roldán Urgoiti, GB; Singh, AD | 1 |
| Jallo, GI; Siu, IM; Thomale, UW; Yoshimura, J | 1 |
| Bronder, E; Garbe, E; Herbst, H; Kauffmann, W; Klimpel, A; Orzechowski, HD; Sarganas, G; Thomae, M | 1 |
| Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M | 1 |
| Blasco, J; Bruna, J; Gil, M; Graus, F; Pineda, E; Simó, M; Velasco, R; Verger, E | 1 |
| Chang, JH; Cho, J; Kim, DS; Kim, JW; Kim, SH; Kim, YS; Lee, KS; Suh, CO | 1 |
| Huang, H; Li, J; Lin, H; Zhang, X | 1 |
| Benner, A; Christians, A; Hartmann, C; Meyer, J; von Deimling, A; Weiler, M; Weller, M; Wick, W | 1 |
| Barker, J; Foltz, G; Honkakoski, P; Küblbeck, J; Li, W; Lin, B; Ma, L; Zhang, J; Zhou, C | 1 |
| Chow, F; Cremer, N; Kim, W; Nagasawa, DT; Yang, I; Yew, A | 1 |
| Boockvar, JA; Burkhardt, JK; Riina, HA; Shin, BJ | 1 |
| Bedford, T; Kelly, S; McGrane, J | 1 |
| Bouchekoua, M; Hieu, PD; Malhaire, JP; Miglierini, P; Pradier, O; Rousseau, B | 1 |
| Breneman, JC; Gerena-Lewis, M; McPherson, CM; Warnick, RE | 1 |
| Ban, HJ; Chi, SY; Kang, HW; Kim, KS; Kim, TO; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Oh, IJ | 1 |
| Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Merchant, MJ | 1 |
| Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Karl, S; Marschall, V; Vucic, D; Wagner, L; Zobel, K | 1 |
| Berger, MS; Brem, S; Browning, JE; Buckner, JC; Chang, SM; Decker, PA; Egan, KM; Fridley, BL; Hansen, HM; Jenkins, RB; Kosel, ML; Lachance, DH; Madden, MH; McCoy, LS; Nabors, LB; O'Neill, BP; Olson, JJ; Patoka, JS; Prados, MD; Rice, T; Smirnov, I; Thompson, RC; Tihan, T; Wiemels, JL; Wiencke, JK; Wrensch, MR; Xiao, Y | 1 |
| Bortoluzzi, S; Cieply, K; Fardo, DW; Hamilton, RL; Hobbs, J; Horbinski, C; Nikiforova, MN | 1 |
| Schmitt, M; Stockhammer, F; Xu, X | 1 |
| Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Rudnick, J; Yu, JS | 1 |
| Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A | 1 |
| Addasi, A; Al-Hussaini, M; Al-Rashdan, A; Almousa, A; Alsharbaji, A; Elyan, M; Ezam, N; Hashem, SA; Mohamad, I; Nour, A; Rejeeth, C; Salem, A; Sughayer, M | 1 |
| Jo, MY; Joo, KM; Kim, HH; Kim, MH; Kim, Y; Kim, YG; Lee, SJ; Nam, DH | 1 |
| Beagley, L; Crough, T; Jones, L; Khanna, R; Smith, C; Walker, DG | 1 |
| Bai, Y; Chen, H; Miao, Y; Qiu, Y; Shen, J; Wu, B; Xu, Y; Ye, M | 1 |
| Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X | 1 |
| Gu, X; Pan, T; Qian, C; Shi, L; Sun, G; Sun, L; Wan, Y; Wang, Z; Xiang, Y; Zhang, S | 1 |
| Guo, RB; Hu, G; Sun, XL; Xue, X; Yuan, Y | 1 |
| Itoh, T; Kimura, T; Kohsaka, S; Mahabir, R; Narita, T; Nishihara, H; Tanaka, S; Tanino, M; Wang, L; Yachi, K | 1 |
| Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Johnson, TD; Lawrence, TS; Lemasson, B; Leopold, JS; Li, F; Mikkelsen, T; Rehemtulla, A; Ross, BD; Williams, TM | 1 |
| Hara, K; Kageji, T; Kitazato, KT; Kuwayama, K; Matsuzaki, K; Mizobuchi, Y; Morigaki, R; Mure, H; Nagahiro, S; Okazaki, T | 1 |
| Beier, CP; Beier, D; Brawanski, K; Hau, P; Schriefer, B; Schulz, JB; Weis, J | 1 |
| Mohammad Alizadeh, A; Zamani, N | 1 |
| Florea, AM; Happold, C; Reifenberger, G; Roth, P; Schmidt, N; Silginer, M; Weller, M; Wick, W | 1 |
| Chen, CC; Hoadley, K; Jiang, C; Jiang, T; Kang, C; Kushwaha, D; Li, S; Ramakrishnan, V; Song, SW; You, Y; Zhang, J; Zhang, W | 1 |
| Caivano, R; Chiumento, C; Clemente, S; Cozzolino, M; Fiorentino, A; Fusco, V; Pedicini, P | 1 |
| Bossert, C; Chastagner, P; Dontenwill, M; Entz-Werle, N; Godet, J; Guenot, D; Guerin, E; Janouskova, H; Leger, DY; Lehmann-Che, J; Maglott, A; Martin, S; Noulet, F; Pinel, S; Plenat, F; Teisinger, J | 1 |
| Bjerkvig, R; Johannessen, TC | 1 |
| Beard, BC; Gori, JL; Ironside, C; Karponi, G; Kiem, HP | 1 |
| Chang, SM; Johnson, DR | 1 |
| Hargreaves, S; Kooner, I; Liu, ZW; Menashy, R; Michalarea, V; Williams, M; Wilson, E; Woolf, D | 1 |
| Atlani, D; Aumont, M; Bernier, V; Bondiau, PY; Clavier, JB; Collin, P; D'Hombres, A; de Crevoisier, R; Durando, X; Feuvret, L; Henzen, C; Huchet, A; Kerr, C; Lagrange, JL; Le Rhun, E; Maire, JP; Missohou, F; Noel, G; Sunyach, MP; Taillandier, L; Thillays, F; Truc, G; Verrelle, P; Vinchon-Petit, S | 1 |
| Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K | 1 |
| Anile, C; Balducci, M; Chiesa, S; Colicchio, G; D'Agostino, GR; De Bari, B; De Bonis, P; Fiorentino, A; Frascino, V; Gambacorta, MA; Manfrida, S; Mangiola, A; Mantini, G; Mattiucci, GC; Miccichè, F; Morganti, AG; Valentini, V | 1 |
| Carlson, BL; Cen, L; Decker, PA; Gupta, SK; Kitange, GJ; Lomberk, GA; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Urrutia, RA; Wu, W | 1 |
| Chen, C; Chen, J; Lu, Y; Wu, S; Xu, T | 1 |
| Barker, CA; Beal, K; Chang, M; Chou, JF; Gutin, PH; Iwamoto, FM; Zhang, Z | 1 |
| Filss, C; Glas, M; Hadizadeh, DR; Herrlinger, U; Kuchelmeister, K; Langen, KJ; Mack, F; Pietsch, T; Schäfer, N; Schüller, H; Scorzin, J; Simon, M; Stuplich, M; Urbach, H | 1 |
| Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW | 1 |
| Barr, JG; Grundy, PL | 1 |
| Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A | 1 |
| Goldenberg, F; Lukas, RV; Nicholas, MK | 1 |
| Brandes, AA; Laperriere, N; Perry, JR; Stupp, R; van den Bent, MJ; Weller, M; Wick, W | 1 |
| Ak, S; Bilir, A; Cecener, G; Egeli, U; Malyer, H; Tezcan, G; Tumen, G; Tunca, B | 1 |
| Chammas, R; da Silva, R; Gimenez, M; Izumi, C; Laure, HJ; Marie, SK; Oba-Shinjo, SM; Otake, A; Rosa, JC; Uno, M | 1 |
| Harasaki, Y; Waziri, A | 1 |
| Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S | 1 |
| Chan, HL; Leung, GK; Li, CH; Wong, ST; Zhang, XQ; Zhuang, JT | 1 |
| Algharabil, J; Begum, G; Clark, PA; Kahle, KT; Kintner, DB; Kuo, JS; Lin, SH; Sun, D; Wang, Q; Yang, SS | 1 |
| Fung, CF; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Wong, ST | 1 |
| Groves, MD; Plummer, AB | 1 |
| Montaldi, AP; Sakamoto-Hojo, ET | 1 |
| Burns, DK; Chen, J; Kernie, SG; Li, Y; McKay, RM; Parada, LF; Yu, TS | 1 |
| Groll, MJ; Kapp, KS; Langsenlehner, T; Mokry, M; Payer, F; Quehenberger, F | 1 |
| Helseth, E; Johannesen, TB; Meling, TR; Rønning, PA | 1 |
| Abacioglu, U; Frappaz, D; Grønberg, BH; Hegi, ME; Henriksson, R; Lhermitte, B; Malmström, A; Marosi, C; Rosell, J; Schultz, H; Stupp, R; Tavelin, B | 1 |
| Cloughesy, T; Nghiemphu, PL | 1 |
| Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V | 1 |
| Easaw, JC; Gui, X; Miller, RJ; Tsang, RY | 1 |
| Otty, Z; Sabesan, S | 1 |
| Chang, NS; Chen, YJ; Chiang, MF; Liao, HF; Yeh, ST | 1 |
| Aguilar, LK; Aguilar-Cordova, E; Arvizu, M; Chiocca, EA | 1 |
| Annibali, D; Bianchi, F; Cenci, T; D'Alessandris, QG; Falchetti, ML; Larocca, LM; Martini, M; Montano, N; Nasi, S; Pallini, R; Pierconti, F; Savino, M | 1 |
| Gilbertson, RJ; Graham, TA | 1 |
| Bannykh, SI; Black, KL; Elramsisy, A; Hu, J; Irvin, DK; Mukherjee, D; Nuño, M; Patil, CG; Yi, A; Yu, JS | 1 |
| Chedid, K; Hong, X; Kalkanis, SN | 1 |
| Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K | 1 |
| Appel, EA; Heywood, RM; Loh, XJ; Rowland, MJ; Scherman, OA; Watts, C | 1 |
| Escalon, E; Melnick, SJ; Nair, SM; Ramachandran, C | 1 |
| Baumert, BG; Fedrigo, CA; Narayan, RS; Sminia, P; Stalpers, LJ | 1 |
| Brewer, J; Hitchins, MP; Kuroiwa-Trzmielina, J; Lu, D; McDonald, KL; Nozue, K; Olivier, J; Rapkins, RW; Tiwari, S; Wheeler, HR; Zhao, L | 1 |
| Huang, S; Huang, Z; Wu, X; Xiao, F; Yang, L; Zhang, H; Zhang, N; Zhou, A | 1 |
| Beal, K; Chan, TA; Gutin, PH; Lassman, AB; Reyngold, M; Yamada, Y | 1 |
| Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M | 1 |
| Homicsko, K; Hottinger, AF; Lhermitte, B; Negretti, L; Stupp, R | 1 |
| Bao, Z; Chen, CC; Jiang, C; Jiang, T; Kang, C; Li, S; Song, SW; Yan, W; You, G; You, Y; Zhang, J; Zhang, W; Zhang, Y | 1 |
| Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F | 1 |
| Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R | 1 |
| Begley, TJ; Braganza, A; Brown, AR; Dyavaiah, M; Lazo, JS; Li, J; Maniar, S; McDonald, PR; Pollack, IF; Shun, TY; Sobol, RW; St Croix, CM; Svilar, D; Tang, JB; Wang, XH | 1 |
| Stupp, R; Weller, M | 1 |
| Bressel, M; Gunjur, A; Ryan, G | 1 |
| Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S | 1 |
| Chen, J; Grogan, PT; Mladek, AC; Nadkarni, A; Sarkaria, JN; Schwingler, PM; Shrivastav, M | 1 |
| Guiot, MC; Panet-Raymond, V; Petrecca, K; Souhami, L | 1 |
| Caporello, P; Enrici, RM; Minniti, G; Scaringi, C | 1 |
| Abbadi, S; Basso, G; Della Puppa, A; Frasson, C; Indraccolo, S; Persano, L; Pistollato, F; Rampazzo, E; Scienza, R; Volpin, F | 1 |
| Bigner, DD; Friedman, HS; Gray, LA; Keir, ST; Reardon, DA | 1 |
| Matsuo, H; Nagatani, K; Nakanishi, K; Nawashiro, H; Osada, H; Otani, N; Shimazaki, H; Shinomiya, N; Takeuchi, S; Toyooka, T; Uozumi, Y; Wada, K | 1 |
| Fujii, T; Saito, N; Takahashi, K; Tanaka, M; Todo, T; Tsuno, NH | 1 |
| De Angelis, F; Giannone, C; Hernandez-Gonzalez, G; Kouleridou, A; Marchione, P; Spallone, A | 1 |
| Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Fan, X; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Yu, JS | 1 |
| Barré, L; Bernaudin, M; Corroyer-Dulmont, A; Delamare, J; Divoux, D; Guillamo, JS; Ibazizène, M; Jacobs, AH; Lecocq, M; MacKenzie, ET; Pérès, EA; Petit, E; Roussel, S; Toutain, J; Valable, S; Varoqueaux, N | 1 |
| Julka, PK; Rath, GK; Sharma, A; Sharma, DN | 1 |
| Payne, CA; Safdar, S; Taite, LJ; Tu, NH | 1 |
| Beier, CP; Bettstetter, M; Gempt, J; Hoepner, I; Koeritzer, J; Meyer, B; Rasper, M; Ringel, F; Schäfer, A; Schlegel, J; Schmidt-Graf, F; Teufel, J | 1 |
| Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H | 1 |
| Bartolotti, M; Brandes, AA | 1 |
| Anderluh, G; Assunção, Fdos S; Biasoli, D; de Souza, JM; Frauches, AC; Garcia, C; Geraldo, LH; Kahn, SA; Lima, FR; Moura-Neto, V; Pontes, B; Romão, L; Sobrinho, M; Soletti, RC; Tovar-Moll, F | 1 |
| Arcella, A; Battaglia, G; Bonelli, M; Ciceroni, C; De Maria, R; Larocca, LM; Laurenza, M; Mastrantoni, E; Melchiorri, D; Niccolini, C; Nicoletti, F; Pallini, R; Ricci-Vitiani, L; Spinsanti, P; Traficante, A | 1 |
| Caivano, R; Chiumento, C; Cozzolino, M; Fiorentino, A; Fusco, V; Pedicini, P | 1 |
| Chan, MD; Debinski, W; Ellis, TL; Hinson, WH; Johnson, AJ; Kearns, WT; Lesser, GJ; McMullen, KP; Paulsson, AK; Peiffer, AM; Shaw, EG; Tatter, SB | 1 |
| Chen, JX; Liu, YH; Mao, Q; Wang, X; You, C | 1 |
| Bauer, R; Freyschlag, CF; Kerschbaumer, J; Obwegeser, AA; Schubert, GA; Seiz, M; Thomé, C | 1 |
| Bharwani, L; Vellayappan, BA | 1 |
| Cance, WG; Eliceiri, BP; Golubovskaya, VM; Ho, B; Huang, G; Lee, J; Morrison, CD; Yemma, M | 1 |
| Alvarez, PJ; Aránega, A; Concha, A; González, B; López, R; Madeddu, R; Melguizo, C; Oliver, JA; Ortiz, R; Perazzoli, G; Prados, J; Rodríguez-Serrano, F | 1 |
| Kimura, T; Kohsaka, S; Nishihara, H; Takahashi, K; Tanaka, S; Tanino, M; Wang, L | 1 |
| Fountzilas, G; Hytiroglou, P; Iliadis, G; Karkavelas, G; Kotoula, V; Lampaki, S; Polyzoidis, KS; Selviaridis, P; Televantou, D | 1 |
| Bock, HC; Brück, W; Giese, A; Gutenberg, A; Reifenberger, G | 1 |
| Bjerkvig, R; Grudic, A; Hegi, ME; Johannessen, TC; Prestegarden, L; Tysnes, BB | 1 |
| Cloughesy, TF; Ellingson, BM; Lai, A; Liau, LM; Nghiemphu, PL; Pope, WB | 1 |
| Chen, J; Xu, T | 1 |
| Berry, I; Cassol, E; Celsis, P; Cohen-Jonathan, EM; Delannes, M; Filleron, T; Franceries, X; Ken, S; Laprie, A; Lotterie, JA; Lubrano, V; Simon, L; Supper, C; Vieillevigne, L | 1 |
| Chang-Chien, YC; Chen, MH; Guo, WY; Ho, DM; Ho, HL; Hsu, CY; Hsu, SP; Lin, SC; Yen, YS | 1 |
| Jiang, Y; Sun, Y; Yuan, Y | 1 |
| Borges, KS; Carlotti, CG; Castro-Gamero, AM; de Oliveira, HF; de Paula Gomes Queiroz, R; Fujinami, MM; Moreno, DA; Scrideli, CA; Suazo, VK; Tone, LG | 1 |
| Jang, WY; Jeong, EH; Jung, S; Jung, TY; Kim, IY; Lee, JH; Moon, KS | 1 |
| Fraefel, C; Fricke, IB; Jacobs, AH; Kuhlmann, MT; Monfared, P; Schelhaas, S; Viel, T | 1 |
| Bowersock, J; Dasgupta, A; Gillespie, GY; Johnson, A; Lamb, LS; Spencer, HT; Su, Y | 1 |
| Ancheta, K; Buchanan, C; Carrillo, JA; Chen, W; Chou, AP; Chowdhury, R; Cloughesy, TF; Elashoff, RM; Ellingson, BM; Green, R; Hanna, R; Khanlou, N; Lai, A; Lalezari, J; Lalezari, S; Li, S; Liau, LM; Lou, JJ; Miller, P; Mischel, PS; Nghiemphu, PL; Ormiston, L; Piccioni, D; Pope, WB; Sanchez, DE; Selfridge, J; Solis, OE; Tran, A; Wang, HJ; Wilson, RW; Yong, WH; Zurayk, M | 1 |
| Abhinav, K; Aquilina, K; Gbejuade, H; Hopkins, K; Iyer, V; La, M | 1 |
| Jiang, R; Li, X; Sun, J; Wang, Z; Yang, S; Yang, W; Yang, X; Yue, S; Zhang, J; Zhu, T | 1 |
| Egensperger, R; Hinske, LC; Hoefig, K; Kreth, FW; Kreth, S; Limbeck, E; Schütz, SV; Thon, N | 1 |
| Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL | 1 |
| Alagu, J; Araki, A; Inoue, M; Itami, M; Iuchi, T; Kageyama, H; Nakagawara, A; Ohira, M; Saeki, N; Suenaga, Y; Takatori, A; Yamaki, T; Yokoi, S | 1 |
| Choi, SH; Heo, DS; Jung, HW; Kim, IH; Kim, TM; Lee, SH; Park, CK; Park, SH | 1 |
| Brookes, C; Cruickshank, G; Jones, B; Sanghera, P; Senthil, L; Sherriff, J; Spooner, D; Tamangani, J | 1 |
| Conroy, J; Golubovskaya, V; Ho, B; Huang, G; Liu, S; Qiang, H | 1 |
| Anile, C; Autorino, R; Balducci, M; Chiesa, S; Ciurlia, E; De Bonis, P; De Filippo, L; De Rose, F; Diletto, B; Fersino, S; Fiorentino, A; Fusco, V; Mangiola, A; Matteucci, P; Rinaldi, C; Valentini, V | 1 |
| Dixit, S; Hingorani, M; Rajaraman, C; Rowland-Hill, C; Salvage, D | 1 |
| Butowski, N; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Molinaro, AM; Nelson, SJ | 1 |
| Nieder, C | 1 |
| Beauchesne, P | 1 |
| Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S | 1 |
| Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH | 1 |
| Blank, A; Bobola, MS; Haroldson, PD; Huynh, MB; Kolstoe, DD; Schoeler, KD; Silber, JR | 1 |
| Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F | 1 |
| Albano, J; Cernuda, M; Garcia, I; Lima, L; Oliveira, C; Portela, I; Teixeira, MM | 1 |
| Belogurova, MB; Borodina, ID; Gorbatykh, SV; Kumirova, EV; Melikian, AG; Prityko, AG; Shcherbenko, OI; Tarasova, IS; Zheludkova, OG | 1 |
| Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R; Vastola, F | 1 |
| Dieckmann, K; Fazeny-Dörner, B; Hainfellner, J; Marosi, C; Piribauer, M; Rössler, K; Ungersböck, K; Veitl, M; Wenzel, C | 1 |
| Baayen, HC; Barkhof, F; Boogerd, W; Castelijns, JA; Elkhuizen, PH; Heimans, JJ; Postma, TJ; Uitdehaag, BM; Vos, MJ | 1 |
| Ariza, A; Balaña, C; Ballester, R; Mendez, P; Ramirez, JL; Rosell, R; Roussos, Y; Sanchez, JJ; Sarries, C; Taron, M | 1 |
| Dieckmann, K; Fazeny-Dörner, B; Marosi, C; Piribauer, M; Rössler, K; Ungersböck, K; Veitl, M; Wenzel, C | 1 |
| Foster, T; Newlands, ES; Zaknoen, S | 1 |
| Baumgartner, G; Budinsky, A; Czech, T; Dieckmann, K; Fazeny-Dörner, B; Gyries, A; Killer, M; Marosi, C; Muhm, M; Piribauer, M; Prayer, D; Rössler, K; Ungersböck, K; Veitl, M | 1 |
| Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M | 1 |
| Artizzu, S; Brogna, C; Caroli, E; Frati, A; Piccirilli, M; Salvati, M | 1 |
| Aoki, T; Hashimoto, N; Ishikawa, M; Mizutani, T; Sugiyama, K | 1 |
| D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G | 1 |
| Bamberg, M; Belka, C; Jendrossek, V | 1 |
| Hartmann, P; Herholz, K; Petereit, HF; Salzberger, B | 1 |
| Berger, MS; Chang, SM; Keles, GE; Lamborn, KR; Prados, MD | 1 |
| Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK | 1 |
| Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM | 1 |
| Chamberlain, MC; Tsao-Wei, DD | 1 |
| de Tribolet, N; Dietrich, PY; Diserens, AC; Godard, S; Hegi, ME; Ostermann, S; Otten, P; Regli, L; Stupp, R; Van Melle, G | 1 |
| Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F | 1 |
| Lobrinus, JA; Matzinger, O; Michielin, O; Périard, D; Stupp, R; Udry, E | 1 |
| Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Frauger, E; Grisoli, F; Hoang-Xuan, K; Martin, PM; Moktari, K; Palmari, J; Peragut, JC | 1 |
| Benítez, E; Gil-Salú, JL; López-Escobar, M; Maestro, E; Pérez-Requena, J; Román, P | 1 |
| Fazeny-Dörner, B; Mader, RM; Marosi, C; Piribauer, M; Rizovski, B; Stögermaier, B | 1 |
| Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W | 1 |
| Aguirre-Cruz, L; Crinière, E; Delattre, JY; Duprez, A; Golmard, JL; Kujas, M; Leuraud, P; Marie, Y; Medioni, J; Poupon, MF; Sanson, M; Taillandier, L | 1 |
| Ataman, F; Fisher, B; Mirimanoff, RO; Poortmans, P; Stupp, R | 1 |
| Gomori, JM; Levin, N; Siegal, T | 1 |
| Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ | 1 |
| Gillespie, GY; Kufe, DW; Weichselbaum, RR; Yamini, B; Yu, X | 1 |
| Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W | 1 |
| Leyvraz, S; Mirimanoff, RO; Ostermann, S; Pica, A; Stupp, R; Villemure, JG; Wasserfallen, JB | 1 |
| Bankiewicz, KS; Berger, MS; Bringas, JR; Panner, A; Pieper, RO; Saito, R; Tamas, M | 1 |
| Bartolomei, M; Bodei, L; Grana, C; Handkiewicz-Junak, D; Maira, G; Mazzetta, C; Paganelli, G; Rocca, P; Sturiale, C; Villa, G | 1 |
| Alliot, C | 1 |
| Branle, F; Everaert, E; Joosens, E; Menten, J; Neyns, B; Strauven, T | 1 |
| Cereda, E; Gariboldi, MB; Monti, E; Ravizza, R | 1 |
| Erber, R; Grobholz, R; Korn, T; Tuettenberg, J; Vajkoczy, P; Wenz, F | 1 |
| Amistà, P; Basso, U; Brandes, AA; Ermani, M; Monfardini, S; Nicolardi, L; Reni, M; Sotti, G; Tosoni, A; Valduga, F | 1 |
| Banik, NL; Das, A; Patel, SJ; Ray, SK | 1 |
| Carpentier, AF | 1 |
| Afra, D; Sipos, L; Vitanovics, D | 1 |
| Balaña, C; Balart, J; Ballester, R; Benavides, M; Berrocal, A; Capellades, J; Cerdá-Nicolás, M; García, JL; Herrero, A; López-Pousa, A; Martín-Broto, J; Yaya-Tur, R | 1 |
| Liccardo, G; Lunardi, P; Menniti, A; Moschettoni, L | 1 |
| Banik, NL; Patel, SJ; Ray, SK; Sribnick, EA; Sur, P | 1 |
| Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M | 1 |
| Bromberg, JE; Cairncross, JG; de Tribolet, N; Diserens, AC; Gorlia, T; Hainfellner, JA; Hamou, MF; Hau, P; Hegi, ME; Janzer, RC; Kros, JM; Mariani, L; Mason, W; Mirimanoff, RO; Stupp, R; Weller, M | 1 |
| DeAngelis, LM | 1 |
| Antonadou, D; Athanassiou, H; Beroukas, K; Karageorgis, P; Maragoudakis, E; Misailidou, D; Paraskevaidis, M; Saris, G; Synodinou, M; Verigos, C | 1 |
| Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A | 1 |
| Butowski, N; Chang, SM; Lamborn, KR; Larson, DA; Malec, M; Page, M; Prados, MD; Rabbitt, J; Sneed, PK; Wara, WM | 1 |
| Shirato, H | 1 |
| Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC | 1 |
| Abrey, LE | 1 |
| Brotchi, J; Camby, I; Darro, F; Gabius, J; Gaussin, JF; James, S; Kiss, R; Lefranc, F | 1 |
| Chinot, O | 1 |
| Combs, SE; Debus, J; Edler, L; Gutwein, S; Schulz-Ertner, D; Thilmann, C; van Kampen, M; Wannenmacher, MM | 1 |
| Berger, MS; Hirose, Y; Katayama, M; Mirzoeva, OK; Pieper, RO | 1 |
| Seiter, K | 1 |
| Ashby, L; LaRocca, R; Ryken, T | 1 |
| Altundag, K; Altundag, MB; Altundag, O; Boruban, C; Turen, S | 1 |
| Weller, M; Wick, W | 1 |
| Bromberg, JE; Postma, TJ | 1 |
| Lang, P; Mazeron, JJ; Simon, JM; Taillibert, S; Toubiana, T | 1 |
| Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P | 1 |
| Yung, WK | 2 |
| Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA | 1 |
| Cohen, MH; Johnson, JR; Pazdur, R | 1 |
| Antipas, VP; Stamatakos, GS; Uzunoglu, NK | 2 |
| Weller, M | 1 |
| Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ | 1 |
| Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD | 1 |
| Kiss, R; Mathieu, V; Mijatovic, T; van Damme, M | 1 |
| Bernays, RL; Gutteck-Amsler, U; Hofer, S; Meier, UR; Meier-Abt, PJ; Peghini, PE; Rentsch, K; Rutz, HP | 1 |
| Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM | 1 |
| Bissola, L; Boiardi, A; Botturi, A; Broggi, G; Eoli, M; Finocchiaro, G; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Bredel, C; Bredel, M; Duran, GE; Harsh, GR; Juric, D; Recht, LD; Scheck, AC; Sikic, BI; Vogel, H; Yu, RX | 1 |
| Barbarisi, M; Moraci, A; Moraci, M; Parlato, C | 1 |
| Hamilton, D | 1 |
| Crausaz, S; McNee, W; Metcalfe, S; Moodie, P | 1 |
| Aghi, M; Martuza, RL; Rabkin, S | 1 |
| Benouaich-Amiel, A; Delattre, JY; Simon, JM | 1 |
| Roitberg, B | 1 |
| Reardon, DA | 1 |
| Mirimanoff, RO | 1 |
| Rasiah, D | 1 |
| Audra, P; Cartalat-Carel, S; Colin, P; Ducray, F; Gaucherand, P; Honnorat, J; Mahla, K; Pelissou-Guyotat, I; Trouillas, P | 1 |
| Addo-Yobo, SO; Donson, AM; Foreman, NK; Gore, L; Handler, MH | 1 |
| Kiem, HP; Partap, S; Peterson, RA; Schuetze, S; Silber, JR; Spence, AM | 1 |
| Collins, CA; Manasanch, EE; Ramaprasad, C; van Besien, K; Villano, JL | 1 |
| Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W | 1 |
| Kiss, R; Lefranc, F | 1 |
| Dehdashti, AR; Hegi, ME; Pica, A; Regli, L; Stupp, R | 1 |
| Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D | 1 |
| Hamilton, DA | 1 |
| Allgeier, A; Brandes, AA; Cairncross, G; Curschmann, J; Fisher, B; Gorlia, T; Kortmann, RD; Lacombe, D; Mason, W; Mirimanoff, RO; Reni, M; Stupp, R; Van den Bent, MJ; Villa, S | 1 |
| Bally, F; Christen, G; de Ribaupierre, S; Ganière, V; Guillou, L; Pica, A; Stupp, R | 1 |
| Bartolomei, M; Boiardi, A; Botturi, A; Broggi, G; Eoli, M; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Eickmeyer, F; Fiedler, VU; Niehoff, H; Schwarzmaier, HJ; Ulrich, F; Ulrich, SD; von Tempelhoff, W; Yang, Q | 1 |
| Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H | 1 |
| Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R | 1 |
| Cairncross, JG; Mason, WP | 1 |
| Alfó, M; Banelli, E; De Sanctis, V; Enrici, RM; Mazzarella, G; Osti, MF; Salvati, M; Tombolini, V; Valeriani, M | 1 |
| Chalmers, L; Chamberlain, MC; Glantz, MJ; Sloan, AE; Van Horn, A | 1 |
| Marosi, C | 1 |
| Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W | 1 |
| Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ | 1 |
| Chalmers, L; Chamberlain, MC | 1 |
| Bertorelle, R; Biscuola, M; Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Ermani, M; Franceschi, E; Gioia, V; Tosoni, A | 1 |
| Boor, S; Hundsberger, T; Kaina, B; Koch, D | 1 |
| Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK | 1 |
| Dickerman, RD; Howes, G; Lee, JM; Nardone, EM; Stevens, QE | 1 |
| Kawaguchi, T; Mirzoeva, OK; Pieper, RO | 1 |
| Cambar, J; L'Azou, B; Liguoro, D; Pédeboscq, S; Pometan, JP | 1 |
| Amini, A; Chin, SS; Schmidt, MH | 1 |
| Chen, ZP; Mu, YG; Sai, K; Shi, HL; Yue, WY; Zhang, JP; Zhang, XH | 1 |
| Baroncini, M; Blond, S; Bordron, A; Dam-Hieu, P; Maurage, CA; Mineo, JF; Ramirez, C | 1 |
| Laigle-Donadey, F; Sanson, M | 1 |
| Gijtenbeek, JM; Kappelle, AC; Soetekouw, PM; van der Maazen, RW; van Herpen, CM | 1 |
| Barcia, JA; Barcia-Mariño, C; Gallego, JM | 1 |
| Berger, W; Buchroithner, J; Fischer, J; Marosi, C; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S | 1 |
| Ducray, F; Honnorat, J | 1 |
| Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A | 1 |
| Dalmau, J; de la Fuente, BP; Rosenfeld, M | 1 |
| Chheda, MG; Doherty, LM; Drappatz, J; Gigas, DC; Greenberger, NJ; Kesari, S; Weiss, SE; Wen, PY | 1 |
| Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR | 1 |
| Goldman, B | 1 |
| Dellinger, CA; Grewal, J; Yung, WK | 1 |
| Gerrard, GE; Khanduri, S; O'Toole, L | 1 |
| Barrié, M; Braguer, D; Chinot, OL; Dufour, H; Eudes, N; Figarella-Branger, D; Fuentes, S; Lancelot, S; Martin, PM; Metellus, P; Muracciole, X; Ouafik, L | 1 |
| Bernhard, EJ; Cerniglia, GJ; Georgescu, MM; Gupta, AK; Hahn, SM; Jiang, Z; Maity, A; Mick, R; Pore, N | 1 |
| Brandes, AA; Franceschi, E; Tosoni, A | 2 |
| Gujral, S; Jalali, R; Menon, H; Singh, P | 1 |
| Brown, MP; Selva-Nayagam, S; Singhal, N | 1 |
| Combs, SE; Debus, J; Herold-Mende, C; Roth, W; Schulz-Ertner, D; Weber, KJ | 1 |
| Ang, EL; Back, MF; Chan, SP; Lim, CC; Ng, WH; See, SJ; Yeo, TT | 1 |
| See, SJ; Ty, A; Wong, MC | 1 |
| Aubrey, MC; Lim, KG; Limper, AH; Maldonado, F | 1 |
| Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Ardito, R; Romano, C; Tartarone, A | 1 |
| Friedman, HS; Maxwell, J | 1 |
| Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK | 1 |
| Boots-Sprenger, SH; Cornelissen, SJ; Dekkers, MM; Errami, A; Jeuken, JW; Sijben, A; Vriezen, M; Wesseling, P | 1 |
| Abe, T; Fukushima, S; Miyagi, N; Ogo, E; Sakata, K; Shigemori, M; Terasaki, M | 1 |
| Berger, MS; Carlson, BL; Dinca, EB; Gupta, N; James, CD; Sarkaria, JN; Schroeder, MA; Voicu, R | 1 |
| Chen, TC; Hofman, FM; Lee, AS; Pyrko, P; Schönthal, AH | 1 |
| Sinkovics, J | 1 |
| Taylor, RE | 1 |
| Hulsebos, TJ; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; van den Berg, J; van Nifterik, KA | 1 |
| Bischof, M; Combs, SE; Debus, J; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T | 1 |
| Biggs, MT; Clarkson, A; Cook, RJ; Little, NS; McDonald, KL; McKenzie, CA; Messina, M; Parkinson, JF; Robinson, BG; Wheeler, HR | 1 |
| Aoki, T; Hashimoto, N; Matsutani, M | 1 |
| Asadpour, B; Eble, MJ; Gagel, B; Pinkawa, M; Piroth, MD; Stanzel, S | 1 |
| Basu, A; Goel, A; Gupta, T; Jalali, R; Menon, H; Munshi, A; Sarin, R | 1 |
| Aldape, K; Archer, GE; Bigner, DD; Crutcher, L; Dey, M; Gilbert, M; Hassenbusch, SJ; Heimberger, AB; Hussain, SF; Mitchell, DA; Sampson, JH; Sawaya, R; Schmittling, B; Sun, W | 1 |
| Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Gorlia, T; Hegi, ME; Lacombe, D; Mirimanoff, RO; Stupp, R; van den Bent, MJ; Weller, M | 1 |
| Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y | 1 |
| Facchini, V; Kiss, R; Lefranc, F | 1 |
| Bredel, M | 1 |
| Al, MJ; Crott, R; Gorlia, T; Jin Seung, S; Lamers, LM; Mittmann, N; Stupp, R; Uyl-de Groot, CA; van den Bent, MJ; Wasserfallen, JB | 1 |
| Avutu, B; Barker, FG; Batchelor, TT; Chakravarti, A; Henson, JW; Hochberg, FH; Loeffler, JS; Martuza, RL; Sher, DJ | 1 |
| Beam, K; Burgan, WE; Camphausen, K; Carter, D; Cerna, D; Kil, WJ; Steeg, PS; Tofilon, PJ | 1 |
| Bozzao, A; De Paula, U; De Sanctis, V; Filippone, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Tombolini, V; Valeriani, M | 1 |
| Bischof, M; Combs, SE; Debus, J; Edler, L; Rausch, R; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T; Zabel-du Bois, A | 1 |
| Aldape, K; Aoki, H; Bogler, O; Conrad, C; Hess, K; Hollingsworth, EF; Iwado, E; Kobayashi, R; Kondo, S; Kondo, Y; Mills, G; Sawaya, R; Shingu, T; Shinojima, N; Tamada, Y; Yamamoto, A; Yokoyama, T; Zhang, L | 1 |
| Boiardi, A; Botturi, A; Broggi, G; Di Meco, F; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Solari, A | 1 |
| Benouaich-Amiel, A; Delattre, JY; Ducray, F; Idbaih, A; Laigle-Donadey, F; Rousseau, A; Sanson, M | 1 |
| Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E | 1 |
| Nakamura, O; Saito, K; Shinoura, N; Tabei, Y; Takahashi, M; Yamada, R | 1 |
| Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH | 1 |
| Ng, W; Steckley, JL; Watling, CJ | 1 |
| Mitchell, SB; Pan, E; Tsai, JS | 1 |
| Kiss, R; Lefranc, F; Mijatovic, T | 1 |
| Adam, M; Grosu, AL; Nieder, C | 1 |
| Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY | 1 |
| Benveniste, RJ; Manzano, G; Petito, CK | 1 |
| Coppola, JM; Rehemtulla, A; Ross, BD | 1 |
| Bontempi, G; Decaestecker, C; Haibe-Kains, B; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Mijatovic, T | 1 |
| Banik, NL; Das, A; Ray, SK | 1 |
| Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Newlands, ES; Wedge, SR | 1 |
| Abe, H; Aida, T; Ikeda, J; Kaneko, S; Kashiwaba, T; Kawamoto, T; Mitsumori, K; Saitoh, H; Sawamura, Y | 1 |
| Glaser, MG; Marcus, K; Newlands, ES; Porteous, JK; Wedge, SR | 1 |
| Ashley, DM; Bigner, DD; Bigner, SH; Cokgor, I; Colvin, OM; Dugan, M; Friedman, AH; Friedman, HS; Haglund, MM; Henry, AJ; Kerby, T; Krischer, J; Lovell, S; Marchev, F; McLendon, RE; Modrich, PL; Provenzale, JM; Rasheed, K; Rich, J; Seman, AJ; Stewart, E | 1 |
| Darling, JL; Sankar, A; Thomas, DG | 1 |
| Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M | 1 |
| Brada, M; Osoba, D; Prados, M; Yung, WK | 1 |
| MacConnachie, AM | 1 |
| Batchelor, T | 1 |
| Prados, MD | 1 |
| Calvert, H; Friedman, HS; Kerby, T | 1 |
| Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Berger, MS; Hirose, Y; Pieper, RO | 2 |
| Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA | 1 |
| Frenkel, EP; Han, Q; Hoffman, RM; Kokkinakis, DM; Schold, SC; Tan, Y; Wick, JB; Xu, M | 1 |
| Macdonald, DR | 1 |
| Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S | 1 |
| de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R | 1 |
| Groves, MD; Hess, KR; Jaeckle, KA; Levin, VA; Peterson, P; Puduvalli, VK; Yung, WK | 1 |
| Brada, M | 1 |
| Cave, C; Dinnes, J; Huang, S; Milne, R | 1 |
| Croteau, D; Mikkelsen, T | 1 |
| Ashley, DL; Cher, L; Rosenthal, MA | 1 |
| Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG | 1 |
| Al-Sarraf, M; Athens, JW; Costanzi, JJ; Eltringham, JR; Eyre, HJ; Fletcher, WS; Gehan, EA; Oishi, N; Talley, RW; Vogel, FS | 1 |
| Albright, RE; Bullard, DE; Burger, PC; Cairncross, JG; DeLong, ER; Friedman, HS; Khandekar, JD; Mahaley, MS; Schold, SC; Vick, NA | 1 |
| Bleyer, WA; Geyer, JR; Heideman, RL; Kosnik, EJ; Milstein, JM; Morris, JD; Mulne, AF; Pendergrass, TW; Ruymann, FB; Stuntz, JT | 1 |
150 review(s) available for dacarbazine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Topics: Adult; Brain Neoplasms; Brain Stem; Dacarbazine; Glioblastoma; Humans; Male; Pyridines; Temozolomide | 2022 |
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neurosurgeons; Platinum Compounds; Temozolomide | 2022 |
Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2023 |
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurrence, Local; Temozolomide | 2022 |
Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Topics: Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2022 |
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Glioblastoma; Humans; MicroRNAs; Temozolomide; Tumor Suppressor Proteins | 2023 |
The impact of survivorship bias in glioblastoma research.
Topics: Aged; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Repair Enzymes; Glioblastoma; Humans; Prognosis; Survivorship; Temozolomide | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Implications of Advances in Studies of O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Methylation; DNA Repair Enzymes; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase | 2023 |
Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Quality of Life; Retrospective Studies; Temozolomide | 2021 |
Does local drug delivery still hold therapeutic promise for brain cancer? A systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Glioblastoma; Humans; Pharmaceutical Preparations | 2021 |
The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome | 2017 |
Managing Glioblastoma in the Elderly Patient: New Opportunities.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Management; Glioblastoma; Humans; Neurosurgical Procedures; Prognosis; Radiotherapy; Temozolomide | 2017 |
Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review).
Topics: Brain; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Pyrans; Temozolomide | 2017 |
Glioblastoma in the elderly: initial management.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Prognosis; Radiation Dose Hypofractionation; Randomized Controlled Trials as Topic; Temozolomide | 2017 |
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Electric Stimulation Therapy; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Safety; Temozolomide; Treatment Outcome; United States | 2017 |
Treatment of Glioblastoma.
Topics: Aftercare; Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cranial Irradiation; Cytoreduction Surgical Procedures; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Mutation; Neoplasm Recurrence, Local; Neurosurgical Procedures; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Temozolomide; Tumor Suppressor Proteins | 2017 |
Treatment of Glioblastoma in Older Adults.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Prognosis; Temozolomide | 2017 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Male; Middle Aged; Radiotherapy Dosage; Temozolomide | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Temozolomide | 2018 |
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cellular Senescence; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Humans; Mice; Resveratrol; Stilbenes; Temozolomide | 2018 |
Treatment of Glioblastoma in the Elderly.
Topics: Aged; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Quality of Life; Temozolomide | 2018 |
Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Phloroglucinol; Seaweed; Temozolomide; Xanthophylls | 2018 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Progression-Free Survival; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2018 |
Essential role of Gli proteins in glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Transcription Factors; Zinc Finger Protein GLI1 | 2013 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms; Captopril; Dacarbazine; Disulfiram; Glioblastoma; Gluconates; Humans; Ketoconazole; Morpholines; Nelfinavir; Neoplasm Recurrence, Local; Sertraline; Succinates; Temozolomide | 2013 |
Enhancing radiation therapy for patients with glioblastoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2013 |
Temozolomide for high grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide | 2013 |
Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Metabolomics; Prognosis; Temozolomide | 2013 |
Epigenetic pathways and glioblastoma treatment.
Topics: Adult; Animals; Brain Neoplasms; Dacarbazine; Drug Discovery; Epigenesis, Genetic; Gene Regulatory Networks; Glioblastoma; Humans; Mice; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Systems Biology; Temozolomide | 2013 |
Extracranial glioblastoma with synchronous metastases in the lung, pulmonary lymph nodes, vertebrae, cervical muscles and epidural space in a young patient - case report and review of literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Chemoradiotherapy, Adjuvant; Dacarbazine; Epidural Space; Fatal Outcome; Glioblastoma; Humans; Lumbar Vertebrae; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Muscle Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Neurosurgical Procedures; Palliative Care; Patient Compliance; Spinal Neoplasms; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2013 |
Elderly patients with glioblastoma: the treatment challenge.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Prognosis; Temozolomide | 2013 |
A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, Bibliographic; Glioblastoma; Humans; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Temozolomide | 2014 |
Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose Fractionation, Radiation; Glioblastoma; Humans; Radiosurgery; Temozolomide; Tumor Suppressor Proteins | 2014 |
Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Temozolomide | 2014 |
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2014 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasm Grading; Particle Accelerators; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide | 2014 |
Treatment options and outcomes for glioblastoma in the elderly patient.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Aged; Prognosis; Temozolomide; Treatment Outcome | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Evidence-Based Medicine; Glioblastoma; Humans; Temozolomide | 2014 |
Neuroimaging of therapy-associated brain tissue abnormalities.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Neuroimaging; Temozolomide | 2014 |
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Topics: Antineoplastic Agents; Carmustine; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Glioblastoma; Health Care Costs; Humans; Quality-Adjusted Life Years; Temozolomide | 2014 |
Predictive biomarkers investigated in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; ErbB Receptors; Glioblastoma; Humans; Molecular Targeted Therapy; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2014 |
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Delivery Systems; Glioblastoma; Humans; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Proto-Oncogene Proteins B-raf; Temozolomide; Tumor Suppressor Proteins | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
Emerging therapies for glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell- and Tissue-Based Therapy; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2014 |
Glioblastoma survival: has it improved? Evidence from population-based studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Community Health Planning; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2014 |
Treatment considerations for MGMT-unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Glioblastoma in the elderly.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Temozolomide; Tumor Suppressor Proteins | 2015 |
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Craniotomy; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Second Primary; Prognosis; Remission Induction; Temozolomide | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cancer Vaccines; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Glioblastoma; Humans; Immunotherapy; Irinotecan; Mice; Temozolomide; Vaccination; Vaccines, Subunit | 2014 |
[Elderly patients with glioblastoma: state of the art].
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Prognosis; Radiotherapy, Adjuvant; Temozolomide | 2015 |
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Design; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Glioblastoma; Humans; Molecular Structure; Phenotype; Signal Transduction; Structure-Activity Relationship; Temozolomide | 2015 |
Dose-dense temozolomide: is it still promising?
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Glioblastoma; Humans; Recurrence; Temozolomide | 2015 |
Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Cholestasis; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Temozolomide | 2015 |
Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose Fractionation, Radiation; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2015 |
Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Neoplasm Staging; Prognosis; Temozolomide | 2015 |
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Canada; Chemoradiotherapy; Cost-Benefit Analysis; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Costs; Glioblastoma; Health Resources; Humans; Kaplan-Meier Estimate; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Temozolomide; Time Factors; Treatment Outcome | 2015 |
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Topics: Biomarkers, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Tissue Extracts | 2015 |
Radiotherapy with temozolomide provides better survival in the newly diagnosed glioblastoma multiforme: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Odds Ratio; Publication Bias; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Primary spinal cord glioblastoma multiforme treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Spinal Cord Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2015 |
Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party.
Topics: Adult; Africa, Northern; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Medical Oncology; Mediterranean Region; Neurology; Practice Guidelines as Topic; Quality of Life; Radiotherapy; Societies, Medical; Standard of Care; Temozolomide | 2016 |
How I treat glioblastoma in older patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Geriatric Assessment; Glioblastoma; Humans; Isocitrate Dehydrogenase; Methylation; Middle Aged; Prognosis; Promoter Regions, Genetic; Quality of Life; Seizures; Standard of Care; Temozolomide; Tumor Suppressor Proteins | 2016 |
Targeting autophagy to sensitive glioma to temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chloroquine; Clinical Trials as Topic; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Sirolimus; Temozolomide | 2016 |
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Radiation-Sensitizing Agents; Radiotherapy; Temozolomide | 2016 |
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Topics: Animals; Brain Neoplasms; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2016 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascularization, Pathologic; Snake Venoms; Temozolomide | 2016 |
Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.
Topics: Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Tumor Suppressor Proteins | 2015 |
Problems of Glioblastoma Multiforme Drug Resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Glioblastoma; Humans; Temozolomide | 2016 |
Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Chemical and Drug Induced Liver Injury; Chemoradiotherapy; Dacarbazine; Drugs, Chinese Herbal; Female; Glioblastoma; Humans; Temozolomide | 2017 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Drug Implants; Glioblastoma; Humans; Middle Aged; Neoplasm Grading; Polyesters; Temozolomide; United States; United States Food and Drug Administration | 2016 |
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Field Therapy; Magnetic Resonance Imaging; Male; Practice Guidelines as Topic; Temozolomide | 2017 |
Microglia in Cancer: For Good or for Bad?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cytokines; Dacarbazine; ErbB Receptors; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Macrophages; Microglia; Oligodeoxyribonucleotides; Signal Transduction; Temozolomide; Treatment Failure; Tumor Microenvironment | 2016 |
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2016 |
Glioblastoma Secondary to Meningioma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Mucin-1; Temozolomide | 2017 |
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Consensus; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Evidence-Based Medicine; Glioblastoma; Humans; Patient Selection; Temozolomide; Treatment Outcome | 2017 |
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Temozolomide | 2017 |
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Medical Oncology; Middle Aged; Randomized Controlled Trials as Topic; Standard of Care; Temozolomide | 2017 |
Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Substrate Specificity; Survival Analysis; Temozolomide | 2008 |
Temozolomide for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2008 |
Recent approaches to improve the antitumor efficacy of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA Repair; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerases; Temozolomide | 2009 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Irinotecan; Neovascularization, Pathologic; Temozolomide; Vascular Endothelial Growth Factor A | 2009 |
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MEDLINE; Molecular Structure; Randomized Controlled Trials as Topic; Temozolomide | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Labeling; Glioblastoma; Glioma; Humans; Temozolomide | 2009 |
Management of glioblastoma multiforme in HIV patients: a case series and review of published studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Glioblastoma; HIV Infections; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2009 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genotype; Glioblastoma; Humans; Lomustine; Loss of Heterozygosity; Molecular Diagnostic Techniques; Pharmacogenetics; Procarbazine; Prognosis; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Glioblastoma; Humans; Leukemia, Myeloid, Acute; Lomustine; Myelodysplastic Syndromes; Neoplasms, Second Primary; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
High-grade glioma mouse models and their applicability for preclinical testing.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomarkers, Tumor; Blood-Brain Barrier; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioblastoma; Mice; Phosphorylcholine; Prognosis; Temozolomide; Transplantation, Heterologous | 2009 |
New advances that enable identification of glioblastoma recurrence.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Diffusion Magnetic Resonance Imaging; Glioblastoma; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiation Injuries; Randomized Controlled Trials as Topic; Temozolomide | 2009 |
Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Frail Elderly; Glioblastoma; Humans; Quality of Life; Radiotherapy Dosage; Temozolomide | 2009 |
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
[Glioblastoma multiforme--new hope due to modern therapeutical approaches].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Prognosis; Temozolomide; Time Factors | 2010 |
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infections; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, B-Cell; Male; Middle Aged; Opportunistic Infections; Temozolomide | 2010 |
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Precision Medicine; Temozolomide; Tumor Suppressor Proteins | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Glioma; Humans; Male; Palliative Care; Recurrence; Temozolomide; Treatment Outcome | 2010 |
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drugs, Investigational; Evidence-Based Medicine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Palliative Care; Retreatment; Survival Rate; Temozolomide | 2011 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diagnosis, Differential; Diagnostic Imaging; Diffusion Magnetic Resonance Imaging; Disease Progression; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Positron-Emission Tomography; Radiation Injuries; Sensitivity and Specificity; Temozolomide; Tumor Burden | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Drug Implants; Glioblastoma; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Polyesters; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Temozolomide; Venous Thromboembolism; Young Adult | 2011 |
Glioblastoma multiforme: enhancing survival and quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Radiotherapy; Seizures; Temozolomide; United States; Venous Thromboembolism | 2011 |
[Glioblastoma in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Developed Countries; Glioblastoma; Humans; Temozolomide | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2011 |
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; Temozolomide | 2011 |
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Liver Neoplasms; Male; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide | 2012 |
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Radiation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Radiotherapy, Computer-Assisted; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2012 |
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Cholestasis; Dacarbazine; Glioblastoma; Hepatitis; Humans; Male; Middle Aged; Prognosis; Temozolomide; United States; United States Food and Drug Administration | 2012 |
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2012 |
Cellular-based immunotherapies for patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Cancer Vaccines; Cell Extracts; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Dacarbazine; Dendritic Cells; Glioblastoma; Humans; Immunomodulation; Immunotherapy; Middle Aged; Temozolomide | 2012 |
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioblastoma; Humans; Neoplasm Proteins; Neoplastic Stem Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prodrugs; Radiation-Sensitizing Agents; Temozolomide; Tumor Suppressor Proteins | 2012 |
Recent medical management of glioblastoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Protein Kinase Inhibitors; Temozolomide | 2012 |
The efficacy of temozolomide for recurrent glioblastoma multiforme.
Topics: Administration, Metronomic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Glioblastoma; Humans; Secondary Prevention; Survival Rate; Temozolomide | 2013 |
Optimal management of elderly patients with glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Randomized Controlled Trials as Topic; Temozolomide | 2013 |
Potential usefulness of radiosensitizers in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Radiation-Sensitizing Agents; Radiotherapy; Temozolomide | 2012 |
The spectrum of vaccine therapies for patients with glioblastoma multiforme.
Topics: Acyclovir; Autoantigens; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Glioblastoma; Humans; Immunotherapy; Immunotherapy, Active; Signal Transduction; Temozolomide; Valacyclovir; Valine | 2012 |
Targeting the Akt-pathway to improve radiosensitivity in glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemoradiotherapy; Dacarbazine; DNA Damage; Drug Design; Drug Resistance, Neoplasm; Glioblastoma; Humans; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Survival Rate; Temozolomide | 2013 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Disease Progression; Drug Approval; Europe; Glioblastoma; Humans; Hungary; Irinotecan; Magnetic Resonance Imaging; Off-Label Use; Recurrence; Temozolomide; Treatment Outcome | 2012 |
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Integrins; Mice; Rats; Signal Transduction; Snake Venoms; Temozolomide | 2012 |
[Adjuvant radiochemotherapy in the elderly affected by glioblastoma: single-institution experience and literature review].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2013 |
Cryptococcemia in a patient with glioblastoma: case report and literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Central Nervous System; Cryptococcosis; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy; Temozolomide; Tomography, X-Ray Computed | 2012 |
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dideoxynucleosides; Glioblastoma; Humans; Immunotherapy; Interleukin-13 Receptor alpha2 Subunit; Neoplasm Recurrence, Local; Radiosurgery; Reoperation; Temozolomide | 2013 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Differentiation; Dacarbazine; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Signal Transduction; Temozolomide | 2003 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2005 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cognition Disorders; Dacarbazine; Disease Progression; Endpoint Determination; Glioblastoma; Health Status; Humans; Neuropsychological Tests; Procarbazine; Quality of Life; Survival Analysis; Temozolomide | 2005 |
[Highly quality-controlled radiation therapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Maximum Tolerated Dose; Quality Assurance, Health Care; Quality Control; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Temozolomide | 2005 |
[New place of the chemotherapy in gliomas].
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Glioblastoma; Humans; Prognosis; Survival Rate; Temozolomide | 2005 |
[Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Radiotherapy, Adjuvant; Temozolomide | 2005 |
[Standards and new developments in the chemotherapy of glioblastomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Cytarabine; Dacarbazine; Decanoic Acids; DNA Modification Methylases; Glioblastoma; Humans; Nimustine; Polyesters; Promoter Regions, Genetic; Temozolomide; Teniposide | 2005 |
[Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Radiation Tolerance; Temozolomide | 2005 |
The evolution of chemoradiation for glioblastoma: a modern success story.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2006 |
Treatment options for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cytotoxins; Dacarbazine; Drug Therapy; Glioblastoma; Growth Inhibitors; Humans; International Agencies; Radiotherapy; Temozolomide | 2006 |
Autophagy, the Trojan horse to combat glioblastomas.
Topics: Antineoplastic Agents, Phytogenic; Autophagy; Brain Neoplasms; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Protein Kinases; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2006 |
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Methyltransferases; Neoplasm Recurrence, Local; Patient Selection; Temozolomide; Treatment Outcome | 2006 |
Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; Drug Resistance, Neoplasm; Glioblastoma; Humans; Prognosis; Temozolomide | 2005 |
Chemotherapy for malignant gliomas.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Radiotherapy, Adjuvant; Survival Rate; Temozolomide | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Epilepsy; Forecasting; Genetic Markers; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Oligodendroglioma; Prognosis; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Thromboembolism; Time Factors; Tomography, X-Ray Computed | 2006 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; DNA Damage; Drug Administration Schedule; Epilepsy; Forecasting; Glioblastoma; Glioma; Humans; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Palliative Care; Prognosis; Promoter Regions, Genetic; Temozolomide; Thrombophilia | 2007 |
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Dose-Response Relationship, Drug; Female; Fever; Glioblastoma; Humans; Middle Aged; Neutropenia; Severity of Illness Index; Temozolomide; Treatment Outcome | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Genetic Therapy; Glioblastoma; Humans; Immunotherapy; Polyesters; Temozolomide | 2007 |
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasms; Temozolomide | 2007 |
Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Prognosis; Temozolomide; Treatment Outcome | 2006 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease Progression; Glioblastoma; Humans; Quality of Life; Temozolomide | 2000 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Genetic Therapy; Glioblastoma; Humans; Temozolomide; Topotecan | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Incidence; Melanoma; Temozolomide | 2000 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Glioma; Humans; Quality of Life; Temozolomide | 2001 |
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Evidence-Based Medicine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Contraindications; Cranial Irradiation; Craniotomy; Dacarbazine; Disease Progression; Epidemiologic Methods; Glioblastoma; Humans; Isotretinoin; Lomustine; Palliative Care; Procarbazine; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Temozolomide; Treatment Outcome; Vincristine | 2001 |
266 trial(s) available for dacarbazine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2021 |
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Prospective Studies; Temozolomide | 2022 |
Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Française (ANOCEF) trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Quality of Life | 2023 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DNA; DNA Methylation; DNA Repair Enzymes; Glioblastoma; Humans; Prospective Studies; Rectal Neoplasms; Temozolomide | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Prognosis; Temozolomide | 2023 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; Male; Mice; Middle Aged; Neoplasm Staging; Prognosis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Communication; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quality of Life; Radiation Dose Hypofractionation; Radiosurgery; Surveys and Questionnaires; Survivors; Temozolomide; Treatment Outcome | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
Short course radiotherapy concomitant with temozolomide in GBM patients: a phase II study.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Temozolomide | 2017 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Temozolomide; Time Factors; Treatment Outcome; Young Adult | 2017 |
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Proportional Hazards Models; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome; Vaccines, Subunit; Young Adult | 2017 |
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therapy; Cross-Over Studies; Dacarbazine; Electric Stimulation Therapy; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Mental Status and Dementia Tests; Middle Aged; Quality of Life; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiation Dose Hypofractionation; Radiation Oncology; Societies, Medical; Temozolomide | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Re-Irradiation; Salvage Therapy; Temozolomide; Time Factors | 2018 |
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Everolimus; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide; Young Adult | 2018 |
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Prognosis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Electric Stimulation Therapy; Female; Follow-Up Studies; Glioblastoma; Humans; Maintenance Chemotherapy; Male; Middle Aged; Mitosis; Survival Analysis; Temozolomide | 2017 |
The effect of an adenosine A
Topics: Adenosine A2 Receptor Agonists; Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Purines; Pyrazoles; Receptor, Adenosine A2A; Temozolomide | 2018 |
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Quality of Life; Radiation Dose Hypofractionation; Surveys and Questionnaires; Temozolomide | 2018 |
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Growth Processes; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiotherapy; Temozolomide; Tumor Suppressor Proteins | 2018 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Thrombocytopenia | 2018 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide | 2019 |
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide; Young Adult | 2013 |
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Recurrence, Local; Neoplasm Staging; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Semustine; Temozolomide | 2013 |
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Pyridines; Supratentorial Neoplasms; Temozolomide | 2013 |
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiography; Temozolomide; Treatment Outcome | 2013 |
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therapy; Communication; Dacarbazine; Disease Progression; Fatigue; Female; Glioblastoma; Health Status; Humans; Karnofsky Performance Status; Male; Neuropsychological Tests; Prospective Studies; Quality of Life; Social Participation; Surveys and Questionnaires; Temozolomide | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide | 2013 |
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Everolimus; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Temozolomide | 2013 |
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neuropsychological Tests; Prospective Studies; Quality of Life; Radiotherapy, Intensity-Modulated; Temozolomide | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Imaging, Three-Dimensional; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Tamoxifen; Temozolomide; Treatment Outcome | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors | 2013 |
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Italy; Middle Aged; Prevalence; Prospective Studies; Risk Assessment; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Hematologic Diseases; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Proton Pump Inhibitors; Temozolomide; Tumor Suppressor Proteins | 2015 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neuropsychological Tests; Proportional Hazards Models; Quality of Life; Temozolomide; Young Adult | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme-Linked Immunosorbent Assay; Glioblastoma; Humans; Magnetic Resonance Imaging; Oxygen; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Statistics, Nonparametric; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; HIV Protease Inhibitors; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nelfinavir; Outcome Assessment, Health Care; Temozolomide; Time Factors | 2014 |
Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Retrospective Studies; RNA, Small Interfering; Survival Rate; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2014 |
Case numbers for a randomized clinical trial of boron neutron capture therapy for Glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Borohydrides; Boron Compounds; Boron Neutron Capture Therapy; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Germany; Glioblastoma; Humans; Male; Middle Aged; Phenylalanine; Prevalence; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome | 2014 |
Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome | 2014 |
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Methylation; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Snake Venoms; Temozolomide; Treatment Outcome | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Temozolomide; Treatment Outcome | 2014 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Neoplasm, Residual; Prospective Studies; Radiation Injuries; Radiotherapy, Intensity-Modulated; Temozolomide | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Glioblastoma; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Quality of Life; Temozolomide; Young Adult | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Double-Blind Method; Glioblastoma; Humans; Proportional Hazards Models; Survival Analysis; Temozolomide | 2014 |
Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2016 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide | 2014 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Temozolomide; Treatment Outcome | 2014 |
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiography; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Failure; Treatment Outcome | 2014 |
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Demography; Female; Glioblastoma; Humans; Hydroxychloroquine; Male; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Follow-Up Studies; Glioblastoma; Humans; Japan; Male; Middle Aged; Prospective Studies; Radiotherapy; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Genetic Therapy; Glioblastoma; Guanine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Prospective Studies; Temozolomide; Tumor Suppressor Proteins | 2014 |
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiosurgery; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2015 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Reference Values; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Combinations; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazoles; Sulfonamides; Temozolomide; Thalidomide; Young Adult | 2015 |
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Disease-Free Survival; Feasibility Studies; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Temozolomide; Treatment Outcome | 2015 |
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2015 |
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Everolimus; Glioblastoma; Humans; Positron-Emission Tomography; Prognosis; Survival Analysis; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Temozolomide | 2015 |
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2015 |
Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM.
Topics: Alleles; Anilides; Cell Division; Cell Line, Tumor; Dacarbazine; Exome; Female; Follow-Up Studies; G2 Phase; Gene Frequency; Glioblastoma; Hedgehog Proteins; Humans; Male; Neoplasm Proteins; Pyridines; Radiography; Spheroids, Cellular; Temozolomide | 2015 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Cortex; Contrast Media; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2015 |
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins | 2015 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; WT1 Proteins | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Metalloporphyrins; Multivariate Analysis; Supratentorial Neoplasms; Temozolomide | 2015 |
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Piperidines; Quinazolines; Temozolomide; Treatment Outcome | 2015 |
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2015 |
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Neoplasm Staging; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Double-Blind Method; Female; Glioblastoma; Humans; Male; Middle Aged; Placebos; Quality of Life; Surveys and Questionnaires; Survival Analysis; Temozolomide | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide; Treatment Outcome | 2015 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Feasibility Studies; Female; Follow-Up Studies; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide | 2015 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Time Factors; Valproic Acid | 2015 |
Standard chemoradiation for glioblastoma results in progressive brain volume loss.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Diffusion Tensor Imaging; Glioblastoma; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2015 |
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Molecular Imaging; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Prognosis; Proton Magnetic Resonance Spectroscopy; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome | 2015 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2015 |
A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; France; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome; Tumor Burden; Tumor Suppressor Proteins | 2016 |
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2016 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Constipation; Dacarbazine; Diarrhea; Fatigue; Female; Glioblastoma; Humans; Hypertension; L-Lactate Dehydrogenase; Leukopenia; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Grading; Neurosurgical Procedures; Neutropenia; Pyridines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2016 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Electric Stimulation Therapy; Europe; Female; Glioblastoma; Humans; Israel; Maintenance Chemotherapy; Male; Middle Aged; Republic of Korea; Temozolomide; United States; Young Adult | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Prognosis; Promoter Regions, Genetic; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2015 |
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide | 2016 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult | 2016 |
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Disulfiram; Dose-Response Relationship, Drug; Drug Repositioning; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Supratentorial Neoplasms; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Tumor-Treating Fields-A Fundamental Change in Locoregional Management for Glioblastoma.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Field Therapy; Male; Middle Aged; Temozolomide | 2016 |
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide | 2016 |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Proportional Hazards Models; Sirolimus; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Psychometrics; Quality of Life; Temozolomide | 2016 |
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Temozolomide; Treatment Outcome | 2016 |
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; Glioma; Humans; Immunotherapy; Male; Middle Aged; Temozolomide; Up-Regulation | 2016 |
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Republic of Korea; Temozolomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoadjuvant Therapy; Pancytopenia; Prospective Studies; Radiation Dose Hypofractionation; Reoperation; Temozolomide; Time Factors; Treatment Failure; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Immunoconjugates; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide; Treatment Outcome | 2017 |
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Epidemiologic Methods; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Proteins; Prognosis; Receptor Protein-Tyrosine Kinases; Temozolomide; Tumor Suppressor Proteins | 2017 |
[Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients].
Topics: Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide | 2016 |
Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; China; Cisplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Quality of Life; Radiotherapy; Survival Analysis; Temozolomide | 2017 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Prospective Studies; Temozolomide | 2008 |
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Topics: Adult; Adult Stem Cells; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Profiling; Genes, Homeobox; Glioblastoma; Humans; Middle Aged; Multigene Family; Radiation Tolerance; Temozolomide | 2008 |
Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Invasiveness; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2008 |
Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results.
Topics: Adult; Antineoplastic Agents, Alkylating; Case-Control Studies; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mutation; Radiotherapy; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Geriatrics; Glioblastoma; Humans; Karnofsky Performance Status; Male; Prospective Studies; Quality of Life; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2009 |
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2009 |
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Magnetic Resonance Imaging; Methionine; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retreatment; Software; Temozolomide; Treatment Failure; Young Adult | 2009 |
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome | 2008 |
Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Ethics, Medical; Female; Glioblastoma; Humans; Male; Middle Aged; Patient Compliance; Patient Selection; Quality of Life; Radiotherapy Dosage; Salvage Therapy; Survival Analysis; Temozolomide | 2008 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome | 2009 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Temozolomide | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Survival Analysis; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2009 |
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Temozolomide; Treatment Outcome | 2009 |
Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome | 2010 |
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Brain Neoplasms; Cranial Irradiation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Excitatory Amino Acid Antagonists; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, AMPA; Risk Assessment; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; United States | 2009 |
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Korea; Male; Middle Aged; Radiation Dosage; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recombinant Proteins; Temozolomide; Treatment Outcome; Young Adult | 2009 |
A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Radiotherapy, Intensity-Modulated; Temozolomide; Tumor Burden | 2010 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Conformal; Temozolomide; Treatment Outcome | 2010 |
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glioblastoma; Humans; Male; Middle Aged; Polyethylene Glycols; Temozolomide; Young Adult | 2009 |
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Community Health Planning; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2009 |
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Follow-Up Studies; Germany; Glioblastoma; Humans; Indomethacin; Karnofsky Performance Status; Male; Middle Aged; Prospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2010 |
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Pyridines; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diverticulitis; Drug Administration Schedule; ErbB Receptors; Female; Gastrointestinal Hemorrhage; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Quinazolines; Temozolomide; Thrombocytopenia; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Male; Middle Aged; Temozolomide; Young Adult | 2010 |
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Quality of Life; Temozolomide; Young Adult | 2010 |
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibroblast Growth Factor 1; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Oligopeptides; Receptor, TIE-1; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Treatment Outcome | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Radiotherapy, Adjuvant; Recurrence; Temozolomide; Time Factors; Treatment Outcome | 2010 |
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Glioblastoma; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Radioimmunotherapy; Radiotherapy, Adjuvant; Temozolomide; Young Adult | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Young Adult | 2010 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neurosurgical Procedures; Probability; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Risk Assessment; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Cytochrome P-450 CYP3A; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Temozolomide | 2011 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioblastoma; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2011 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose Sodium; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Interferon Inducers; Kaplan-Meier Estimate; Male; Middle Aged; Poly I-C; Polylysine; Radiotherapy; Temozolomide; Young Adult | 2010 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Odds Ratio; Organophosphorus Compounds; Temozolomide; Time Factors; Tomography, X-Ray Computed | 2011 |
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Celecoxib; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Pyrazoles; Radiotherapy; Sulfonamides; Supratentorial Neoplasms; Temozolomide; Thalidomide; Young Adult | 2010 |
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Prognosis; Proton Therapy; Radiotherapy Dosage; Relative Biological Effectiveness; Survival Rate; Temozolomide | 2010 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Membrane Proteins; Middle Aged; Phthalazines; Polymorphism, Single Nucleotide; Pyridines; Radiotherapy; Receptor, TIE-2; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Etoposide; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2011 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Everolimus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sirolimus; Temozolomide | 2011 |
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Injections, Intradermal; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Sample Size; Temozolomide; Time Factors; Tumor Suppressor Proteins; United States | 2010 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prospective Studies; Radiotherapy, Intensity-Modulated; Temozolomide; Tumor Burden | 2011 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Quinolones; Temozolomide | 2011 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Craniotomy; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Glucocorticoids; Humans; Injections, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Burden; Young Adult | 2012 |
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prospective Studies; Temozolomide | 2011 |
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; DNA Methylation; ErbB Receptors; Female; Glioblastoma; Humans; Hypersensitivity, Delayed; Immunoenzyme Techniques; Lymphopenia; Male; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Survival Rate; T-Lymphocytes; T-Lymphocytes, Regulatory; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2011 |
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cancer Vaccines; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioblastoma; HLA-A Antigens; HLA-A24 Antigen; Humans; Japan; Male; Middle Aged; Precision Medicine; Recurrence; Survival Analysis; T-Lymphocytes, Cytotoxic; Temozolomide; Vaccines, Subunit | 2011 |
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Gliosarcoma; Humans; Immunoenzyme Techniques; Male; O(6)-Methylguanine-DNA Methyltransferase; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Survival Rate; Tamoxifen; Temozolomide; Thrombocytopenia; Venous Thrombosis; Young Adult | 2012 |
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Conformal; Temozolomide; Treatment Failure; Treatment Outcome | 2011 |
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Europe; Glioblastoma; Humans; Prognosis; Radiotherapy; Recurrence; Standard of Care; Temozolomide; Treatment Outcome | 2011 |
Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2011 |
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Glycoproteins; Humans; Male; Middle Aged; Neoplasm Staging; Peptides; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Epitopes; Female; Glioblastoma; Humans; Immunity, Cellular; Male; Middle Aged; Radiotherapy; Research Design; Survival Analysis; T-Lymphocytes; Temozolomide; Transplantation, Autologous; Treatment Outcome | 2011 |
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; North America; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Temozolomide; Vascular Endothelial Growth Factor A | 2011 |
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; France; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Polymerase Chain Reaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Daclizumab; Drug Evaluation, Preclinical; Glioblastoma; Humans; Immunoglobulin G; Immunotherapy; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Lymphopenia; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Substrate Specificity; T-Lymphocytes, Regulatory; Temozolomide; Young Adult | 2011 |
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Europe; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Valproic Acid; Young Adult | 2011 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Case-Control Studies; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Gliosarcoma; Humans; Immunoenzyme Techniques; Indoles; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiosurgery; Reoperation; Survival Rate; Temozolomide; Vomiting | 2012 |
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; Prognosis; Recurrence; Temozolomide; Treatment Outcome | 2012 |
Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
Topics: Adult; Aged; Alberta; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Neutropenia; Temozolomide; Thrombocytopenia | 2012 |
Going past the data for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2012 |
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Combinations; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; PTEN Phosphohydrolase; Sirolimus; Temozolomide; Young Adult | 2012 |
A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Ireland; Male; Middle Aged; Prevalence; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2012 |
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide; Young Adult | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Iodine Radioisotopes; Male; Middle Aged; Prognosis; Prospective Studies; Temozolomide | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Reoperation; Temozolomide; Tumor Burden | 2012 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Integrins; Male; Middle Aged; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Comorbidity; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Radiosurgery; Radiotherapy; Temozolomide; Young Adult | 2012 |
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Temozolomide; Young Adult | 2012 |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Evidence-Based Medicine; Female; Glioblastoma; Humans; Male; Middle Aged; Palliative Care; Prognosis; Quality of Life; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated; Temozolomide | 2013 |
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Radiotherapy, Conformal; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome; Victoria | 2012 |
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Immunotherapy, Active; Male; Middle Aged; Nimustine; Temozolomide | 2013 |
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Radiation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Failure; Young Adult | 2014 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Neurosurgical Procedures; Prospective Studies; Radiotherapy; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Patient Selection; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Outcome | 2015 |
Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Procarbazine; Recurrence; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioblastoma; Humans; Middle Aged; Portugal; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
A prospective study on glioblastoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Male; Neurosurgical Procedures; Procarbazine; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Temozolomide; Vincristine | 2003 |
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Survival Rate | 2003 |
Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Salvage Therapy; Survival Rate | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Procarbazine; Sleep Stages; Temozolomide; Thrombocytopenia; Treatment Outcome | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Survival Rate; Temozolomide | 2003 |
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Supratentorial Neoplasms; Temozolomide; Treatment Outcome | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence Intervals; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Temozolomide | 2004 |
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2004 |
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Promoter Regions, Genetic; Proportional Hazards Models; Survival Analysis; Temozolomide; Time Factors | 2004 |
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Interactions; Female; Glioblastoma; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Prognosis; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Sex Factors | 2004 |
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gastrointestinal Diseases; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Life Tables; Male; Middle Aged; Neoplasms, Neuroepithelial; Oligodendroglioma; Prospective Studies; Temozolomide; Treatment Outcome | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy; Temozolomide | 2004 |
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Thalidomide | 2004 |
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Delivery Systems; Female; Glioblastoma; Humans; Italy; Male; Middle Aged; Radioimmunotherapy; Radiopharmaceuticals; Survival Analysis; Temozolomide; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Computer-Assisted; Survival Analysis; Temozolomide | 2005 |
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2005 |
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Isotretinoin; Male; Middle Aged; Proportional Hazards Models; Supratentorial Neoplasms; Temozolomide | 2005 |
Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Radiotherapy; Temozolomide; Treatment Outcome | 2005 |
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide; Time Factors | 2005 |
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Approval; Female; Glioblastoma; Humans; Male; Middle Aged; Pneumocystis; Pneumocystis Infections; Proportional Hazards Models; Quality of Life; Radiotherapy; Salvage Therapy; Temozolomide; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Temozolomide | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Quality of Life; Radiotherapy; Temozolomide; Time Factors; Treatment Outcome | 2006 |
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease Progression; ErbB Receptors; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2006 |
Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Glioblastoma; Humans; Quality of Life; Temozolomide | 2006 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Europe; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Polyethylene Glycols; Radioimmunotherapy; Temozolomide | 2003 |
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Feasibility Studies; Female; Glioblastoma; Humans; Laser Coagulation; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Temperature | 2006 |
Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide | 2006 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Necrosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Temozolomide; Treatment Outcome | 2007 |
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Temozolomide | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Survival Analysis; Temozolomide; Thalidomide | 2007 |
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Statistics, Nonparametric; Temozolomide; Time Factors; Treatment Outcome | 2007 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Probability; Prospective Studies; Risk Assessment; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Procarbazine; Salvage Therapy; Temozolomide | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide | 2008 |
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Nomograms; Prognosis; Proportional Hazards Models; Survival Analysis; Temozolomide | 2008 |
Nomograms as clinicobiological predictors of survival in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioblastoma; Humans; Nomograms; Predictive Value of Tests; Prognosis; Temozolomide | 2008 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Glioblastoma; Health Care Costs; Humans; Middle Aged; Quality-Adjusted Life Years; Survival Rate; Temozolomide | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Glioblastoma; Humans; Male; Middle Aged; Prevalence; Radiotherapy; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabine; Cyclooxygenase 2 Inhibitors; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Edema; Efferent Pathways; Erythema; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Immunohistochemistry; Lactones; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pioglitazone; PPAR gamma; Predictive Value of Tests; Quality of Life; Sulfones; Temozolomide; Thiazolidinediones; Treatment Outcome | 2007 |
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Pilot Projects; Temozolomide | 2008 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Dacarbazine; Disease-Free Survival; DNA Methylation; Endostatins; Female; Fibroblast Growth Factor 2; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Pyrazoles; Sulfonamides; Temozolomide; Thalidomide; Thrombospondins; Vascular Endothelial Growth Factor A | 2008 |
Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Child; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Nimustine; Radiation Dosage; Supratentorial Neoplasms; Treatment Outcome; Vincristine | 1996 |
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Ifosfamide; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 1999 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Health Status; Humans; Male; Middle Aged; Procarbazine; Quality of Life; Temozolomide | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Gliosarcoma; Humans; Male; Middle Aged; Procarbazine; Prognosis; Quality of Life; Recurrence; Temozolomide; Time Factors | 2000 |
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Temozolomide | 2001 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Implants; Drug Synergism; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Safety; Supratentorial Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2001 |
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pneumocystis Infections; Temozolomide | 2002 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2002 |
Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Procarbazine | 1986 |
1288 other study(ies) available for dacarbazine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Quality of Life; Retrospective Studies; Temozolomide | 2021 |
Dramatic clinical response in the treatment of small cell glioblastoma multiforme.
Topics: Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis | 2022 |
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Immunotherapy; Isocitrate Dehydrogenase; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2022 |
Evaluating Quality Indicators of Glioblastoma Care: Audit Results From an Indian Tertiary Care Cancer Center.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Quality Indicators, Health Care; Retrospective Studies; Temozolomide; Tertiary Healthcare | 2022 |
Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Republic of Korea; Surveys and Questionnaires; Temozolomide | 2022 |
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gliosarcoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2022 |
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Levetiracetam; Male; Middle Aged; Prognosis; Retrospective Studies; Seizures; Temozolomide; Tumor Suppressor Proteins | 2022 |
Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era.
Topics: Brain Neoplasms; COVID-19; Dacarbazine; Glioblastoma; Hospitals; Humans; Pandemics; SARS-CoV-2; Vaccines | 2022 |
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; DNA; Glioblastoma; Humans; Isocitrate Dehydrogenase; Methyltransferases; Temozolomide | 2022 |
Mechanism-based design of agents that selectively target drug-resistant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Design; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2022 |
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; MutS Homolog 2 Protein; Neoplasm Recurrence, Local; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2022 |
Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Purines; Signal Transduction; Temozolomide | 2023 |
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2023 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retrospective Studies; Temozolomide | 2022 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Phosphatidylinositol 3-Kinases; Recombinational DNA Repair; Temozolomide; Triterpenes; Zebrafish | 2023 |
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transcription Factors | 2022 |
Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Temozolomide | 2023 |
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide | 2023 |
Letter to the editor regarding "The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies".
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Radiotherapy, Adjuvant; Temozolomide | 2023 |
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Methylation; O(6)-Methylguanine-DNA Methyltransferase; Progression-Free Survival; Temozolomide; Tumor Suppressor Proteins | 2023 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Prognosis; Temozolomide | 2023 |
Combination of SIX4-siRNA and temozolomide inhibits the growth and migration of A-172 glioblastoma cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Homeodomain Proteins; Humans; RNA, Small Interfering; Temozolomide; Trans-Activators | 2023 |
Disruption of Glioblastoma Multiforme Cell Circuits with Cinnamaldehyde Highlights Potential Targets with Implications for Novel Therapeutic Strategies.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans | 2023 |
GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; GTP-Binding Proteins; Humans; Temozolomide | 2023 |
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Prognosis; Temozolomide | 2023 |
Discovery of new imidazotetrazinones with potential to overcome tumor resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide; Thiazoles | 2023 |
Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.
Topics: Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Methylation; Prognosis; Tumor Suppressor Proteins | 2023 |
The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2023 |
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Precision Medicine; Temozolomide | 2023 |
Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Lipids; Temozolomide; Tumor Suppressor Proteins | 2023 |
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; Nitric Oxide; Stem Cells; Temozolomide | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolomide; Tumor Microenvironment | 2023 |
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Temozolomide | 2023 |
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Suppressor Proteins | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Temozolomide; TOR Serine-Threonine Kinases | 2023 |
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genomics; Glioblastoma; Humans; Phenotype; Temozolomide | 2023 |
Treatment of glioblastoma in Greenlandic patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Proteomics; Tandem Mass Spectrometry; Temozolomide | 2023 |
Electrospun PVA-Dacarbazine nanofibers as a novel nano brain-implant for treatment of glioblastoma: in silico and in vitro characterization.
Topics: Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Cell Survival; Dacarbazine; Delayed-Action Preparations; Drug Implants; Drug Liberation; Glioblastoma; Humans; Molecular Dynamics Simulation; Nanofibers; Polyvinyl Alcohol; Technology, Pharmaceutical | 2020 |
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide | 2020 |
Management of glioblastoma: an Australian perspective.
Topics: Australia; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Temozolomide | 2020 |
Chemotherapy toxicities and geriatric syndromes in older patients with malignant gliomas.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Glioma; Humans; Retrospective Studies; Syndrome | 2021 |
Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?"
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Rate; Temozolomide; Treatment Outcome | 2020 |
The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2021 |
Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Prognosis; Temozolomide | 2020 |
Desquamative skin rash associated with temozolomide in a patient with glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Exanthema; Glioblastoma; Humans; Temozolomide | 2021 |
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Guanine; Humans; Mice; Poly ADP Ribosylation; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Suppressor Proteins | 2021 |
Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology).
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Italy; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2021 |
Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
Letter: Is the Stupp Protocol an Expensive and Unsustainable Standard of Care for Glioblastoma in Low- and Middle-Income Country Settings? A Call to Action!
Topics: Dacarbazine; Glioblastoma; Humans; Standard of Care; Temozolomide | 2021 |
Silencing glioblastoma networks to make temozolomide more effective.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Retrospective Studies; Tumor Suppressor Proteins | 2021 |
Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Glioma; Humans; Male; Methadone; Middle Aged; Patient Safety; Proportional Hazards Models; Retrospective Studies; Risk; Surveys and Questionnaires; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Answer to the comment of Hai Lu et al. regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report and review of the literature. Arch Toxicol (2016)".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2017 |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Spheroids, Cellular; Temozolomide | 2017 |
MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Male; MicroRNAs; Neoplastic Stem Cells; PAX6 Transcription Factor; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Neoplasm; Signal Transduction; Temozolomide | 2017 |
Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma.
Topics: Adipocytes; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastoma; Humans; Lactic Acid; Magnetite Nanoparticles; Male; Mice, Inbred C57BL; Molecular Targeted Therapy; Oleic Acid; Paclitaxel; Particle Size; Permeability; Polyglutamic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Stem Cells; Surface Properties; Temozolomide; Tissue Distribution | 2017 |
Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cytochromes c; Dacarbazine; Drug Synergism; Glioblastoma; Glutathione; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Nitric Oxide; Reactive Oxygen Species; Staining and Labeling; Temozolomide | 2017 |
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
Topics: Aged; Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Fas Ligand Protein; Female; Gene Knockdown Techniques; Glioblastoma; Glycogen Synthase Kinase 3; Humans; Lithium; Male; Mice; Middle Aged; Neoplasm Transplantation; NFATC Transcription Factors; Primary Cell Culture; Protein Transport; Signal Transduction; Survival Rate; Temozolomide; Tumor Suppressor Protein p53 | 2017 |
Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Temozolomide | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Management; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Neuroepithelial; Neurosurgical Procedures; Oligodendroglioma; Proportional Hazards Models; Retrospective Studies; SEER Program; Survival Rate; Temozolomide | 2017 |
Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 7; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Central Nervous System Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Hydrazones; Membrane Potential, Mitochondrial; Neoplastic Stem Cells; Pyrazoles; Temozolomide | 2018 |
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Tumor Suppressor Proteins | 2017 |
Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorescence; Glioblastoma; Humans; Mice; Mice, SCID; Nanoconjugates; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Laminectomy; Male; Middle Aged; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome; Young Adult | 2017 |
How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.
Topics: Adult; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2017 |
Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Lateral Ventricles; Male; Middle Aged; Prognosis; Radiation Dosage; Retrospective Studies; Survival Rate; Temozolomide | 2017 |
Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Naphthoquinones; Temozolomide | 2017 |
Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Movement; Dacarbazine; Glioblastoma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Temozolomide; Transcription, Genetic | 2017 |
[Combining radiation plus temozolomide in glioblastoma patients older than 65 years of age].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2017 |
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Binding Sites; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glioblastoma; Glycolysis; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Models, Molecular; Molecular Conformation; Permeability; Phosphorylation; Protein Binding; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma.
Topics: Adult; Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; RNA, Small Nucleolar; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The sustained delivery of temozolomide from electrospun PCL-Diol-b-PU/gold nanocompsite nanofibers to treat glioblastoma tumors.
Topics: Cell Line, Tumor; Dacarbazine; Drug Implants; Glioblastoma; Humans; Nanocomposites; Nanofibers; Temozolomide | 2017 |
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Transplantation; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2017 |
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Demethylases; Humans; Hydrazones; Mice; Phosphorylation; Proto-Oncogene Proteins c-akt; Retinoblastoma-Binding Protein 2; Small Molecule Libraries; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Expression and function of ABCG2 and XIAP in glioblastomas.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Brain Neoplasms; Cells, Cultured; Dacarbazine; Diketopiperazines; Female; Follow-Up Studies; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Temozolomide; X-Linked Inhibitor of Apoptosis Protein | 2017 |
Recurrence Pattern Analysis of Primary Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Retrospective Studies; Survival Rate; Temozolomide | 2017 |
EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cytokines; Dacarbazine; G2 Phase; Glioblastoma; Humans; Mitosis; Neoplasm Proteins; Neoplastic Stem Cells; RNA-Binding Proteins; Signal Transduction; Temozolomide | 2017 |
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Neoplasm Invasiveness; Proto-Oncogene Proteins pp60(c-src); Signal Transduction; Temozolomide | 2017 |
Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Population Surveillance; Registries; SEER Program; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ARNTL Transcription Factors; Cell Line, Tumor; Cell Proliferation; Circadian Rhythm; Dacarbazine; DNA Repair; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Period Circadian Proteins; Temozolomide | 2017 |
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Topics: Adult; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Temozolomide | 2017 |
Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Temozolomide | 2018 |
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Micelles; Signal Transduction; Temozolomide; Tumor Stem Cell Assay; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2017 |
Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Glioblastoma; Humans; Phosphotransferases (Alcohol Group Acceptor); Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Glioma; Humans; Hypoxia; Mitochondria; Neoplastic Stem Cells; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Recurrence, Local; Neoplasm Transplantation; Random Allocation; Temozolomide | 2017 |
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Exosomes; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Oncogene Proteins, Fusion; Phenotype; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Temozolomide | 2017 |
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; CpG Islands; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; ROC Curve; Temozolomide; Tumor Suppressor Proteins | 2017 |
Telodendrimers for Physical Encapsulation and Covalent Linking of Individual or Combined Therapeutics.
Topics: Acetazolamide; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Survival; Dacarbazine; Dendrimers; Drug Delivery Systems; Glioblastoma; Humans; Lactates; Micelles; Polyesters; Polyethylene Glycols; Quercetin; Spheroids, Cellular; Temozolomide | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniotomy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Postoperative Complications; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Serbia; Survival Analysis; Temozolomide | 2017 |
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Heterografts; Humans; Neoplastic Stem Cells; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Proportional Hazards Models; Temozolomide | 2017 |
When less is better: care of the elderly with glioblastoma.
Topics: Aged; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2017 |
Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Cytotoxins; Dacarbazine; Electromagnetic Fields; Glioblastoma; Humans; Magnetic Field Therapy; Temozolomide | 2017 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornithine; Glioblastoma; HL-60 Cells; Humans; Melarsoprol; Temozolomide; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Glioblastoma; Humans; Mice; Neoplasms, Experimental; ras Proteins; Signal Transduction; Temozolomide; Tumor Cells, Cultured | 2017 |
Radiation plus Temozolomide in Patients with Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans | 2017 |
Radiation plus Temozolomide in Patients with Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans | 2017 |
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cohort Studies; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; HEK293 Cells; Humans; Mice; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oncolytic Virotherapy; Simplexvirus; Temozolomide; TNF-Related Apoptosis-Inducing Ligand | 2017 |
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Computer Simulation; Dacarbazine; Databases, Factual; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Glycolysis; Humans; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Isocitrate Dehydrogenase; Mutation; Neoplasm Invasiveness; Neoplastic Stem Cells; Prognosis; RNA, Messenger; Temozolomide; Tumor Hypoxia; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Kaplan-Meier Estimate; Methylation; Multivariate Analysis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Temozolomide; Time Factors; Tumor Suppressor Proteins | 2017 |
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Glypicans; Humans; Isocitrate Dehydrogenase; Karnofsky Performance Status; Ki-67 Antigen; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2017 |
Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connective Tissue Growth Factor; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Glioblastoma; Humans; Hyaluronan Receptors; Male; Mice; Mice, Nude; Neoplasm Transplantation; Signal Transduction; Smad Proteins; Temozolomide; Transforming Growth Factor beta1 | 2017 |
New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Nanoparticles; Polymers; Temozolomide | 2017 |
A Novel Theranostic Strategy for
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Ferric Compounds; Flow Cytometry; Gene Expression; Glioblastoma; Humans; Magnetic Resonance Imaging; Mass Spectrometry; Matrix Metalloproteinase 14; Mice; Nanoparticles; Temozolomide; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2017 |
Liposomal temozolomide drug delivery using convection enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Convection; Dacarbazine; Drug Delivery Systems; Gadolinium DTPA; Glioblastoma; Liposomes; Male; Nanoparticles; Particle Size; Polyethylene Glycols; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Survival Rate; Temozolomide; Tumor Burden | 2017 |
Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; RNA, Long Noncoding; Temozolomide; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2017 |
A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation.
Topics: Antineoplastic Agents; Astrocytes; Bone Morphogenetic Protein 2; Cell Differentiation; Dacarbazine; Glioblastoma; Humans; Mesenchymal Stem Cells; Molecular Mimicry; Neoplastic Stem Cells; Osteogenesis; Peptide Fragments; Temozolomide | 2017 |
[Combination Therapy with Radiation, Temozolomide, and Bevacizumab after Partial Tumor Removal in Glioblastoma Patients with Low Performance Status].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide; Treatment Outcome | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Dacarbazine; Furans; Glioblastoma; Humans; Lactic Acid; Phosphorylcholine; Proton Magnetic Resonance Spectroscopy; Pyridines; Pyrimidines; Temozolomide; Treatment Outcome | 2017 |
Glioblastoma entities express subtle differences in molecular composition and response to treatment.
Topics: Apoptosis; Astrocytoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Glioblastoma; Humans; Neoplasm Grading; Protein Kinase C; Signal Transduction; Tamoxifen; Temozolomide | 2017 |
Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; Oligonucleotide Array Sequence Analysis; RNA, Long Noncoding; RNA, Messenger; Temozolomide | 2017 |
The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; HLA-A2 Antigen; Humans; Leukocytes, Mononuclear; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Knockout; Mice, Nude; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; Cohort Studies; Dacarbazine; Databases, Factual; Delivery of Health Care; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2017 |
A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glioblastoma; Heterografts; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Nanocomposites; Nanoparticles; Nestin; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Perfusion; Spin Labels; Temozolomide | 2017 |
Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Glycolysis; Humans; Lactate Dehydrogenases; Structure-Activity Relationship; Temozolomide | 2017 |
FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Integrins; Male; Membrane Proteins; Middle Aged; Neoplasm Proteins; Temozolomide; Wnt Signaling Pathway | 2017 |
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Horses; Humans; Middle Aged; Myocarditis; Nivolumab; Temozolomide | 2017 |
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Hong Kong; Humans; Male; Middle Aged; Registries; Retrospective Studies; Temozolomide | 2017 |
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Topics: Animals; Brain Neoplasms; Cells, Cultured; CRISPR-Cas Systems; Dacarbazine; Dependovirus; DNA Mutational Analysis; Female; Gene Knock-In Techniques; Gene Knockout Techniques; Glioblastoma; Humans; Male; Mice; Mutation; Suppression, Genetic; Temozolomide; Transcriptome | 2017 |
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Histoplasmosis; Humans; Lung Diseases, Fungal; Male; Middle Aged; Opportunistic Infections; Radiotherapy, Adjuvant; Temozolomide | 2016 |
Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Reactive Oxygen Species; Sp1 Transcription Factor; Superoxide Dismutase; Temozolomide; Tumor Suppressor Proteins | 2017 |
Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Lomustine; Temozolomide | 2018 |
Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Doxycycline; Drug Synergism; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Oxidative Stress; Random Allocation; Reactive Oxygen Species; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Evaluation of drug combination for glioblastoma based on an intestine-liver metabolic model on microchip.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caco-2 Cells; Coculture Techniques; Cyclophosphamide; Dacarbazine; Drug Combinations; Drug Delivery Systems; Glioblastoma; Hep G2 Cells; Humans; Intestinal Absorption; Intestines; Irinotecan; Liver; Models, Biological | 2017 |
A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2017 |
[Corticosteroids compromise survival in glioblastoma patients after radio- and chemotherapy].
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2017 |
Hospitalizations in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Costs and Cost Analysis; Dacarbazine; Emergency Service, Hospital; Glioblastoma; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Temozolomide | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Glioma; Humans; Hydrogels; Mice; Neoplasm Recurrence, Local; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Zika virus has oncolytic activity against glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; Combined Modality Therapy; Dacarbazine; Female; Fluorescent Antibody Technique; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neoplastic Stem Cells; Oncolytic Virotherapy; Temozolomide; Vero Cells; Zika Virus | 2017 |
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Karnofsky Performance Status; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome | 2018 |
MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Membrane Proteins; MicroRNAs; Neoplastic Stem Cells; Phenotype; RNA Interference; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2017 |
Identification of WISP1 as a novel oncogene in glioblastoma.
Topics: Brain Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Temozolomide; Up-Regulation | 2017 |
Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, SCID; Neoplastic Stem Cells; Oxidative Stress; Sp1 Transcription Factor; Temozolomide; Treatment Outcome | 2017 |
Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Proteome; Temozolomide | 2017 |
HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Heparin-binding EGF-like Growth Factor; Histones; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Proteolysis; RNA, Messenger; RNA, Neoplasm; Temozolomide; Ubiquitin Thiolesterase | 2017 |
PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Topics: Animals; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Lentivirus; Mice; N-Acetylglucosaminyltransferases; Neoplasm Recurrence, Local; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; MicroRNAs; Neoplasm Recurrence, Local; Signal Transduction; Temozolomide; TNF Receptor-Associated Factor 6; Xenograft Model Antitumor Assays | 2017 |
Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Databases, Factual; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2018 |
Probing the Oncolytic and Chemosensitizing Effects of Dihydrotanshinone in an
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Furans; Glioblastoma; Humans; In Vitro Techniques; Phenanthrenes; Quinones; Temozolomide; Tumor Cells, Cultured | 2017 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Reproducibility of Results; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Temozolomide | 2017 |
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Female; Germany; Glioblastoma; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Regression Analysis; Retrospective Studies; Temozolomide | 2017 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Temozolomide | 2018 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Ganglioglioma; Glioblastoma; Glioma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2017 |
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Glutathione; Glutathione Reductase; Homeostasis; Humans; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Oxidants; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; RNA, Small Interfering; Temozolomide; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2018 |
Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication.
Topics: Analgesics, Opioid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cell Line, Tumor; Connexin 43; Dacarbazine; Drug Interactions; Gap Junctions; Glioblastoma; Humans; Temozolomide; Tramadol; Transfection | 2018 |
FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Gene Knockdown Techniques; Glioblastoma; Heme Oxygenase-1; Humans; NF-E2-Related Factor 2; RNA, Messenger; RNA, Small Interfering; Temozolomide | 2017 |
Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Dose-Response Relationship, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2017 |
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Hydrogels; Injections; Iodine Radioisotopes; Male; Mice; Mice, Nude; Prognosis; Temozolomide | 2018 |
Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 8; Cell Line, Tumor; Cholesterol; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Intracellular Fluid; Membrane Microdomains; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide | 2018 |
Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Topics: Aging; Animals; Antigens, CD; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Communication; Cell Proliferation; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Dacarbazine; Disease Models, Animal; Endothelial Cells; Glioblastoma; Humans; Mice, Inbred C57BL; Neoplastic Stem Cells; Neural Stem Cells; Organ Specificity; Stem Cell Niche; Temozolomide; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Dacarbazine; Databases, Genetic; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Magnetic Resonance Imaging; Neural Networks, Computer; Regulatory Sequences, Nucleic Acid; Temozolomide; Tumor Suppressor Proteins | 2018 |
Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Coordination Complexes; Dacarbazine; Female; Glioblastoma; HeLa Cells; Humans; Kaplan-Meier Estimate; Mice, Nude; Neoplastic Stem Cells; Osmium; Temozolomide; Xenograft Model Antitumor Assays | 2018 |
Calvarium mass as the first presentation of glioblastoma multiforme: A very rare manifestation of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; Male; Middle Aged; Skull; Skull Neoplasms; Temozolomide | 2018 |
Integrative analysis of rewired central metabolism in temozolomide resistant cells.
Topics: Amino Acids; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Glucose; Humans; Metabolic Flux Analysis; Pyruvic Acid; Systems Integration; Temozolomide | 2018 |
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation; Cell Survival; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Janus Kinase 2; Male; Mice; Mice, SCID; Microsomes, Liver; Permeability; Pyrimidines; STAT3 Transcription Factor; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design.
Topics: Administration, Intravenous; Animals; Brain; Dacarbazine; Drug Liberation; Glioblastoma; Liposomes; Polyethylene Glycols; Rats; Temozolomide | 2018 |
Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mutation; Protein Binding; Sequestosome-1 Protein; Temozolomide | 2018 |
Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxycycline; Drug Resistance, Neoplasm; Fucosyltransferases; Glioblastoma; Humans; Lewis X Antigen; Mitochondria; Neoplastic Stem Cells; Nestin; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2018 |
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation | 2018 |
Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cerebrovascular Circulation; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Photons; Proton Therapy; Temozolomide; White Matter; Young Adult | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2018 |
Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Databases, Factual; Glioblastoma; Humans; Ki-67 Antigen; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Proteasome Endopeptidase Complex; RNA Interference; Temozolomide | 2018 |
Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Decision Making; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Down-Regulation; F-Box-WD Repeat-Containing Protein 7; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Prognosis; Receptor, Notch1; RNA, Small Interfering; Temozolomide; Ubiquitin-Protein Ligases | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cysts; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Implants; Drug Synergism; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Postoperative Hemorrhage; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Microenvironment | 2018 |
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Topics: AC133 Antigen; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; RNA, Messenger; Temozolomide; Tumor Hypoxia; Vascular Endothelial Growth Factors | 2018 |
Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nimustine; Proportional Hazards Models; Quality of Life; Radiotherapy; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.
Topics: Aged; CpG Islands; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2018 |
Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; Protein Array Analysis; Protein Interaction Maps; src-Family Kinases; Temozolomide | 2018 |
Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Humans; Temozolomide | 2018 |
A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; Female; Glioblastoma; Humans; Lateral Ventricles; Male; Methyltransferases; Middle Aged; Temozolomide; Tumor Suppressor Proteins | 2018 |
Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neoplasm Proteins; Proteomics; Ribosomal Protein L3; Signal Transduction; Temozolomide; Up-Regulation | 2018 |
Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.
Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Mitosis; Molecular Structure; Molecular Targeted Therapy; Necrosis; Neoplasm Proteins; Reactive Oxygen Species; Tacrine; Temozolomide | 2018 |
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Liberation; Glioblastoma; Humans; Kinetics; Lactic Acid; Nanoparticles; Nanotechnology; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Receptors, Transferrin; Technology, Pharmaceutical; Temozolomide | 2018 |
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2018 |
Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Ferritins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Neovascularization, Pathologic; Oxidoreductases; Temozolomide; Transcription Factor CHOP; Young Adult | 2018 |
Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans | 2018 |
Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide.
Topics: Antioxidants; Apoptosis; Brain Neoplasms; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydrogen Peroxide; Mitochondria; Oxidative Stress; Oxygen Consumption; Radiation Tolerance; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured; Ubiquinone | 2018 |
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Blood-Brain Barrier; Brain Neoplasms; Cerebral Angiography; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Craniotomy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Mannitol; Middle Aged; Temozolomide; Treatment Outcome | 2018 |
Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Memory; Middle Aged; Temozolomide; Treatment Outcome | 2018 |
Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Topics: Adenine Phosphoribosyltransferase; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Female; Genes, Neoplasm; Genetic Markers; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mismatch Repair Endonuclease PMS2; Poly(ADP-ribose) Polymerases; Prospective Studies; RNA Polymerase II; RNA, Messenger; Temozolomide | 2018 |
Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Drug Administration Schedule; Drug Synergism; Glioblastoma; Gossypol; Humans; Hydroxychloroquine; Temozolomide | 2018 |
Improved survival of Swedish glioblastoma patients treated according to Stupp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Survival Rate; Sweden; Temozolomide | 2018 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2018 |
Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; beta Catenin; Binding Sites; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice, Nude; MicroRNAs; RNA Interference; Temozolomide; Wnt Proteins; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2018 |
Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Temozolomide; Verapamil | 2018 |
Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caffeine; Cell Line, Tumor; Central Nervous System Stimulants; Dacarbazine; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Brainstem Glioblastoma Multiforme in a Patient with NF1.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Stem; Brain Stem Neoplasms; Chemoradiotherapy; Codon, Nonsense; Dacarbazine; Glioblastoma; Humans; Male; Neurofibromin 1; Temozolomide; Young Adult | 2018 |
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Databases, Factual; Focal Adhesion Protein-Tyrosine Kinases; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Myosin Light Chains; Phosphorylation; Pyrazoles; Temozolomide; Transplantation, Heterologous; TRPC Cation Channels | 2018 |
MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Dacarbazine; Databases, Genetic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Protein Interaction Maps; Temozolomide | 2018 |
MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Temozolomide; Thiazoles | 2018 |
Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Glioblastoma; Humans; Juniperus; Mice; Mice, Inbred BALB C; Mice, Nude; Plant Extracts; Proliferating Cell Nuclear Antigen; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma.
Topics: Animals; Apoptosis; Aurora Kinase B; Blood-Brain Barrier; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Lactoferrin; Mice; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2018 |
NEO212, a conjugate of temozolomide and perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Coculture Techniques; Dacarbazine; Endothelial Cells; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Receptors, Notch; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2019 |
Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Enzyme Inhibitors; Glioblastoma; Guanine; Liposomes; Magnetic Resonance Imaging; Mice; O(6)-Methylguanine-DNA Methyltransferase; Ultrasonic Waves | 2019 |
Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
Topics: Antineoplastic Agents, Alkylating; Cholesterol; Dacarbazine; Dimyristoylphosphatidylcholine; Drug Interactions; Glioblastoma; Humans; Membranes, Artificial; Temozolomide | 2019 |
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Neoplastic Stem Cells; Silicon Dioxide; Temozolomide | 2019 |
[Lomustine and temozolomide in combination with radiotherapy : New treatment option for patients with MGMT promoter methylated Glioblastoma].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Lomustine; Temozolomide; Tumor Suppressor Proteins | 2019 |
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Modification Methylases; Female; Glioblastoma; Humans; Male; Middle Aged | 2019 |
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Topics: Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Dacarbazine; Forkhead Transcription Factors; Glioblastoma; HEK293 Cells; Humans; Mice; Mitosis; Neoplastic Stem Cells; Neural Stem Cells; Peptides; Phosphorylation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Temozolomide; Up-Regulation | 2013 |
Reversing the Warburg effect as a treatment for glioblastoma.
Topics: Adenosine Triphosphate; Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Energy Metabolism; Female; Glioblastoma; Humans; Lactates; Methylene Blue; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxygen Consumption; Structure-Activity Relationship; Temozolomide; Tolonium Chloride | 2013 |
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Radiometry; Radiotherapy; Temozolomide | 2013 |
The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neurosurgical Procedures; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Prognosis; Retrospective Studies; Temozolomide | 2013 |
Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apitherapy; Biological Transport; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Glioblastoma; Humans; NF-kappa B; Propolis; Temozolomide | 2013 |
Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Data Interpretation, Statistical; Endpoint Determination; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Grading; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Spain; Survival Rate; Temozolomide; Time Factors; Young Adult | 2013 |
Steroid management in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Glucocorticoids; Humans; Male; Middle Aged; Radiotherapy; Randomized Controlled Trials as Topic; Retrospective Studies; Temozolomide | 2013 |
Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspartic Acid; Cell Survival; Cells, Cultured; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Stability; Drug Synergism; Flow Cytometry; Glioblastoma; Gold; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Neoplastic Stem Cells; Temozolomide | 2013 |
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Glioblastoma; Humans; Immunoenzyme Techniques; Mice; Prognosis; Real-Time Polymerase Chain Reaction; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Meningeal Neoplasms; Middle Aged; Muscle Weakness; Prognosis; Reoperation; Spinal Cord Neoplasms; Temozolomide | 2013 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Fatal Outcome; Frontal Lobe; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Topics: Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Enzyme Inhibitors; Fluorescent Antibody Technique; Glioblastoma; Humans; Poly(ADP-ribose) Polymerases; Temozolomide | 2013 |
Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Organic Cation Transport Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide | 2013 |
Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Comet Assay; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Purines; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2013 |
Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cellular Senescence; Checkpoint Kinase 2; Cyclin B; Dacarbazine; DNA Damage; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Histones; Humans; Mitosis; Nuclear Proteins; Phosphorylation; Protein-Tyrosine Kinases; Resveratrol; Stilbenes; Temozolomide; Time Factors | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Seizures; Survival Analysis; Temozolomide; Treatment Outcome; Valproic Acid; Young Adult | 2013 |
Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioblastoma; Magnetic Resonance Imaging; Male; Rats; Sound; Temozolomide | 2013 |
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Microsatellite Instability; Neoplasms, Complex and Mixed; Neurosurgical Procedures; Oligodendroglioma; Phenotype; Temozolomide | 2013 |
Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Ventricles; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Temozolomide | 2013 |
Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Prognosis; Radiosurgery; Retrospective Studies; Sex Factors; Survival Analysis; Temozolomide; Young Adult | 2013 |
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbon; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Organ Culture Techniques; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; X-Rays | 2013 |
Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines - does scheduling matter?
Topics: Carbon; Cell Cycle; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Photons; Radiation-Sensitizing Agents; Temozolomide | 2013 |
Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Caspase 12; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Cytochromes c; Dacarbazine; Endoplasmic Reticulum Stress; Enzyme Activation; Glioblastoma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Quercetin; Temozolomide | 2013 |
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; Cancer Vaccines; Dacarbazine; Glioblastoma; Humans; Lymphocyte Depletion; Lymphopenia; Temozolomide | 2013 |
Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioblastoma; Humans; Lentivirus; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2013 |
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide | 2013 |
Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.
Topics: Amyloid Precursor Protein Secretases; Animals; Cell Proliferation; Cyclic S-Oxides; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Receptors, Notch; Signal Transduction; Temozolomide; Thiadiazoles; Xenograft Model Antitumor Assays | 2013 |
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Proliferation; Cesium Radioisotopes; Dacarbazine; Drug Synergism; Everolimus; Flow Cytometry; Gamma Rays; Glioblastoma; Humans; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Case-Control Studies; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Postoperative Period; Prognosis; Survival Rate; Temozolomide | 2013 |
Isotretinoin maintenance therapy for glioblastoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Isotretinoin; Male; Middle Aged; Retrospective Studies; Temozolomide | 2014 |
Defining pseudoprogression in glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Radiation Injuries; Retrospective Studies; Risk Factors; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Levetiracetam; Male; Middle Aged; Neoplasm Recurrence, Local; Piracetam; Prognosis; Retrospective Studies; Seizures; Survival Rate; Temozolomide; Valproic Acid; Young Adult | 2013 |
Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; Brain Neoplasms; Caspase 3; Caspase 9; Caspases; Cell Survival; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Mitochondrial Proteins; Temozolomide; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphoma; Male; Temozolomide | 2013 |
TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chickens; Dacarbazine; Drug Resistance, Neoplasm; Epilepsy; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; NF-kappa B; Proto-Oncogene Proteins c-akt; Receptors, Tumor Necrosis Factor; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Signal Transduction; Temozolomide | 2013 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Computational Biology; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Imatinib Mesylate; Microarray Analysis; Piperazines; Pyrimidines; rac1 GTP-Binding Protein; Receptors, Notch; RNA, Neoplasm; Signal Transduction; Temozolomide | 2013 |
Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Flow Cytometry; Glioblastoma; Humans; Inhibitory Concentration 50; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2013 |
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; MicroRNAs; Radiation, Ionizing; Temozolomide; Ubiquitin-Activating Enzymes | 2013 |
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Dacarbazine; Glioblastoma; Humans; Practice Patterns, Physicians'; Spain; Surveys and Questionnaires; Temozolomide | 2014 |
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeodomain Proteins; Humans; Kruppel-Like Transcription Factors; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Nerve Tissue Proteins; Proto-Oncogene Proteins c-myb; Receptors, Immunologic; Roundabout Proteins; Temozolomide; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; Zinc Finger E-box-Binding Homeobox 1 | 2013 |
Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Space; Glioblastoma; Humans; Intracellular Space; Lysophospholipids; Models, Biological; Neoplastic Stem Cells; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Temozolomide | 2013 |
MicroRNA-125b inhibitor sensitizes human primary glioblastoma cells to chemotherapeutic drug temozolomide on invasion.
Topics: Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Vitro Techniques; MicroRNAs; Neoplasm Invasiveness; Receptor, Notch1; Temozolomide | 2013 |
Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Mice; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Random Allocation; Temozolomide; Tomography, X-Ray Computed; Tumor Burden | 2013 |
LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Topoisomerases, Type II; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Temozolomide | 2013 |
miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.
Topics: Animals; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; MicroRNAs; Molecular Chaperones; Neoplastic Stem Cells; Protein Inhibitors of Activated STAT; RNA, Small Interfering; Temozolomide | 2014 |
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Brain Neoplasms; Dacarbazine; Early Diagnosis; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Injections, Intraventricular; Injections, Subcutaneous; Mice; Mice, Nude; Neoplasms, Experimental; Temozolomide; Tomography, Emission-Computed; Treatment Outcome; Tumor Burden | 2013 |
Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Division; Cell Proliferation; Dacarbazine; Disease Models, Animal; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Neoplasm Transplantation; Phenyl Ethers; Temozolomide; Thiazolidines; Tubulin Modulators; Tumor Cells, Cultured | 2013 |
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Temozolomide; Tumor Stem Cell Assay | 2013 |
Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model.
Topics: Acridine Orange; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Culture Techniques; Cell Death; Cell Line, Tumor; Curcumin; Dacarbazine; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Magnetics; Nanoparticles; Propidium; Staining and Labeling; Temozolomide | 2013 |
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta Catenin; Brain Neoplasms; Dacarbazine; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3; Humans; Mice; Neoplastic Stem Cells; Temozolomide; Tumor Cells, Cultured; Wnt Signaling Pathway; Wnt3A Protein | 2013 |
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Recurrence; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplastic Stem Cells; NF-kappa B; Prognosis; RNA Interference; Temozolomide; Tissue Array Analysis; TNF Receptor-Associated Death Domain Protein | 2013 |
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Nimustine; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2014 |
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Combined Modality Therapy; Dacarbazine; Gamma Rays; Genetic Vectors; Glioblastoma; Humans; Mice; Neural Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Survival Analysis; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2013 |
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Dacarbazine; Glioblastoma; Humans; Markov Chains; Temozolomide; Time Factors; United States | 2013 |
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Burden; United States | 2013 |
An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Clinical Laboratory Services; Dacarbazine; Female; Glioblastoma; Hematologic Diseases; Humans; Male; Medication Adherence; Middle Aged; Self Administration; Software; Temozolomide | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cryopreservation; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Dosage; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Temozolomide; Tumor Cells, Cultured; Vincristine | 2013 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dacarbazine; Epstein-Barr Virus Infections; Fatal Outcome; Glioblastoma; Headache; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Temozolomide; Tomography, X-Ray Computed | 2014 |
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Melanoma; Methylnitronitrosoguanidine; Phosphorylation; Protein Kinases; Signal Transduction; Temozolomide; Tumor Suppressor Proteins | 2013 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarbazine; Drug Synergism; Female; Flucytosine; Gene Expression; Gene Transfer Techniques; Genetic Vectors; Glioblastoma; Mice; Mice, Nude; Retroviridae; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Meningeal Neoplasms; Neoplasm Seeding; Temozolomide | 2017 |
Glioblastoma management in the temozolomide era: have we improved outcome?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Management; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2013 |
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Reoperation; Risk Factors; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Glioblastoma occurring after the surgical resection of a craniopharyngioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Craniopharyngioma; Dacarbazine; Glioblastoma; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Pituitary Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2014 |
APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Fas Ligand Protein; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Recombinant Fusion Proteins; Temozolomide | 2013 |
Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quercetin; Signal Transduction; Temozolomide | 2013 |
Time trends in glioblastoma multiforme survival: the role of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide; Time Factors | 2013 |
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; ATPases Associated with Diverse Cellular Activities; Blotting, Western; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Chemoradiotherapy; Dacarbazine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Membrane Proteins; Middle Aged; Mitochondria; Mitochondrial Proteins; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Radiation Tolerance; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Temozolomide; Tumor Cells, Cultured | 2013 |
Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioblastoma; Heme Oxygenase-1; Humans; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Radiation; RNA, Messenger; Temozolomide | 2014 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neurosurgical Procedures; Scotland; Survival Analysis; Temozolomide; Young Adult | 2014 |
Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Oxidation-Reduction; Oxidoreductases Acting on CH-CH Group Donors; Paclitaxel; Reactive Oxygen Species; Temozolomide | 2013 |
Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment.
Topics: Apoptosis; Astrocytoma; Autophagy; Caspase 12; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; Dacarbazine; Endoplasmic Reticulum Stress; Gene Silencing; Glioblastoma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Molecular Chaperones; Quercetin; Temozolomide | 2013 |
High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Receptors, Leptin; Signal Transduction; SOXB1 Transcription Factors; STAT3 Transcription Factor; Temozolomide | 2013 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Tumor Suppressor Proteins | 2014 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Glioblastoma; Hematologic Diseases; Humans; Ifosfamide; Interferons; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2013 |
Treatment results of glioblastoma during the last 30 years in a single institute.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Hospitals, University; Humans; Japan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neuronavigation; Nimustine; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiosurgery; Regression Analysis; Statistics, Nonparametric; Temozolomide; Treatment Outcome | 2014 |
Employment following chemoradiotherapy in glioblastoma: a prospective case series.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Employment; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Radiotherapy, Intensity-Modulated; Severity of Illness Index; Survivors; Temozolomide; Young Adult | 2014 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Glioblastoma; Guanosine; Humans; Methylation; Middle Aged; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2013 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cognition Disorders; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide; Transfection | 2013 |
Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence.
Topics: Adaptation, Physiological; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Glucose; Humans; Signal Transduction; Stem Cells; Stress, Physiological; Temozolomide; Up-Regulation | 2013 |
Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results.
Topics: Adolescent; Adult; Aged; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Temozolomide; Young Adult | 2013 |
NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cellular Senescence; Dacarbazine; Dose-Response Relationship, Drug; Gene Expression; Gene Silencing; Glioblastoma; Humans; Integrin beta4; Nerve Growth Factors; Netrins; Phosphorylation; Proto-Oncogene Proteins c-akt; Temozolomide | 2013 |
Is there pseudoprogression in secondary glioblastomas?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromosomes, Human, 1-3; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Deletion; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2013 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Retrospective Studies; Temozolomide | 2014 |
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide; Translocation, Genetic | 2014 |
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Mutation; Temozolomide; Treatment Outcome | 2014 |
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Chemoradiotherapy; Dacarbazine; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Phenotype; Temozolomide; Tumor Cells, Cultured | 2014 |
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Topics: Anthracenes; Antineoplastic Agents, Alkylating; Blotting, Western; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Kinase 4; Neoplastic Stem Cells; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2014 |
Lobarstin enhances chemosensitivity in human glioblastoma T98G cells.
Topics: Antineoplastic Agents; Base Sequence; Benzofurans; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Damage; DNA Primers; DNA Repair; Drug Synergism; Glioblastoma; Humans; Hydroxybenzoates; O(6)-Methylguanine-DNA Methyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2013 |
[Results of postoperative radiochemotherapy of glioblastoma multiforme].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Hungary; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Sex Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
[Our experience with targeted therapy in glioblastoma multiforme].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neurosurgical Procedures; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Temozolomide | 2015 |
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Blood-Brain Barrier; Catalytic Domain; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; Glioblastoma; Humans; Imidazoles; Mice; Mice, Transgenic; Phosphoinositide-3 Kinase Inhibitors; Protein Interaction Domains and Motifs; Quinolines; Radiation-Sensitizing Agents; Temozolomide; TOR Serine-Threonine Kinases | 2014 |
Concomitant viral and bacterial encephalitis after temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Encephalitis, Viral; Glioblastoma; Humans; Infectious Encephalitis; Male; Middle Aged; Temozolomide | 2014 |
A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Gas Analysis; Brain Neoplasms; Bronchoalveolar Lavage Fluid; Dacarbazine; Electrocardiography; Fatal Outcome; Female; Glioblastoma; Humans; Lung; Lung Diseases, Interstitial; Physical Examination; Pneumocystis carinii; Pneumonia, Pneumocystis; Temozolomide; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; Glioblastoma; Hippocampus; Humans; Magnetic Resonance Imaging; Organs at Risk; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Temozolomide; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Notification; Disease-Free Survival; DNA Methylation; DNA-Cytosine Methylases; Female; Glioblastoma; Humans; Male; O(6)-Methylguanine-DNA Methyltransferase; ROC Curve; Sequence Analysis, DNA; Survival Analysis; Temozolomide; Treatment Outcome | 2014 |
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Proliferation; Dacarbazine; Diploidy; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycolysis; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Spheroids, Cellular; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2014 |
Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Flow Cytometry; Glioblastoma; HEK293 Cells; Humans; Male; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Protein Binding; Proto-Oncogene Proteins c-cbl; Rho Guanine Nucleotide Exchange Factors; RNA Interference; Signal Transduction; Spheroids, Cellular; Temozolomide; Transplantation, Heterologous; Tumor Burden; Tumor Cells, Cultured | 2014 |
Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Conformal; Retreatment; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Failure; Treatment Outcome | 2014 |
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Reoperation; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Young Adult | 2014 |
Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Probability; Prognosis; Retrospective Studies; Temozolomide; Time Factors; Young Adult | 2014 |
The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM.
Topics: Adherens Junctions; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Caspase 7; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; HEK293 Cells; Histone Deacetylases; Humans; In Situ Nick-End Labeling; Melanoma-Specific Antigens; Neoplasm Proteins; Temozolomide; Transcription, Genetic; Tumor Suppressor Protein p53 | 2014 |
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Gene Expression; Glioblastoma; Humans; Mice; Receptors, Notch; Signal Transduction; Temozolomide; Transfection | 2014 |
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Glioblastoma; Immunotherapy; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Temozolomide; Thymidine Kinase | 2014 |
Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Asparagine; Aspartate-Ammonia Ligase; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Synergism; Glioblastoma; Glutamine; Humans; Male; Medulloblastoma; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Inhibitory Concentration 50; Necrosis; Temozolomide | 2014 |
Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Cervical Vertebrae; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Quadriplegia; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Interferon-beta; K562 Cells; MCF-7 Cells; Molecular Sequence Data; Neoplastic Stem Cells; Receptor, Interferon alpha-beta; Signal Transduction; Temozolomide | 2014 |
Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; Drug Resistance, Neoplasm; Ependymoma; Glioblastoma; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Stem Cells; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |
Bevacizumab in glioblastoma--still much to learn.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2014 |
Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome | 2014 |
Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hungary; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Temozolomide; Treatment Outcome | 2013 |
The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation; Glioblastoma; Heterografts; Humans; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; NF-kappa B; Peptides; Temozolomide; Tumor Cells, Cultured | 2014 |
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; CpG Islands; Cytosine; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Quantitative Trait Loci; Temozolomide; Tumor Suppressor Proteins | 2014 |
miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
Topics: Actins; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeleton; Dacarbazine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; Molecular Sequence Data; rap GTP-Binding Proteins; Temozolomide; Up-Regulation | 2014 |
Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Management; Female; France; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Palliative Care; Temozolomide; Treatment Outcome | 2014 |
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; CpG Islands; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Temozolomide | 2014 |
Polish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell line.
Topics: Animals; Antineoplastic Agents; Bees; Biological Products; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioblastoma; Honey; Humans; Neoplasm Metastasis; Temozolomide | 2014 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; Glioblastoma; Humans; Male; Mice, Nude; Neoplastic Stem Cells; Phenotype; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Proportional Hazards Models; Temozolomide; Treatment Outcome; United States | 2014 |
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blotting, Western; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Young Adult | 2014 |
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Mice; Mice, SCID; Prognosis; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Topics: Apoptosis; Azepines; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Protein Kinase Inhibitors; Pyrimidines; Radiation, Ionizing; Temozolomide | 2014 |
Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2014 |
miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; Neoplastic Stem Cells; Temozolomide | 2014 |
ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Blood-Brain Barrier; Blotting, Western; Brain; Cell Line, Tumor; Dacarbazine; Dogs; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; LLC-PK1 Cells; Madin Darby Canine Kidney Cells; Metabolic Clearance Rate; Mice, Knockout; Mice, Nude; PTEN Phosphohydrolase; Swine; Temozolomide; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Lateral Ventricles; Male; Middle Aged; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coloring Agents; Connexin 43; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Knockdown Techniques; Glioblastoma; Humans; JNK Mitogen-Activated Protein Kinases; Protein Binding; Signal Transduction; Temozolomide; Transcription Factor AP-1 | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarbazine; Dose Fractionation, Radiation; G2 Phase; Glioblastoma; HMGB1 Protein; HSP70 Heat-Shock Proteins; Humans; Mutation; Necrosis; Temozolomide; Tumor Suppressor Protein p53; Valproic Acid | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Disease Progression; Drugs, Chinese Herbal; Female; Glioblastoma; Herb-Drug Interactions; Humans; Irinotecan; Liver; Middle Aged; Phytotherapy; Temozolomide | 2014 |
First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Methylmalonic Acid; Positron-Emission Tomography; Temozolomide; Treatment Outcome | 2014 |
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplastic Stem Cells; Survival Rate; Temozolomide; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Topics: Autophagy; Autophagy-Related Protein 7; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Clone Cells; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Gene Silencing; Glioblastoma; Humans; Radiation Tolerance; Radiation, Ionizing; RNA, Small Interfering; Sirolimus; Temozolomide; Transfection; Ubiquitin-Activating Enzymes | 2014 |
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Iron; Mice; Nanoparticles; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Scorpion Venoms; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide | 2015 |
Targeted therapies: Further delineating bevacizumab's response spectrum.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Uterine Cervical Neoplasms | 2014 |
Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.
Topics: Acylation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chitosan; Dacarbazine; Drug Synergism; ErbB Receptors; Gene Silencing; Glioblastoma; Humans; Lipids; Nanocapsules; Particle Size; RNA, Small Interfering; Temozolomide; Treatment Outcome | 2014 |
Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H⁺ extrusion, cell migration and survival.
Topics: Acid-Base Equilibrium; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Biological Transport; Cation Transport Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Signaling System; Mice; Neural Stem Cells; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Temozolomide; Up-Regulation | 2014 |
Glioblastoma: If this is the "Temozolomide Era" Where is the Evidence?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evidence-Based Medicine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Temozolomide | 2014 |
Glioblastoma treatment in the elderly in the temozolomide therapy era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Heme Oxygenase-1; Humans; MAP Kinase Signaling System; O(6)-Methylguanine-DNA Methyltransferase; Oxidative Stress; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Withanolides | 2014 |
Lessons learned from Radiation Therapy Oncology Group 0525 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2014 |
Reply to M.C. Chamberlain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2014 |
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Grading; Temozolomide; Transcriptome; Tumor Suppressor Proteins | 2014 |
Experimental study of combined therapy for malignant glioma.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indoles; Neoplasm Transplantation; Nitrosourea Compounds; Oligodendroglioma; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Rats, Wistar; Temozolomide | 2014 |
Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Movement; Cell Proliferation; Curcumin; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Progranulins; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; RNA Interference; RNA, Small Interfering; Temozolomide; Transcription Factor AP-1; Transcription Factors; Tumor Cells, Cultured | 2015 |
Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Protein Array Analysis; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proteomics; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Signal Transduction; Small Molecule Libraries; Staurosporine; Temozolomide; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Genetic Therapy; Glioblastoma; Humans; Mice; Microscopy, Atomic Force; Nanomedicine; Nanoparticles; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Nude; Protein-Tyrosine Kinases; Radiation Tolerance; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms, Experimental; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome | 2014 |
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Humans; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Blotting, Western; Cell Differentiation; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Glycoproteins; Heterografts; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Peptides; Sesquiterpenes; Temozolomide | 2014 |
YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Topics: Adipokines; Animals; Antigens, Neoplasm; Biomarkers, Tumor; Cell Line, Tumor; Chitinase-3-Like Protein 1; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Lectins; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Experimental; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Bevacizumab for newly diagnosed glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2014 |
Bevacizumab for newly diagnosed glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2014 |
β-Elemene inhibits proliferation through crosstalk between glia maturation factor β and extracellular signal‑regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Flavonoids; Glia Maturation Factor; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Sesquiterpenes; Survivin; Temozolomide | 2014 |
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy; Temozolomide | 2014 |
miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; MicroRNAs; Nuclear Proteins; ras Proteins; RNA, Neoplasm; Temozolomide; Tumor Necrosis Factor alpha-Induced Protein 3 | 2014 |
Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; Glioblastoma; HSP27 Heat-Shock Proteins; Humans; Quercetin; Temozolomide | 2014 |
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Failure; Young Adult | 2014 |
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Genetic Vectors; Glioblastoma; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Neoplastic Stem Cells; Neural Cell Adhesion Molecule L1; Repressor Proteins; RNA, Messenger; RNA, Small Interfering; Telomeric Repeat Binding Protein 2; Temozolomide; Tubulin | 2014 |
NMR as evaluation strategy for cellular uptake of nanoparticles.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glioblastoma; Gold; Humans; Magnetic Resonance Spectroscopy; Nanoparticles; Rhamnose; Temozolomide | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Irinotecan; Middle Aged; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide; Vascular Endothelial Growth Factor A | 2014 |
Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis.
Topics: Carrier Proteins; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Regulatory Networks; Glioblastoma; Humans; MicroRNAs; Repressor Proteins; RNA, Messenger; Temozolomide; Up-Regulation | 2014 |
Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Glioblastoma; Humans; Hyperoxia; Procollagen-Proline Dioxygenase; Protein Disulfide-Isomerases; Temozolomide; Tumor Cells, Cultured; Unfolded Protein Response | 2014 |
A topical matter: toxic epidermal necrolysis.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents; Anticonvulsants; Antiemetics; Antineoplastic Agents; Dacarbazine; Dexamethasone; Drug Combinations; Erythema; gamma-Globulins; Glioblastoma; Humans; Immunologic Factors; Levetiracetam; Male; Methylprednisolone; Middle Aged; Omeprazole; Oxycodone; Piperidines; Piracetam; Proton Pump Inhibitors; Quinazolines; Stevens-Johnson Syndrome; Temozolomide; Wound Healing | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Choline; Contrast Media; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gadolinium; Glioblastoma; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy Dosage; Temozolomide; Time Factors | 2014 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Fatal Outcome; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Pineal Gland; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeleton; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; rap GTP-Binding Proteins; Temozolomide; Up-Regulation | 2014 |
Analyzing temozolomide medication errors: potentially fatal.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, Factual; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Medication Errors; Middle Aged; Pharmaceutical Preparations; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; United States | 2014 |
Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Leukemia, Myeloid, Acute; Middle Aged; Temozolomide | 2014 |
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Young Adult | 2014 |
Potential novel role of bevacizumab in glioblastoma and cervical cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2014 |
Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Mice; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Dacarbazine; ErbB Receptors; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Signal Transduction; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2014 |
Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Dichloroacetic Acid; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Glioblastoma; Glycolysis; Humans; Kaplan-Meier Estimate; Polymers; Pyruvates; Rats; Rats, Inbred F344; Temozolomide | 2015 |
Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Proportional Hazards Models; Retrospective Studies; Temozolomide | 2014 |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Genotype; Glioblastoma; Humans; Male; Mice; Middle Aged; Mutation; Oligodendroglioma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays; Young Adult | 2014 |
Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; HMGB1 Protein; HSP70 Heat-Shock Proteins; Humans; Temozolomide; Tumor Microenvironment | 2014 |
ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.
Topics: Age Factors; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cluster Analysis; Dacarbazine; Disease Models, Animal; DNA Copy Number Variations; DNA Glycosylases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Models, Biological; Phosphorylation; RNA Interference; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide | 2014 |
Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Combined Modality Therapy; Connexin 43; Dacarbazine; Drug Administration Schedule; Female; Gamma Rays; Glioblastoma; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Protein Structure, Tertiary; Rats; Rats, Wistar; Stereotaxic Techniques; Survival Analysis; Temozolomide; Tumor Burden | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; HEK293 Cells; Humans; Introns; Male; Middle Aged; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-met; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, RNA; Temozolomide; Translocation, Genetic; Young Adult | 2014 |
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2014 |
Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Chemoradiotherapy; Cohort Studies; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Female; Follow-Up Studies; France; Glioblastoma; Health Care Costs; Hospital Costs; Hospitals, University; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome | 2014 |
The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide; Tertiary Care Centers; Treatment Outcome | 2014 |
Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Metabolome; Mice; Mice, Inbred C57BL; Mitosis; Pattern Recognition, Automated; Temozolomide; Tumor Burden | 2014 |
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Lysosomes; Mice; Mice, Nude; Nanostructures; Phosphatidylserines; Random Allocation; Saposins; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auranofin; Brain Neoplasms; Captopril; Celecoxib; Dacarbazine; Disulfiram; Glioblastoma; Humans; Itraconazole; Molecular Targeted Therapy; Morpholines; Neoplasm Recurrence, Local; Pyrazoles; Ritonavir; Sertraline; Signal Transduction; Sulfonamides; Temozolomide; Treatment Outcome | 2014 |
Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemical Fractionation; Dacarbazine; Ficus; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Situ Nick-End Labeling; Latex; MicroRNAs; Models, Biological; Neoplasm Invasiveness; Neovascularization, Physiologic; Phytotherapy; Plant Extracts; Temozolomide | 2015 |
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lateral Ventricles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Young Adult | 2014 |
DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Cohort Studies; Dacarbazine; Diacylglycerol Kinase; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Nomograms; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2014 |
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Transfer Techniques; Glioblastoma; Humans; Mice; Nanoparticles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Glioblastoma; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins c-akt; Snail Family Transcription Factors; Temozolomide; Transcription Factors; Twist-Related Protein 1 | 2014 |
Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; Pentacyclic Triterpenes; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Death; Cell Line, Tumor; Ceramides; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Glioblastoma; Humans; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Temozolomide | 2014 |
Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Ouabain; Sodium; Sodium-Potassium-Exchanging ATPase; Temozolomide; Valinomycin | 2014 |
The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines.
Topics: Adult; Animals; Astrocytes; Astrocytoma; Bees; Cell Line, Tumor; Dacarbazine; Fatty Acids; Glioblastoma; Honey; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Propolis; Specimen Handling; Temozolomide | 2014 |
Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Maintenance Chemotherapy; Male; Middle Aged; Radiotherapy Planning, Computer-Assisted; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation.
Topics: Antineoplastic Agents, Alkylating; bcl-Associated Death Protein; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; JNK Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Temozolomide | 2014 |
N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Histones; Humans; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |
A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
Topics: Astrocytes; Brain Neoplasms; Cell Compartmentation; Cell Count; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Glioblastoma; Humans; Luminescence; Models, Biological; Reproducibility of Results; Spheroids, Cellular; Stromal Cells; Temozolomide | 2014 |
Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Glioblastoma; Humans; Longitudinal Studies; Male; Middle Aged; Pneumonia, Pneumocystis; Retrospective Studies; T-Lymphocytes; Temozolomide; Young Adult | 2014 |
Pine (Pinus morrisonicola Hayata) needle extracts sensitize GBM8901 human glioblastoma cells to temozolomide by downregulating autophagy and O(6)-methylguanine-DNA methyltransferase expression.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Synergism; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pinus; Plant Extracts; Plant Leaves; Temozolomide | 2014 |
KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
Topics: Animals; Apoptosis; Arsenites; Dacarbazine; DNA Damage; Drug Synergism; Glioblastoma; Humans; Mice; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Sodium Compounds; Telomere; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Improvement in treatment results of glioblastoma over the last three decades and beneficial factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Temozolomide | 2015 |
RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Prognosis; Protein Stability; Protein Transport; ras Proteins; Spheroids, Cellular; STAT3 Transcription Factor; Temozolomide; Tumor Cells, Cultured | 2014 |
Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Enzyme Activation; Flavones; Glioblastoma; Humans; Reactive Oxygen Species; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Mutation; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.
Topics: Apoptosis; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; DNA Damage; DNA Repair; Gene Expression; Glioblastoma; Humans; L-Lactate Dehydrogenase; Magnetic Resonance Imaging; Membrane Proteins; Methyltransferases; NAD; Protein Kinases; Pyruvic Acid; Temozolomide; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult | 2015 |
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group D2 Protein; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 2-Ring; Humans; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Hypoxia; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitor of Apoptosis Proteins; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Protein Binding; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Radiation; Everolimus; Gamma Rays; Glioblastoma; Histones; Humans; Linear Energy Transfer; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Primary glioblastoma of the trigeminal nerve root entry zone: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modality Therapy; Cranial Nerve Neoplasms; Dacarbazine; Disease Progression; Glioblastoma; Humans; Male; Temozolomide; Trigeminal Nerve Diseases | 2015 |
Synergistic Anti-Cancer Effects of Icariin and Temozolomide in Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Flavonoids; Glioblastoma; Humans; Neoplasm Invasiveness; NF-kappa B; Signal Transduction; Temozolomide | 2015 |
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autoantibodies; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Glioblastoma; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Temozolomide | 2015 |
MGMT methylation in glioblastoma: tale of the tail.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Kaplan-Meier Estimate; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Neoplasm Proteins; Polycomb Repressive Complex 2; RNA Interference; RNA, Messenger; Temozolomide; Time Factors; Transfection | 2014 |
Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Contrast Media; Dacarbazine; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Radiography; Temozolomide; Young Adult | 2014 |
Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Topics: Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Shape; Cell Survival; Dacarbazine; Glioblastoma; Humans; Ligands; Neoplastic Stem Cells; Receptor, Adenosine A1; Receptor, Adenosine A2B; Temozolomide | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Diphosphonates; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Male; Mice; Mice, Inbred Strains; Nanoparticles; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Transferrin; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Cholestyramine Resin; Common Bile Duct Diseases; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Immunohistochemistry; Jaundice; Liver Function Tests; Middle Aged; Syndrome; Temozolomide; Treatment Outcome; Ursodeoxycholic Acid | 2014 |
Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transfection | 2015 |
Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antirheumatic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Death; Cell Line, Tumor; Chloroquine; Dacarbazine; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Glioblastoma; Heat-Shock Proteins; Humans; Membrane Proteins; Mice; Mice, Nude; Poly(ADP-ribose) Polymerases; Temozolomide; Transcription Factor CHOP; Transfection; Xenograft Model Antitumor Assays | 2014 |
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Ki-67 Antigen; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Sulfites; Temozolomide; Time Factors; Tumor Suppressor Proteins | 2014 |
Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; O(6)-Methylguanine-DNA Methyltransferase; Propensity Score; Radiotherapy Dosage; Regression Analysis; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome | 2015 |
LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.
Topics: Adult; Aged; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Membrane Glycoproteins; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Superoxide Dismutase; Temozolomide; Young Adult | 2015 |
Factorial clinical trials: a new approach to phase II neuro-oncology studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Isotretinoin; Male; Pyrazoles; Sulfonamides; Thalidomide | 2015 |
Does cilengitide deserve another chance?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Snake Venoms; Tumor Suppressor Proteins | 2014 |
Does cilengitide deserve another chance?-Authors' reply.
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Snake Venoms; Tumor Suppressor Proteins | 2014 |
Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Neoplasm Grading; Retrospective Studies; Supratentorial Neoplasms; Temozolomide; Treatment Outcome | 2015 |
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.
Topics: Aged; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Databases, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Grading; Prognosis; Regression Analysis; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Topics: Antineoplastic Agents, Alkylating; Antipsychotic Agents; Apoptosis; Benzodiazepines; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Olanzapine; Phosphoproteins; Protein Array Analysis; Temozolomide; Tumor Cells, Cultured | 2015 |
Glioblastoma multiforme and hepatitis B: do the right thing(s).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hepatitis B; Hepatitis B virus; Humans; Male; Middle Aged; Temozolomide; Virus Activation | 2014 |
miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene Knockdown Techniques; Glioblastoma; Humans; In Vitro Techniques; MicroRNAs; Mitogen-Activated Protein Kinase 13; Mitogen-Activated Protein Kinase 14; Oxidative Stress; Temozolomide | 2015 |
Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Curcumin; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Glioblastoma; Humans; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Rats; Temozolomide | 2015 |
Anticancer potential and mechanism of action of mango ginger (Curcuma amada Roxb.) supercritical CO₂ extract in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carbon Dioxide; Cell Line, Tumor; Cell Survival; Curcuma; Dacarbazine; Etoposide; Glioblastoma; Humans; Mice; Plant Extracts; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2015 |
Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Glioblastoma; Histones; Humans; Indoles; Male; Middle Aged; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Quinazolines; Temozolomide | 2015 |
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Phosphorylation; Protein Kinase C; Tamoxifen; Temozolomide | 2015 |
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Single-Cell Analysis; Temozolomide | 2015 |
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Transport; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cystathionine gamma-Lyase; Cysteine; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Activation; Glioblastoma; Glutathione; Humans; NF-E2-Related Factor 2; Piperazines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Sulfasalazine; Temozolomide | 2015 |
Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Humans; Immunohistochemistry; Male; Matrix Metalloproteinases; Middle Aged; Neoplasm Invasiveness; STAT3 Transcription Factor; Temozolomide; Tumor Stem Cell Assay | 2016 |
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Hedgehog Proteins; HEK293 Cells; Humans; MicroRNAs; Neoplasm Proteins; Patched Receptors; Patched-1 Receptor; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Temozolomide | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiosurgery; Reoperation; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2015 |
Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; HEK293 Cells; Humans; Kruppel-Like Factor 4; MicroRNAs; Neoplastic Stem Cells; Neurofilament Proteins; Proteomics; RNA Interference; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Temozolomide; Time Factors; Transfection; Two-Dimensional Difference Gel Electrophoresis | 2015 |
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Topics: Animals; Blood-Brain Barrier; Cell Cycle Proteins; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Humans; Mice; Nuclear Proteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Longitudinal Studies; Male; Microsurgery; Middle Aged; Neurosurgical Procedures; Positron-Emission Tomography; Prospective Studies; Temozolomide; Treatment Outcome; Tumor Burden; Tyrosine | 2015 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Thioguanine; Treatment Failure | 2015 |
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Gene Expression; Glioblastoma; Glycoproteins; Humans; Immunophenotyping; Mice; Neoplastic Stem Cells; Peptides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Transcription, Genetic; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Dose escalation for GBM in the temozolamide era: in regard to Badiyan et al.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2015 |
In reply to Gondi and Mehta.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2015 |
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Galectin 1; Gene Silencing; Glioblastoma; Humans; Lipids; Mice, Nude; Nanocapsules; RNA, Small Interfering; Temozolomide; Tumor Burden | 2015 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Cells, Cultured; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Gene Expression Profiling; Glioblastoma; Humans; Mice, Inbred NOD; Mice, SCID; Microarray Analysis; Neoplasm Transplantation; Promoter Regions, Genetic; Radiation-Sensitizing Agents; Temozolomide; Tumor Suppressor Proteins; Valproic Acid | 2015 |
Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Multivariate Analysis; Promoter Regions, Genetic; Radiotherapy; Retrospective Studies; Survival Analysis; Temozolomide | 2015 |
The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Growth Processes; Cell Line, Tumor; Chloroquine; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Protein p53 | 2015 |
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Epithelial-Mesenchymal Transition; Female; Glioblastoma; Humans; Insulin-Like Growth Factor II; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy, Needle; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neuronavigation; Neurosurgical Procedures; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Prospective Studies; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome | 2015 |
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Topics: Administration, Metronomic; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Odds Ratio; Proportional Hazards Models; Temozolomide; Up-Regulation | 2015 |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Topics: AC133 Antigen; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression Profiling; Glioblastoma; Glycoproteins; Humans; Hyaluronan Receptors; Mesoderm; Neoplastic Stem Cells; Neural Stem Cells; Peptides; Predictive Value of Tests; Temozolomide | 2015 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompatible Materials; Boron Compounds; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Lactic Acid; Magnetic Resonance Spectroscopy; Methacrylates; Methylmethacrylates; Micelles; Nanoconjugates; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectrometry, Fluorescence; Temozolomide | 2015 |
Temozolomide nanoparticles for targeted glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Delivery Systems; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Nanoparticles; Temozolomide | 2015 |
A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression; Glioblastoma; Homeodomain Proteins; Humans; Mice; Oncogenes; Prognosis; Temozolomide; Tissue Array Analysis; Transcriptome; Transfection; Xenograft Model Antitumor Assays | 2015 |
Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biphenyl Compounds; Brain Neoplasms; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Glioblastoma; Homeodomain Proteins; Humans; Lignans; Neoplastic Stem Cells; Receptor, Notch3; Receptors, Notch; Temozolomide; Transcription Factor HES-1; Tumor Cells, Cultured | 2015 |
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Temozolomide | 2015 |
Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth.
Topics: beta Catenin; Blotting, Western; Cell Dedifferentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Reprogramming; Cellular Reprogramming Techniques; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Induced Pluripotent Stem Cells; Mitogens; Neoplastic Stem Cells; Neural Stem Cells; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Spheroids, Cellular; Temozolomide | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Tissue Distribution | 2015 |
LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Membrane Glycoproteins; Methylation; Neoplasm Proteins; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins; Up-Regulation | 2015 |
The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Topics: ADAM Proteins; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Fluorescence Resonance Energy Transfer; Glioblastoma; Humans; Immunoblotting; Membrane Proteins; Neoplasm Invasiveness; Real-Time Polymerase Chain Reaction; Temozolomide; Transcriptome | 2015 |
[Radiation and temozolomide therapy].
Topics: Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Risk Factors; Temozolomide | 2015 |
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Multivariate Analysis; Propensity Score; Retrospective Studies; Selection Bias; Temozolomide | 2015 |
Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2015 |
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine CXCL12; Chemoradiotherapy; Child; Child, Preschool; Cyclams; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Gene Expression Profiling; Glioblastoma; Heterocyclic Compounds; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Retrospective Studies; Signal Transduction; Temozolomide; Time Factors; Tissue Culture Techniques; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2015 |
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioblastoma; Glycolysis; Humans; Metformin; Mice; Mice, Nude; Mitochondria; Temozolomide; Transcription Factors; Xenograft Model Antitumor Assays | 2015 |
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Brain Neoplasms; China; Cluster Analysis; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Temozolomide; Treatment Outcome | 2015 |
Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells.
Topics: Apoptosis; Caspase 3; Cell Proliferation; Curcumin; Dacarbazine; Diarylheptanoids; Glioblastoma; Humans; Neoplastic Stem Cells; Primary Cell Culture; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2015 |
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Mutation; Sirolimus; Temozolomide | 2015 |
miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
Topics: Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Models, Biological; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins | 2015 |
The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Glioblastoma; Humans; Paclitaxel; Temozolomide | 2015 |
Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Topics: Amino Acids; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Interferon-beta; Male; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Inbred F344; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Tissue Distribution; Treatment Outcome | 2015 |
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Genotype; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk Factors; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Nervous System Neoplasms; Neurosurgery; Prospective Studies; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2015 |
Risk factors for glioblastoma therapy associated complications.
Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Karnofsky Performance Status; Logistic Models; Male; Middle Aged; Motor Disorders; Multivariate Analysis; Neurosurgical Procedures; Odds Ratio; Postoperative Complications; Postoperative Hemorrhage; Prognosis; Psychotic Disorders; Retrospective Studies; Risk Factors; Seizures; Surgical Wound Infection; Temozolomide | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Doxorubicin; Genotype; Glioblastoma; Humans; Kaplan-Meier Estimate; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Proteins; Temozolomide; Valproic Acid | 2015 |
Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Glioblastoma; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rats; Rats, Wistar; Survival Rate; Temozolomide; Transplantation, Homologous | 2015 |
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Exosomes; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunomagnetic Separation; Mice, Nude; Microfluidics; RNA, Messenger; Temozolomide; Treatment Outcome | 2015 |
miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Membrane Glycoproteins; Mice, Nude; MicroRNAs; Temozolomide | 2015 |
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
Topics: Antineoplastic Agents; Dacarbazine; Disulfiram; Glioblastoma; Humans; Interleukin-18; Ritonavir; Temozolomide | 2015 |
Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Health Care Surveys; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Temozolomide | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Levetiracetam; Male; Middle Aged; Piracetam; Proportional Hazards Models; Retrospective Studies; Temozolomide; Young Adult | 2015 |
Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
Topics: Adenosine A3 Receptor Antagonists; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase Inhibitors; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Ligands; Neoplastic Stem Cells; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic; Receptors, Purinergic P1; Receptors, Purinergic P2X7; Temozolomide | 2015 |
Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Female; Glioblastoma; Humans; Hydrogels; Light; Methacrylates; Mice, Nude; Microglia; Polyethylene Glycols; Temozolomide; Tumor Burden | 2015 |
Neuro-oncology: The many challenges of treating elderly glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose Fractionation, Radiation; Glioblastoma; Humans; Tumor Suppressor Proteins | 2015 |
Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Isothiocyanates; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Models, Biological; Neoplasm Proteins; Phytotherapy; Random Allocation; RNA, Neoplasm; Sulfoxides; Temozolomide; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Brain Neoplasms; Dacarbazine; Dexamethasone; Female; Glioblastoma; Humans; Hyperglycemia; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Temozolomide | 2015 |
A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Models, Biological; Promoter Regions, Genetic; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2017 |
[Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Topics: Alkylating Agents; Brain Neoplasms; Dacarbazine; Epilepsies, Partial; Excitatory Amino Acid Antagonists; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Mutation; Nitriles; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Pyridones; Survival Analysis; Temozolomide | 2015 |
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, p53; Glioblastoma; Humans; Mice, Inbred C57BL; MutS Homolog 2 Protein; Radiation, Ionizing; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; CD11b Antigen; Cell Line, Tumor; Cell Nucleus; Cytosol; Dacarbazine; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Microscopy, Fluorescence; Nuclear Proteins; RNA Interference; Temozolomide; Transcription Factors; Twist-Related Protein 1; von Willebrand Factor | 2015 |
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Complex and Mixed; Neurosurgical Procedures; Oligodendroglioma; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Glioblastoma; Glioma; Histones; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Mice; Potassium Channel Blockers; Pyrazoles; Radiation-Sensitizing Agents; RNA, Messenger; Signal Transduction; Temozolomide | 2015 |
Resveratrol Inhibits the Invasion of Glioblastoma-Initiating Cells via Down-Regulation of the PI3K/Akt/NF-κB Signaling Pathway.
Topics: Animals; Cell Adhesion; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Glioblastoma; Humans; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduction; Stilbenes; Temozolomide | 2015 |
TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Prognosis; Temozolomide; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Up-Regulation | 2015 |
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Chemoradiotherapy; Comorbidity; Cyclooxygenase 2 Inhibitors; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hypertension; Male; Middle Aged; Outcome Assessment, Health Care; Supratentorial Neoplasms; Temozolomide | 2015 |
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Damage; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gene Knockout Techniques; Glioblastoma; Heterografts; Humans; Mice; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Small Interfering; Temozolomide | 2015 |
β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Repair; Drug Synergism; Glioblastoma; Humans; Radiation-Sensitizing Agents; Rats; Sesquiterpenes; Temozolomide | 2015 |
[A pleural transudate with a 0 g/L protein level].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Catheters, Indwelling; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diuretics; Drainage; Dyspnea; Exudates and Transudates; Fluid Therapy; Glioblastoma; Humans; Male; Methylene Blue; Middle Aged; Pleural Cavity; Pleural Effusion; Pneumothorax; Proteins; Radiography; Temozolomide | 2015 |
Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Chemoradiotherapy; Cisplatin; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Temozolomide | 2015 |
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Temozolomide; Tumor Burden; Young Adult | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells; Endothelin Receptor Antagonists; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; NIH 3T3 Cells; Pyrimidines; Sulfonamides; Temozolomide | 2015 |
The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Phosphoinositide-3 Kinase Inhibitors; Progesterone; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DNA; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Management of glioblastoma in Victoria, Australia (2006-2008).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Temozolomide; Victoria | 2015 |
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Furans; Glioblastoma; Humans; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Clinical Trials, Phase III as Topic; Dacarbazine; Disease-Free Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Temozolomide; Treatment Outcome | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells; Proto-Oncogene Proteins c-cbl; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand | 2015 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brain Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dacarbazine; Dogs; Female; Glioblastoma; Madin Darby Canine Kidney Cells; Male; Mice; Piperazines; Protein Kinase Inhibitors; Pyridines; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Mice, SCID; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Spheroids, Cellular; Temozolomide | 2015 |
PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Cell Movement; Cell Survival; Chromones; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Morpholines; Neoplasm Invasiveness; Neoplastic Stem Cells; Phosphoinositide-3 Kinase Inhibitors; Primary Cell Culture; Temozolomide; Tumor Cells, Cultured; Wnt Proteins; Wnt Signaling Pathway | 2015 |
PI3K pathway inhibition in GBM—is there a signal?
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Everolimus; Female; Glioblastoma; Gonanes; Humans; Male | 2015 |
[Exceptional metastasis of glioblastoma].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Soft Tissue Neoplasms; Temozolomide | 2015 |
In vitro and in vivo effect of human lactoferrin on glioblastoma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Lactoferrin; Male; Mice; Mice, Nude; Temozolomide; Tumor Cells, Cultured | 2015 |
Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Costs; Female; Glioblastoma; Humans; Male; Quality of Life | 2015 |
Can We Predict Bevacizumab Responders in Patients With Glioblastoma?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2015 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastoma; Glioma; Lipids; Mice; Nanostructures; Phosphatidylethanolamines; Polyethylene Glycols; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Binding, Competitive; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cricetinae; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluoresceins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Temozolomide; Transcription, Genetic; Transcriptional Activation; Transfection; Up-Regulation | 2015 |
Comment: Chemoradiotherapy for glioblastoma patients--the double-edged sword.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Glioblastoma; Humans; Male | 2015 |
Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
Topics: Adult; Aged; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Postoperative Care; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Topics: Brain Neoplasms; Chondroitin Sulfate Proteoglycans; Dacarbazine; Decorin; Glioblastoma; Humans; Keratan Sulfate; Lumican; Neoplastic Stem Cells; Neuroblastoma; Temozolomide; Tumor Microenvironment | 2015 |
Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; NF-kappa B; Signal Transduction; Temozolomide | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Japan; Karnofsky Performance Status; Male; Middle Aged; Polyesters; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Mice; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Radiation-Sensitizing Agents; Survival Analysis; Temozolomide | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contrast Media; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; ROC Curve; Temozolomide; Time Factors; Treatment Outcome | 2015 |
Radiation as a foundation for glioblastoma therapy in elderly patients. In Regard to Arvold et al.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2015 |
In Reply to Levra et al.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Ependyma; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Sensitivity and Specificity; Temozolomide; Young Adult | 2015 |
Diagnosis and Management of Spinal Metastasis of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Spinal Neoplasms; Temozolomide | 2015 |
Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Neoplasm Proteins; RNA, Neoplasm; STAT3 Transcription Factor; Temozolomide | 2015 |
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Metabolomics; Purines; Temozolomide; Tritium; Tumor Suppressor Proteins | 2015 |
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Female; Glioblastoma; Humans; Mice, Nude; Nanocapsules; Temozolomide; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents; Autophagy; Brain Neoplasms; Carbazoles; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase; Glioblastoma; Humans; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Metformin influences progression in diabetic glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Diabetes Complications; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Hyperglycemia; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Retrospective Studies; Temozolomide; Young Adult | 2015 |
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2015 |
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Smac mimetic-induced upregulation of interferon-β sensitizes glioblastoma to temozolomide-induced cell death.
Topics: Apoptosis; Caspases; Cell Death; Dacarbazine; Glioblastoma; Humans; Interferon-beta; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Dual loading miR-218 mimics and Temozolomide using AuCOOH@FA-CS drug delivery system: promising targeted anti-tumor drug delivery system with sequential release functions.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chitosan; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Fatty Acids; Female; Glioblastoma; Gold Compounds; Humans; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nanogels; Polyethylene Glycols; Polyethyleneimine; Sulfhydryl Compounds; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Nucleus; Comet Assay; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Kinase 4; MAP Kinase Signaling System; Membrane Proteins; Nimustine; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; RNA, Small Interfering; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2015 |
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Italy; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Radiotherapy Dosage; Retrospective Studies; Temozolomide | 2015 |
A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Peptides, Cyclic; Polyethylene Glycols; Proto-Oncogene Proteins c-mdm2; Temozolomide; Tumor Burden; Tumor Suppressor Protein p53 | 2015 |
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Male; Metformin; Mice; Mice, SCID; Neoplastic Stem Cells; Random Allocation; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Central Nervous System; Dacarbazine; Dogs; Glioblastoma; Humans; Indoles; Madin Darby Canine Kidney Cells; Mice; Mice, Knockout; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycoproteins; Guanine; Humans; Inhibitory Concentration 50; Peptides; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA-Binding Proteins; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; MicroRNAs; Proto-Oncogene Proteins c-myc; Signal Transduction; Temozolomide | 2015 |
The radiosensitivity index predicts for overall survival in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Radiation Tolerance; Temozolomide; Transcriptome; Treatment Outcome | 2015 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide | 2016 |
Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Curcumin; Dacarbazine; Diarylheptanoids; Drug Synergism; G1 Phase; Glioblastoma; Humans; Janus Kinases; Mice; Mice, Nude; Neoplasm Proteins; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Reoperation; Retrospective Studies; Survival Rate; Temozolomide | 2017 |
Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neoplastic Stem Cells; Phosphorylation; Resveratrol; Signal Transduction; Stilbenes; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Immunoenzyme Techniques; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Prospective Studies; Registries; Survival Rate; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MicroRNAs; Nanotechnology; Temozolomide | 2015 |
Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Culture Media, Conditioned; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Ontology; Genomic Instability; Glioblastoma; Humans; Microscopy, Fluorescence; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transcriptome | 2015 |
APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Humans; RNA, Small Interfering; Temozolomide | 2015 |
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dexamethasone; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Temozolomide | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Compounding; Glioblastoma; Humans; Irinotecan; Liposomes; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
In Regard to Arvold et al.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2015 |
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Comorbidity; Dacarbazine; Female; Glioblastoma; Hematologic Diseases; Humans; Longitudinal Studies; Male; Middle Aged; Prevalence; Radiotherapy, Conformal; Republic of Korea; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Middle Aged; Nucleolin; Peptides; Phosphoproteins; RNA-Binding Proteins; Temozolomide; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetic Materials; Brain Neoplasms; Cell Line, Tumor; Connexin 43; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Peptides; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Bone Morphogenetic Protein 7; Cell Proliferation; Cell Survival; Dacarbazine; DNA Modification Methylases; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Humans; Neoplastic Stem Cells; Temozolomide; Tumor Cells, Cultured | 2015 |
MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation.
Topics: Adult; Aged; alpha Karyopherins; Animals; Autophagy; Cadherins; Cell Line, Tumor; Cell Movement; Dacarbazine; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; MicroRNAs; Middle Aged; Nuclear Proteins; Phenotype; Temozolomide; Tumor Suppressor Protein p53 | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MicroRNAs; Nanoparticles; PTEN Phosphohydrolase; Temozolomide | 2015 |
[Survival benefit from the addition of bevacizumab to first-line radiochemotherapy for the treatment of proneural glioblastoma?].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2016 |
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Shape; Dacarbazine; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genotype; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Neoplastic Stem Cells; Phenotype; Retinoblastoma-Binding Protein 2; RNA Interference; Temozolomide; Time Factors; Transfection | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Caspase 8; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Female; Glioblastoma; Humans; Luteolin; Mice; Mice, Nude; MicroRNAs; Signal Transduction; Silybin; Silymarin; Sirolimus; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
New insights into acquired temozolomide resistance in glioblastoma?
Topics: Animals; Dacarbazine; DNA-Binding Proteins; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Proto-Oncogene Proteins c-myc; Signal Transduction | 2015 |
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Apoptosis; Aprepitant; Brain Neoplasms; Cell Proliferation; Dacarbazine; Glioblastoma; HIV Protease Inhibitors; Humans; Immunoenzyme Techniques; Morpholines; Ritonavir; Temozolomide; Tumor Cells, Cultured | 2016 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; DNA Methylation; Female; Glioblastoma; Guanine; Humans; Isocitrate Dehydrogenase; Japan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Temozolomide | 2016 |
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Polymerase Chain Reaction; Random Allocation; Temozolomide; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Reply to M.C. Chamberlain.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Quality of Life | 2016 |
Similar Trials With Differing Outcomes: Reconciliation in Glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Quality of Life | 2016 |
Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calmodulin-Binding Proteins; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Temozolomide | 2015 |
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Nerve Tissue Proteins; Prognosis; RNA Interference; Temozolomide | 2016 |
Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Glioblastoma; Humans; Isothiocyanates; Mice; Mice, Nude; NF-kappa B; Signal Transduction; Sulfoxides; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2016 |
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Caspase 8; Cell Line, Tumor; Cell Survival; Dacarbazine; Dipeptides; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Humans; In Vitro Techniques; Indoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Phase-Contrast; Neoplasm Transplantation; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Alternating Electric Fields for the Treatment of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Maintenance Chemotherapy; Male | 2015 |
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neurosurgical Procedures; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Temozolomide | 2016 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lomustine; Male; Neurosurgical Procedures; Procarbazine; Prognosis; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Survival Rate; Temozolomide; Vincristine | 2016 |
Polymer Nanocomposites Based Thermo-Sensitive Gel for Paclitaxel and Temozolomide Co-Delivery to Glioblastoma Cells.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Nanocomposites; Paclitaxel; Polyesters; Polyethylene Glycols; Rats; Temozolomide | 2015 |
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Gene Expression; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2016 |
Downregulation of TRAP1 sensitizes glioblastoma cells to temozolomide chemotherapy through regulating metabolic reprogramming.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide | 2016 |
In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dacarbazine; Electric Stimulation Therapy; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; RNA Interference; RNAi Therapeutics; Temozolomide; Transfection; Tumor Cells, Cultured | 2016 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphopenia; Male; Neoplasm Grading; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide | 2016 |
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Costs; Female; Follow-Up Studies; France; Glioblastoma; Health Care Costs; Hospitalization; Hospitals, University; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide | 2016 |
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
Topics: Antibodies; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; B-Lymphocytes, Regulatory; Cancer Vaccines; Dacarbazine; ErbB Receptors; Glioblastoma; Humans; Immunotherapy; Interleukin-10; Lymphocyte Activation; Lymphocyte Count; Temozolomide; Vaccines, Subunit | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cyclophosphamide; Dacarbazine; Glioblastoma; Humans; Irinotecan; Lomustine; Neoplasm Grading; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Radiotherapy; Singapore; Temozolomide; Teniposide; Vincristine | 2015 |
SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cytokine TWEAK; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Guanine Nucleotide Exchange Factors; Humans; NF-kappa B; Receptors, Tumor Necrosis Factor; Signal Transduction; Temozolomide; Tumor Necrosis Factors; TWEAK Receptor; Up-Regulation | 2016 |
Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Gene Library; Genome; Glioblastoma; HEK293 Cells; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins; RNA, Small Interfering; Temozolomide; Up-Regulation | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials as Topic; Dacarbazine; Epilepsy; Female; Glioblastoma; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Prognosis; Survival Analysis; Temozolomide; Valproic Acid | 2016 |
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Mice, Transgenic; Mutation; Neoplastic Stem Cells; Signal Transduction; Temozolomide | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Valproic Acid; Young Adult | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Craniospinal Irradiation; Dacarbazine; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphopenia; Male; Neoplasm Staging; Neuroectodermal Tumors, Primitive; Neutropenia; Prognosis; Survival Rate; Temozolomide; Thrombocytopenia; Young Adult | 2016 |
Temozolomide-induced biliary ductopenia: a case report.
Topics: Antineoplastic Agents, Alkylating; Bile Duct Diseases; Bile Ducts, Intrahepatic; Chemoradiotherapy; Cholestasis; Dacarbazine; Female; Glioblastoma; Humans; Hyperbilirubinemia; Middle Aged; Temozolomide | 2016 |
Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall survival in high-grade glioma patients.
Topics: Area Under Curve; Astrocytoma; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; ROC Curve; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Ginsenosides; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Sirolimus; SOX9 Transcription Factor; SOXB1 Transcription Factors; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Genetic Association Studies; Genotype; Glioblastoma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Quality of Life | 2016 |
Reply to T.J. Kruser et al.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Quality of Life | 2016 |
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Radiation Tolerance; Radiotherapy; STAT3 Transcription Factor; Survival Analysis; Temozolomide; Ubiquitin-Protein Ligases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Nuclear Proteins; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Temozolomide; Transcription Factors | 2016 |
Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation.
Topics: Biophysical Phenomena; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Delivery Systems; Glioblastoma; Humans; Lactic Acid; Microscopy, Confocal; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Temozolomide; Time Factors | 2016 |
SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Proteoglycans; Temozolomide | 2016 |
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.
Topics: Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Engineering; Glioblastoma; Humans; Magnetic Resonance Imaging; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2016 |
Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Gene Expression Profiling; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Promoter Regions, Genetic; Prospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2016 |
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Glycosylases; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Endoplasmic Reticulum Stress; Glioblastoma; Humans; Mice; Pyrans; Rad51 Recombinase; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2016 |
Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Cinnamates; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Glioblastoma; Humans; Neuropilin-1; Promoter Regions, Genetic; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Standard chemoradiation for glioblastoma results in progressive brain volume loss.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Glioblastoma; Humans; Male | 2016 |
The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dacarbazine; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Polyesters; Polyethylene Glycols; Rats; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Glioblastoma; Heterografts; Humans; Mice; Signal Transduction; Temozolomide | 2016 |
Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Chromatin Immunoprecipitation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; E1A-Associated p300 Protein; Glioblastoma; Histones; Humans; Microscopy, Fluorescence; Phosphorylation; Promoter Regions, Genetic; Rad51 Recombinase; Real-Time Polymerase Chain Reaction; Retinoblastoma-Binding Protein 4; RNA Interference; RNA, Small Interfering; Temozolomide | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cancer Vaccines; Cell Line, Tumor; Dacarbazine; Glioblastoma; Mice; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Valproic Acid; Xenograft Model Antitumor Assays | 2016 |
Suppressing H19 Modulates Tumorigenicity and Stemness in U251 and U87MG Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Neoplastic Stem Cells; RNA, Long Noncoding; RNA, Neoplasm; Temozolomide; Up-Regulation | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Seizures; Temozolomide; Valproic Acid | 2016 |
Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Shape; Cell Survival; Cell Transformation, Neoplastic; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Neoplastic Stem Cells; Promoter Regions, Genetic; Temozolomide; Valproic Acid | 2016 |
Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Glioblastoma; Humans; Mice, Nude; Micelles; Phosphatidylethanolamines; Protons; Receptors, Platelet-Derived Growth Factor; Temozolomide | 2016 |
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Models, Animal; Disulfiram; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Profiling; Glioblastoma; High-Throughput Screening Assays; Humans; Mice; Neoplastic Stem Cells; Proteasome Endopeptidase Complex; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Opportunistic Infections; Pneumonia, Pneumocystis; Pulmonary Embolism; Temozolomide; Tomography, X-Ray Computed | 2016 |
Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Topics: Biomarkers, Tumor; Dacarbazine; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Matrix Metalloproteinase 9; Neoplasm Grading; Prognosis; Proportional Hazards Models; RNA, Messenger; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.
Topics: Animals; Cell Hypoxia; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Endothelial Cells; Female; Glioblastoma; Humans; Male; Matrix Metalloproteinase 14; Mice; Mice, Knockout; Neovascularization, Pathologic; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins c-met; Temozolomide | 2016 |
A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; India; Radium; Retrospective Studies; Temozolomide | 2016 |
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Female; Glioblastoma; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Molecular Imaging; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome | 2016 |
Too Little, Too Soon: Short-Course Radiotherapy in Elderly Patients With Glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Patients | 2016 |
One Week of Radiotherapy for Glioblastoma: A Noninferiority Trial?
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2016 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Topics: Anisotropy; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Blood Volume; Choline; Creatine; Dacarbazine; Electric Stimulation Therapy; Electromagnetic Fields; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Outcome Assessment, Health Care; Temozolomide; Thalamus | 2016 |
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
Topics: 5'-Nucleotidase; Animals; Brain Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Glioblastoma; Glycoproteins; Humans; Mice, SCID; Temozolomide; Uracil; Uridine | 2016 |
Pseudo progression identification of glioblastoma with dictionary learning.
Topics: Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Machine Learning; Male; Temozolomide | 2016 |
CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Dacarbazine; Drug Combinations; Drug Synergism; Epithelial-Mesenchymal Transition; fas Receptor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoglobulin G; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Primary Cell Culture; Prognosis; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Spheroids, Cellular; Survival Analysis; Temozolomide | 2016 |
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Repair; Estrogen Receptor beta; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Persistent bone marrow depression following short-term treatment with temozolomide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Brain Neoplasms; Dacarbazine; Fatal Outcome; Filgrastim; Glioblastoma; Hemoglobinuria, Paroxysmal; Humans; Male; Receptors, Fc; Recombinant Fusion Proteins; Temozolomide; Thrombopoietin; Treatment Failure | 2016 |
Protein Markers Predict Survival in Glioma Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Prognosis; Proportional Hazards Models; Proteomics; Survival Analysis; Temozolomide; Young Adult | 2016 |
Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carriers; Drug Delivery Systems; Glioblastoma; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanostructures; Particle Size; Polymers; Temozolomide | 2016 |
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Mice; Mice, Nude; Receptors, Notch; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Accelerated hyperfractionation plus temozolomide in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Young Adult | 2016 |
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Databases, Factual; Female; Glioblastoma; Humans; Male; Radiotherapy; Temozolomide; Treatment Outcome | 2016 |
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Protein Stability; Signal Transduction; Temozolomide; Time Factors; Transfection; Up-Regulation | 2016 |
Clonal evolution of glioblastoma under therapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Clonal Evolution; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Genomics; Glioblastoma; Humans; Isocitrate Dehydrogenase; Latent TGF-beta Binding Proteins; Longitudinal Studies; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Transcriptome; Transforming Growth Factor beta; Tumor Suppressor Proteins | 2016 |
Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; MicroRNAs; RNA, Long Noncoding; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Treatment for Patients With Newly Diagnosed Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Maintenance Chemotherapy; Male | 2016 |
Treatment for Patients With Newly Diagnosed Glioblastoma--Reply.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Maintenance Chemotherapy; Male | 2016 |
ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Endoplasmic Reticulum Stress; Glioblastoma; Humans; Hydroxyquinolines; Male; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Valproate in Adjuvant Glioblastoma Treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Treatment Outcome; Valproic Acid | 2016 |
Connection between Proliferation Rate and Temozolomide Sensitivity of Primary Glioblastoma Cell Culture and Expression of YB-1 and LRP/MVP.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Real-Time Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Y-Box-Binding Protein 1 | 2016 |
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Mutation; Neoplasms, Multiple Primary; Neurosurgical Procedures; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Telomerase; Temozolomide; Temporal Lobe | 2017 |
Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; bcl-2-Associated X Protein; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Dacarbazine; Deoxyglucose; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Gene Expression; Glioblastoma; Humans; Morpholines; Oxygen; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2016 |
Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Cranial Irradiation; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Radiation Dose Hypofractionation; Survival Analysis; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2016 |
Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytotoxins; Dacarbazine; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Sulfasalazine; Temozolomide | 2016 |
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Neoplasm Transplantation; Recombinational DNA Repair; Temozolomide; Tumor Suppressor Proteins | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Large-Conductance Calcium-Activated Potassium Channels; Microfilament Proteins; Real-Time Polymerase Chain Reaction; RNA, Messenger; Temozolomide | 2016 |
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Proliferation; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Glioblastoma; High Mobility Group Proteins; Humans; Mice; Mice, Nude; Temozolomide; Transcriptional Elongation Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytoplasmic Dyneins; Dacarbazine; Disease Models, Animal; Drug Resistance; Fluorescent Antibody Technique; Gene Expression Profiling; Glioblastoma; Heterografts; Humans; Immunohistochemistry; Kinesins; Mice, Nude; Neoplasm Transplantation; Neuroglia; Proteome; Real-Time Polymerase Chain Reaction; Temozolomide | 2016 |
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2017 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Irinotecan; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Author Response.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Glioblastoma; Humans; Male | 2016 |
Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Gene Transfer Techniques; Genetic Therapy; Glioblastoma; Rats; Temozolomide; Thymidine Kinase | 2017 |
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Regression Analysis; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Organometallic Compounds; Polymerase Chain Reaction; Retrospective Studies; Temozolomide; Treatment Outcome | 2017 |
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.
Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Mice; Mice, Nude; Oxidative Stress; Physical Conditioning, Animal; Reactive Oxygen Species; Temozolomide | 2016 |
Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism?
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Cyclin D1; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2016 |
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeodomain Proteins; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Phenotype; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2016 |
Glioblastoma in the elderly - How do we choose who to treat?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Brain Neoplasms; Cognition Disorders; Cross-Sectional Studies; Dacarbazine; Frail Elderly; Geriatric Assessment; Glioblastoma; Humans; Neurologists; Oncologists; Patient Care Team; Patient Selection; Practice Patterns, Physicians'; Referral and Consultation; Temozolomide | 2016 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Dacarbazine; Depression; Drug Interactions; Fluoxetine; Glioblastoma; Humans; Imipramine; Temozolomide; Tranylcypromine; Tumor Hypoxia | 2017 |
Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Protein p53 | 2016 |
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Gene Silencing; Glioblastoma; HMGA1a Protein; Humans; Neoplastic Stem Cells; RNA, Small Interfering; Temozolomide | 2016 |
Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Knockdown Techniques; Glioblastoma; Humans; Integrin alphaVbeta3; Integrin beta3; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; NF-KappaB Inhibitor alpha; Peptides, Cyclic; Phosphorylation; Proto-Oncogene Proteins c-akt; Rad51 Recombinase; Receptor-Interacting Protein Serine-Threonine Kinases; Receptors, Vitronectin; Recombinational DNA Repair; RNA Interference; RNA, Small Interfering; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Models, Theoretical; Nitrophenols; Piperazines; Signal Transduction; Sulfonamides; Systems Biology; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome | 2016 |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Japan; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Survival Analysis; Telomerase; Temozolomide; Tumor Suppressor Proteins | 2016 |
Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Lactic Acid; MicroRNAs; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Real-Time Polymerase Chain Reaction; Temozolomide | 2016 |
Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
Topics: Animals; Annexin A5; Apoptosis; Benzoic Acid; Cell Line, Tumor; Cell Movement; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; para-Aminobenzoates; Platelet Endothelial Cell Adhesion Molecule-1; Radiation; Radiation-Sensitizing Agents; STAT3 Transcription Factor; Sulfonamides; Temozolomide; Tumor Suppressor Proteins; Wound Healing | 2016 |
Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Nimustine; Proton Therapy; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Aspartic Acid; Bevacizumab; Brain Neoplasms; Choline; Creatine; Dacarbazine; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Proton Therapy; Statistics, Nonparametric; Temozolomide; Young Adult | 2016 |
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Prospective Studies; Reproducibility of Results; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Systems, Clinical; DNA Repair; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioblastoma; Glioma; High-Throughput Nucleotide Sequencing; Histone Deacetylase Inhibitors; Histones; Humans; RNA; RNA, Small Interfering; Temozolomide; Transcription, Genetic; Treatment Outcome; Valproic Acid | 2016 |
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Drug Synergism; Glioblastoma; Humans; Ki-67 Antigen; Mice; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays; Zinc | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotaxis; Cyclic GMP-Dependent Protein Kinase Type I; Dacarbazine; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neoplastic Stem Cells; Neurons; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Stem Cells; Temozolomide | 2016 |
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Hepatocyte Growth Factor; Humans; Male; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-met; Radiotherapy; RNA, Messenger; Survival Analysis; Temozolomide | 2016 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choline; Cohort Studies; Combined Modality Therapy; Creatine; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Grading; Prognosis; Radiotherapy, Conformal; Survival Rate; Temozolomide; Tumor Burden | 2017 |
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Guanidines; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; Pyrrolidines; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Dacarbazine; DNA Damage; Glioblastoma; HEK293 Cells; Hexokinase; Humans; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; RNA Interference; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Survival Analysis; Temozolomide | 2016 |
Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines.
Topics: Acetylation; Active Transport, Cell Nucleus; Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; NF-kappa B; Signal Transduction; Temozolomide; Transcription Factor RelA; Transcription, Genetic; Transcriptional Activation; Tumor Suppressor Proteins | 2016 |
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Methionine; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Positron-Emission Tomography; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Glioblastoma; Glutathione; Humans; Mice; Neoplasm Transplantation; Reactive Oxygen Species; Sulfasalazine; Temozolomide | 2016 |
The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines.
Topics: Animals; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Kinetics; Mice; Temozolomide | 2016 |
Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Perfusion Imaging; Prognosis; Radiotherapy; Retrospective Studies; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Cell Survival; Cells, Cultured; Dacarbazine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Glioblastoma; Humans; Interferon-Stimulated Gene Factor 3, gamma Subunit; Mice; Mice, Nude; Survival Analysis; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2016 |
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Topics: Acetazolamide; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Caspase 3; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Micelles; Spheroids, Cellular; Temozolomide; Time Factors; Tumor Cells, Cultured | 2016 |
Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Choline; Choline Kinase; Dacarbazine; Energy Metabolism; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Glioblastoma; Humans; Neoplastic Stem Cells; Phenotype; SOXB1 Transcription Factors; Temozolomide; Vimentin; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Interferons; Male; Mice, Inbred NOD; MicroRNAs; Neoplasm Invasiveness; RNA Interference; Signal Transduction; STAT1 Transcription Factor; Temozolomide; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Mice; Neoplasm Invasiveness; Phosphotransferases (Alcohol Group Acceptor); Rats; Spheroids, Cellular; Temozolomide; Time-Lapse Imaging; Tumor Cells, Cultured | 2016 |
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2017 |
[RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Furans; Glioblastoma; Humans; Temozolomide | 2016 |
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; Inhibitory Concentration 50; Metformin; Mice, SCID; Neoplasm Invasiveness; SOXB1 Transcription Factors; Temozolomide; Time Factors; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Promoter Regions, Genetic; RNA Interference; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Suppressor Proteins | 2016 |
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Models, Theoretical; ROC Curve; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Pulsed Electromagnetic Field with Temozolomide Can Elicit an Epigenetic Pro-apoptotic Effect on Glioblastoma T98G Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Bioreactors; Cell Proliferation; Dacarbazine; Electromagnetic Fields; Epigenesis, Genetic; Glioblastoma; Humans; MicroRNAs; Temozolomide | 2016 |
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Glioblastoma; Histone Deacetylase 2; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; RNA, Small Interfering; Temozolomide | 2016 |
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Temozolomide; Young Adult | 2016 |
The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Electromagnetic Fields; Glioblastoma; Humans; Neoplastic Stem Cells; Neurons; Temozolomide; Tumor Suppressor Proteins | 2017 |
Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Aged; Aspergillosis; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Skin; Temozolomide | 2017 |
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Longitudinal Studies; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Prospective Studies; Salvage Therapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2017 |
pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Guanosine; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Transmission; O(6)-Methylguanine-DNA Methyltransferase; Polymers; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Temozolomide | 2017 |
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Repositioning; Female; Glioblastoma; Humans; Mice; Mice, Nude; Rats; Rats, Inbred F344; Ribavirin; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Cytokines; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Immunotherapy; Leukocytes, Mononuclear; Male; Middle Aged; T-Lymphocytes, Regulatory; Temozolomide; Vascular Endothelial Growth Factor A | 2017 |
Microtubule actin cross-linking factor 1, a novel target in glioblastoma.
Topics: Animals; Axin Protein; beta Catenin; Dacarbazine; Drug Resistance, Neoplasm; Genetic Heterogeneity; Glioblastoma; Humans; Mice; Microfilament Proteins; Temozolomide; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Autoimmunity; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Neoplasm Staging; Nivolumab; Programmed Cell Death 1 Receptor; Temozolomide; Tumor Suppressor Proteins | 2016 |
BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2016 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; Dacarbazine; Dexamethasone; Glioblastoma; Humans; Levetiracetam; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Regression, Spontaneous; Neoplasms, Second Primary; Piracetam; Temozolomide | 2016 |
CBX Chromodomain Inhibition Enhances Chemotherapy Response in Glioblastoma Multiforme.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; Doxorubicin; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Polycomb Repressive Complex 1; Polycomb-Group Proteins; Temozolomide | 2016 |
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiosurgery; Re-Irradiation; Survival Analysis; Temozolomide | 2017 |
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Exome; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Male; Oxadiazoles; Protein Kinase Inhibitors; Quinolines; Signal Transduction; STAT3 Transcription Factor; Temozolomide; TOR Serine-Threonine Kinases | 2017 |
Comments regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2017 |
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Topics: 3' Untranslated Regions; Antagomirs; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; PAX6 Transcription Factor; RNA Interference; RNA, Small Interfering; Sequence Alignment; Signal Transduction; Temozolomide | 2017 |
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Activated Protein Kinase; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hyaluronan Receptors; Ku Autoantigen; Male; Middle Aged; Nuclear Proteins; Oligodendrocyte Transcription Factor 2; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide; Tissue Array Analysis | 2017 |
Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Topics: Alleles; Amino Acid Substitution; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; Chondroitin ABC Lyase; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression; Genetic Vectors; Glioblastoma; Herpesvirus 1, Human; Humans; Mice; Mutation; Oncolytic Virotherapy; Temozolomide; Transduction, Genetic; Treatment Outcome; Tumor Burden; Tumor Cells, Cultured; Vero Cells; Xenograft Model Antitumor Assays | 2017 |
Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Topics: Acrylamides; Anthracenes; Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Cytokines; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase 8; Nicotinamide Phosphoribosyltransferase; Piperidines; Reactive Oxygen Species; Signal Transduction; Temozolomide; Tocopherols | 2016 |
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Aurintricarboxylic Acid; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cytokine TWEAK; Dacarbazine; Drug Synergism; Glioblastoma; HEK293 Cells; Humans; Kaplan-Meier Estimate; Mice, Nude; Molecular Structure; Receptors, Tumor Necrosis Factor; RNA Interference; Signal Transduction; Small Molecule Libraries; Temozolomide; Tumor Necrosis Factors; TWEAK Receptor; Xenograft Model Antitumor Assays | 2017 |
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Glioblastoma; Humans; Indazoles; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Radiation-Sensitizing Agents; Signal Transduction; Sulfonamides; Temozolomide | 2017 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Radiation; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2017 |
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; Neoplasm Staging; Prognosis; RNA, Long Noncoding; Survival Rate; Temozolomide; Thymidylate Synthase; Tumor Cells, Cultured | 2017 |
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Contrast Media; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Medication Adherence; Middle Aged; Neural Stem Cells; Radiotherapy Dosage; Survival Rate; Temozolomide; Tomography, X-Ray Computed; Tumor Suppressor Proteins | 2017 |
The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Dacarbazine; DNA Damage; Drug Synergism; Etoposide; Glioblastoma; Humans; Temozolomide | 2018 |
Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2017 |
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Glioblastoma; Glioma; Glycogen Synthase Kinase 3; Humans; In Situ Nick-End Labeling; Phosphorylation; Phytotherapy; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Sesquiterpenes; Temozolomide; TOR Serine-Threonine Kinases | 2017 |
Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Nucleus; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Gene Silencing; Glioblastoma; Heat Shock Transcription Factors; Humans; Matrix Metalloproteinase 2; Neoplastic Stem Cells; Protein Transport; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; SOXB1 Transcription Factors; Temozolomide; Transcription Factors; Transcription, Genetic | 2017 |
miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Base Sequence; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Nucleic Acid; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Temozolomide; Up-Regulation | 2017 |
Role of
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2017 |
Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Mice; Mice, Nude; Rutin; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Sex Factors; Statistics, Nonparametric; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2017 |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2017 |
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Methylation; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Burden | 2009 |
The role of temozolomide in newly-diagnosed glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2008 |
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Topics: Adenoviridae; Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; Glioblastoma; Mice; Oncolytic Virotherapy; Oncolytic Viruses; Sirolimus; Temozolomide | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Etoposide; Female; Glioblastoma; Glioma; Hepatocytes; Humans; Lomustine; Male; Membrane Glycoproteins; Middle Aged; Procarbazine; Recombinant Fusion Proteins; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Vincristine | 2008 |
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cells, Cultured; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Temozolomide; Tumor Suppressor Proteins | 2008 |
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Radiography; Radiotherapy; Randomized Controlled Trials as Topic; Temozolomide | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2008 |
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Frequency; Genotype; Glioblastoma; Humans; K562 Cells; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Convection; Dacarbazine; Female; Genetic Vectors; Genome, Viral; Glioblastoma; Green Fluorescent Proteins; Herpesvirus 1, Human; Humans; Immediate-Early Proteins; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Radiation Tolerance; Temozolomide; Ubiquitin-Protein Ligases | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Repair Enzymes; Fatal Outcome; Glioblastoma; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Remission Induction; Temozolomide | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Glioblastoma; Glioma; Humans; Temozolomide | 2008 |
TMZ-BioShuttle--a reformulated temozolomide.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Comet Assay; Dacarbazine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Carriers; Glioblastoma; Humans; Male; Nuclear Localization Signals; Peptide Fragments; Prostatic Neoplasms; Temozolomide; Tumor Cells, Cultured | 2008 |
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lineage; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Intermediate Filament Proteins; Nerve Tissue Proteins; Nestin; Neurons; Phenotype; Prognosis; Research Design; Temozolomide; Treatment Outcome | 2008 |
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy Dosage; Survival Rate; Temozolomide; Young Adult | 2009 |
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2009 |
[Alveolo-interstitial pneumonia due to Temozolamide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Bronchoalveolar Lavage; Dacarbazine; Female; Glioblastoma; Humans; Lung Diseases, Interstitial; Lymphocytosis; Middle Aged; Radiography, Thoracic; Temozolomide; Time Factors; Tomography, X-Ray Computed | 2008 |
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Humans; Mice; Mice, Nude; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Anticholesteremic Agents; Anticonvulsants; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Combined Modality Therapy; Cyclosporine; Dacarbazine; Dexamethasone; Female; Fluoxetine; Glioblastoma; Heptanoic Acids; Humans; Immunosuppressive Agents; Isoniazid; Middle Aged; Omeprazole; Phenobarbital; Prednisone; Pyrazinamide; Pyrroles; Radiotherapy; Red-Cell Aplasia, Pure; Rifampin; Temozolomide; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary | 2009 |
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Sequence Data; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; KATP Channels; Mice; Minoxidil; Survival Rate; Temozolomide; Transplantation, Heterologous; Trastuzumab | 2009 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Glioblastoma; Humans; Reproducibility of Results; Survival Analysis; Survival Rate; Temozolomide; Time Factors | 2008 |
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neurosurgical Procedures; Pancytopenia; Polymerase Chain Reaction; Radiotherapy; Temozolomide; Thrombocytopenia; Tumor Suppressor Proteins | 2009 |
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Retrospective Studies; Survival Rate; Temozolomide | 2009 |
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Endothelium, Vascular; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Temozolomide | 2008 |
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Brain Neoplasms; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Mice; Poly(ADP-ribose) Polymerases; Temozolomide; Toluene; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2008 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; France; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome; Waiting Lists | 2009 |
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cytoskeleton; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Endothelial Cells; Focal Adhesion Kinase 1; Glioblastoma; Humans; Oncogene Protein v-akt; Phosphorylation; Promoter Regions, Genetic; Snake Venoms; src-Family Kinases; Swine; Temozolomide; Tight Junctions; Tumor Suppressor Proteins | 2008 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Confusion; Dacarbazine; Diagnosis, Differential; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Radiation Injuries; Radiation Tolerance; Radiotherapy, Adjuvant; Reoperation; Temozolomide; Treatment Outcome | 2009 |
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 9; Combined Modality Therapy; Craniotomy; Dacarbazine; Gastric Bypass; Glioblastoma; Humans; Male; Middle Aged; Obesity, Morbid; Temozolomide | 2009 |
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Dacarbazine; Exploratory Behavior; Flow Cytometry; Glioblastoma; Male; Peptide Fragments; Rats; Rats, Wistar; Receptors, Bombesin; Temozolomide | 2009 |
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Repair; Enzyme Inhibitors; Glioblastoma; Humans; In Vitro Techniques; Mice; Mitosis; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiotherapy; Temozolomide | 2009 |
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Temozolomide; Tumor Suppressor Proteins | 2009 |
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Temozolomide | 2009 |
Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance; Glioblastoma; Humans; Neoplasm Invasiveness; Neurosurgical Procedures; Patient Care Team; Sodium-Potassium-Exchanging ATPase; Temozolomide | 2009 |
Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Squamous Cell; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tonsillar Neoplasms | 2009 |
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Odds Ratio; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Treatment Outcome | 2009 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cholestasis; Dacarbazine; Glioblastoma; Humans; Liver Failure; Male; Middle Aged; Temozolomide; Valproic Acid | 2008 |
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoquinones; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; NAD(P)H Dehydrogenase (Quinone); RNA, Messenger; Temozolomide | 2009 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Mismatch Repair; DNA Mutational Analysis; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Silencing; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Temozolomide | 2008 |
Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Carbon; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; Heavy Ion Radiotherapy; Humans; Radiation Tolerance; Relative Biological Effectiveness; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide; Time; Treatment Outcome | 2009 |
Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; beta-Galactosidase; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Damage; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Histones; Humans; Immunohistochemistry; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Temozolomide; Time Factors; Tumor Suppressor Protein p53 | 2009 |
BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Inducing Factor; Cell Death; Cell Line; Cell Nucleus; Chromatin Immunoprecipitation; Dacarbazine; DNA Fragmentation; Electrophoresis, Gel, Pulsed-Field; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase 1; Histone Deacetylases; Humans; Membrane Proteins; Protein Binding; Proto-Oncogene Proteins; PTB-Associated Splicing Factor; RNA-Binding Proteins; Temozolomide; Transfection | 2009 |
Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Nimustine; Retrospective Studies; Salvage Therapy; Survival Analysis; Temozolomide | 2009 |
Efficacy of temozolomide treatment in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Etoposide; Female; Glioblastoma; Gliosarcoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligodendroglioma; Prognosis; Temozolomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Glioblastoma; Humans; Mice; Radiation, Ionizing; Survival Analysis; Survivors; Temozolomide | 2009 |
Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Interferon-beta; Oligodendroglia; Signal Transduction; STAT3 Transcription Factor; Temozolomide | 2009 |
Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Neck; Radiotherapy; Scalp; Stevens-Johnson Syndrome; Temozolomide; Thorax | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Temozolomide | 2009 |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Male; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Survival Rate; Temozolomide | 2009 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Glioblastoma; Humans; Models, Economic; Quality-Adjusted Life Years; Survival Analysis; Temozolomide; Treatment Outcome | 2009 |
Non-Hodgkin lymphoma following temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, Non-Hodgkin; Neoplasms, Second Primary; Temozolomide | 2009 |
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Hospitals, Community; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Survival; Temozolomide | 2009 |
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Cycle Proteins; Dacarbazine; DNA Damage; Enzyme Inhibitors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Glioblastoma; Mice; Mice, SCID; Neuroblastoma; Polo-Like Kinase 1; Protein Phosphatase 2; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Temozolomide | 2009 |
Glioblastoma stem cells resistant to temozolomide-induced autophagy.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Blotting, Western; Caspase 3; Cells, Cultured; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Membrane Proteins; Microtubule-Associated Proteins; Peptides; Temozolomide | 2009 |
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Mutational Analysis; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Microsatellite Instability; Mutation; RNA Interference; Temozolomide; Tumor Cells, Cultured | 2009 |
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Suppressor Proteins | 2009 |
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Topics: Aniline Compounds; Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Glioblastoma; Humans; Indicator Dilution Techniques; Oligonucleotide Array Sequence Analysis; Phosphotransferases (Alcohol Group Acceptor); Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Thiazoles | 2009 |
Comment re: Temozolomide preferentially depletes cancer stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplastic Stem Cells; Temozolomide | 2009 |
Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brachytherapy; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Reoperation; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2009 |
A rare case of aplastic anemia caused by temozolomide.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Temozolomide | 2009 |
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Genes, erbB-1; Genes, p53; Glioblastoma; Humans; Methylation; Mice; O(6)-Methylguanine-DNA Methyltransferase; PTEN Phosphohydrolase; Radiation-Sensitizing Agents; Random Allocation; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Predictive Value of Tests; Prognosis; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Nitrosourea Compounds; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2009 |
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Disorders; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Memory; Mental Processes; Middle Aged; Neuropsychological Tests; Psychomotor Performance; Radiotherapy, Adjuvant; Temozolomide; Verbal Learning | 2010 |
Glioblastoma masquerading as a hypertensive putaminal hemorrhage: a diagnostic pitfall.
Topics: Antihypertensive Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Diabetes Complications; Diagnosis, Differential; Diagnostic Errors; Fatal Outcome; Glioblastoma; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Putaminal Hemorrhage; Risk Factors; Temozolomide; Tomography, X-Ray Computed; Treatment Failure | 2009 |
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Gliosarcoma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide | 2010 |
Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Conformal; Retrospective Studies; Temozolomide | 2010 |
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Temozolomide | 2010 |
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2009 |
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.
Topics: Antineoplastic Agents, Alkylating; Colonic Neoplasms; Consensus Sequence; Dacarbazine; DNA Repair; Down-Regulation; Glioblastoma; HCT116 Cells; Humans; Lung Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Protein Binding; Sp1 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Skin; Temozolomide | 2009 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Models, Theoretical; Radiosurgery; Regression Analysis; Statistics as Topic; Temozolomide; Tumor Burden | 2009 |
Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Survivors; Temozolomide; Treatment Outcome | 2009 |
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Combined Modality Therapy; Dacarbazine; DNA Repair; DNA-Binding Proteins; Drug Administration Schedule; G2 Phase; Glioblastoma; Humans; Morpholines; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Pyrones; Radiation Tolerance; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2009 |
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Cluster Analysis; Dacarbazine; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; RNA Interference; Temozolomide; Transplantation, Heterologous; Tumor Burden; Y-Box-Binding Protein 1 | 2009 |
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carotenoids; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Diffusion; Disease Models, Animal; Glioblastoma; Hypoxia, Brain; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Neoplasm Transplantation; Oxygen; Radiation-Sensitizing Agents; Rats; Rats, Sprague-Dawley; Temozolomide; Vitamin A | 2010 |
Therapeutic windows.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; History, 20th Century; Humans; Molecular Structure; Temozolomide | 2009 |
Up-front temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Geriatrics; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Medical oncology: treatment and management of malignant gliomas.
Topics: Angiogenesis Inhibitors; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Salvage Therapy; Temozolomide; Treatment Outcome | 2010 |
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Dideoxynucleosides; Fluorine Radioisotopes; Glioblastoma; Humans; Methionine; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Temozolomide | 2010 |
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2010 |
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methylation; Epigenesis, Genetic; Female; Genomic Imprinting; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide | 2010 |
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Safety; Survival Rate; Temozolomide; Young Adult | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Retrospective Studies; Temozolomide; Time Factors | 2010 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2009 |
Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Central Nervous System Neoplasms; Cerebrospinal Fluid; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival; Temozolomide | 2010 |
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Infant; Male; Mice; Mice, Nude; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.
Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glioma; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Quinazolines; Temozolomide; Tumor Stem Cell Assay | 2010 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasms; Carboxymethylcellulose Sodium; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Interferon Inducers; Male; Middle Aged; Poly I-C; Polylysine; Receptors, AMPA; Snake Venoms; Survival Rate; Temozolomide; Treatment Outcome; United States; Young Adult | 2010 |
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Microsurgery; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Nimustine; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Reoperation; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Dacarbazine; Drug Interactions; Glioblastoma; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Sulfonamides; Temozolomide | 2010 |
Sensitivity to temozolomide in brain tumor initiating cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2010 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Radiotherapy Planning, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Young Adult | 2011 |
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Portugal; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell Culture Techniques; Cell Death; Cell Division; Cell Line, Tumor; Dacarbazine; DNA Primers; DNA, Complementary; Exons; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2010 |
Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Tonsillar pseudotumor: complications of chronically-administered temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Palatine Tonsil; Temozolomide | 2010 |
miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Primers; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Temozolomide | 2010 |
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorine Radioisotopes; Follow-Up Studies; Glioblastoma; Humans; Male; Methylation; Middle Aged; Positron-Emission Tomography; Pyrazoles; Retrospective Studies; Sulfonamides; Temozolomide; Tumor Suppressor Proteins; Tyrosine | 2010 |
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gamma Rays; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Maximum Tolerated Dose; Radiation Tolerance; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Cyclic S-Oxides; Dacarbazine; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Neural Stem Cells; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; STAT3 Transcription Factor; Temozolomide; Tumor Cells, Cultured | 2011 |
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diffusion Tensor Imaging; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Prognosis; Radiotherapy; Temozolomide | 2010 |
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; CpG Islands; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Nucleic Acid Amplification Techniques; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2010 |
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA Repair; Drug Delivery Systems; Glioblastoma; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Craniotomy; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Retreatment; Temozolomide; Treatment Outcome | 2010 |
Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Drug Implants; Female; Glioblastoma; Humans; Independent Living; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Perioperative Period; Postoperative Period; Retrospective Studies; Risk Assessment; Supratentorial Neoplasms; Survival; Temozolomide; Treatment Outcome | 2011 |
Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.
Topics: Anticonvulsants; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Humans; Levetiracetam; Piracetam; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Damage; DNA Repair; Glioblastoma; Methylnitronitrosoguanidine; Mice; Mice, Transgenic; Poly(ADP-ribose) Polymerase Inhibitors; PTEN Phosphohydrolase; Recombination, Genetic; Temozolomide | 2010 |
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; International Cooperation; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Telomerase; Telomere; Temozolomide; Young Adult | 2010 |
Temozolomide (Temodar).
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Costs; Glioblastoma; Humans; Temozolomide | 2010 |
MGMT gene promoter methylation in pediatric glioblastomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoenzyme Techniques; Infant; Male; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Boron Compounds; Boron Neutron Capture Therapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease-Free Survival; Fructose; Glioblastoma; Humans; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Randomized Controlled Trials as Topic; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Brain Neoplasms; Cell Survival; Convection; Dacarbazine; Drug Delivery Systems; Glioblastoma; Humans; Longevity; Male; Micelles; Polymers; Rats; Rats, Inbred F344; Rats, Nude; Rats, Sprague-Dawley; Retinoids; Temozolomide; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2010 |
Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monitoring, Intraoperative; Neurosurgical Procedures; Prospective Studies; Retrospective Studies; Surgery, Computer-Assisted; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Rats; Survival Analysis; Temozolomide; Tumor Burden | 2010 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Division; Cell Line, Tumor; Dacarbazine; Flow Cytometry; Glioblastoma; Glioma; Humans; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Temozolomide | 2010 |
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Databases, Factual; Female; Glioblastoma; Humans; Italy; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neurosurgical Procedures; Patient Care; Radiotherapy; Retrospective Studies; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Temozolomide; Tyrosine | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxib; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Glioblastoma; Gliosarcoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Thioguanine; Treatment Outcome; Young Adult | 2011 |
Long-term outcomes in children with glioblastoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Infant; Male; Neoplasm Recurrence, Local; Radiosurgery; Radiotherapy, Adjuvant; Reoperation; Republic of Korea; Retrospective Studies; Survival Rate; Temozolomide | 2010 |
Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bordetella bronchiseptica; Bordetella Infections; Brain Neoplasms; Cats; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Immunocompromised Host; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Respiratory Tract Infections; Temozolomide; Zoonoses | 2011 |
[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Nervous System Diseases; Pancytopenia; Radiotherapy, Adjuvant; Temozolomide | 2010 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Epigenomics; Female; Glioblastoma; Humans; Male; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nervous System Diseases; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Hepatic encephalopathy after treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Hepatic Encephalopathy; Humans; Temozolomide; Treatment Outcome | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Linear Models; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy Dosage; Reoperation; Retreatment; Salvage Therapy; Temozolomide; Time Factors; Young Adult | 2011 |
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dipeptides; Glioblastoma; Humans; Mice; Neoplasm Recurrence, Local; Receptors, Notch; RNA, Messenger; Signal Transduction; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Immunohistochemistry; Interleukin-2; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Temozolomide; Tissue Distribution | 2010 |
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Death; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Frontal Lobe; Glioblastoma; Hemorrhagic Disorders; Humans; Magnetic Resonance Imaging; Middle Aged; Parietal Lobe; Temozolomide | 2010 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Phenothiazines; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Psychotropic Drugs; Pyrimidines; Selective Serotonin Reuptake Inhibitors; Temozolomide | 2010 |
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glucose Transport Proteins, Facilitative; HT29 Cells; Humans; Mice; Mice, Nude; Temozolomide; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Cervical Vertebrae; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Neurosurgical Procedures; Radiotherapy; Spinal Cord Neoplasms; Temozolomide | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2011 |
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Male; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Temozolomide | 2010 |
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 2010 |
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Prospective Studies; Sequence Analysis; Stereotaxic Techniques; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2011 |
Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioblastoma; Guanine; Humans; Mechanistic Target of Rapamycin Complex 1; Methylnitronitrosoguanidine; Multiprotein Complexes; Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2010 |
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Female; Glioblastoma; Humans; Hypericum; Magnetic Resonance Imaging; Middle Aged; Optic Nerve; Optic Nerve Diseases; Radiation; Radiation Injuries; Radiotherapy; Temozolomide | 2010 |
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Cluster Analysis; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeobox A10 Proteins; Homeodomain Proteins; Humans; Inhibitory Concentration 50; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Temozolomide | 2010 |
Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2010 |
High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Monitoring, Intraoperative; Neurosurgical Procedures; Retrospective Studies; Temozolomide | 2011 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolomide | 2010 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Perfusion; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stereotaxic Techniques; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Radiographic patterns of relapse in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiography; Retrospective Studies; Salvage Therapy; Temozolomide; Time Factors; Treatment Outcome; Young Adult | 2011 |
Clinical significance of molecular biomarkers in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; PTEN Phosphohydrolase; Regression Analysis; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Young Adult | 2010 |
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; Female; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Molecular Probe Techniques; Nucleic Acid Amplification Techniques; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dacarbazine; Enzyme Activation; Firefly Luciferin; Flow Cytometry; Glioblastoma; Humans; Luminescent Measurements; Luminescent Proteins; Mice; Mice, Nude; Oligopeptides; Staining and Labeling; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dacarbazine; Glioblastoma; Humans; Immunotherapy, Adoptive; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Glioblastoma; Humans; Radiotherapy Dosage; Radiotherapy, Conformal; Temozolomide; Translational Research, Biomedical | 2011 |
FDA accelerated approval benefits glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Dacarbazine; Drug Approval; Glioblastoma; Humans; Temozolomide; United States; United States Food and Drug Administration | 2010 |
Taming glioblastoma by targeting angiogenesis: 3 years later.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Neovascularization, Pathologic; Temozolomide | 2011 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chi-Square Distribution; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy; Radiotherapy, Intensity-Modulated; Regression Analysis; Reproducibility of Results; Retrospective Studies; Temozolomide | 2011 |
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dacarbazine; Dronabinol; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Mice; Mice, Nude; Random Allocation; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2011 |
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Primers; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Glycolysis; Hexokinase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Neovascularization, Pathologic; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Vascular Endothelial Growth Factor A | 2011 |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Camellia sinensis; Catechin; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Glioblastoma; Humans; Immunohistochemistry; Mice; Mice, Knockout; Temozolomide | 2011 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Thrombocytopenia; Tumor Burden; Tumor Suppressor Proteins; Young Adult | 2012 |
Treatment of glioblastoma multiforme with radiotherapy and concomitant and adjuvant temozolomide: translation of randomised controlled trial evidence into routine clinical practice.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Temozolomide | 2011 |
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Glioblastoma; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Survival Rate; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Retrospective Studies; Temozolomide; Treatment Outcome | 2011 |
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Female; Flow Cytometry; Glioblastoma; Humans; Lymphocyte Subsets; Male; Middle Aged; Prognosis; Radiotherapy Dosage; T-Lymphocytes, Regulatory; Temozolomide; Young Adult | 2011 |
Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2012 |
Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Flow Cytometry; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Radiation, Ionizing; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins | 2011 |
Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
Topics: Acrylamides; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Glycosylases; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Hydroxylamines; Immunoblotting; Methyl Methanesulfonate; NAD; Piperidines; Poly(ADP-ribose) Polymerases; RNA Interference; Temozolomide | 2011 |
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepines; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Energy Metabolism; Enzyme Activation; Glioblastoma; Humans; Metformin; Olanzapine; Temozolomide | 2011 |
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Mismatch Repair; DNA Repair Enzymes; DNA-Binding Proteins; Female; Glioblastoma; Humans; Male; Middle Aged; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Recurrence, Local; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2011 |
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Outcome | 2011 |
Computational modeling of tumor response to vascular-targeting therapies--part I: validation.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Vessels; Computer Simulation; Cytotoxins; Dacarbazine; Glioblastoma; Humans; Models, Biological; Neoplasms; Stilbenes; Temozolomide; Treatment Outcome | 2011 |
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; GATA4 Transcription Factor; Glioblastoma; Humans; Mice; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2011 |
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Interferon-beta; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide | 2011 |
Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Positron-Emission Tomography; Temozolomide | 2010 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2011 |
Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Cell Line, Tumor; Cord Blood Stem Cell Transplantation; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; Guanine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Survival Analysis; Temozolomide; Transplantation Chimera; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Fluorine Radioisotopes; Gadolinium DTPA; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Tumor Burden; Tyrosine | 2011 |
Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Female; Formaldehyde; Frontal Lobe; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome | 2011 |
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
Topics: Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Glioblastoma; Humans; Temozolomide; Tumor Escape; Tumor Suppressor Proteins | 2011 |
Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Central Nervous System Neoplasms; Cisplatin; Dacarbazine; Doxorubicin; Drug Synergism; Etoposide; Glioblastoma; Histone Deacetylase Inhibitors; Histones; Humans; Microtubules; Pyridines; Temozolomide | 2011 |
FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ.
Topics: Animals; BRCA2 Protein; Cell Line; Dacarbazine; DNA Damage; DNA Repair; Down-Regulation; Fanconi Anemia; Gene Silencing; Glioblastoma; Humans; Mice; Models, Biological; Nimustine; Rad51 Recombinase; Recombination, Genetic; RNA, Small Interfering; Temozolomide | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Child; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Infusions, Intravenous; Male; Nausea; Neutropenia; Nimustine; Temozolomide; Teniposide; Thrombocytopenia; Young Adult | 2011 |
Another cause of pancytopenia in a patient receiving temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Pancytopenia; Risk Factors; Temozolomide; Vitamin B 12 Deficiency; Young Adult | 2011 |
Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Quality of Life; Retrospective Studies; Survival Rate; Temozolomide | 2011 |
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Isotopes; Cell Line, Tumor; Dacarbazine; Drug Monitoring; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Imaging; Male; Neoplasm Transplantation; Pyruvic Acid; Rats; Temozolomide; Treatment Outcome | 2011 |
Rare phenomenon: liver metastases from glioblastoma multiforme.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Immunohistochemistry; Liver Neoplasms; Male; Radiotherapy; Temozolomide | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Tomography, X-Ray Computed | 2011 |
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiotherapy; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Immunotherapy for glioblastoma: the devil is in the details.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; ErbB Receptors; Glioblastoma; Humans; Mutation; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide | 2011 |
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide | 2012 |
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Infant; Kaplan-Meier Estimate; Male; Nucleic Acid Amplification Techniques; Polymerase Chain Reaction; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Tumor Suppressor Proteins | 2011 |
[Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Dose Fractionation, Radiation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Proton Therapy; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Planning, Computer-Assisted; Temozolomide; Treatment Failure; Tumor Burden | 2011 |
Method for novel anti-cancer drug development using tumor explants of surgical specimens.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Flow Cytometry; Glioblastoma; Humans; Injections, Intralesional; Temozolomide | 2011 |
Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Survival Rate; Temozolomide; Young Adult | 2011 |
MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Cytochromes c; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Mitochondria; Neoplastic Stem Cells; Temozolomide; Tumor Cells, Cultured | 2012 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Dacarbazine; Dendritic Cells; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Ipilimumab; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2011 |
Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; SEER Program; Temozolomide; Treatment Outcome; United States | 2012 |
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Retrospective Studies; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tyrphostins; Young Adult | 2011 |
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Posterior Leukoencephalopathy Syndrome; Temozolomide | 2011 |
Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid Shunts; Chemoradiotherapy, Adjuvant; Craniology; Dacarbazine; Female; Glioblastoma; Humans; Hydrocephalus; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Retrospective Studies; Temozolomide | 2011 |
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Isocitrate Dehydrogenase; Medical Oncology; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2011 |
Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Mice; Mice, Nude; Noscapine; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Topics: Aminoacetonitrile; Animals; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imidazoles; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Piperazines; Proto-Oncogene Proteins c-mdm2; RNA Interference; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell Line, Tumor; Dacarbazine; Docosahexaenoic Acids; Down-Regulation; gamma-Linolenic Acid; Glioblastoma; Glioma; Humans; MicroRNAs; Neoplasm Proteins; Osmolar Concentration; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Up-Regulation | 2011 |
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Factors; Temozolomide | 2011 |
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Flow Cytometry; Glioblastoma; Humans; In Situ Nick-End Labeling; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Temozolomide; Wound Healing | 2012 |
The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Costs and Cost Analysis; Dacarbazine; Developing Countries; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quality of Health Care; Radiotherapy, Adjuvant; Temozolomide; Young Adult | 2011 |
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Temozolomide | 2012 |
American Society of Clinical Oncology 2011 CNS tumors update.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Temozolomide | 2011 |
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Risk; Temozolomide; Time Factors; Treatment Outcome | 2011 |
Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Glioblastoma; Hepatitis B; Hepatitis B virus; Humans; Male; Middle Aged; Temozolomide; Virus Activation | 2011 |
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Base Sequence; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Protein p53 | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Etoposide; Female; Glioblastoma; Glioma; Humans; Male; Neoplasm Recurrence, Local; Salvage Therapy; Supratentorial Neoplasms; Temozolomide | 2012 |
Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Temozolomide; Young Adult | 2011 |
Glioblastoma survival in the United States before and during the temozolomide era.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; United States; Young Adult | 2012 |
Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Methionine; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Salvage Therapy; Survival Rate; Temozolomide; Tissue Distribution; Young Adult | 2012 |
In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.
Topics: Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gene Expression Profiling; Glioblastoma; Hedgehog Proteins; Humans; Mice; Mice, Nude; Pyridines; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Temozolomide; Transcription Factors; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.
Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Transformation, Neoplastic; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Molecular Sequence Data; Neoplastic Stem Cells; Octamer Transcription Factor-3; Polyethyleneimine; Polyurethanes; Radiation Tolerance; SOXB1 Transcription Factors; Temozolomide | 2012 |
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Dacarbazine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Glioblastoma; Humans; Male; Poly-ADP-Ribose Binding Proteins; Prognosis; RNA, Messenger; Temozolomide; Topoisomerase II Inhibitors | 2012 |
Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diagnostic Imaging; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Cell death forms and HSP70 expression in U87 cells after ionizing radiation and/or chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Chemoradiotherapy; Dacarbazine; Dose-Response Relationship, Radiation; Flow Cytometry; Gamma Rays; Glioblastoma; HSP70 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Temozolomide; Tumor Cells, Cultured | 2011 |
Temozolomide: mechanisms of action, repair and resistance.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Glycosylases; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Suppressor Proteins | 2012 |
Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Hemoglobinometry; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Temozolomide; Tumor Suppressor Proteins | 2011 |
Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells.
Topics: Aged; Antigens, Surface; CD8-Positive T-Lymphocytes; Dacarbazine; Dendritic Cells; Female; Glioblastoma; Humans; Interleukin-2; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Monocytes; Phagocytosis; Phenotype; Temozolomide | 2012 |
Temozolomide induced liver injury.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Temozolomide | 2011 |
Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Glycosylases; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Temozolomide; Time Factors | 2012 |
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Genetic Vectors; Glioblastoma; Humans; Immunoblotting; Immunohistochemistry; Methylation; Mice; Mice, Nude; Neoplastic Stem Cells; Oncolytic Virotherapy; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Simplexvirus; Temozolomide; Tumor Suppressor Proteins; Vero Cells; Virus Replication | 2012 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Dacarbazine; Electric Impedance; Female; Gene Knockout Techniques; Glioblastoma; Glioma; Humans; Immunohistochemistry; Male; Microtubule-Associated Proteins; Middle Aged; Neurofilament Proteins; Phosphopyruvate Hydratase; Real-Time Polymerase Chain Reaction; Temozolomide; Tubulin; Young Adult | 2011 |
Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Dacarbazine; Dexamethasone; Glioblastoma; Glucocorticoids; Humans; Male; Striae Distensae; Supratentorial Neoplasms; Temozolomide; Vascular Endothelial Growth Factor A | 2012 |
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2012 |
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Temozolomide | 2012 |
Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Profiling; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Prospective Studies; Survival Analysis; Temozolomide; Tumor Burden; Tumor Suppressor Proteins | 2012 |
Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Germany; Glioblastoma; Humans; Male; Prevalence; Prognosis; Radiotherapy, Conformal; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Central Nervous System Neoplasms; Ceramides; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glucosyltransferases; Humans; Paclitaxel; Temozolomide | 2012 |
Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Patient Care; Temozolomide; United States; Young Adult | 2012 |
Expression of EGFRvIII in glioblastoma: prognostic significance revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; ErbB Receptors; Female; Gene Expression; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Recurrence; Spheroids, Cellular; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Young Adult | 2011 |
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Dacarbazine; DNA Methylation; ErbB Receptors; Female; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Irinotecan; Lomustine; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide | 2012 |
Prognostic significance of MRP5 immunohistochemical expression in glioblastoma.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Multivariate Analysis; Prognosis; Retrospective Studies; Sex Factors; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Postoperative Complications; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
Invasive Mycoleptodiscus fungal cellulitis and myositis.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Ascomycota; Cellulitis; Cluster Analysis; Dacarbazine; DNA, Fungal; DNA, Ribosomal; DNA, Ribosomal Spacer; Glioblastoma; Humans; Leg; Male; Molecular Sequence Data; Mycoses; Myositis; Phylogeny; Sequence Analysis, DNA; Temozolomide | 2012 |
Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Membrane Proteins; Microtubule-Associated Proteins; Radiation-Sensitizing Agents; RNA Interference; RNA, Small Interfering; Sirolimus; Temozolomide | 2012 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Glioblastoma; Humans; Induction Chemotherapy; Membrane Proteins; Mice; Mice, Nude; Neoplastic Stem Cells; Propylene Glycols; Proto-Oncogene Proteins; Receptors, Lysosphingolipid; Sphingosine; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide | 2012 |
Cotard's syndrome with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Corpus Callosum; Dacarbazine; Delusions; Depressive Disorder, Major; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Psychotic Disorders; Suicide, Attempted; Syndrome; Temozolomide | 2012 |
Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.
Topics: Astrocytes; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dacarbazine; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Glioblastoma; Histones; Humans; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Repressor Proteins; Temozolomide; Thioxanthenes; Tripartite Motif-Containing Protein 28; Tumor Suppressor Proteins | 2012 |
Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Prognosis; Reoperation; Survival; Temozolomide; Young Adult | 2012 |
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2012 |
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Feasibility Studies; Female; Glioblastoma; Infusions, Intraventricular; Microinjections; Rats; Rats, Inbred F344; Survival Rate; Temozolomide; Transplantation, Homologous; Treatment Outcome | 2012 |
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2012 |
Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Epilepsy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Survival Rate; Temozolomide; Thrombocytopenia | 2012 |
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Promoter Regions, Genetic; Radiotherapy, Conformal; Reoperation; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2012 |
Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Glioblastoma; Humans; NF-kappa B; Resveratrol; Stilbenes; Temozolomide; Tumor Suppressor Proteins | 2012 |
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
Topics: Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA Repair Enzymes; Glioblastoma; Humans; Kaplan-Meier Estimate; Likelihood Functions; Molecular Probe Techniques; Nucleic Acid Amplification Techniques; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Prospective Studies; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins | 2012 |
Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system.
Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; Dacarbazine; Diffusion Chambers, Culture; Glioblastoma; Humans; Ifosfamide; Liver; Microscopy, Electron, Scanning; Perfusion; Polyesters; Porosity; Precision Medicine; Temozolomide; Tissue Engineering; Tissue Scaffolds | 2012 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Cetuximab; Dacarbazine; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Male; Mannitol; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Treatment Outcome | 2012 |
Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Temozolomide | 2012 |
Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Polyesters; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid.
Topics: Antineoplastic Agents, Alkylating; Cryptogenic Organizing Pneumonia; Dacarbazine; Dyspnea; Female; Glioblastoma; Glucocorticoids; Humans; Methylprednisolone; Middle Aged; Temozolomide; Tomography, X-Ray Computed | 2012 |
In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma.
Topics: Alpha Particles; Cell Division; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Glioblastoma; Humans; In Vitro Techniques; Linear Energy Transfer; Neoplasm Proteins; Particle Accelerators; Photons; Promoter Regions, Genetic; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; NF-kappa B; Nuclear Pore Complex Proteins; Oligopeptides; Prognosis; RNA-Binding Proteins; Temozolomide | 2013 |
SSBP2 variants are associated with survival in glioblastoma patients.
Topics: Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Genome-Wide Association Study; Glioblastoma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Temozolomide | 2012 |
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Amplification; Genes, erbB-1; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Temozolomide; Young Adult | 2012 |
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retrospective Studies; Signal Transduction; Survival Analysis; Temozolomide; Young Adult | 2012 |
Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Male; Mice; Mice, Inbred BALB C; Microvessels; Piperidines; Quinazolines; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; CD57 Antigens; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Chemokine CCL4; Cohort Studies; Combined Modality Therapy; Cytomegalovirus; Dacarbazine; Epitopes; Female; Flow Cytometry; Glioblastoma; HLA Antigens; Humans; Immunotherapy, Adoptive; Interferon-gamma; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; Peptides; Temozolomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Subgroup economic analysis for glioblastoma in a health resource-limited setting.
Topics: Antineoplastic Agents, Alkylating; China; Cohort Studies; Cost-Benefit Analysis; Dacarbazine; Glioblastoma; Health Resources; Humans; Markov Chains; Middle Aged; Models, Economic; Prognosis; Quality-Adjusted Life Years; Survival Analysis; Temozolomide; Uncertainty | 2012 |
MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; MicroRNAs; Temozolomide | 2012 |
Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Calcium-Binding Proteins; Cell Line, Tumor; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Nude; Reactive Oxygen Species; Resveratrol; Signal Transduction; Stilbenes; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; RNA, Small Interfering; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Proteins | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherapy; Dacarbazine; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Drug Screening Assays, Antitumor; Gemcitabine; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Neoplasms, Experimental; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome; Tumor Burden | 2012 |
Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Base Sequence; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Primers; DNA-Binding Proteins; Glioblastoma; Humans; Interferon-beta; Nuclear Proteins; Phosphoproteins; Promyelocytic Leukemia Protein; Real-Time Polymerase Chain Reaction; Temozolomide; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins; Up-Regulation; YAP-Signaling Proteins | 2012 |
Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Humans; Neoplastic Stem Cells; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
Drug-induced cholestatic hepatitis: how late can it occur even after the cessation of the culpable drug?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Cholestasis; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Temozolomide | 2012 |
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatin; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair; DNA Repair Enzymes; DNA Replication; Drug Resistance, Neoplasm; Flow Cytometry; Gene Silencing; Genes, Reporter; Glioblastoma; Humans; p21-Activated Kinases; Polymerase Chain Reaction; RNA Interference; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoblotting; Luciferases; MicroRNAs; Oligonucleotide Array Sequence Analysis; Prognosis; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2012 |
Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Comorbidity; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Integrin alpha5beta1; Mice; Piperazines; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2012 |
In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Topics: Animals; Carmustine; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dogs; Genetic Therapy; Glioblastoma; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lentivirus; Temozolomide; Transplantation Conditioning; Tumor Suppressor Proteins | 2012 |
Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Platelet Count; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; France; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Waiting Lists | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioblastoma; Glioma; Hyperbaric Oxygenation; Rats; Rats, Wistar; Temozolomide | 2012 |
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Topics: Acetylation; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Methylation; Mice; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins; Up-Regulation; Vorinostat; Xenograft Model Antitumor Assays | 2012 |
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Geriatrics; Glioblastoma; Humans; Longitudinal Studies; Male; Retrospective Studies; Sex Factors; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Dacarbazine; Disease Progression; Fatal Outcome; Female; Gadolinium; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2012 |
The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Delayed-Action Preparations; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Temozolomide; Treatment Outcome | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2012 |
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Subarachnoid Hemorrhage, Traumatic; Temozolomide; Tomography, X-Ray Computed; Ultrasonography, Doppler, Transcranial | 2012 |
Olea europaea leaf extract alters microRNA expression in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dacarbazine; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Olea; Plant Extracts; Plant Leaves; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2012 |
Quantitative proteomic analysis and functional studies reveal that nucleophosmin is involved in cell death in glioblastoma cell line transfected with siRNA.
Topics: Adult; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Nuclear Proteins; Nucleophosmin; Prognosis; Proteome; Proteomics; RNA Interference; RNA, Small Interfering; Temozolomide; Transfection | 2012 |
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Mutation; Neoplasms, Multiple Primary; Oligodendroglioma; Radiotherapy; Retrospective Studies; Second-Look Surgery; Temozolomide | 2013 |
MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Glioblastoma; Humans; MicroRNAs; Oligonucleotides, Antisense; Temozolomide; Transfection | 2012 |
Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells.
Topics: Apoptosis; Bumetanide; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Size; Chlorides; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Minor Histocompatibility Antigens; Neoplastic Stem Cells; Potassium; Protein Serine-Threonine Kinases; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 2; Temozolomide; Time-Lapse Imaging; WNK Lysine-Deficient Protein Kinase 1 | 2012 |
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Hyperoxia; Mitogen-Activated Protein Kinase Kinases; Temozolomide | 2012 |
Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Neurosurgical Procedures; Physician-Patient Relations; Practice Patterns, Physicians'; Radiotherapy; Temozolomide | 2012 |
Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.
Topics: Alkylating Agents; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydroxylamines; Neuroglia; Temozolomide | 2013 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Dacarbazine; Disease Models, Animal; Disease Progression; Female; Ganciclovir; Glioblastoma; Green Fluorescent Proteins; Male; Mice; Mice, Transgenic; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Transgenes | 2012 |
Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Conformal; Survival Rate; Temozolomide | 2012 |
A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Norway; Prognosis; Prospective Studies; Radiotherapy Dosage; Registries; Survival Rate; Temozolomide | 2012 |
Glioblastoma therapy in the elderly: one age does not fit all.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
Chemotherapy-associated steatohepatitis with temozolomide and dexamethasone.
Topics: Antineoplastic Agents; Dacarbazine; Dexamethasone; Diabetes Mellitus, Type 2; Fatty Liver; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Time Factors | 2012 |
Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Lymphoma, Non-Hodgkin; Male; Temozolomide | 2012 |
Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Shape; Cell Survival; Chromatin Assembly and Disassembly; Dacarbazine; DNA Fragmentation; Glioblastoma; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Molecular Targeted Therapy; Mutant Proteins; Oxidoreductases; Ploidies; Recombinant Proteins; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation; WW Domain-Containing Oxidoreductase | 2012 |
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Nuclear Proteins; Polycomb Repressive Complex 1; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; Repressor Proteins; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplastic Stem Cells; Skin Neoplasms; Temozolomide | 2012 |
Prognosis of patients with multifocal glioblastoma: a case-control study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Multiple Primary; Neurosurgical Procedures; Prognosis; Radiotherapy; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: a comparison of cancer stem cell properties.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Serum-Free; Dacarbazine; Glioblastoma; Humans; Intermediate Filament Proteins; Neoplastic Stem Cells; Nerve Tissue Proteins; Nestin; RNA-Binding Proteins; SOXB1 Transcription Factors; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2012 |
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dacarbazine; Eukaryotic Translation Initiation Factor 5A; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Lysine; Male; Mixed Function Oxygenases; Molecular Targeted Therapy; Neoplasm Grading; Oxidoreductases Acting on CH-NH Group Donors; Peptide Initiation Factors; RNA-Binding Proteins; Temozolomide | 2012 |
Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Bridged-Ring Compounds; Calorimetry; Cell Survival; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Imidazoles; Temozolomide; Thermodynamics; Tumor Cells, Cultured | 2012 |
Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Curcuma; Curcumin; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Glioblastoma; Humans; Inhibitory Concentration 50; Medulloblastoma; Phytotherapy; Plant Extracts; Plants, Medicinal; Rhizome; Temozolomide | 2012 |
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Genotype; Glioblastoma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Transfection; Tumor Suppressor Proteins; Young Adult | 2013 |
FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
Topics: Antineoplastic Agents, Alkylating; Binding Sites; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Humans; Prognosis; Promoter Regions, Genetic; Protein Binding; Rad51 Recombinase; Recurrence; Temozolomide; Transcription, Genetic; Transcriptional Activation | 2012 |
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Prognosis; Quality of Life; Survival Rate; Temozolomide | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Fasting; Glioblastoma; Glioma; Insulin-Like Growth Factor I; Luminescence; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Rats; Temozolomide | 2012 |
Decision making and management of gliomas: practical considerations.
Topics: Aged; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Meta-Analysis as Topic; Oligodendroglioma; Temozolomide; Tumor Suppressor Proteins | 2012 |
Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Central Nervous System Neoplasms; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; MicroRNAs; Middle Aged; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Transcriptome; Tumor Suppressor Proteins | 2013 |
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Humans; Recurrence; Temozolomide | 2012 |
Alkylation sensitivity screens reveal a conserved cross-species functionome.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Bacterial Proteins; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Glycosylases; DNA Repair; Drug Resistance, Neoplasm; Escherichia coli; Glioblastoma; Humans; N-Glycosyl Hydrolases; Reactive Oxygen Species; Saccharomyces cerevisiae; Temozolomide; Ubiquitin-Protein Ligases; Uracil-DNA Glycosidase | 2012 |
Prime time for molecular marker diagnostics in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Prognosis; Promoter Regions, Genetic; Radiotherapy; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Resistance, Neoplasm; Glioblastoma; Humans; Immunoenzyme Techniques; Temozolomide | 2012 |
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; Cell Division; Cell Proliferation; Dacarbazine; DNA Damage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Flow Cytometry; G2 Phase; Glioblastoma; Humans; Immunoenzyme Techniques; Mice; Morpholines; Neurons; Protein Serine-Threonine Kinases; Pyrones; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Temozolomide; Treatment Failure | 2013 |
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Morphogenetic Protein 2; Cell Differentiation; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Signal Transduction; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Glioblastoma; Humans; Kaplan-Meier Estimate; Mibefradil; Mice; Neoplasm Transplantation; Skin Neoplasms; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amino Acid Transport System y+; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Excitatory Amino Acid Transporter 2; Female; Glioblastoma; Glutamate Plasma Membrane Transport Proteins; Humans; Immunohistochemistry; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neuropsychological Tests; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2013 |
Long-term survival in cerebellar glioblastoma multiforme. Case report.
Topics: Adult; Antineoplastic Agents; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Treatment Outcome | 2012 |
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mitogen-Activated Protein Kinases; Phosphorylation; Prognosis; PTEN Phosphohydrolase; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Brain Neoplasms; Dacarbazine; Fluorodeoxyglucose F18; Glioblastoma; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Nude; Survival Rate; Temozolomide; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Treatment options in elderly patients with glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male | 2012 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Nitric Oxide; O(6)-Methylguanine-DNA Methyltransferase; Scorpion Venoms; Temozolomide; Tumor Suppressor Protein p53 | 2013 |
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Retinal Dehydrogenase; Temozolomide; Transfection; Tumor Suppressor Proteins | 2012 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Repair; Drug Combinations; Drug Synergism; Glioblastoma; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Hydrocarbons, Brominated; Hypoxia; Mice; Mice, SCID; Mitochondria; Neoplastic Stem Cells; Propionates; Temozolomide | 2013 |
Neuro-oncology: treatment decisions in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Temozolomide | 2012 |
Equinatoxin II potentiates temozolomide- and etoposide-induced glioblastoma cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cnidarian Venoms; Dacarbazine; Drug Synergism; Etoposide; Glioblastoma; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Temozolomide | 2012 |
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Neoplastic Stem Cells; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Receptors, Metabotropic Glutamate; RNA, Messenger; Signal Transduction; Survival Rate; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xanthenes | 2013 |
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, p53; Glioblastoma; Humans; Mutation; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide; Up-Regulation | 2013 |
Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Glioblastoma; Health Services Accessibility; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2012 |
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Female; Focal Adhesion Protein-Tyrosine Kinases; Glioblastoma; Humans; Mice; Mice, Knockout; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Random Allocation; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Peptides; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Bystander Effect; Catalase; Cell Proliferation; Culture Media, Conditioned; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Glutathione; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Superoxide Dismutase; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Topics: Apoptosis; Brain Neoplasms; Dacarbazine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Messenger; STAT3 Transcription Factor; STAT5 Transcription Factor; Survivin; Temozolomide | 2013 |
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Matched-Pair Analysis; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Dacarbazine; Dioxygenases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2013 |
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Follow-Up Studies; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Neoplasm Staging; Prognosis; Retrospective Studies; ROC Curve; Survival Rate; Temozolomide | 2013 |
Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.
Topics: Brain Neoplasms; Contrast Media; Dacarbazine; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Spectroscopy; Middle Aged; Radiometry; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Recurrence; Temozolomide; Tomography, X-Ray Computed | 2013 |
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Endothelium, Vascular; Female; Glioblastoma; Histiocytes; Humans; Male; Middle Aged; Predictive Value of Tests; Promoter Regions, Genetic; Staining and Labeling; Survival Rate; Taiwan; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2013 |
[Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Humans; Reactive Oxygen Species; Signal Transduction; Sirtuin 1; Temozolomide | 2012 |
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Male; Masoprocol; Mitotic Index; Radiation-Sensitizing Agents; RNA Splicing; RNA, Messenger; Sp1 Transcription Factor; Survivin; Temozolomide; Transcription, Genetic | 2013 |
Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Prognosis; Radiotherapy; Temozolomide; Treatment Outcome | 2013 |
Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation; Genetic Vectors; Glioblastoma; Humans; Lentivirus; Mice; Mice, Nude; RNA, Small Interfering; Temozolomide; Transduction, Genetic; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytotoxicity, Immunologic; Dacarbazine; Diphosphonates; Drug Resistance, Neoplasm; Flow Cytometry; Genetic Engineering; Genetic Vectors; Glioblastoma; GPI-Linked Proteins; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Interleukin-2; Lentivirus; O(6)-Methylguanine-DNA Methyltransferase; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Temozolomide; Zoledronic Acid | 2013 |
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2013 |
A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Neurosurgical Procedures; O(6)-Methylguanine-DNA Methyltransferase; Pilot Projects; Prognosis; Survival; Treatment Outcome | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Mice; Oncogene Protein v-akt; Signal Transduction; src-Family Kinases; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Humans; MicroRNAs; O(6)-Methylguanine-DNA Methyltransferase; Polyadenylation; Promoter Regions, Genetic; Temozolomide | 2013 |
Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Proto-Oncogene Proteins c-myc; Temozolomide; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2013 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2013 |
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Failure; Young Adult | 2013 |
The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.
Topics: Aniline Compounds; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Interactions; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Microarray Analysis; Phosphorylation; Temozolomide | 2014 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine; Diabetes Mellitus; Fatal Outcome; Glioblastoma; Humans; Hypernatremia; Hypertension; Liver Diseases; Male; Middle Aged; Neoplasms, Second Primary; Radiotherapy, Conformal; Sepsis; Temozolomide; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide | 2013 |
Treatment of newly diagnosed glioblastoma multiforme.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Meta-Analysis as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Tenascin; Treatment Outcome | 2002 |
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2002 |
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chromatography, High Pressure Liquid; Cyclophosphamide; Dacarbazine; Dactinomycin; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Medulloblastoma; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Mice, SCID; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive; Radiation Chimera; Random Allocation; Rhabdoid Tumor; Rhabdomyosarcoma, Embryonal; Sesquiterpenes; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; Dacarbazine; DNA Adducts; DNA Damage; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Induction; Glioblastoma; Humans; Hypochlorous Acid; Methyl Methanesulfonate; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Oxidative Stress; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Dacarbazine; DNA Repair; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; G2 Phase; Glioblastoma; Glioma; Humans; Mitosis; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinases; Proteins; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2002 |
[Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Brain Stem Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; Data Interpretation, Statistical; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Time Factors | 2002 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplatin; Dacarbazine; Ependymoma; Female; Glioblastoma; Glioma; Humans; Image Enhancement; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Oligodendroglioma; Paclitaxel; Procarbazine; Sensitivity and Specificity; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; CpG Islands; Dacarbazine; Disease Progression; DNA; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors | 2003 |
Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Cobalt Radioisotopes; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Radiotherapy Dosage; Survival Analysis; Time Factors; Tomography, X-Ray Computed | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2003 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Survival Rate; Temozolomide | 2003 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Glioblastoma; Humans; Lymphoma; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Survival Rate; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neutrophils; Phagocytosis; Superoxides; Temozolomide | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Diagnosis, Differential; Frontal Lobe; Glioblastoma; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Radiography; Temozolomide | 2004 |
[Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme].
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Temozolomide; Time Factors | 2004 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarbazine; Glioblastoma; Humans; Ifosfamide; Loss of Heterozygosity; Mice; Mice, Nude; Mutation; Oligodendroglioma; Temozolomide; Xenograft Model Antitumor Assays | 2004 |
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Guideline Adherence; Humans; Multicenter Studies as Topic; Practice Guidelines as Topic; Quality Assurance, Health Care; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Temozolomide | 2004 |
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Mice; Mice, Nude; Temozolomide; Transcription, Genetic; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2004 |
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Europe; Female; Glioblastoma; Health Care Costs; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2004 |
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Male; Membrane Glycoproteins; Rats; Rats, Nude; Recombinant Proteins; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population.
Topics: Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Patient Selection; Selection Bias; Temozolomide; Treatment Outcome | 2004 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Supratentorial Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Cell Cycle; Cyclic N-Oxides; Dacarbazine; Drug Interactions; Glioblastoma; Humans; Spin Labels; Temozolomide; Tumor Cells, Cultured | 2004 |
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Immunohistochemistry; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Sulfones; Survival Analysis; Temozolomide | 2005 |
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Calcium; Calpain; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; Dexamethasone; Glioblastoma; Humans; Proto-Oncogene Proteins c-bcl-2; Spectrin; Temozolomide | 2004 |
Low-grade primary meningeal lymphoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hemangioma; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Radiation-Induced; Paresis; Seizures; Temozolomide; Tinea Capitis | 2005 |
Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Blotting, Western; Calpain; Cell Line, Tumor; Cell Survival; Dacarbazine; Dexamethasone; DNA Fragmentation; Enzyme Activation; Glioblastoma; Humans; In Situ Nick-End Labeling; Temozolomide; Trypan Blue | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; Gene Silencing; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide | 2005 |
Chemotherapy for brain tumors--a new beginning.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Child, Preschool; Dacarbazine; Gene Silencing; Glioblastoma; Humans; Medulloblastoma; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2005 |
Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cimetidine; Dacarbazine; Female; Glioblastoma; Mice; Mice, Nude; Temozolomide; Transplantation, Heterologous | 2005 |
Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Line, Transformed; Cell Line, Tumor; Checkpoint Kinase 2; Dacarbazine; Enzyme Activation; G2 Phase; Glioblastoma; Humans; Methylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Temozolomide | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Gene Silencing; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Salvage Therapy; Survival Analysis; Temozolomide | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide | 2005 |
Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma.
Topics: Dacarbazine; DNA Repair; Glioblastoma; Humans; Methylation; O(6)-Methylguanine-DNA Methyltransferase; Phenytoin; Temozolomide | 2005 |
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
[Temozolomide in patients with a glioblastoma multiforme: new developments].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Finland; Glioblastoma; Humans; Recurrence; Temozolomide | 2005 |
Current therapies for glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cranial Irradiation; Craniotomy; Dacarbazine; Drug Delivery Systems; Drug Design; Genetic Therapy; Glioblastoma; Humans; Neoplasm Proteins; Patient Acceptance of Health Care; Quality of Life; Research Design; RNA, Antisense; Survival Rate; Temozolomide; Vascular Endothelial Growth Factor A | 2004 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Glioma; Gliosarcoma; Humans; Male; Methionine; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Positron-Emission Tomography; Prospective Studies; Statistics, Nonparametric; Stereotaxic Techniques; Temozolomide; Tomography, Emission-Computed, Single-Photon | 2005 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer Graphics; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Necrosis; Oligonucleotide Array Sequence Analysis; Software; Temozolomide | 2006 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 9; Cytogenetics; Dacarbazine; Female; Gene Deletion; Genetic Markers; Glioblastoma; Glioma; Humans; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Models, Genetic; Multivariate Analysis; Nucleic Acid Hybridization; Paraffin; Prognosis; Proportional Hazards Models; Sex Factors; Temozolomide; Time Factors; Treatment Outcome | 2005 |
Gastrin exerts pleiotropic effects on human melanoma cell biology.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Cholecystokinin; Cisplatin; Cytoskeleton; Dacarbazine; DNA Primers; DNA, Complementary; Flow Cytometry; Gastrins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Melanoma; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Poly(ADP-ribose) Polymerases; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Time Factors; Wound Healing | 2005 |
Avoiding glucocorticoid administration in a neurooncological case.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Celecoxib; Cerebellum; Cyclooxygenase Inhibitors; Dacarbazine; Follow-Up Studies; Glioblastoma; Glucocorticoids; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pyrazoles; Sulfonamides; Temozolomide; Time Factors; Treatment Outcome | 2005 |
Salvage temozolomide for prior temozolomide responders.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Oligodendroglioma; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Temozolomide | 2005 |
Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Time Factors; Tumor Burden | 2005 |
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Profiling; Glioblastoma; Humans; Hyaluronan Receptors; Intracellular Signaling Peptides and Proteins; NF-kappa B; Nuclear Proteins; Proteins; Temozolomide; Tumor Necrosis Factor alpha-Induced Protein 3 | 2006 |
Evidence, economics, and emotions: the case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Female; Glioblastoma; Humans; Male; National Health Programs; New Zealand; Temozolomide | 2005 |
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Glioblastoma; Humans; National Health Programs; New Zealand; Social Values; Temozolomide; Terminal Care | 2005 |
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Guanine; Humans; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Oncolytic Viruses; Plasmids; Protein Phosphatase 1; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Small Interfering; Simplexvirus; Temozolomide; Transcription, Genetic; Transfection; Transplantation, Heterologous | 2006 |
Chemotherapy for glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2006 |
Glioblastoma--more questions than answers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Signal Transduction; Temozolomide | 2006 |
More from PHARMAC on temozolomide: feedback needed.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Glioblastoma; Humans; National Health Programs; New Zealand; Temozolomide | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamazepine; Carmustine; Case Management; Cesarean Section; Chemotherapy, Adjuvant; Cranial Irradiation; Craniotomy; Dacarbazine; Female; Frontal Lobe; Glioblastoma; Humans; Infant, Newborn; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Paresis; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Radiotherapy, Adjuvant; Remission Induction; Supratentorial Neoplasms; Temozolomide; Temporal Lobe | 2006 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Child; Child, Preschool; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Gene Silencing; Glioblastoma; Humans; Kaplan-Meier Estimate; Neoplasm Proteins; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2007 |
Complications of a temozolomide overdose: a case report.
Topics: Antineoplastic Agents, Alkylating; Bacterial Infections; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Pancytopenia; Temozolomide | 2006 |
Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Glioblastoma; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Risk Factors; Temozolomide | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Down-Regulation; Drug Synergism; Glioblastoma; Growth Inhibitors; Humans; Male; Mice; Mice, Nude; Perylene; Tamoxifen; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2006 |
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Listeriosis; Male; Middle Aged; Neoadjuvant Therapy; Pneumocystis carinii; Pneumonia, Pneumocystis; Sarcoma, Kaposi; Temozolomide | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma; Colonic Neoplasms; Dacarbazine; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Guanine; Humans; Methylation; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Proliferation; Cell Survival; Computer Simulation; Dacarbazine; Drug Therapy; Drug Therapy, Computer-Assisted; Glioblastoma; Humans; Models, Biological; Temozolomide; Treatment Outcome | 2006 |
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance; Enzyme Inhibitors; Glioblastoma; Guanine; Humans; Infusions, Intralesional; Male; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2007 |
Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion?
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Dose Fractionation, Radiation; Female; Ganglioglioma; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Neuroglia; Neurologic Examination; Radiotherapy, Adjuvant; Reoperation; Temozolomide; Temporal Lobe | 2007 |
The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.
Topics: Acid Anhydride Hydrolases; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatin; Dacarbazine; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Fluorescent Antibody Technique; G2 Phase; Glioblastoma; Humans; Models, Biological; MRE11 Homologue Protein; MutL Protein Homolog 1; Nuclear Proteins; Signal Transduction; Temozolomide | 2006 |
Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Drug Screening Assays, Antitumor; Female; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Temozolomide; Tumor Cells, Cultured | 2007 |
Malignant transformation of conus medullaris ganglioglioma: case report.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Ganglioglioma; Glioblastoma; Humans; Lumbosacral Region; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Paraplegia; Radiotherapy; Spinal Cord Neoplasms; Temozolomide | 2007 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Male; Middle Aged; Nausea; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Remission Induction; Temozolomide; Young Adult | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Male; Radiotherapy Dosage; Survival Rate; Temozolomide | 2006 |
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide | 2007 |
[Temozolomide, an oral chemotherapeutic agent with potential severe toxicity].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Female; Fever; Glioblastoma; Humans; Male; Middle Aged; Neutropenia; Temozolomide | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Drug Implants; Fatal Outcome; Female; Glioblastoma; Humans; Hydrocephalus; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Reoperation; Temozolomide; Temporal Lobe; Ventriculostomy | 2007 |
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromosomal Instability; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Nucleic Acid Hybridization; Temozolomide | 2007 |
Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA, Viral; Glioblastoma; Hepatitis B; Humans; Immunocompromised Host; Immunosuppression Therapy; Lamivudine; Liver; Male; Middle Aged; Patient Selection; Reverse Transcriptase Inhibitors; Risk Factors; Spinal Neoplasms; Temozolomide; Treatment Outcome; Viral Load; Virus Activation | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins | 2007 |
Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Mutation; Temozolomide | 2007 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Hepatitis B; Hepatitis B virus; Humans; Temozolomide; Temporal Lobe; Valproic Acid; Viral Load; Virus Activation | 2007 |
A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Practice Guidelines as Topic; State Medicine; Temozolomide; United Kingdom | 2007 |
Methylguanine methyltransferase testing in glioblastoma: when and how?
Topics: Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Temozolomide | 2007 |
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Interactions; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Mice; Mice, Nude; Nelfinavir; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Radiation Tolerance; Temozolomide | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Temozolomide | 2007 |
Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Topics: Adult; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Marrow; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Pancytopenia; Sepsis; Temozolomide | 2007 |
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cetuximab; Chemotherapy, Adjuvant; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Epidermal Growth Factor; Glioblastoma; Humans; Radiation Dosage; Temozolomide | 2007 |
Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prospective Studies; Singapore; Survival Analysis; Temozolomide | 2007 |
Salvage chemotherapy in progressive high-grade astrocytoma.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Singapore; Survival Analysis; Temozolomide | 2007 |
Temozolomide-associated organizing pneumonitis.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Male; Pneumocystis carinii; Pneumonia, Pneumocystis; Temozolomide | 2007 |
Prophylactic radiotherapy for glioblastoma in the elderly.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2007 |
The fallacy of single-agent chemotherapy for cancer.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Sensitivity and Specificity; Temozolomide | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Dosage; Gene Expression; Glioblastoma; Glioma; Humans; Immunohistochemistry; Molecular Sequence Data; Netherlands; Polymerase Chain Reaction; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Tumor Suppressor Proteins | 2007 |
Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Reoperation; Retrospective Studies; Supratentorial Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Glioblastoma; Luminescence; Luminescent Agents; Mice; Mice, Nude; Monitoring, Physiologic; Salvage Therapy; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Glioblastoma; Heat-Shock Proteins; Humans; Irinotecan; Molecular Chaperones; RNA, Small Interfering; Temozolomide; Transcription Factor CHOP; Transfection | 2007 |
[The effect of oxygenation on the biological behaviour of tumours].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Deoxyglucose; Glioblastoma; Glycolysis; Humans; Hyperbaric Oxygenation; Kidney Neoplasms; Neoplasms; Oncogene Proteins; Oncolytic Virotherapy; Temozolomide; Transplantation, Heterologous | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2008 |
Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dacarbazine; DNA Methylation; Dose Fractionation, Radiation; Genes, Tumor Suppressor; Glioblastoma; Humans; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Survival Analysis; Temozolomide | 2008 |
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2008 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniotomy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Temozolomide; Topotecan | 2007 |
Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Survival Analysis; Temozolomide | 2007 |
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Flow Cytometry; Glioblastoma; Humans; Immunotherapy; Male; Middle Aged; Radiotherapy; T-Lymphocyte Subsets; T-Lymphocytes; Temozolomide; Vaccines, Subunit | 2008 |
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Central Nervous System Neoplasms; Child; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prognosis; Temozolomide; Treatment Outcome | 2007 |
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Selection Bias; Survival Analysis; Temozolomide | 2008 |
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Replication; Glioblastoma; Humans; Mitosis; Radiation-Sensitizing Agents; Temozolomide; Tumor Stem Cell Assay | 2008 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Neurosurgical Procedures; Survival; Temozolomide | 2008 |
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3.
Topics: Animals; Antibodies; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Ceramides; Dacarbazine; Female; Glioblastoma; Humans; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Oxides; Paclitaxel; Phagosomes; Survival Rate; Temozolomide; Transplantation, Heterologous; Tubulin Modulators | 2008 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neurosurgical Procedures; Positron-Emission Tomography; Retrospective Studies; Survival; Temozolomide; Treatment Outcome | 2008 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Temozolomide; Tomography, X-Ray Computed; Tumor Suppressor Proteins | 2008 |
[Temozolomide: Temodal].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Temozolomide | 2008 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Headache; Humans; International Normalized Ratio; Male; Neurosurgical Procedures; Pedigree; Temozolomide; Tomography, X-Ray Computed | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Implants; Glioblastoma; Humans; Kaplan-Meier Estimate; Radiotherapy; Retrospective Studies; Temozolomide | 2008 |
[The sodium pump could constitute a new target to combat glioblastomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Brain Neoplasms; Calotropis; Cardenolides; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Mice; Neoplasm Invasiveness; Neoplasm Proteins; Neovascularization, Pathologic; Signal Transduction; Sodium-Potassium-Exchanging ATPase; Temozolomide | 2008 |
[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Movement; Clinical Trials as Topic; Dacarbazine; Forecasting; Glioblastoma; Humans; Prognosis; Sirolimus; Temozolomide; Transcription Factors | 2007 |
Multifocal glioblastoma multiforme with synchronous spontaneous hemorrhage: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Cerebral Hemorrhage; Cerebrum; Dacarbazine; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Male; Neoplasms, Multiple Primary; Paresis; Radiotherapy; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Noninvasive imaging of apoptosis and its application in cancer therapeutics.
Topics: Animals; Apoptosis; Caspase 3; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Dacarbazine; Glioblastoma; Humans; Luminescent Measurements; Mice; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous | 2008 |
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoribonucleases; Female; Galectin 1; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Therapy; Glioblastoma; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Membrane Proteins; Mice; Molecular Chaperones; Neovascularization, Pathologic; Oxidative Stress; Protein Serine-Threonine Kinases; Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Temozolomide; Transplantation, Heterologous | 2008 |
Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells.
Topics: Acetazolamide; Apoptosis; Aquaporin 1; Brain Edema; Brain Neoplasms; Calpain; Carbonic Anhydrases; Caspases; Cell Line, Tumor; Dacarbazine; Dexamethasone; Drug Interactions; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Inflammation; Mitochondria; Neoplasm Proteins; NF-kappa B; RNA, Messenger; RNA, Neoplasm; Temozolomide; Vascular Endothelial Growth Factor A | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2008 |
Adjuvant temozolomide: how long and how much?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Administration Schedule; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2008 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Dacarbazine; Glioblastoma; Guanine; Humans; Kinetics; Methyltransferases; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
In vitro evaluation of temozolomide combined with X-irradiation.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Colonic Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Adducts; DNA Repair; Glioblastoma; Humans; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1997 |
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; DNA, Neoplasm; Drug Administration Schedule; Female; Glioblastoma; Humans; Imidazoles; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Temozolomide; Treatment Outcome | 1998 |
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Inhibitory Concentration 50; Lomustine; Oligodendroglioma; Temozolomide; Tumor Cells, Cultured | 1999 |
Temozolomide (Temodal) for treatment of primary brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Monitoring; Glioblastoma; Humans; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide; United States | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; G2 Phase; Glioblastoma; Humans; Mitosis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbon-Sulfur Lyases; Carmustine; Choline; Dacarbazine; Diet; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Methionine; Mice; Mice, Inbred BALB C; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Temozolomide; Xenograft Model Antitumor Assays | 2001 |
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Topics: Alkaloids; Antineoplastic Agents, Alkylating; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Dacarbazine; Drug Synergism; Enzyme Inhibitors; G2 Phase; Glioblastoma; Humans; Mitosis; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
NICE verdict on Temozolomide: where next?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Approval; Evidence-Based Medicine; Glioblastoma; Humans; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Temozolomide | 2002 |
Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
Topics: Adult; Brain Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Glioblastoma; Humans; Leukopenia; Lomustine; Male; Methylnitrosourea; Middle Aged; Thrombocytopenia; Triazenes | 1975 |
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Aziridines; Benzoquinones; Carmustine; Cerebellar Neoplasms; Child; Dacarbazine; Drug Evaluation; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics as Topic | 1987 |
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Evaluation; Glioblastoma; Humans; Hydroxyurea; Lomustine; Medulloblastoma; Methylprednisolone; Neoplasm Recurrence, Local; Procarbazine; Vincristine | 1987 |